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Chapter 1 
General introduction and outline of the thesis 
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Esophageal cancer is a highly lethal malignancy, as reflected by an overall 5-year survival 
of 17%.1 In the Netherlands, the incidence of esophageal cancer resembles the growing 
trend in Western countries, with an incidence of 15/100,000 for men and 6/100,000 for 
women, and more than 2,600 new cases annually.2 Two main histological subtypes can 
be distinguished, i.e. esophageal adenocarcinoma (AC) and esophageal squamous cell 
carcinoma (SCC). Globally, SCC is the most common subtype, especially in areas with 
high incidence such as eastern and southern Africa and eastern Asia. However, in most 
Western countries, the incidence of esophageal and esophogastric-junctional (EGJ) AC 
has surpassed that of SCC. 
At the time of diagnosis, only 50% of all patients are potentially curable. Surgical re-
section has long been considered the primary curative treatment modality for esophage-
al and junctional cancer. Historically, the Ivor-Lewis procedure has been widely applied, 
including a thoracotomy with limited lymphadenectomy and thoracic anastomosis.3 
Ever since, two main surgical techniques have evolved. First, the extended en bloc trans-
thoracic esophagectomy (TTE) was developed, with extensive two-field lymphadenec-
tomy (upper abdomen and posterior mediastinum). This technique attempts to increase 
locoregional tumor control by enhancing the radicality of resection.4-8 It is well estab-
lished that extensive lymphadenectomy provides the benefit of more accurate staging, 
but its beneficial effect on survival is still unclear.9-12 Second, the limited transhiatal 
esophagectomy (THE) was introduced, which focused on minimization of postoperative 
morbidity and mortality by preventing a formal thoracotomy. The optimal surgical 
approach for the treatment of patients with esophageal cancer is still topic of debate. 
In the literature reported 5-year survival rates for patients treated with primary sur-
gical resection range from six to 50%, but rarely exceed 35% in Western countries.13-17 
To improve long-term survival, many trials investigated the added value of neoadjuvant 
chemo- and/or radiotherapy.18-24 
In most countries, two neoadjuvant approaches have been adopted as standard of 
care. The first is neoadjuvant chemoradiotherapy (nCRT), now generally based on the 
CROSS regimen, which resulted in a 5-year overall survival benefit of 14%, compared to 
surgery alone.22, 23 An alternative option is perioperative or preoperative chemotherapy 
using the OEO2, MAGIC or FLOT protocol, which showed an absolute risk reduction 
of 6%, 13% and 16% at 5-years, respectively.19, 24, 25 Except partly in Japan and China, it is 
widely accepted that chemoradiotherapy is the neoadjuvant treatment of choice for 
patients with squamous cell carcinoma.26 For patients with adenocarcinoma the optimal 
multimodality regimen is still topic of debate.27-29  
The ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study 
(CROSS) was a multicenter, randomized phase-III trial, comparing neoadjuvant chemo-
radiotherapy followed by surgery with surgery alone.22 The study included and analyzed 
366 patients from five academic and two non-academic high-volume teaching hospitals 
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in The Netherlands during a five-year period. Most patients (75%) had an adenocarci-
noma and most tumors were located at the EGJ (24%) or in the distal esophagus (58%). 
Results from the CROSS-trial showed that the addition of nCRT (carboplatin, paclitaxel 
and 41.4 Gy of concurrent RT) to surgery significantly increases survival as compared to 
surgery alone in patients with potentially curable SCC or AC of the esophagus or EGJ. 
Neoadjuvant treatment was well tolerated, with >90% of all patients receiving full treat-
ment. Therefore, neoadjuvant CRT plus surgery is now considered the therapy of first 
choice in the Netherlands and several other countries for potentially curable esophageal 
cancer (cT2-3N0-1M0 and cT1N1M0) in patients fit to undergo this treatment. 
Application of nCRT prior to surgery has important implications for prognostica-
tion and surgical treatment. Most of the conventional prognostic factors identified in 
the era of primary esophagectomy lose their prognostic value in patients treated with 
nCRT plus surgery.30 After nCRT, only the number of clinically suspected metastatic 
regional lymph  nodes (cN-stage) prior to treatment and the number of metastatic re-
gional lymph nodes in the resection specimen (ypN-stage) are independently associated 
with survival after application of nCRT plus surgery. A model using these parameters to 
determine prognosis showed only limited prognostic strength. This emphasizes the need 
for new prognostic parameters. One such parameter is the pretreatment p-TNM staging. 
This novel staging system aims to determine the pretreatment tumor extent based on 
the extent of tumor fibrosis, the location of residual tumor cells and regressional chang-
es of lymph nodes in the resection specimen after nCRT. Previously, this staging system 
has been shown reproducible.31 Furthermore, it was demonstrated that especially the 
number of pretreatment metastatic lymph nodes is an important and independent 
prognostic parameter. Patients with pre-treatment metastastic lymph nodes, which 
became negative for disease thanks to nCRT, have worse prognosis than patients with-
out pretreatment nodal involvement.31 
Neoadjuvant CRT downstages both the primary tumor and the regional lymph 
nodes. The first leads to an increase in the radical resection rate, whereas the latter ques-
tions the necessity of extended lymphadenectomy. Some studies have shown previously 
that the number of resected lymph nodes has prognostic impact on survival, and proba-
bly even therapeutic impact in patients after surgery alone.32 However, after nCRT the 
number of resected nodes has been shown unrelated to survival.33 These data question 
the necessity for maximization of lymphadenectomy after nCRT as can be performed 
during TTE.  
Furthermore, the effects of nCRT on health-related quality of life (HRQOL) are 
largely unknown. Esophagectomy has a profound and lasting impact on patients’ 
HRQOL.34 Patients who undergo nCRT might experience a deterioration in HRQOL 
after nCRT, which might impact postoperative recovery.35 Furthermore, long-term 
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effects of especially radiotherapy on heart and lungs have insufficiently been investigat-
ed and might have an impact on long-term HRQOL. 
In subsequent analyses of secondary endpoints in the CROSS-trial it was found that 
nearly a third of the patients had a pathologically complete response (pCR) in the resec-
tion specimen. A pCR after nCRT was seen in 49% of patients with SCC and 23% of 
patients with AC. In the OEO2 and MAGIC trials this was substantially less, i.e. 4% and 
5%, respectively.22, 36 This observation raises the question whether a surgical resection is 
of benefit to patients in whom no vital tumor cells can be detected in the resection spec-
imen. Theoretically, an organ sparing approach might be feasible since, intuitively, an 
esophagectomy in patients with no residual viable tumor cells in the resection specimen 
has probably no effect on clinical outcome. This imposes an ethical imperative to recon-
sider the necessity of standard esophagectomy in patients after nCRT. An individualized 
approach to surgery after nCRT needs to be studied and defined; a new treatment algo-
rithm in which not every patient with potentially curable esophageal cancer needs a 
resection after completion of nCRT to achieve long-term survival. In an active surveil-
lance approach, patients will be subjected to frequent clinical investigations after nCRT. 
Esophagectomy will be offered only to those with a proven locoregional recurrence, in 
the absence of distant metastases. An active surveillance approach could have great 
advantages given the high postoperative morbidity and substantial mortality, and the 
impact of surgery on quality of life.22, 37, 38 However, an active surveillance approach 
would be justified only if oncological outcome is non-inferior to standard surgery. In 
order to select patients for active surveillance, the disease should be re-staged after 
nCRT by means of meticulous clinical response evaluation (CRE). CREs need to accu-
rately categorize patients as clinically complete responders (cCR) or clinically incom-
plete responders. Such an active surveillance strategy is currently applied in selected 
patients who refuse surgery or are medically unfit for major surgery after completion of 
nCRT.39-42 Explorative retrospective studies in such patients show promising results, 
with comparable long-term survival for active surveillance (i.e. postponed esophagec-
tomy only in patients who develop a locoregional regrowth in the absence of distant 
metastases) vs immediate standard surgery.39-42 
Outline of the thesis 
This thesis consists of two parts. In part I the implications of neoadjuvant chemoradio-
therapy on surgical treatment of esophageal cancer are described. Part II is focused on 
the feasibility of an active surveillance approach instead of standard esophagectomy in 
clinically complete responders after nCRT. 
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PART I. Implications of neoadjuvant chemoradiotherapy on surgical treatment 
Since the publication of the CROSS-trial, nCRT followed by surgery is the standard of 
care in several countries, including the Netherlands. Overviews of nCRT and surgery are 
provided in chapters 3 and 4, respectively. In some other countries, perioperative 
chemotherapy is applied in patients with esophageal adenocarcinoma. The optimal 
multimodality treatment for these patients remains undetermined. In chapter 5, the 
CROSS nCRT-regimen is retrospectively compared with perioperative chemotherapy 
regimens in terms of survival, tumor down-staging and effect of lymphadenectomy on 
survival.  
Earlier studies have shown that nCRT leads to substantial down staging of both pri-
mary tumor and regional lymph nodes. This questions the need for extended lymphad-
enectomy. In chapter 6-8, the role of lymphadenectomy after application of nCRT is 
critically appraised and further explored.  
In chapter 9-11, we investigate the effect of nCRT as standard treatment on health-
related quality of life early after completion of neoadjuvant treatment, in the postopera-
tive phase and in the long-term.  
In chapter 12, we aim to externally validate a previously introduced pre-treatment 
pathological staging system in the resection specimen after nCRT. 
PART II. Active surveillance after neoadjuvant chemoradiotherapy 
The high pathologically complete response rate after nCRT provides the rationale to  
explore an organ-sparing active surveillance approach after nCRT. In order to select 
patients who might benefit from active surveillance, the disease should be re-staged after 
nCRT by means of clinical response evaluation (CRE). CREs need to accurately catego-
rize patients as clinically complete responders (cCR) or clinically incomplete respond-
ers. In chapter 13 a systematic review and meta-analysis of the literature is described on 
the accuracy of detecting residual disease after neoadjuvant chemoradiotherapy. In 
chapter 14, we describe the study protocol of a diagnostic trial aimed to determine 
which combination of diagnostic tests is adequate for CRE by determining the accuracy 
of detecting substantial residual disease after nCRT. The main results of this trial are 
described in chapter 15. Chapter 16 and 17 report the results of in depth analyses on 
the accuracy of detecting residual disease using endosonographic measurements and 
PET-CT, respectively. Active surveillance and standard esophagectomy carry specific 
risks and benefits.  Active surveillance may avoid the risk of postoperative complications 
and decreased health-related quality of life (HRQOL), but patients need to undergo 
frequent diagnostic tests and it is unknown if survival is non-inferior compared to 
nCRT plus standard surgery. In chapter 18, we investigated factors that influence pa-
tients’ preferences, and trade-offs that patients are willing to make in their choice be-
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tween surgery and active surveillance after nCRT. This will likely improve shared deci-
sion making in the future. In chapter 19, we provide an overview of the current litera-
ture on active surveillance after nCRT for esophageal cancer. Based on this literature 
and based on the results of chapter 14 and 15, we have designed the phase-III SANO-
trial (Surgical As Needed for Oesophageal cancer), assessing the (cost)effectiveness of 
active surveillance after nCRT, as compared to standard surgery. The protocol of this 
multicenter stepped wedge randomized controlled trial is described in chapter 20. Fi-
nally, in chapter 21, we illustrate the possible scenarios of an active surveillance strategy, 
by describing clinical outcomes of three typical patients who underwent active surveil-
lance after nCRT in the Erasmus MC – University Medical Center – Rotterdam. 
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Summary 
Changes in the diagnosis, evaluation and pre-, per- and postoperative treatment of can-
cer of the esophagus and esophagogastric junction have resulted in improved prognosis 
for patients with this uncommon, but deadly, disease. A tailored approach to the man-
agement of these patients can now result in an overall 5-year survival of about 50%, 
which is a dramatic improvement compared to the dismal results reported in the (re-
cent) past. Nevertheless, the optimal surgical approach remains unclear. The widely 
applied use of multimodality treatment (especially nCRT) questions the necessity of 
maximization of surgical lymph node retrieval and the introduction MIE might further 
decrease postoperative morbidity, with reduction of especially pulmonary complica-
tions. However, the lack of high-quality evidence on these topics has led to persistence 
of substantial differences in treatment approach between individual institutions. These 
differences underline the ongoing need for well-designed clinical trials on specific topics 
in the field of esophageal cancer surgery. 
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Surgical therapy 
Surgical resection remains the cornerstone of therapy for patients with resectable cancer 
of the esophagus in the absence of systemic metastases. Surgery, in current practice most 
of the times combined with neoadjuvant therapy, offers the highest likelihood of cure 
for patients with locoregional disease. To obtain the best results, the management of 
esophageal cancer should be individualized and based on a combination of factors in-
cluding the physiologic status of the patient, tumor type and location, and stage of dis-
ease.  In this chapter, we describe the different open surgical approaches to remove the 
esophagus in patients with esophageal cancer. Although minimally invasive techniques 
are increasingly applied, the benefits of fully minimally invasive esophagectomy have 
not yet been proven unequivocally and an open or hybrid esophagectomy remains the 
standard procedure to remove the esophagus in many leading high-volume centers 
worldwide.1 At present, the only strong available evidence comes from preliminary 
results of the French randomized MIRO trial comparing hybrid transthoracic esoph-
agectomy (TTE, laparoscopic gastric mobilization and open thoracotomy) with fully 
open TTE. These results suggest that hybrid TTE significantly reduces postoperative 
complications compared to open TTE (odds ratio [OR] for postoperative morbidity 
0.31, 95% CI 0.18–0.55, p=0.0001; percentage of pulmonary complications: 17.7% vs. 
30.1%, p =0.037).2 
Patient assessment 
Esophageal cancer is a disease that occurs predominantly in the sixth and seventh dec-
ades of life. Advanced age alone should not be considered a contraindication for esoph-
ageal resection. Although the risk of mortality is higher in patients older than 70 years of  
age, this increased risk is due to the higher frequency of medical comorbidities such as 
heart, liver, and kidney disease in the elderly population rather than age per se.3 It is 
important to note that when operative mortality is excluded, long-term survival after 
resection in the elderly population is similar to that observed in younger patients.4, 5 As a 
result, octogenarians and nonagenarians can be considered candidates for potentially 
curative resection, but particular attention needs to be paid to the preoperative assess-
ment of patients’ general condition. 
The strong etiologic ties between (squamous cell) cancer of the esophagus and alco-
hol and tobacco usage make it imperative that patients be carefully screened for the 
presence of cardiovascular, pulmonary, and hepatic dysfunction regardless of their age. 
It has been estimated that between 20% and 30% of patients with esophageal cancer will 
have evidence of cardiovascular disease if carefully screened.6 This evaluation should at 
least consist of electrocardiography for all patients. The preoperative evaluation should 
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also include pulmonary function testing. Patients with significant impairment in the 
forced expiratory volume at 1 second (FEV1 < 1 L) and those with chronic obstructive 
pulmonary disease are at increased risk of respiratory complications following surgery.7, 
8  Cirrhosis of the liver is not uncommon in patients with esophageal cancer, particularly 
those with squamous cell carcinoma. Well-compensated cirrhosis (Child classification 
A) alone is not a contraindication to resection of an otherwise curable esophageal can-
cer, but one should be careful when considering resection in the setting of more ad-
vanced stages of cirrhosis, especially in the presence of ascites. Furthermore, patients 
who are planned to undergo neoadjuvant chemo(radio)therapy should be screened for 
renal insufficiency. 
Extent of resection for locoregional esophageal cancer 
For several decades the optimal surgical strategy for the potentially curative treatment of 
patients with locoregional esophageal cancer is under debate. Historically, the Ivor-
Lewis procedure has been widely applied, including a thoracotomy with limited lym-
phadenectomy and thoracic anastomosis.9 Ever since, two main surgical techniques have 
evolved. First, the extended en bloc TTE was developed. With extensive two-field lym-
phadenectomy (upper abdomen and posterior mediastinum), this technique attempts to 
increase locoregional tumor control by enhancing of the radicality of resection.10-14 It is 
established that extensive lymphadenectomy provides the benefit of more accurate stag-
ing, but its beneficial effect on survival is still unclear.15-18 Second, the limited transhiatal 
esophagectomy (THE) was introduced, which focused on minimization of postoperative 
morbidity and mortality by preventing a thoracotomy. 
Lymphatic dissemination in esophageal cancer occurs early and is unpredictable.19 
Once the tumor has penetrated the submucosal layer, up to one-half of patients will 
have nodal metastases.20 More than 80% of patients with invasion of the muscularis 
propria will have at least one involved lymph node.21 In the presence of transmural inva-
sion, nodal involvement will be present in more than 85%, and the median number of 
involved nodes and the proportion of patients with more than four involved nodes in-
crease (Table 1a).22 Extended lymphadenectomy as performed during TTE increases the 
chance of removal of all tumor-positive lymph nodes and theoratically improves region-
al tumor control and perhaps even long-term survival. However, high-quality clinical 
evidence on the optimal extent of lymphadenectomy is absent, especially in the present 
era of neoadjuvant treatment. Consequently, individual opinions and institutional pref-
erences currently dominate the choice of surgical technique and extent of lymphadenec-
tomy. 
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Technique of open en bloc transthoracic esophagectomy 
En bloc TTE is performed through a right thoracotomy and a midline laparotomy. The 
proximal anastomosis is performed either through an extra incision made at the left side 
of the neck or in the chest (see “anastomosis”). When a cervical anastomosis is per-
formed, the procedure starts with a thoracotomy followed by the abdominal part of the 
operation, whereas in case of an intrathoracic anastomosis the laparotomy is performed 
prior to the thoracic phase.  
The thoracic dissection includes removal of the azygos vein with its associated 
nodes, the thoracic duct, and the paratracheal, subcarinal, paraesophageal, and para-
hiatal nodes in continuity with the resected esophagus. Nodes in the aortopulmonary 
window are removed separately. The block of tissue removed is bounded laterally on 
each side by the excised mediastinal pleura, anteriorly by the pericardium and membra-
nous part of the trachea, and posteriorly by the aorta and vertebral bodies. 
During the thoracic phase the patient is placed in the left lateral decubitus position, 
with a posterolateral thoracotomy performed entering the chest through the fifth or 
sixth intercostal space. The inferior pulmonary ligament is divided to the level of the 
inferior pulmonary vein. The pleura overlying the right main bronchus is divided taking 
into account its membranous part. The pleura lying on both sides of the azygos arch is 
incised and the arch is ligated or closed with a stapling device and subsequently tran-
sected. The pleura cranial to the azygos arch is incised and saved to create a pedicled 
“flap” to cover the subsequent intrathoracic anastomosis. The right paratracheal nodes 
are removed in between the trachea, superior vena cava and the azygos arch. The right 
vagal nerve and the bronchial artery are divided. The vagal nerve should not be dived 
with use of electrocautery to prevent injury to the right recurrent nerve. The pleura 
overlying the lateral aspect of the vertebral bodies is incised from the level of the azygos 
arch to the diaphragm and the intercostal veins are divided between ligatures or clips 
where they enter the azygos vein. A dissection plane is then created following each intact 
intercostal artery to reach the adventitial plane of the aorta. Dissection continues across 
the anterior surface of the aorta, until the left mediastinal pleura is reached. Direct 
branches of the thoracic aorta to the esophagus should be carefully ligated before divid-
ing. One or two communicating veins to the hemiazygos need to be ligated as they pass 
behind the aorta. The mediastinal tissue posteriorly between the azygos vein and the 
aorta just above the diaphragm includes the thoracic duct, which should be identified 
and transected at this stage. A heavy non-resorbable ligature should be placed caudally 
to prevent the development of a chylothorax. The dissection can be ended at the level of 
both crura of the diaphragm.  
The anterior portion of the dissection is performed along the previously incised infe-
rior pulmonary ligament. Hereby the posterior aspect of the pericardium is freed by 
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blunt and sharp dissection. The pericardium should only be removed when the tumor is 
adherent. Once the left mediastinal pleura is reached, the plane can be connected with 
the previous dissection over the aorta. Sometimes the left pleura is incised. The thoracic 
esophagus is then encircled with a Penrose drain for traction. The anterior dissection is 
then continued cephalad along the pericardium until the subcarinal nodes are encoun-
tered. Careful dissection along the right main bronchus up to the carina and then distal-
ly along the left main bronchus allows for removal of the entire subcarinal node basin in 
continuity with the resected esophagus. At this point, the anterior dissection is also 
transitioned to the wall of the esophagus by dividing the left vagal nerve where it crosses 
the left main bronchus. The esophagus is separated from the membranous part of the 
trachea. In case of an intrathoracic anastomosis, the esophagus is divided above the level 
of the azygos arch. In case of a cervical anastomosis the dissection is continued towards 
the root of the neck. The lymph nodes in the aortopulmonary window can be dissected 
after identification of the left vagal nerve. The left vagal nerve is divided between liga-
tures at the level of the left main bronchus. The proximal side is carefully moved upward 
with use of the same ligature, thus preventing damage to the left recurrent nerve when 
dissecting the AP window nodes. The proximal thoracic duct is also ligated and cut at 
the level of the fourth vertebral body where it crosses from right to left.  
The abdominal portion of the operation begins with a midline laparotomy and in-
spection of the peritoneal cavity and liver. Normally segment two and three of the liver 
are mobilized by incising the left triangular ligament with electrocautery. The flaccid 
part of the lesser omentum is identified and incised in the direction of the right crus. 
The right gastric artery is identified and the lesser omentum is further mobilized. Then 
the gastrocolic omentum is divided, carefully preserving the gastroepiploic arcade. This 
dissection should begin distally at the level of the pylorus, continuing proximally to 
include division of the short gastric vessels. The short gastric vessels should be divided 
as close as possible to the spleen to preserve as many collateral vessels to the fundus as 
possible. In this fashion also an omental wrap around the future anastomosis can be 
created.  
All of the lymph node–bearing tissue overlying the proximal border of the hepatic 
artery and portal vein is removed. This dissection is continued proximally along the 
hepatic artery to its origin from the celiac axis. The retroperitoneal tissue above the 
pancreas overlying the right crus of the diaphragm is dissected medially and superiorly 
to remain attached to the esophagectomy specimen. Attention is then turned to the 
greater curvature of the stomach where the gastrocolic omentum is divided.  The gastric 
fundus is rotated to the right to continue the dissection in the retroperitoneum, remov-
ing all of the node-bearing tissue above the splenic artery and overlying the left crus of 
the diaphragm. The musculature of the diaphragmatic hiatus is then incised (in case of a 
bulky tumor) to meet the incision made in the diaphragm during the thoracic dissec-
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tion. Often the diaphragmatic vein needs to be ligated. Retracting the stomach anterior-
ly, ample exposure of the celiac axis can be achieved to allow for ligation of the coronary 
vein (= left gastric vein). After this, the upper abdominal lymphadenectomy around the 
celiac trunk can be completed. The left gastric artery is dived at  its origin. A Kocher 
maneuver can be performed if needed to allow additional mobility of the stomach. 
Reconstruction is preferably performed by creation of a gastric tube after resection 
of the gastric cardia. The gastric tube is created using a linear stapling device. The staple 
line should begin on the upper fundus at least 5 cm from the distal limit of the tumor 
and should continue to a point along the lesser curvature corresponding to the fourth or 
fifth branch of the right gastric artery, in case of a cervical anastomosis, where more 
length can be achieved by staying closer to the greater curve (consequently a narrower 
tube).  When an intrathoracic anastomosis is performed, more of the right gastric ves-
sels can be preserved and consequently a wider tube can be created. Finally, the staple 
line is oversewn. 
Technique of transhiatal esophagectomy 
The operation begins with an abdominal lymph node dissection and gastric mobiliza-
tion (see “Technique of open en bloc transthoracic esophagectomy”). Next, the tendi-
nous part of the esophageal hiatus is incised anteriorly or the muscular part is incised 
circumferentially after division of the diaphragmatic vein with ligatures. This ensures 
removal of any potentially involved parahiatal nodes, but it also enlarges the hiatal 
opening that facilitates the lower mediastinal dissection. Placement of appropriate re-
tractors through the widened esophageal hiatus allows for en bloc dissection of all the 
fatty tissue and lymph nodes surrounding the lower thoracic esophagus under visual 
control as far as possible. Under normal circumstances this can be done up to the level 
of the inferior pulmonary veins. In order not to damage the thoracic duct, care should 
be taken not to dissect at the right side of the thoracic aorta. Subsequently, the gastric 
tube is created and the cervical esophagus is exposed (see “cervical anastomosis”). The 
upper thoracic esophagus is delivered into the cervical wound and it is divided in the 
neck. A large bore vein stripper is inserted through the cervical esophagus and brought 
out to the gastric remnant. After a long tape is tied to the distal part of the transected 
esophagus, it is bluntly stripped from the neck towards the abdomen, whilst the adhe-
sions between the esophagus and surrounding structures are manually freed via the 
widened hiatus. In the lower mediastinum, the vagal nerve trunks that are separated 
from the esophagus by this maneuver can be divided below the carina with use of scis-
sors. The right lateral attachments are mobilized by a similar maneuver passing the right 
hand anterior to the esophagus and using the thumb and index finger to bluntly dissect 
the right lateral attachments. The tape tied follows the inverting esophagus from the 
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neck to the abdomen. The esophagus is everted again and the resection specimen is sent 
for pathological examination. The tape is now sutured onto the top of the gastric tube 
(which has been created at an earlier stage: see above) . The gastric tube can be wrapped 
in a bowel bag or laparoscopic camera bag to facilitate atraumatic passage and can be 
brought up to the neck by pulling gently on the tape and pushing the gastric tube into 
the mediastinum. Care should be taken to avoid rotation of the gastric tube. A cervical 
anastomosis can subsequently be performed (see “Cervical Anastomosis”). 
Reconstruction 
In the far majority of patients undergoing resection for esophageal cancer, reconstruc-
tion is performed using a gastric conduit, where only a single anastomosis is required.  
The major disadvantages of using the stomach include the almost complete lack of 
peristaltic activity and the tendency for persistent reflux into the remaining cervical 
esophagus that is directly connected to the acid-secreting stomach. In long-term survi-
vors, this ongoing reflux can result in the development of interstitial metaplasia (Bar-
rett) in the cervical remnant.23 The need to preserve length may also result in more lim-
ited margins, especially for large or very distal tumors that can result in local recurrence. 
As a result, when there is extensive involvement of the stomach and the esophagus, the 
use of an antiperistaltic or isoperistaltic left colon interposition is preferred. Also, in 
cases where creation of a (sufficiently oxygenated) gastric tube is technically not possible 
(e.g. history of gastric surgery or aberrant blood supply of the stomach), reconstruction 
is performed using a colonic interposition. 
During TTE, the surgeon can choose between an anastomosis at the cervical level or 
in the chest. In contrast, a THE always requires an anastomosis in the neck. Despite the 
increased rate of recurrent laryngeal nerve damage, leakage and possible stricture for-
mation, some surgeons prefer a cervical anastomosis during TTE, because of a longer 
proximal tumor-free margin and a theoretically reduced morbidity in case of an anas-
tomotic leak.24, 25 The latter is founded on the assumption that a leakage of a cervical 
anastomosis is more likely to be confined to the neck, instead of leaking into the pleural 
cavity and mediastinum. However, a meta-analysis on this topic did not show differ-
ences in pulmonary complications (OR 0.86, 95% CI 0.13 – 5.59, p=0.87) and tumor 
recurrence (OR 2.01, 95% CI 0.68 – 5.91, p=0.21), which suggests that a cervical anas-
tomosis after TTE does not decrease the risk of thoracic complications compared to an 
intrathoracic anastomosis.26 Interestingly, in two large retrospective studies, it was 
found that the risk of intrathoracic manifestations due to leakage of a cervical anasto-
mosis is significantly less in patients after THE than in patients who underwent TTE. 
This is probably explained by the difference in mediastinal dissection and pleural resec-
tion. After THE, the bilaterally intact parietal pleura may confine infections, which pre-
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vents extension to the pleural cavity and mediastinum.27, 28 Notably, these studies were 
performed before the introduction of neoadjuvant therapy. Studies comparing cervical 
with intrathoracic anastomoses in patients who underwent neoadjuvant therapy are 
lacking. The CROSS trial comparing neoadjuvant chemoradiotherapy plus surgery with 
surgery alone, in which most anastomoses were performed at cervical level, showed  no 
significant difference in leakage rate.29 Nevertheless, preoperative radiotherapy likely 
affects anastomotic healing, especially if the fundus (i.e. the future tip of the gastric tube) 
was located within the radiation field. Theoretically, the gastric tube can be shorter in 
case of an intrathoracic anastomosis, with potentially improved oxygenation of the tip 
and thus enhanced anastomotic healing. On the contrary, radiation damage on the in-
trathoracic esophageal remnant might hamper intrathoracic anastomotic healing. This 
topic is currently subject of investigation in an ongoing Dutch randomized trial com-
paring cervical with intrathoracic anastomosis after neoadjuvant chemoradiotherapy 
(ICAN trial, Dutch Trial Registry number: NTR4333).  
Cervical anastomosis 
When a cervical anastomosis is performed after transthoracic esophagectomy, dissec-
tion of the proximal part of the thoracic esophagus should be performed as far as possi-
ble into the base of the neck to facilitate the later dissection. Exposure of the cervical 
esophagus is accomplished through an oblique left neck incision placed along the ante-
rior border of the sternocleidomastoid muscle. This incision should extend from the 
sternal notch to a point halfway to the ear lobe. The omohyoid, sternohyoid, and sterno-
thyroid muscles are divided laterally and the jugular vein and carotid sheath are lateral-
ized. The middle thyroid vein and inferior thyroid artery are ligated. Dissection is then 
continued posteriorly to the esophagus, down to the dissection plane with the preverte-
bral fascia, into the thoracic inlet where the dissection plane performed during the thor-
acotomy is reached. A dissection plane is then created between the esophagus and the 
trachea. The esophagus is encircled with a Penrose drain and the upper thoracic esoph-
agus is delivered into the neck. The esophagus is divided at the level of the thoracic inlet 
and the specimen is removed via the abdomen after tying a tape to the esophagus.  The 
cervical remnant should not be too long, thus preventing that the anastomosis will ulti-
mately retract into the upper chest with a possibly increased risk of intra-thoracic mani-
festation in case of leakage. 
With use of the tape, which is tied to top of  the gastric tube, the gastric pull-up can 
be completed.  The previously created gastric tube can be wrapped in a plastic bag to 
facilitate atraumatic passage to the neck. Care should be taken to avoid excessive tension 
on the stomach or its gastroepiploic arcade during this maneuver, and to avoid twisting 
of the stomach. The anastomosis is performed between the remaining cervical esopha-
gus and the gastric tube. We prefer to perform an end-to-end anastomosis with single-
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layer running suture. Several nonabsorbable sutures should be placed to normalize the 
size of the hiatus to prevent visceral herniation into the thorax. A nasogastric decom-
pression tube is then carefully passed as well as a nasojejunal feeding tube. Alternatively, 
one can choose for a percutaneous jejunal feeding tube. 
Intrathoracic anastomosis 
In case of an intrathoracic anastomosis, the proximal part of the esophagus is divided 
just above the arch of the azygos vein. With care to prevent rotation, the cardia together 
with the gastric tube, is delivered through the hiatus into the thoracic cavity, and the 
surgical specimen (i.e. esophagus and cardia) is removed. After placement of 4-8 sutures 
around the esophagus (PDS 3.0), a purse string prolene 1.0 is placed and after careful 
inflation of a 30ml balloon of a catheter the diameter of the circular stapler is estimated 
and the anvil is placed. Subsequently, the gastrotomy is made at the tip of the gastric 
tube, the circular stapling device is introduced and an end-to-side anastomosis is creat-
ed using a 25 mm or 29 mm circular stapling device. The gastrotomy is closed with a 
linear stapler and the linear staple line is oversewn.  A naso-gastric tube is passed into 
the distal stomach. After completion of the anastomosis, omental tissue is wrapped 
around the anastomosis (omentoplasty). 
Colon interposition 
When a colon interposition is performed, the complete stomach is removed with the 
esophagectomy specimen by dividing the duodenum just distal from the pylorus. There 
are several alternatives to use the colon for interposition. Frequently the left colon is 
used in an isoperistaltic position. For this purpose the ascending and descending colon 
are mobilized completely. The left segment of the colon to be interposed derives its 
arterial supply from the ascending branch of the left colic artery and usually corre-
sponds to the segment extending from the mid-transverse colon to the proximal de-
scending colon. This segment is mobilized by dissecting the middle colic artery back to 
its origin from the superior mesenteric artery where it arises as a single trunk in most 
patients. After the middle colic artery and vein are have temporarily been occluded to 
ensure adequate collateral flow through the marginal artery, these vessels are ligated and 
divided. 
The apex of the arc portended by the vascular pedicle is then marked with a suture 
and the distance from this point to the neck is measured with an umbilical tape. This 
tape is used to measure proximally from the first marking stitch to determine the point 
of transection of the proximal colon. The divided colon is then passed through the bed 
of the resected esophagus wrapped in a bowel bag, and a single-layer monofilament 
running anastomosis is performed to the remaining cervical esophagus. Traction is 
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gently applied to the colon from within the abdomen to eliminate redundancy and the 
colon is secured to the left crus of the diaphragm with a non-absorbable suture. 
The colon is then divided with a linear stapler 5 to 10 cm below the point where it 
enters the abdomen. Care should be exercised not to leave too long of an in-
traabdominal segment of colon as this will result in food retention. The mesentery 
should be divided immediately adjacent to the wall of the colon to avoid injury to the 
vascular pedicle. A single-layered anastomosis is then performed between the distally 
divided colon and the Roux-en-Y jejunal loop, and colon continuity is restored by a 
colo-colostomy. 
Alternatively the left colon can be used in antiperistaltic position, which is based on 
a vascular pedicle of the middle colic artery and vein. In this way the interposed segment 
can be longer, by making use not only of the descending colon, but also (part of) the 
sigmoid colon. 
Finally, the right colon can be used including the ileocecal valve in an isoperistaltic 
position and again based on the middle colic vessels. The advantage of this technique is 
that the ileocecal valve will act as an antifreflux mechanism at the proximal anastomosis.  
We routinely perform a catheter jejunostomy to provide early postoperative enteral 
feeding, and to avoid the need for parenteral nutrition in the event of postoperative 
complications such as an anastomotic leak. The jejunostomy catheter is removed when 
the patient is able to maintain body weight by oral feedings, usually 3 to 4 weeks postop-
eratively. 
Complications 
Despite recent improvements in perioperative management, postoperative morbidity 
and mortality following esophagectomy for cancer remain significant. These are large, 
technically demanding operations that are often performed on patients with compro-
mised cardiopulmonary function. Nutritional disturbances are also common, because of 
the combined effects of the cancer itself and the obstructing mass in the esophagus. 
Recent audits suggest a hospital mortality rate varying from 3.5 to 9% in the West.30, 
31 Complication rates varying from 17 to 74% are reported in both open and minimally 
invasive esophagectomy series.32, 33 This wide range of complication rates can be ex-
plained by the variations in definitions of complications and the absence of standardiza-
tion of time periods defining postoperative deaths.34, 35 Accurate comparison of out-
comes between centers to improve the quality of care requires consistency in definitions 
and data collection. Therefore, an international system for defining and recording post-
operative complications associated with esophagectomy has been developed.36  
Complications occurring in a randomized trial comparing open TTE with open THE 
for esophageal adenocarcinoma are summarized in Table 1b.37 Pulmonary complica-
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tions including pneumonia (defined as isolation of a pathogen from a sputum culture 
and an infiltrate on chest x-ray) and atelectasis (defined as lobar collapse on chest x-ray) 
are among the most common complications, occurring in 57% and 27% of patients who 
underwent TTE or THE, respectively. These complications can be minimized by early 
ambulation and careful attention to adequate pain control. Prevention of aspiration can 
be achieved by keeping the patient in the semi-upright position at all times, and by me-
ticulous attention to maintaining a functioning nasogastric tube. When necessary, a 
mini-tracheostomy can provide invaluable assistance in clearing retained secretions. 
Cardiac complications occur in approximately 26% and 16% of TTE and THE pa-
tients, with the development of atrial fibrillation accounting for the majority of these 
complications. The shift of body fluids and the extensive mediastinal dissection which 
causes a systemic inflammatory response likely play a role in the pathogenesis.  Alt-
hough these are generally self-limiting, they do require cardiac monitoring and treat-
ment, which can prolong the ICU stay. Atrial fibrillation can also e.g. be caused by anas-
tomotic dehiscence with secondary mediastinitis or by mechanical irritation by a chest 
tube. For these underlying causes specific measures are needed. 
Anastomotic complications occur in 10% to 30% of patients depending on the defi-
nition and the type of reconstruction performed.38 Most of these leaks can be managed 
with local drainage and antibiotic administration as long as the vascular supply to the 
reconstruction is adequate. We recommend early endoscopy in any patient who is 
known or suspected to have a substantial leak to exclude potentially life-threatening 
conduit ischemia, which can be present in as many as 14% of patients with an anasto-
motic leak.39 
Results 
Long-term survival following esophagectomy depends on several factors including age, 
gender, weight loss, histological subtype, depth of tumor invasion, radicality of the re-
section and the number of involved lymph nodes.29, 40, 41 The impact of surgical approach 
on long-term survival remains the subject of debate.  
In a retrospective analysis from nine high-volume centers on 2,303 patients (60% 
adenocarcinoma [AC], 40% squamous cell carcinoma [SCC]) who underwent R0-
resections, it was shown that a high total number of resected nodes is an independent 
prognostic factor of (favorable) survival after primary surgery. The optimal threshold 
for survival benefit was removal of 23 nodes, and the operation most likely to achieve 
this number was found to be an en bloc transthoracic resection.42 These findings are 
arguments in favor of TTE over THE. In contrast, a non-randomized study by two Brit-
ish high-volume centers showed similar long-term survival after THE and TTE for pa-
tients with SCC (12%) or AC (88%), while hospital stay was significantly shorter after 
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THE.43 This advantage in short-term recovery after THE over TTE without substantially 
jeopardizing oncological outcome was confirmed in a recent meta-analysis of 52 studies 
that included 3,389 TTE patients and 2,516 THE patients (48% SCC, 52% AC). In addi-
tion to the significantly shorter hospital stay (4 days less in patients who underwent 
THE, 95% CI: 1–7, p<0.01), THE was associated with shorter operation time (85 
minutes shorter, 95% CI 40–129, p<0.001), less pulmonary complications (17.3% vs. 
21.4%, odds ratio [OR] 1.37, 95% CI 1.05–1.79, p=0.02) and lower postoperative mortal-
ity (7.2% vs. 10.6%, OR 1.48, 95% CI 1.20– 1.83, p<0.001). On the other hand, anasto-
motic leaks and recurrent nerve palsies occurred more frequently after THE than after 
TTE. Moreover, lymph node yield was higher after TTE (mean difference of eight nodes, 
95% CI 1–14, p=0.02). The results of this meta-analysis should be interpreted with cau-
tion, because both randomized and non-randomized studies were included. This proba-
bly introduced a selection bias in favor of the THE group, because patients with more 
advanced tumors probably have been treated preferentially via the chest.44 On the other 
hand, more frail patients may have been offered a THE because of  no need for a thora-
cotomy. Finally, the enhanced short-term recovery after THE could not be confirmed in 
a large (more than 17,000 patients), multicenter observational study that compared TTE 
with THE; no differences were found in morbidity and mortality. However, a preference 
for THE in patients with poor performance status probably resulted in selection bias in 
favor of patients who underwent TTE.45 
Proponents of the transhiatal approach explain differences in survival by stage that 
have been consistently reported as being due to stage migration. This occurs when posi-
tive nodes in the extended part of the dissection increase pN-stage in patients with a 
more favourable prognosis compared to patients with the same number of positive 
nodes after a limited dissection during THE. In an attempt to address this issue, Altorki 
et al.. have reported outcome following en bloc TTE and transhiatal resections per-
formed in patients with T3N-positive (stage III) disease.46 In this group of patients, the 
effect of stage migration was supposed to be limited because all had locally advanced 
tumors with lymph node involvement. They reported 4-year survival of 35% after en 
bloc resection, which was significantly better than the 11% survival observed after 
transhiatal esophagectomy. Ultimately, this debate can only be resolved by the comple-
tion of a large randomized controlled trial. To date, only one such large trial (HIVEX) 
has been reported by Hulscher et al.37 This trial randomized 220 patients with AC of the 
mid-to-distal esophagus or the gastric cardia substantially involving the esophagus be-
tween THE and TTE. By avoiding a thoracotomy, artificial ventilation time (1 day after 
THE vs. 2 days after TTE, p<0.001) and hospital stay (15 days after THE vs. 19 days after 
TTE, p<0.001) were shorter and pulmonary complications were reported less frequently 
(27% after THE vs. 57% after TTE, p<0.001) after THE than after TTE. Nevertheless, in-
hospital mortality was comparable between both groups (2% after THE and 4% after 
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TTE, p=0.45). Interestingly, the more extended TTE was not associated with a higher 
percentage of tumor-free resection margins (72% after THE vs. 71% after TTE), whereas 
the median number of resected lymph nodes was two times higher after TTE than after 
THE (median 31 vs. 16, p<0.001). This high lymph node yield did not translate into a 
significantly better five-year overall survival (34% after THE and 36% after TTE 
(p=0.71)).47 However, in a subsequent subgroup-analysis of patients with a truly esoph-
ageal (Siewert type-1) cancer, and more specifically in patients with a limited number 
(1–8) of positive lymph nodes, an improved long-term survival was found after TTE, 
(23% after THE vs. 64% TTE, p=0.02). Given the post-hoc design of this analysis, the 
effect of stage migration on improved survival of TTE patients cannot be excluded, 
because more lymph nodes were resected after TTE. Furthermore, the relevance of these 
results is unclear for patients with SCC (only patients with AC were included). The final 
conclusion of the HIVEX trial was that in patients with advanced truly esophageal can-
cer (Siewert type-1) TTE is the preferred technique (especially in case of a limited num-
ber of positive nodes), while THE suffices in patients with a tumor located at the EGJ 
(Siewert type-2) and in patients with a poor performance status (especially in case of 
pulmonary comorbidities), without clinically suspected nodes at or above the carina.47 
The role of neoadjuvant therapy 
Increasingly, the management of esophageal cancer has focused nowadays on multimo-
dality therapy, with neoadjuvant chemotherapy or chemoradiotherapy being adminis-
tered to nearly all patients with locally advanced disease in many centers. The concept of 
neoadjuvant therapy in esophageal cancer was spurred by a general disappointment in 
the results of primary resections, which resulted in survival of 35% or less at 5 years.37 
Many studies have been performed to test the additional value of preoperative neo-
adjuvant therapy to surgical resection. A meta-analysis showed that both neoadjuvant 
chemotherapy and neoadjuvant chemoradiotherapy improve long-term survival.48 Fur-
thermore, this meta-analysis showed am (nonsignificant) benefit of neoadjuvant 
chemoradiotherapy (nCRT) over neoadjuvant chemotherapy (nCT) by comparison of 
the treatment arms of several trials (HR for overall mortality for nCRT vs. nCT 0.88, 
95% CI 0.76-1.01, p=0.07). Unfortunately, direct comparisons are limited, especially for 
patients with AC. 
Since the publication of this meta-analysis, the multicenter randomized CROSS trial 
was completed, comparing nCRT plus surgery with surgery alone in patients with 
esophageal or junctional cancer (both SCC and AC).29, 49 The applied regimen (car-
boplatin and paclitaxel with 41.4 Gy concurrent radiotherapy) had low toxicity com-
pared to earlier trials that mostly used cisplatin and fluorouracil. Median survival dou-
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bled from 24% in the surgery alone group to 49% in the nCRT group (HR 0.68, 95% CI 
0.53-0.88, p=0.003), with a 5-year survival advantage of 14% (33% vs. 47%). The superi-
or survival in the surgery alone arm of the CROSS trial compared to that in earlier ran-
domized trials, indicates that the survival benefit can be attributed to improved survival 
in the multimodality arm, and is not due to poor survival in the surgery alone arm.50, 51 
Based on these results, nCRT according to the CROSS regimen plus surgery is now 
considered standard of care in many countries.  
It should be noted that the favorable results of the CROSS trial were not confirmed 
in a recently completed French randomized trial (Fédération Francophone de Cancérol-
ogie Digestive (FFCD) 9901 trial) comparing nCRT plus surgery with surgery alone in 
stage I and II esophageal cancer patients. The applied neoadjuvant regimen consisted of 
cisplatin and fluorouracil with 45 Gy concurrent radiotherapy. No differences in 3-year 
overall survival rate and radical resection rate were found between both treatment 
arms.52 
Based on the FFCD 9901 trial, the standard use of nCRT for early-stage tumors can 
be debated. Possibly, surgery alone suffices in this subgroup of patients. This is support-
ed by the high rate of radical resections (92%) in the surgery alone arm of the French 
trial. However, the generalizability of the FFCD 9901 trial is questionable due to the low 
case volume of most participating centers, the high toxicity of the nCRT regimen with 
less sophisticated radiation techniques compared to the CROSS trial and a remarkably 
high postoperative mortality rate (11.1%). Therefore, we caution to conclude that pa-
tients with early-stage esophageal cancer should not undergo nCRT. We believe that in 
the absence of high quality evidence on the specific effect of nCRT on early-stage tu-
mors, the results from the CROSS trial (which also included stage-II-cancers) should be 
leading.53 
The CROSS trial as well as the FFCD 9901 trial included both AC and SCC.  Alt-
hough nCRT also significantly improves survival in patients with AC, the maximum 
benefit of nCRT is observed in SCC, which is known to be more radiosensitive than 
AC.29, 49 Three small underpowered randomized trials comprising 119, 75 and 131 pa-
tients respectively with esophageal AC did not show significant differences in survival 
between nCRT followed by surgery and nCT followed by surgery. Nevertheless, higher 
rates of pCR, R0 and ypN0 were found in the nCRT groups and two of these three trials 
showed a (non-significant) benefit in favor of nCRT.54-57 The optimal neoadjuvant 
treatment for esophageal AC remains undetermined and is currently investigated in the 
randomized Neo-AEGIS (perioperative MAGIC chemotherapy vs. preoperative CROSS 
chemoradiotherapy, in adenocarcinoma of the esophagus and esophago-gastric junc-
tion) trial which is likely to be reported in 2021.58 
NCRT has a significant down staging effect on both the primary tumor and the re-
gional lymph nodes. In the nCRT-arm of the CROSS trial, a substantial number of pa-
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tients (29% overall, 49% SCC, 23% AC) did not have any vital tumor left in the resection 
specimen. This observation led to the imperative to reconsider the necessity of standard 
esophagectomy in all patients who undergo nCRT. Therefore, the feasibility of an active 
surveillance strategy in patients with a clinically complete response (cCR) after nCRT is 
currently being explored. In this so called SANO (i.e. Surgery As Needed in Oesophage-
al cancer patients) approach, surgical resection would be offered only to patients in 
whom residual disease is highly suspected or proven after nCRT. Before SANO can be 
tested in a prospective clinical trial, we aim to determine the accuracy of clinical detec-
tion of residual disease after nCRT in the present preSANO trial.59 Furthermore, the 
French phase II/III randomized ESOSTRATE trial comparing standard surgery with 
surgery on demand in case of recurrence in patients with a clinically complete response 
after nCRT is currently being initiated (ClinicalTrials.gov identifier: NCT02551458).60 
As outlined above, the randomized HIVEX trial comparing THE with TTE for sub-
carinal AC only included patients with primary surgery. In that trial TTE did not im-
prove the rate of tumor-free margins (72% after THE vs.71% after TTE), but roughly 
doubled the number of resected nodes (median ± standard deviation = 16 ± 9 after THE 
vs. 31 ± 14 after TTE, p<0.001). As discussed above, a retrospective international study 
has shown that after primary surgery the number of resected nodes is correlated with a 
favorable long-term survival.42 However, it has been reported that chemoradiotherapy 
reduces lymph node yield from within the radiotherapy field.61-63 Importantly, in the 
patients after primary surgery from the CROSS trial, the total number of resected nodes 
and the number of resected positive nodes were positively correlated. However, this 
positive association completely disappeared in patients who underwent nCRT. Fur-
thermore, after surgery alone the total number of removed nodes was positively corre-
lated with overall survival (hazard ratio (HR) per 10 additionally resected nodes, 0.76; 
p=0.007), which corresponds with the earlier retrospective international study.42, 64 In-
terestingly, this positive correlation between the number of resected nodes and survival 
was absent after nCRT (HR 1.00; p=0.98). The randomized design of the CROSS trial 
renders differences between both treatment groups unlikely as an explanation for the 
(disappearance of the) association in this post-hoc analysis. These results question the 
necessity of maximization of surgical lymph node dissection after nCRT, both for prog-
nostication and for therapeutic purposes. 
The same phenomenon was identified in a large retrospective comparison of 307 pa-
tients who underwent nCRT according to CROSS plus surgery and 301 patients who 
underwent nCT according to MAGIC followed by surgery. In the nCRT group, the 
association between lymph node harvest and survival was absent. However, in the nCT 
group, extent of lymphadenectomy seemed to be positively correlated with progression 
free survival. Again, these data question the necessity for maximization of surgical 
lymph node retrieval specifically after nCRT. However, extended lymphadenectomy 
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seems of importance in patients who undergo nCT followed by surgery (or surgery 
alone).65 
These indirect arguments need confirmation in a randomized trial comparing TTE 
with extended lymphadenectomy and THE with limited lymphadenectomy in patients 
with (Siewert type-1) esophageal cancer who undergo nCRT. We believe that such trial 
should focus on truly esophageal cancer, and not on junctional cancer, because it al-
ready has been shown that THE suffices in junctional cancer if they undergo primary 
surgery; let alone in patients with junctional cancer who have been treated with pre-
operative nCRT. 
Salvage surgery 
Definitive CRT (dCRT) is frequently applied in patients with SCC of the proximal part 
of the esophagus (i.e. above the carina) and in patients not fit for surgery. Although 
organ preservation is a considerable advantage in the non-operative strategy of dCRT, 
this approach is associated with high rates (up to 51%) of recurrence or persistence of 
locoregional disease.66 In these patients, salvage esophagectomy is an option after failed 
dCRT with curative intent. This selective surgery is more demanding than primary 
esophagectomy. Thanks to centralization of care with improvement in patient selection, 
in surgical technique and in perioperative management, perioperative morbidity and 
mortality nowadays have substantially decreased.67 Furthermore, the increased applica-
tion of nCRT has familiarized surgeons with surgical resection in an irradiated surgical 
field. 
Results of salvage surgery after failed dCRT were analyzed in a non-randomized 
phase II trial.68 Forty-three patients were treated with induction CT (5-FU, cisplatin and 
paclitaxel) followed by CRT (5-FU and cisplatin with concurrent 50.4 Gy). CT scans of 
the chest and abdomen, positron emission tomography (PET, optional but encouraged), 
esophagogastroscopy with biopsies and endoscopic ultrasound (EUS) were performed 
after completion of CRT and serially thereafter. Twenty patients underwent salvage 
esophagectomy because of residual or recurrent disease without signs of distant metas-
tases. One-year overall survival was 71% (95% CI 54% - 82%). Nevertheless, a subse-
quent phase III trial was not initiated, because the intended predefined minimal one-
year survival rate of 77.5% was not achieved. This predefined one-year survival rate was 
deducted from the RTOG database, consisting mainly of SCC patients. The proportion 
of ACs in this trial was 73%. Moreover, three CRT related deaths were reported. Theo-
retically, elimination or mitigation of induction CT from the regimen might have re-
duced treatment-related toxicity and increased the chance of achieving the target one-
year survival rate of 77.5%.68 
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Furthermore, a more recent retrospective propensity matched analysis compared pa-
tients undergoing salvage esophagectomy (n = 308) with patients who underwent nCRT 
followed by planned esophagectomy (n = 540). In-hospital mortality was comparable 
(but high) in both groups (8.4% versus 9.3%). Differences in postoperative complica-
tions were found for anastomotic leak (17.2% vs. 10.7%; p=0.007) and wound infection 
(18.5% vs. 12.3%; p=0.026), which were both more frequent in patients who underwent 
salvage surgery. At three-year follow-up, groups had comparable overall (43.3% versus 
40.1%; p=0.542) and disease-free survival rates (39.2% vs. 32.8%; p=0.232), suggesting 
that salvage surgery can offer acceptable short- and long-term results in a selected group 
of patients.69 
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Table 1a. Relationship Between Tumor Depth (T-stage) and Lymph Node Status (N-stage) for Esophageal 
Adenocarcinoma.54 
Tumor Depth Prevalence of Node 
Metastases (%)* 
Number of Involved 
Nodes [median 
(IQR)]** 
Number With 1-4 
Involved Nodes (%)† 
Number With >4 
Involved Nodes (%)‡ 
Intramucosal 
(T1A) 
1/16 (6) 2 (n/a) 1/16 (6) 0/16 (0) 
Submucosal 
(T1B) 
5/16 (31) 1 (n/a) 4/16 (25) 1/16 (6) 
Intramuscular 
(T2) 
10/13 (77) 2 (1-4) 9/13 (69) 1/13 (8) 
Transmural 
(T3) 
47/55 (85) 5 (3-13.5) 22/55 (40) 25/55 (45) 
*χ2 = 42.0, p< 0.0001 (chi-square test for trend). 
**χ2 = 11.02, p=0.0116 (Kruskal-Wallis; includes only patients with involved nodes). 
†χ2 = 13.64, p=0.0035 (chi-square test for trend). 
‡χ2 = 21.38, p< 0.0001 (chi-square test for trend). 
 
Table 1b. Postoperative Complications Occurring in 220 Primary Resections for Esophageal Adenocarcinoma 
in a Randomized Trial Comparing TTE and THE.68 
Complication Transthoracic 
Esophagectomy (%) 
Transhiatal Esophagectomy 
(%) 
P Value 
Pulmonary complications* 65 (57) 29 (27) <0.001 
Cardiac complications 30 (26) 17 (16) 0.10 
Anastomotic leakage** 
 Subclinical 
 Clinical 
18 (16) 
8 (7) 
10 (9) 
15 (14) 
9 (8) 
6 (6) 
0.85 
Vocal-cord paralysis† 24 (21) 14 (13) 0.15 
Chylous leakage 11 (10) 2 (2) 0.02 
Wound infection 11 (10) 8 (8) 0.53 
* Pulmonary complications include pneumonia (indicated by isolation of a pathogen from a sputum culture 
and an infiltrate on chest x-ray) and atelectasis (indicated by lobar collapse on chest x-ray). 
** The definition for subclinical anastomotic leakage was anastomotic leakage seen only on contrast radiog-
raphy, and clinical anastomotic leakage was defined as anastomotic leakage resulting in a cervical salivary 
fistula (all patients had cervical anastomoses).  
†In most cases, vocal-cord paralysis was temporary. 
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Introduction 
For decades, primary surgery as well as radiotherapy (RT) alone were two treatment 
options for potentially curable esophageal cancer. Outcomes were poor, with most pa-
tients developing recurrent disease with associated morbidity and mortality. Both 
treatment options evolved over time as a result of better staging1-3 and improved surgi-
cal-4-6 and radiation techniques.7, 8 Furthermore, the addition of chemotherapy (CT) to 
RT and the combination of surgical and nonsurgical approaches were important devel-
opments in the treatment of esophageal cancer. However, due to a lack of high-quality 
evidence, treatment of choice for esophageal cancer still remains controversial. Institu-
tional preferences and clinical opinions still dominate the applied treatments. In this 
chapter we give an overview of the role of chemoradiotherapy (CRT) in the treatment of 
adenocarcinomas (AC) of the distal esophagus and esophagogastric junction (EGJ). 
Classification of junctional tumors 
In 1997, the Siewert classification was introduced for the classification of ACs of the 
esophagus and EGJ (see chapter 7). Using the Siewert classification, three different tu-
mor entities (esophageal, cardiac and subcardiac) are distinguished, based on specific 
anatomical landmarks.9 Because advanced tumors often obscure these landmarks and 
frequent discrepancy is encountered between endoscopic, radiologic, peroperative and 
pathologic localization, its usefulness and applicability was shown to be limited.10 Some 
studies on neoadjuvant therapies selected patients based on histology type (AC or 
squamous cell carcinoma (SCC)) irrespective of location, others classified patients ac-
cording to location of the tumor (e.g. lower/upper esophagus, EGJ) irrespective of his-
tology. Most studies included all patients with esophageal or junctional tumors, regard-
less of the histology type. As a consequence, the majority of studies on esophageal can-
cer are only to a limited extent applicable for patients with ACs of the EGJ. In this chap-
ter, we focus on studies in patients with ACs originating in a Barrett segment or with 
cardia carcinomas substantially invading the distal esophagus.  
Rationale for combination of chemotherapy and radiotherapy 
Studies have tested the safety and efficacy of combining CT and RT. Theoretically, both 
modalities may be active against different tumor cell populations (additive effect). CT 
may be effective against distant micrometastases while radiation acts locoregionally 
(spatial cooperation). Furthermore, CT increases the effect of radiation by inhibiting the 
repair of sublethal radiation damage, may synchronize cells to a specific cell-cycle phase 
that has increased sensitivity to RT, may decrease repopulation after RT and, by shrink-
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ing the tumor, may enhance reoxygenation, which is advantageous for RT (synergistic 
effect).11-13  
Definitive chemoradiotherapy 
Definitive chemoradiotherapy vs. definitive radiotherapy alone 
Earliest references to the treatment of esophageal cancer with RT alone date back to the 
beginning of the 20th century. Outcomes were generally very disappointing with five-
year overall-survival rates ranging from 0 to 5%.14 With the advent of more potent 
chemotherapeutic agents, combined CRT became a more effective treatment option. 
Due to the observed synergistic effect of the combination of CT and RT, definitive CRT 
in patients with potentially curable esophageal cancer was further explored. 
Addition of CT to RT in patients with esophageal cancer was studied in a stratified 
phase III trial performed by the Radiation Therapy Oncology Group (RTOG 85-01 
trial).15 Patients (n=121) with potentially curable ACs or SCCs of the esophagus were 
randomized between RT alone (64 Gy in 32 fractions) and CRT (two courses of 5-
fluoruracil (5-FU) and cisplatin combined with 50 Gy RT, followed by two courses 5-FU 
and cisplatin). Interim analysis showed a significant difference in median survival be-
tween the RT (8.9 months) and combined therapy group (12.5 months, p<0.001). This 
led to an early closure of the trial. Of all analyzed patients, only fifteen (12%) had ACs 
and 37 (31%) had a primary tumor located in the lower esophagus. The remaining pa-
tients had SCC, mainly located in the mid-esophagus. No subgroup analysis based on 
histology or location was presented.15 Therefore, it remains unclear to what extent these 
results are applicable to ACs of the EGJ. Interestingly, long term results did not show 
any survival difference related to histology in patients treated with CRT, but separate 
results based on tumor location were still not presented. In line with the medium term 
results, five-year overall survival was improved in the combined modality group, as 
compared to patients treated with RT alone: 26% (95% confidence interval (CI) 15%-
37%) vs. 0%, respectively.16  
Dose of radiotherapy in definitive chemoradiotherapy 
Although the combination of CT and RT improved results compared to RT alone, the 
incidence of locoregional residual or recurrent disease remained high (e.g. 47% in the 
RTOG 85-01 trial).16 In an attempt to improve locoregional control and overall survival, 
the subsequent RTOG 94-05 (intergroup 0123) phase III trial intensified RT dose.17 This 
trial compared the same CRT regimen as was used in the RTOG 85-01 trial (50 Gy) with 
a higher dose RT (64.8) combined with the standard CT dose. After interim analysis the 
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RTOG 94-05 trial was closed prematurely because of a high number of treatment related 
deaths in the high-dose radiotherapy group, albeit that some of these deaths occurred 
before the end of study treatment. There was no significant difference in locoregional 
control or long-term survival between the two arms. This study included 31 (14%) pa-
tients with ACs. Patients whose tumors extended to within 2.0 cm of the EGJ were ex-
cluded because of the concern that the stomach could not tolerate 64.8 Gy. No subgroup 
analyses were performed.17 Hence, these results cannot be translated directly to EGJ 
tumors, but suggest that higher radiation dose is not favorable. However, recent im-
provements in RT techniques using conformal multiple field techniques or intensity 
modulated radiotherapy (IMRT) will reduce doses to the normal tissues (especially 
heart, anterior mediastinum and lung) and might lead to improved tolerability of in-
creased radiation dose in an attempt to improve locoregional control. 
Sequential vs. concurrent chemoradiotherapy 
The effects of sequential versus concurrent CRT were studied in a Cochrane meta-
analysis by Wong et al. Eight studies including 857 patients on sequential CRT were 
analyzed. No clinical benefit in terms of mortality (hazard ratio (HR) 0.87, 95% CI 0.74-
1.02) and local control was found, as compared to the RT alone group. Moreover, pa-
tients in the sequential CRT group experienced significant toxicities. Concurrent CRT 
was shown to improve overall survival significantly, compared to RT alone (HR 0.73, 
95% CI 0.64-0.84). This analysis on concurrent CRT was based on eleven studies includ-
ing 998 patients (Table 1). In these meta-analyses patients with AC and SCC were 
pooled and no subgroup analysis on tumor location was presented.18 
Due to the superior effects of concurrent CRT over a sequential regimen, subsequent 
studies mainly focused on concurrent CRT. Taken together, these studies suggest that 
concurrent CRT should be recommended over RT alone or sequential CRT as a non-
surgical therapy for potentially curable ACs of the distal esophagus and EGJ. A high 
dose of RT (64 vs. 50 Gy) combined with CT increases toxicity rates with no difference 
in survival, but more sophisticated radiation techniques might change this viewpoint in 
the future. 
Salvage surgery 
Although organ preservation is a notable advantage of the non-operative strategy of 
CRT, this approach is associated with a high rate (up to 40%) of recurrent or persistent 
locoregional disease.16 Selective surgical resection is a treatment option in patients after 
failed definitive CRT with curative intent. This so-called salvage surgery is more de-
manding than primary esophagectomy. Due to improvements in patient selection, peri-
operative management, surgical technique and centralization of care perioperative mor-
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bidity and mortality are nowadays substantially lower.19 Furthermore, the increased use 
of neoadjuvant CRT in addition to surgery for esophageal cancer familiarized surgeons 
with the resection of an irradiated esophagus. 
Results of surgical salvage after failed definitive CRT were presented in a non-
randomized phase II trial.20 Forty-three patients, of whom 41 were eligible for analysis, 
were treated with definitive CRT. This consisted of induction CT (5-FU, cisplatin and 
paclitaxel) followed by concurrent CRT (50.4 Gy with 5-FU and cisplatin). Esoph-
agogastroscopy with biopsies, endoscopic ultrasound (EUS), CT scans of the chest and 
abdomen and positron emission tomography (PET, optional but encouraged) were 
performed after completion of CRT and serially thereafter. Seventeen patients with 
residual or recurrent disease, but without distant metastases, underwent salvage esoph-
agectomy. During follow-up, esophageal resection was performed in three additional 
patients because of clinical suspicion of recurrent disease. Tumor cells were found in all 
these resected specimens. One-year overall survival rate was 71% (95% CI 54%-82%). 
However, since the intended predefined one-year survival rate of 77.5% was not 
achieved, a subsequent phase III trial was not initiated. It should be noted that the pre-
set one-year survival rate of 77.5% is deducted from the RTOG database, which consists 
mainly of SCC patients, whereas the proportion of patients with ACs in this trial was 
73%. Moreover, a total of three CRT related deaths were reported. As suggested by the 
authors, elimination of induction CT from the regimen might lead to less treatment-
related toxicity and perhaps achievement of the target one-year survival rate.20 
Also in this study, patients with AC were not analyzed separately. Given the high 
proportion of patients with ACs in the study population and the possibly more positive 
effect of surgical salvage that might be feasible than was achieved by the authors of the 
study, salvage surgery in addition to definitive CRT in patients with ACs of the distal 
esophagus and EGJ is an interesting topic, which remains to be investigated more exten-
sively. 
Definitive chemoradiotherapy vs. surgery alone 
Historically, primary surgical resection was considered as the only curative treatment 
for esophageal cancer.21 With more effective and less toxic chemotherapeutic agents and 
more sophisticated radiotherapeutic techniques, curative treatment of esophageal cancer 
with definitive CRT is now also potentially feasible. But is definitive CRT preferred over 
surgery alone? High quality evidence on this subject is absent. 
Two randomized trials comparing definitive CRT with curative intent to primary 
esophagectomy have been conducted. Results of the CURE (Chinese University Re-
search group for Esophageal cancer) trial were reported by Chiu et al in 2005.22 The 
CRT regimen consisted of 5-FU and cisplatin CT, combined with concurrent 50-60 Gy 
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RT. In case of incomplete clinical response or recurrence without systemic disease, sal-
vage surgery was performed. No significant difference in two-year overall survival be-
tween the CRT group (n=36) and the surgery group (n=45) was found (relative risk 
0.89, 95% CI 0.37-2.17, p=0.45).22 Given the higher incidence of SCC in the East, this 
study only included SCC patients, thus results are not necessarily applicable to patients 
with EGJ cancer. In 2007, results of a the second trial comparing definitive CRT (64 Gy 
and 3 courses of cisplatin and 5-FU) to surgery alone were published as abstract by Car-
stens et al. Patients (n=91) with both AC (50%)  and SCC (50%) were included. There 
was no significant difference in survival between the two treatment arms. Unfortunately, 
detailed information about study design and results is not available, because so far the 
trial has not been published as a full paper.23  
Neoadjuvant chemo- and/ or radiotherapy plus surgery 
Neoadjuvant radiotherapy plus surgery 
The earliest reports on neoadjuvant RT plus surgery date back to the early 1970s.24 
These reports all consist of uncontrolled case series from often single institutions. In 
those days, the majority of esophageal cancers were SCC and treatment consisted of 
either surgery or RT, depending on patient- and tumor characteristics and individual 
and institutional preferences. Due to disappointing long-term locoregional control after 
primary surgery, interest developed in the addition of preoperative RT to surgery as a 
possible means of downstaging the primary tumor. The rationale was that tumor down-
staging might increase the radical resectability rate, thereby reducing locoregional recur-
rence rate and – possibly – improving long-term survival.  
A Cochrane meta-analysis from 2005 by Arnott et al. reviewed the effects of the ad-
dition of preoperative RT to surgery as compared to surgery alone.25 This review was 
based on five randomized controlled trials, published between 1981 and 1992, totaling 
1,147 patients (Table 2).26-30 The majority of patients were men (78%), younger than 65 
years (80%) with SCCs (89%). The planned total dose of RT ranged from 20 to 40 Gy 
given in 10 to 20 fractions over a period of one to four weeks, with the delay from end of 
RT to surgery ranging from one to four weeks. Median follow-up time was nine years. 
In patients that received neoadjuvant RT, the risk of death was reduced by 11%, HR of 
0.89 (95% CI 0.78-1.01) and absolute survival at two- and five years improved (non-
significantly) from 30 to 34% and 15 to 18%, respectively. Radical resectability rates 
were reported as not significantly different between the groups. A subgroup analysis did 
not show a difference in benefit from preoperative RT for patients with tumors located 
at the upper/middle esophagus compared to patients with a tumor of the lower esopha-
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gus. Due to the high number of patients with SCC, the authors considered analysis by 
histology as uninformative. 
The authors of this meta-analysis concluded that, based on the existing randomized 
data, there is no clear evidence that preoperative RT alone improves the survival of pa-
tients with potentially resectable esophageal cancer. 
Neoadjuvant chemotherapy plus surgery 
With the advent of more effective and less toxic chemotherapeutic regimens similar 
interest developed in the addition of neoadjuvant CT to surgery as a means of reducing 
locoregional tumor burden, thereby potentially increasing locoregional resectability. 
Moreover, systemic therapy might be able to eradicate distant micrometastatic disease. 
It is often concluded that compared to historical controls the outcome improves after 
treatment with pre-operative CT.31 In summary, results of the individual trials and a 
recent update of an earlier published meta-analysis indicate that preoperative CT plus 
surgery offers a slight survival advantage (HR for all-cause mortality 0.87, 95% CI 0.79–
0.96, p=0.005) as compared to surgery alone for resectable thoracic esophageal cancer of 
any histological type.32 For detailed information on neoadjuvant CT combined with 
surgery, we refer to Chapter 18.  
Neoadjuvant chemoradiotherapy plus surgery 
In their meta-analysis, Sjoquist et al.32 identified 13 randomized trials comparing neoad-
juvant CRT plus surgery to surgery alone30, 33-44, published between 1992 and 2012, total-
ing 1,932 patients (Table 3). Two trials, by Mariette et al. and Van der Gaast et al., were 
only available as abstracts at the time of this meta-analysis, but have now been complet-
ed and fully reported.45, 46. The largest of these trials, the CROSS trial45, will be discussed 
separately in more detail below. 
Sample sizes of included trials ranged from 56 to 364 patients. Seven trials included 
only SCCs30, 33-35, 37, 39, 42, five trials included both SCC and ACs38, 40, 41, 45, 47  and one trial 
included ACs only.36 Various CT and RT regimens were used. The pooled HR for all-
cause mortality in these included trials, when comparing neoadjuvant CRT plus surgery 
with surgery alone, was 0.78 (95% CI 0.70–0.88, p<0.0001). This corresponds to an abso-
lute survival benefit of 8.7% at two years. The survival benefit for neoadjuvant CRT was 
similar for AC and SCC. In AC the HR was  0.75 (95% CI 0.59–0.95, p=0.02) and in SCC 
the HR was 0.80 (95% CI 0.68–0.93, p=0.004). Assessment of the effects of neoadjuvant 
CRT on survival by tumor site was not possible, because this information was not pro-
vided in most included trials.  
The conclusion of this meta-analysis was that there is a significant survival benefit 
for preoperative CRT in patients with AC or SCC of the esophagus.  
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CROSS trial 
The recently completed CROSS trial was a multicenter, randomized phase III trial.45 The 
study included and analyzed 366 patients during a five-year period. It included patients 
from five academic and two non-academic high-volume teaching hospitals in The Neth-
erlands. Most patients (75%) had an AC and most tumors were located at the EGJ (24%) 
or in the distal esophagus (58%). The study compared neoadjuvant CRT followed by 
surgery with surgery alone in patients with potentially curable esophageal cancer (cT2-
3N0-1M0 and cT1N1M0), with a planned inclusion of 175 patients per arm. The neoad-
juvant regimen consisted of carboplatin (AUC=2) and paclitaxel (50 mg/m2) given by 
intravenous infusion on days 1, 8, 15, 22 and 29, combined with concurrent radiation 
therapy using a multiple field technique. A total dose of 41.4 Gy was given in 23 frac-
tions of 1.8 Gy, five fractions per week, starting on the first day of the first cycle of CT. 
The aim of this trial was to compare overall survival between patients treated with neo-
adjuvant CRT followed by surgery and patients treated with surgery alone for potential-
ly curable, esophageal AC or SCC. 
Neoadjuvant treatment was well tolerated, with >90% of all patients receiving full 
treatment. The most common toxic effects in the CRT followed by surgery group were 
leukopenia (6%), anorexia (5%), fatigue (3%) and neutropenia (2%). One patient died of 
major bleeding while awaiting surgery, probably due to an esophago-aortic fistula. Me-
dian overall survival of patients who received neoadjuvant CRT plus surgery was 49 
months, compared to 24 months for those who underwent surgery alone. With a medi-
an follow-up of 32 months, 70 patients had died in the neoadjuvant CRT group vs. 97 in 
the surgery-alone group. Three-year overall survival was superior in the neoadjuvant 
CRT arm (HR 0.66, 95% CI 0.50-0.87, p=0.003). Patients with an AC had a significant 
survival advantage (p=0.049). No subgroup analysis based on location of the tumor was 
provided.  
In conclusion, results from the CROSS trial show that the addition of neoadjuvant 
CRT (carboplatin, paclitaxel and 41.4 Gy of concurrent RT) to surgery significantly 
increases survival as compared to surgery alone in patients with potentially curable AC 
and SCC of the esophagus or EGJ. Therefore, neoadjuvant CRT plus surgery is now 
considered the therapy of first choice in the Netherlands and several other countries for 
potentially curable esophageal cancer (cT2-3N0-1M0 and cT1N1M0) in patients fit to 
undergo this treatment.  
The improvement of survival after neoadjuvant CRT as found in the CROSS-trial, 
was not demonstrated in the recent FFCD9901 study by Mariette et al. This group ran-
domized 195 patients with stage I or II (cT1-2N0-1M0 and T3N0M0) esophageal cancer 
between neoadjuvant CRT (45 Gy with concurrent 5-FU and cisplatin) or surgery alone. 
Of all included patients only 29% had an AC. Tumor location was separated in above 
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(9%) or below the carina. The difference in outcome as compared to the CROSS trial, 
might be explained by a more toxic CT regimen and a lower tumor stage in the French 
trial. A majority of patients in the French trial had middle-third SCC, whereas the 
CROSS trial consisted of mostly lower-third ACs. Since SCCs tend to be more radiosen-
sitive than ACs, the absence of improvement of survival after neoadjuvant CRT in this 
study is surprising. Furthermore, a postoperative mortality rate of 11.1% in the multi-
modality group was reported, vs. 3.4% in the surgery only group. The CROSS study 
reported an in hospital mortality of 4% in both groups. In the French trial 86% of the 
neoadjuvant CRT patients underwent surgery compared to 92% in the CROSS study, 
which could be the result of the more toxic chemotherapy regimen and is expected to 
have a negative influence on survival. Another important point, is that the 195 included 
patients were recruited from 30 centers during a period of 9 years, corresponding with 
less than one inclusion per center per year. It is well known that high volume is associat-
ed with improved survival.48 Despite this limitation, state of the art results were achieved 
in the surgery alone group. Finally, increased radiation dose as compared to the CROSS 
trial (45 Gy vs. 41.4 Gy, respectively), or differences in radiation technique (convention-
al APPA-technique vs. more sophisticated conformal four-field radiation) might be 
responsible for the relatively high mortality rate. 
Neoadjuvant chemotherapy vs. neoadjuvant chemoradiotherapy 
Although results on neoadjuvant RT or neoadjuvant CT did not show convincing im-
provement of survival, the additive effect of both modalities led to studies on neoadju-
vant CRT. The addition of RT to neoadjuvant CT was compared to neoadjuvant CT 
alone by Stahl et al. and Burmeister et al.49, 50 The first group included 126 patients with 
locally advanced (T3-4NxM0) EGJ ACs (Siewert type 1-3), of whom 119 eligible patients 
were randomized in their POET (PreOperative chemotherapy or radiochemotherapy in 
Esophago-gastric adenocarcinoma Trial) trial. The neoadjuvant CT regimen consisted 
of cisplatin, 5-FU and leucovorin followed by esophagectomy. Patients in the CRT 
group received the same induction CT, followed by concurrent CRT (cisplatin and 
etoposide combined with 30Gy). The trial was closed prematurely due to poor accrual. 
Although not significantly, preoperative CRT improved three-year survival with 20% 
(47.4% compared to 27.7% in the neoadjuvant CT group, p=0.07). Furthermore, pa-
tients in the CRT arm had a significantly higher probability of showing tumor-free 
lymph nodes (64.4% vs. 36.7%, p=0.01) and pathologically complete response (15.6% vs. 
2.0%, p=0.03) at resection. A few comments can be made. First, postoperative mortality 
in the CRT group was more than doubled (10.2% vs. 3.8%). Given the low total radia-
tion dose applied, it seems likely that other factors than radiation therapy were respon-
sible for this relatively high mortality rate. If these deaths could have been prevented, 
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significantly improved three-year survival might have been achieved. For comparison, 
in the CROSS trial, postoperative mortality in the neoadjuvant CRT group was 3.8%.45 
Second, the low radiation dose might have contributed to a relatively low pathologically 
complete response (pCR) rate (15.6% vs. 23% in the CROSS trial), but still significantly 
higher than after CT (2%, p=0.03). Increased radiation dose, as used in the CROSS 
study, might have led to increased pCR rates, which are known to be associated with 
increased survival. Third, the trial closed prematurely and was consequently underpow-
ered. Significant results might have been achieved if more patients were included. Taken 
together, these considerations suggest a more positive conclusion than was made by the 
authors of the trial and seem to point to superiority of neoadjuvant CRT over neoadju-
vant CT.49 
In 2011 Burmeister et al. published the results of a phase II trial that randomized pa-
tients with ACs of the esophagus and EGJ to preoperative CT or preoperative CRT. The 
regimen consisted of cisplatin and 5-FU with or without concurrent radiation therapy 
(35 Gy). Seventy-five patients were included, of whom 66 proceeded to resection. Medi-
an overall survival did not differ significantly between the neoadjuvant CT group and 
the neoadjuvant CRT group (29 months and 32 months, respectively, p=0.83). Never-
theless, R0 resection rate (100% in the neoadjuvant CRT group, 86% in the neoadjuvant 
CT group) and histopathological response rate (<10% viable cells, 31% in neoadjuvant 
CRT group and 8% in the neoadjuvant CT group, p=0.01) favored those receiving neo-
adjuvant CRT. Toxicity and surgical morbidity were not increased by the addition of RT 
to neoadjuvant CT. An explanation for the absence of improved survival in the neoad-
juvant CRT group, despite improvement of two well-known prognostic indicators, 
might be the restricted size of the cohort. Furthermore, increased dose of RT might have 
led to further improvement of survival rates. This study only included patients with 
ACs, but did not distinguish between patients based on location of the tumor.47 
A significant advantage of both neoadjuvant CRT and neoadjuvant CT was found in 
the meta-analysis by Sjoquist et al. To quantify the relative survival benefits of neoadju-
vant CRT compared to neoadjuvant CT, treatment arms of different trials were com-
pared. This indirect comparison showed a trend in favor of neoadjuvant CRT (HR for 
all-cause mortality for neoadjuvant CRT vs. neoadjuvant CT 0.88, 95% CI 0.76-1.01, 
p=0.07).32 A recent meta-analysis of perioperative mortality and postoperative morbidi-
ty in 23 studies on neoadjuvant CT and neoadjuvant CRT in esophageal carcinoma did 
not find a difference in mortality or morbidity between both modalities. Furthermore, 
no increase in mortality or morbidity attributable to neoadjuvant therapy as compared 
to surgery alone was found. Subgroup analysis of neoadjuvant CRT in patients with SCC 
suggested an increased risk of treatment-related mortality compared with surgery alone 
(RR 1.95, 95% CI 1.06-3.60, p=0.032)51, which is in line with the increased postoperative 
mortality rate as reported in the FFCD9901 study.46 
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Definitive chemoradiotherapy vs. neoadjuvant chemoradiotherapy 
plus surgery 
In recent years two randomized trials were reported in literature comparing definitive 
CRT to neoadjuvant CRT plus surgery for esophageal cancer. Results of both studies 
were mainly based on patients with SCC.  
The first study, by Stahl et al., included 172 patients from eleven centers.52 In this tri-
al definitive CRT (without salvage surgery) was compared with neoadjuvant CRT plus 
surgery for ‘locally advanced’ (T3-4N0-1M0) SCCs of the upper and mid third of the 
esophagus. The design of the study is debatable in some points, but this is beyond the 
scope of this chapter. In summary, no difference in overall survival was found. However, 
locoregional failure was less common, and treatment-related death was more common 
in the neoadjuvant CRT plus surgery group. 
In 2007, Bedenne et al. reported the second randomized trial (FFCD 9102) compar-
ing definitive CRT with neoadjuvant CRT plus surgery.53 Patients with resectable T3N0-
1M0 AC or SCC of the esophagus (SCC >90%) were included. All patients were treated 
with neoadjuvant CT (5-FU and cisplatin) combined with 30 Gy RT in two split courses 
or 46 Gy RT given continuously. Subsequently, clinical response was evaluated by ab-
dominal ultrasonography, chest X-ray, esophagography and when possible endoscopic 
ultrasonography. Of all included patients, 259 (58.3%) showed an objective clinical re-
sponse after neoadjuvant CRT. These patients were randomized between surgery or 
definitive CRT (15 Gy or 20 Gy in the split course regimen or the continuous regimen, 
respectively). Both concurrent and sequential CRT were used in the neoadjuvant CRT 
and definitive CRT treatment strategies. The authors considered both treatment modali-
ties as equivalent if there would be a difference in two-year survival rate of less than 10% 
between the two treatment arms. Two-year survival rates for the definitive CRT arm and 
neoadjuvant CRT plus surgery arm were 39.8% and 33.6%, respectively, leading to the 
conclusion that both treatment modalities are equivalent (p=0.03, representing the 
chance that the actual difference is >10%). Conclusions of this trial are limited by a few 
remarkable results. For example, survival rates are substantially lower as compared to 
survival rates as reported in other trials.45 Furthermore, locoregional progression dif-
fered significantly between definitive CRT and neoadjuvant CRT plus surgery (64.3% 
and 40.7%, respectively, p=0.003), but this was not translated in different survival rates. 
Most importantly, the study included mainly patients with SCCs and therefore applica-
bility for patients with EGJ tumors is questionable.53 
In conclusion, the role for definitive CRT in patients with ACs of the EGJ remains 
unclear. However, these studies have addressed an important topic, which is relevant in 
patients with EGJ cancer. Specifically, whether definitive CRT can replace neoadjuvant 
CRT plus surgery in patients with a clinical complete response on CRT. Larger studies 
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comparing definitive CRT versus neoadjuvant CRT plus surgery in this group of pa-
tients are needed. 
Future perspectives 
Classification by location and histology 
Currently, most tumors of the esophagus, regardless of location and histology, are 
staged and treated similarly. However, these different tumor types differ in etiology, 
biology and radiosensitivity. Therefore, when adopting an evidence based approach for 
optimal management, it is important to consider the proportions of tumors for anatom-
ical subsite and histological type enrolled in a study. Absence of proper subgroup anal-
yses often complicates applicability of results to specific groups of patients. Consequent-
ly, current and future trials should focus more on tumor location and histological sub-
type. Given the strong association between geographic location and histology - in the 
West the majority of the patients have AC, while in the East most esophageal cancers are 
SCC – a current three-arm phase III trial in Japan compares two neoadjuvant CT regi-
mens with neoadjuvant CRT in patients with SCC specifically.54 In parallel with this 
Japanese study, the Irish ICORG 10-14 study investigates the effect of neoadjuvant CRT 
vs. neoadjuvant plus adjuvant CT in patients with AC only. These studies will hopefully 
lead to a more biology-directed treatment strategy. 
Dose escalation in definitive chemoradiotherapy 
Definitive concurrent CRT is the treatment of choice for esophageal cancer when a non-
surgical approach is preferred. Driven by the high rates of recurrent or persistent lo-
coregional disease,  current studies in the field of definitive CRT focus on improvement 
of locoregional control. Although previous studies showed increased treatment related 
toxicity and no benefit in terms of locoregional control, recent developments in radia-
tion techniques led to the present Dutch ART DECO (A Randomized Trial of Dose 
Escalation in definitive Chemoradiotherapy for patients with Oesophageal cancer) 
study. This study aims to improve locoregional control after definitive CRT for patients 
with potentially curable esophageal cancer (T1-4N0-3M0 AC or SCC) using a conformal 
multiple field radiation technique. Patients are randomized between standard definitive 
CRT (carboplatin and paclitaxel plus concurrent 50.4 Gy) and an escalated radiation 
dose. Patients in the escalated radiation dose arm receive a daily concomitant boost to 
the primary tumor leading to a total tumor dose of 61.6 Gy. Overall treatment time and 
chemotherapy are similar in both arms. Primary endpoints in this study are local recur-
rence rate, survival and treatment related toxicity. 
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Surgery as needed approach 
By the addition of CT and salvage surgery to definitive RT and the use of neoadjuvant 
CRT in addition to primary surgery, non-operative and operative treatment modalities 
have moved closer towards each other. However, the benefits of adding salvage surgery 
to definitive CRT has never been proven. The high pCR rate in the CROSS study led to 
the imperative to reconsider the necessity of standard esophagectomy in all patients 
after neoadjuvant CRT. Therefore, we propose a “surgery as needed” approach after 
completion of neoadjuvant CRT for patients with potentially curable esophageal cancer. 
In this approach, patients will undergo close surveillance after completion of neoadju-
vant CRT according to CROSS. Surgical resection will be offered only to patients in 
whom a locoregional recurrence is highly suspected or proven, without signs of distant 
metastases. Such an organ-preserving strategy would have great advantages, but only if 
long term survival would be comparable to that of the neoadjuvant chemoradiotherapy 
followed by standard surgery approach. As a first step towards an organ-preserving 
strategy, we are currently performing the multicenter phase II feasibility preSANO (Sur-
gery As Needed approach in Oesophageal cancer) study to determine the accuracy by 
which residual disease after neoadjuvant chemoradiotherapy can be detected. After 
completion of neoadjuvant CRT, patients will undergo two clinical response evaluations 
(CRE). The first CRE (CRE-I) consists of endoscopy with (random) conventional muco-
sal biopsies of the primary tumor site and of any other suspected lesions in the esopha-
gus and radial endo-ultrasonography (EUS) for measurement of tumor thickness and -
area. Patients who are found to be clinically complete responders (i.e. those patients in 
whom no locoregional or disseminated disease can be proven by histology) will be of-
fered a postponed surgical resection, which will be scheduled approximately six weeks 
after CRE-I (i.e. approximately 12-14 weeks after completion of neoadjuvant CRT). In 
the two weeks preceding the postponed surgical resection a second clinical response 
evaluation (CRE-II) will be planned, which will include a whole body PET-CT, plus the 
investigations as performed at CRE-I. If this preSANO study shows that residual tumor 
can be predicted reliably, a trial (SANO trial) comparing neoadjuvant chemoradiother-
apy plus standard surgery with neoadjuvant chemoradiotherapy plus ‘surgery as needed’ 
will be conducted.* 
 
*results of the preSANO trial are described in chapter 14.  
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Table 1. Randomized controlled trials – Definitive concurrent CRT vs. definitive RT 
First Author Year Period N Tumor CRT/RT Survival,  HR  (95% 
CI) (RT vs CRT) 
Andersen et al. 55 1984 1977-1981 82 SCC CRT: Ble+55Gy 
RT: 63Gy 
0.94 (0.59- 1.50) 
Araujo et al. 56 1991 1982-1985 59 SCC CRT: 5-FU, Ble, Mit+50Gy 
RT: 50Gy 
0.64 ( 0.36- 1.14 ) 
Cooper et al. 16 1999 1985-1990 123 SCC/AC CRT: 5-FU+50Gy 
RT: 64Gy 
0.59 ( 0.45- 0.77 ) 
Earle et al. 57 1980 N/A 77 SCC CRT: Ble+50-60Gy 
RT: 50-60Gy 
1.43 ( 0.81- 2.54 ) 
Gao et al. 58 2002 N/A 81 SCC CRT: Cis+60Gy 
RT: 60Gy 
0.79 ( 0.46- 1.37 ) 
Kaneta et al. 59  1997 1994-1996 24 SCC CRT: Cis+70-72Gy 
RT: 70-72Gy 
0.75 ( 0.23- 2.40 ) 
Li et al. 60 2000 N/A 96 SCC/AC CRT: Cis, 5-FU+50-60Gy 
RT: 60-70Gy 
0.65 ( 0.43- 1.00 ) 
Roussel et al. 61 1994 N/A 221 SCC CRT: Cis+40Gy 
RT: 40Gy 
0.82 ( 0.62- 1.09 ) 
Slabber et al. 62 1998 1991-1995 70 SCC CRT: Cis, 5-FU+40Gy 
RT: 40Gy 
0.83 ( 0.50- 1.40 ) 
Zhang et al. 63 1984 N/A 99 N/A CRT: Ble+39-73Gy 
RT: 39-73Gy 
0.63 ( 0.39- 1.01 ) 
Zhu et al. 64 2000 N/A 66 SCC CRT: Car+60Gy 
RT: 60Gy 
0.62 ( 0.36- 1.06 ) 
5-FU: 5-fluorouracil, AC: adenocarcinoma, Ble: bleomycin, Car: carboplatin, CI: confidence interval, Cis: 
cisplatin, CRT: chemoradiotherapy, Gy: Gray (J/kg), HR: hazard ratio, Mit: mitomycin, N/A: not available, N: 
number of patients, RT: radiotherapy, SCC: squamous cell carcinoma (reprinted with permission and adapted 
from Wong et al.18) 
 
Table 2.  Randomized controlled trials – Neoadjuvant RT plus surgery vs. surgery alone 
First Author Year Period N Tumor RT Survival (RT + S vs S 
alone) 
Launois et al. 26 1981 1973- 1976 107 SCC 40Gy/8-12d 1.01 (0.67- 1.53) 
Gignoux et al. 27 1988 1976- 1982 229 SCC 33Gy/10 frc/28d 1.02 (0.78- 1.33) 
Wang  et al. 28 1989 1977-1988 418 SCC 40Gy/10 frc/12d 0.81 (0.65- 1.01) 
Arnott et al. 29 1992 1979- 1983 176 SCC/AC 20Gy/10 frc/14d 1.19 (0.87- 1.62) 
Nygaard et al. 30 1992 1983- 1988 108 SCC 35Gy/20 frc/ 28d 0.60 (0.40- 0.91) 
AC: adenocarcinoma, d: days, frc: fractions, Gy: Gray (J/kg), N: number of patients, RT: radiotherapy, S: 
surgery, SCC: squamous cell carcinoma (reprinted with permission and adapted from Arnott et al.25) 
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Table 3. Randomized controlled trials – Neoadjuvant CRT plus surgery vs. surgery alone 
First Author Year Period N Tumor CRT  pCR Survival,  HR  (95% 
CI) (CRT + S vs S) 
Walsh et al. 35 1990 N/A 61 SCC CT: Cis, 5-FU 
RT: 40Gy/ 15 frc/ 21d 
Con  0.74 (0.46-1.18) 
Nygaard et al. 30 1992 1983-1988 106 SCC CT: Cis, Ble 
RT: 35Gy/20 frc/ 28d 
Seq  0.76 (0.45– 1.28) 
Apinop et al. 33 1994 1986-1992 69 SCC CT: Cis, 5-FU 
RT: 40Gy/20 frc/ 28d 
Con  0.80 (0.48– 1.34) 
Le Prise et al. 34 1994 1988-1991 86 SCC CT: Cis, 5-FU 
RT: 20Gy/10 frc/ 10d 
Seq 9.8% 0.85 (0.50– 1.46) 
Walsh et al. 36 1996 1990-1995 113 AC CT: Cis, 5-FU 
RT: 40Gy/ 15 frc/ 21d 
Con 25% 0.58 (0.38– 0.88) 
Bosset et al. 37 1997 1989-1995 293 SCC CT: Cis 
RT: 37Gy/10 frc/ 14d 
Seq 21% 0.96 (0.73– 1.27) 
Urba et al. 38 2001 1989-1994 100 SCC/AC CT: Cis, 5-FU, Vinb 
RT: 45Gy/30 frc/ 21d 
Con 28% 0.74 (048– 1.12) 
Lee et al. 39 2004 1999-2002 101 SCC/AC CT: Cis, 5-FU 
RT: 45.6Gy/38 frc/28d 
Con 43% 0.88 (0.48– 1.62) 
Burmeister et al. 40 2005 1994- 2000 256 SCC/AC CT: Cis, 5-FU 
RT: 35Gy/15 frc/21d 
Con 16% 0.94 (0.70– 1.26) 
Tepper et al. 41 2008 1997-2000 56 SCC CT: Cis, 5-FU 
RT: 50.4Gy/28 frc/35d 
Con 40% 0.40 (0.18– 0.87) 
Lv et al. 42 2010 2000-2009 160 SCC CT: Cis, Pac 
RT: 40Gy/20 frc/28d 
Con  0.55 (0.36– 0.84) 
Van Hagen et al. 45 2012 2004-2008 366 SCC/AC CT: Cis, Pac 
RT: 41.4Gy/23 frc/35d 
Con 29% 0.66 (0.50– 0.87) 
Mariette et al. 46 2014 2000-2009 195 SCC/AC CT: Cis, 5-FU 
RT: 45Gy/25 frc/35d 
Con 33.3% 0.92 (0.63– 1.34) 
5-FU: 5-fluorouracil, AC: adenocarcinoma, Ble: bleomycin, CI: confidence interval, Cis: cisplatin, Con: con-
current, CRT: chemoradiotherapy, CT: chemotherapy, d: days, frc: fractions, Gy: Gray (J/kg), HR: hazard 
ratio, N: number of patients, Pac: paclitaxel S: surgery, pCR; pathologically complete response, RT: radiother-
apy, SCC: squamous cell carcinoma, seq: sequential, Vinb: vinblastine (reprinted with permission and adapted 
from Sjoquist et al.32) 
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Abstract 
Background 
The primary aim of this study was to compare survival from neoadjuvant chemoradio-
therapy plus surgery (NCRS) versus neoadjuvant chemotherapy plus surgery (NCS) for 
the treatment of esophageal or junctional adenocarcinoma. The secondary aims were to 
compare pathological effects, short-term mortality and morbidity, and to evaluate the 
effect of lymph node harvest upon survival in both treatment groups. 
Methods 
Data were collected from 10 European centers from 2001 to 2012. Six hundred and eight 
patients with stage II or III esophageal or esophago-gastric junctional adenocarcinoma 
were included; 301 in the NCRS group and 307 in the NCS group. Propensity score 
matching and Cox regression analyses were used to compensate for differences in base-
line characteristics. 
Results 
NCRS resulted in significant pathological benefits with more ypT0 (26.7% versus 5%; 
P<0.001), more ypN0 (63.3% versus 32.1%; p<0.001), and reduced R1/2 resection mar-
gins (7.7% versus 21.8%; p<0.001). Analysis of short-term outcomes showed no statisti-
cally significant differences in 30-day or 90-day mortality, but increased incidence of 
anastomotic leak (23.1% versus 6.8%; p<0.001) in NCRS patients. There were no statisti-
cally significant differences between the groups in 3-year overall survival (57.9% versus 
53.4%; hazard ratio [HR]=0.89, 95% CI 0.67-1.17, p=0.391) nor disease-free survival 
(52.9% versus 48.9%; HR=0.90, 95% CI 0.69-1.18, p=0.443). The pattern of recurrence 
was also similar (p=0.660). There was a higher lymph node harvest in the NCS group 
(27 versus 14; p<0.001), which was significantly associated with a lower recurrence rate 
and improved disease free survival within the NCS group. 
Conclusion 
The survival differences between NCRS and NCS maybe modest, if present at all, for the 
treatment of locally advanced esophageal or junctional adenocarcinoma. Future large-
scale randomized trials must control and monitor indicators of the quality of surgery, as 
the extent of lymphadenectomy appears to influence prognosis in patients treated with 
NCS, from this large multi-center European study. 
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Introduction 
Multimodality treatment of esophageal cancer is the standard of care in Western cen-
ters, although surgery remains the primary curative modality. Two neoadjuvant ap-
proaches have been adopted. The first is neoadjuvant chemoradiotherapy, based in 
recent years on the CROSS regimen which resulted in a 5-year survival advantage of 
14% in comparison with surgery alone.1, 2 An alternative option is perioperative or pre-
operative chemotherapy using the MAGIC or OEO2 protocol, which showed, respec-
tively, 5-year survival improvements of 13% and 6% compared with surgery alone.3, 4 
The maximum benefit in the CROSS-trial was observed in squamous cell carcinoma, 
with highly significant (hazard ratio [HR] =0.48; 95% CI 0.28–0.83; p=0.009) benefit 
compared with surgery alone, in comparison with adenocarcinoma, where the benefit 
was more modest (HR=0.73; 95% CI 0.55–0.98; p=0.037), but the benefit of neoadjuvant 
chemoradiotherapy was consistent across subgroups, without any significant interaction 
identified.1, 2 Moreover, two small underpowered randomized trials comprising 119 and 
75 patients with esophageal adenocarcinoma did not show a significant difference in 
survival between neoadjuvant chemoradiotherapy plus surgery versus neoadjuvant 
chemotherapy plus surgery.5, 6 The recently reported NeoRES trial in a mixed cohort of 
181 patients with esophageal adenocarcinoma and squamous cell carcinoma, showed 
pathological benefits without any changes in survival associated with the addition of 
radiotherapy to neoadjuvant chemotherapy.7 
Therefore, the optimal multimodality treatment for esophageal adenocarcinoma re-
mains undetermined and is the subject of investigation in the more recently initiated 
Neo-AEGIS trial, which randomizes patients (n=574) with adenocarcinoma of the 
esophagus or esophago-gastric junction to the CROSS or MAGIC regimens, and is likely 
to be reported in 2021.8 
The primary aim of the present retrospective multicenter European study was to 
compare survival from neoadjuvant chemoradiotherapy plus surgery (NCRS) versus 
neoadjuvant chemotherapy plus surgery (NCS) for the treatment of adenocarcinoma of 
the esophagus or esophago-gastric junction. The secondary aims were to compare 
pathological effects, short-term mortality and morbidity and to evaluate the effect of 
lymph node harvest upon survival in both treatment groups. The current retrospective 
study described herein was aimed to reach a sample size similar to the ongoing Neo-
AEGIS trial.8 
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Methods 
Datasets 
Consecutive patient data were retrieved from 10 prospectively maintained surgical Eu-
ropean single-center databases; (i) Erasmus MC—University Medical Centre, Rotter-
dam, Netherlands; (ii) Academic Medical Centre, Amsterdam, Netherlands; (iii) VU 
Medical Centre, Amsterdam, Netherlands; (iv) Catharina Hospital, Eindhoven, Nether-
lands; (v) University Medical Centre, Groningen, Netherlands; (vi) Radboud University 
Nijmegen Medical Centre, Nijmegen, Netherlands; (vii) Rijnstate Hospital, Arnhem, 
Netherlands; (viii) St James’s Hospital, Dublin, Ireland; (ix) Imperial College London, 
UK; and (x) Oxford University Hospitals, Oxford, UK. The datasets have been external-
ly validated and are maintained as part of their respective countries national cancer 
audits. All patients with adenocarcinoma of the NCRS-arm within the CROSS-trial were 
included.1, 2 Management plans and allocation of neoadjuvant therapy were decided 
upon at multi-disciplinary tumor boards at all centers participating in this study. The 
study period was from 2001 to 2012 with patient follow-up until December 2015.  
Inclusion criteria 
The study included patients with stage II or III esophageal or esophagogastric junctional 
(Siewert type I and II) adenocarcinoma treated with neoadjuvant chemoradiotherapy 
plus surgery (CROSS regimen; NCRS group)1, 2 or peri-/preoperative chemotherapy plus 
surgery (mainly MAGIC, OEO2 or OEO5 regimens; NCS group) (supplementary Ap-
pendix).3, 4, 9 
Exclusion criteria  
The study did not include (i) patients with esophageal squamous cell carcinoma; (ii) 
patients with Siewert type III adenocarcinoma; and (iii) patients treated with definitive 
chemoradiotherapy. Furthermore, patients who underwent exploratory surgery but did 
not undergo surgical resection of the tumor due to tumor progression were excluded, as 
data were not routinely collected as part of the datasets included.  
Clinical staging and follow-up 
The approach to clinical pretreatment staging used a combination of endoscopic ultra-
sound (EUS), computerized tomography (CT) and on demand CT-positron emission 
tomography (CT-PET). EUS was used in 98.3% of patients in the NCRS group and 
90.2% of patients in the NCS group. In all centers, after surgery patients were reviewed 
every 3 months during the first year. In the second year, follow-up took place every 6 
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months, and annually thereafter until 5 years. In cases of suspected recurrence, thoraco-
abdominal CT, PET-CT, and/or upper gastrointestinal endoscopy were performed. 
Histological, cytological, or unequivocal radiological proof was required before a diag-
nosis of recurrence was made. The first site of recurrence was used to define whether 
loco-regional, distant, or mixed relapse had occurred. Median follow-up was 33.5 
months (range 0.03–177.8 months), with 46 patients having follow-up of less than 3 
years during the study period; 29 (15.8%) in the NCS group and 17 (11.8%) in the NCRS 
group. 
Outcomes 
The primary outcome measure was 3-year overall survival. Secondary outcomes includ-
ed: 3-year disease-free survival; pattern of recurrence (within 3-years); pathological T-
stage and N-stage (TNM7)10; tumor regression grade (TRG) as reported by Chirieac et 
al.11; 30-day and 90-day mortality; and 30-day morbidity, specifically anastomotic and 
chyle leak, pulmonary and cardiac complications, and reoperation. The time for overall 
survival was defined from date of surgery to date of death or date of last follow-up. The 
time for disease-free survival was defined from date of surgery and the earliest occur-
rence of disease progression resulting from loco-regional recurrence or distant dissemi-
nation, or death from any cause.2, 12 
Statistical analysis 
Data are presented as prevalence (percentage), median (range), and for survival as me-
dian (95% CI). Continuous variables are expressed as mean +/- standard deviation or 
median (range) and categorical variables as percentage. A Mann–Whitney test was used 
for intergroup comparisons of continuous variables, whereas a χ2 test or Fisher’s exact 
test was used to compare categorical data. Overall and disease-free survivals were esti-
mated using the Kaplan–Meier method. The log rank test was used to compare survival 
curves. Missing data were at random and, therefore, only available data were analyzed, 
in multivariate regression analysis list wise deletion was used. 
Propensity matching 
In order to reduce the effects of potential confounding factors in the comparisons of 
short and mid-term outcomes between groups, a propensity score (PS) was calculated to 
create well-balanced groups. The PS was estimated using a multivariable logistic regres-
sion model, with the treatment groups as the dependent variables and potential con-
founders as covariates. The following  confounders were included in the propensity 
matching: age≥70 years; male gender; American Society of Anesthesiologists (ASA) 
grade; clinical tumour (cT) stage; and clinical nodal (cN) positivity or negativity. All 
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patients in the NCS group were matched 1:1 to patients in the NCRS group according to 
the propensity score using the global optimum method.13 
Cox regression analysis 
Year of surgery and age as continuous variables were not included in the PS matching, 
as this would have further reduced the dataset dramatically to maintain a good level of 
matching (fewer than 10 patients per group, and neither demonstrated multivariate 
associations with endpoints). Therefore, overall- and disease-free survivals were also 
compared between groups using a multivariable Cox regression model. In this model, 
adjustment was performed for the same characteristics as in the PS approach, with the 
addition of year of surgery and age as continuous variable.14 
Risk-adjusted cumulative sum (RA-CUSUM) curve analysis for the effect of 
lymph node harvest on survival 
RA-CUSUM analysis was used to determine a lymph node harvest threshold that affect-
ed overall survival in each of NCRS and NCS groups.14 The threshold was defined as the 
minimum lymph node harvest for an alteration in overall survival relationships. Risk 
prediction models for overall survival were created using regression models. Potential 
risk factors included in the models were: age, male gender, ASA grade, and clinical T 
and N stages. The risk prediction models were used to calculate the predicted probabil-
ity of survival in each case. For the CUSUM curve, the sum of all events was compared 
with the expected sum of events according to the risk-adjustment model, using the 
CUSUM equation Si=Si-1+( Σ i- ΣR); S0=0: Si is the cumulative sum, Σ i the sum of events 
at procedure number i, and ΣR the sum of expected events at procedure number i. The 
clinical impact of the threshold was determined by comparing the survival and recur-
rence rates before and after the change-point in overall survival. To ascertain whether 
the change-points observed in the CUSUM curves were reliable, we bootstrapped each 
curve with 1000 iterations to identify the confidence level (CL) of the change point. We 
computed the CUSUM values at the change point (n=1000). We hypothesized that a 
reliable change point would have a CUSUM value that was greater than at least 95% of 
the simulated CUSUM values (CL>95%). 
CUSUM curves were computed using Excel (Excel for Mac 2011, version 14.1.4, Mi-
crosoft Corporation, Redmond, WA, USA). For the remaining statistical analysis, SPSS 
software was used (Statistical Package for the Social Sciences software, Version 22, SPSS, 
Chicago, IL, USA). 
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Results 
Over the 12-year study period 608 patients were included: 301 in the NCRS group and 
307 in the NCS group. The NCRS group consisted of patients from the centers, which 
participated in the CROSS-trial1, 2 and St James’s Hospital, Dublin, whereas NCS pa-
tients were provided by Imperial College in London, Oxford University Hospitals in 
Oxford and St James’s Hospital in Dublin. During the study period, no patients with 
esophageal adenocarcinoma from Imperial College London or Oxford University hospi-
tal received neoadjuvant chemoradiotherapy. Within the Dutch cohort, during the study 
period, less than 3% of patients could not undergo radiotherapy (e.g. due to history of 
radiotherapy) or had lymph nodes outside the maximum radiation field, received neo-
adjuvant chemotherapy, and were excluded from the study. From the NCS group, the 
number of patients receiving MAGIC/ECF regime was 51 (16.6%), OEO2/CF 138 
(45%), OEO5/ECX was 87 (28.3%), EOX 21 (6.8%), and other regimes 10 (3.3%). After 
propensity matching, 442 patients were included in the analysis; 221 in the NCRS group 
and 221 in the NCS group.  
Comparison of patient demographics and treatment strategies (Table 1) 
Analysis of patient demographics before matching, showed a significantly lower median 
age and greater numbers of patients with ASA I in NCRS versus NCS group. After pro-
pensity matching, there were no significant differences between the groups in age, pa-
tients aged 70 years or older, distribution of patients by ASA grade, WHO performance 
status and clinical T- and N-stages. After matching, there were significantly more 
transhiatal resections (61.5% versus 0.5%; p<0.001) and significantly fewer transthoracic 
resections (36.7% versus 94.6%; p<0.001) for NCRS versus NCS. 
Comparison of tumor pathology and short-term outcomes (Tables 2 and 3) 
Both before and after matching, utilization of chemoradiotherapy was associated with 
significantly more down-staging. This is reflected in the matched comparison by signifi-
cantly increased incidence of ypT0 (26.7% versus 5%; p<0.001), ypN0 (63.3% versus 
32.1%; p<0.001) in the NCRS group compared with the NCS group. Neoadjuvant 
chemoradiotherapy was also associated with a significant reduction in the incidence of 
R1/2 resection margins (7.7% versus 21.8%; p<0.001). The NCRS group had a signifi-
cantly lower median number of harvested lymph nodes (14 versus 27; p<0.001) and 
positive lymph nodes (0 versus 2; p<0.001) in comparison with the NCS group. After 
matching, analysis of short-term outcomes showed no significant differences in 30-
daymortality (4.1% versus 1.4%, p=0.140) or 90-day mortality (5.9% versus 2.3%) and 
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morbidity apart from an increased incidence of anastomotic leak (23.1% versus 6.8%; 
p<0.001) in the NCRS group.  
Comparison of survival and recurrence, propensity matched (Table 3 and Figure 
1) 
Unmatched survival analysis suggested that NCRS was associated with a small im-
provement in 3-year overall survival (57.8% versus 49.8%; HR 0.79, 95% CI 0.63–1.00; 
p=0.052) (Figure 1A: log rank test p=0.047). There was no significant difference in 3-
year disease-free survival between unmatched groups (52.8% versus 46.9%; HR 0.85; 
95% CI 0.68–1.07; p=0.163). After matching, observed differences between the groups in 
3-year overall (57.9% versus 53.4%; HR 0.89, 95% CI 0.67–1.17, p=0.391) (Figure 1B) or 
disease-free survival (52.9% versus 48.9%; HR 0.90, 95% CI 0.69–1.18, p=0.443) were 
small and statistically non-significant. Following matching, there were no significant 
differences between the groups in the pattern of recurrence (p=0.660) (Table 3). 
Comparison of survival and recurrence, Cox regression (Table 4) 
Cox regression analysis including year of treatment and age, as continuous variables did 
not show significant differences between NCRS and NCS in 3-year overall (HR 0.86; 
95% CI 0.66–1.11; p=0.232) and 3-year disease-free survival (HR 0.91; 95% CI 0.71–
1.16; p=0.459) (Table 4).  
RA-CUSUM analysis of lymph node harvest (Figure 2) 
In the NCRS group, RA-CUSUM analysis showed that lymph node harvest did not 
affect survival or recurrence with no identifiable change-point in the RA-CUSUM curve 
(Figure 2A). In the NCS group, lymph node harvest significantly influenced survival and 
recurrence. The mean change-point in overall survival was seen to lie between 22 and 52 
lymph nodes (confidence level 95.4%) (Figure 2B). At a lymph node harvest threshold of 
52 lymph nodes, there were significant improvements in disease-free survival (22–36 
months; p=0.028), and overall recurrence (47.1%–15.9%; p<0.001). However, the im-
provement in overall survival remained non-significant (27–38 months; p=0.171). 
Discussion 
The present study showed no significant differences in overall or disease-free 3-year 
survival or pattern of recurrence between NCRS and NCS groups after propensity 
matching and Cox regression analysis. This is despite neoadjuvant chemoradiotherapy 
conferring significant pathological benefits in terms of tumor and nodal down staging 
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and tumor regression grade. Lymph node harvest uniquely in the NCS group was shown 
to be significantly associated with disease-free survival and recurrence with an optimal 
threshold between 22 and 52 lymph nodes removed. Although the incidence of anasto-
motic leak was higher in the NCRS group, in-hospital mortality and other major post-
operative complications were similar. 
This study is the largest available analysis that compares NCRS with NCS for the 
treatment of esophageal and junctional adenocarcinoma. Despite higher rates of ypT0, 
ypN0, and R0 in the NCRS group, only small nonsignificant survival differences in 
overall and disease-free 3-year survival were evident. This might be partially explained 
by a non-significant increase in postoperative mortality rate in the NCRS group. This 
apparent paradox of significant down-staging at primary and nodal sites, yet no survival 
benefit, was also evident in three small underpowered randomized trials.5-7 Taken to-
gether, these results suggest that survival differences between NCRS and NCS may be 
relatively modest, if present at all, and suggest that a large sample size is required for 
prospective RCTs that compare these modalities. 
One intriguing element of the analysis is that the extent of lymphadenectomy may 
have impacted on disease-free survival and cancer recurrence exclusively in the NCS 
group. The absence of an association between lymph node harvest and survival in the 
NCRS group is consistent with the analysis of patients from the CROSS trial and further 
non-randomized data, which found that the total number of resected nodes was associ-
ated with survival in the surgery-alone group but not in the NCRS group.15, 16 These 
results suggest that regional control of esophageal adenocarcinoma is essential and 
might either be achieved through chemotherapy with radical lymphadenectomy or 
neoadjuvant chemoradiotherapy with limited lymphadenectomy.  
It was not possible to match for surgical technique as only one patient had 
transhiatal resection in the NCS group. At the centers where both transhiatal and trans-
thoracic esophagectomies were performed, no significant difference in survival between 
the two techniques has been reported.17 The difference in technique may be responsible 
for the observed differences in lymph node harvest between the NCRS and NCS groups, 
in line with results from randomized controlled trials.17-19 Moreover, in the CROSS-trial 
lymph node, retrieval after neoadjuvant chemoradiotherapy appeared to be lower than 
after surgery alone (14 versus 18 lymph nodes, respectively), even when using the same 
surgical technique.16 Other authors have also reported that chemoradiotherapy reduces 
lymph node harvest from within the radiotherapy field, e.g. in rectal cancer.20, 21 The 
median number of lymph nodes retrieved in the NCRS group was 14. Consequently, in 
the present study, it was not possible to examine the added value of radical lymphade-
nectomy to neoadjuvant chemoradiotherapy on survival for esophageal adenocarcino-
ma, and this aspect will be of great interest in future trials such as Neo-AEGIS. The 
analysis in our study indicates that the quality of surgery, using lymph node retrieval as 
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a proxy for quality and extent of lymphadenectomy, remains an important prognostic 
factor affecting the outcome from multimodality treatment of esophageal adenocarci-
noma. We have previously shown that assurance of surgical quality within randomized 
controlled trials for the treatment of esophago-gastric cancer is an important aspect of 
study design and can affect variation in lymph node harvest and mortalit.22 Neverthe-
less, a recent analysis of the MAGIC trial has also shown that the presence of lymph 
node metastases after chemotherapy is an independent predictor of overall survival, 
although authors did not include lymph node count in the multivariate analysis.23 
Analysis of short-term outcomes showed no significant difference between NCRS 
and NCS apart from an increased incidence of anastomotic leak in the NCRS group. 
There was a non-significant increase in 30-day (4.1% versus 1.4%; p=0.140) and 90-day 
mortality (5.9% versus 2.3%; p=0.090) in the NCRS group. The centers involved in this 
study were high volume units, with all procedures performed by high volume surgeons, 
thus minimizing the effect of surgeon and hospital volume on short-term outcomes.24-26 
A significantly higher proportion of patients in the NCRS group had transhiatal resec-
tion with cervical esophageal anastomosis, which is known to be associated with a high-
er leak rate than thoracic anastomosis.27 Theoretically, radiotherapy might affect perfu-
sion of the gastric tube and thus anastomotic healing; this notwithstanding, no differ-
ences in anastomotic leak were found between the NCRS and surgery alone groups of 
the CROSS-trial. This effect is currently being further explored in an ongoing Dutch 
randomized trial comparing cervical with thoracic anastomosis after neoadjuvant 
chemoradiation.28 
There are limitations that must be considered in interpreting the results of this anal-
ysis, foremost its design as a retrospective, observational study. The propensity-matched 
analysis controlled for important factors that can influence long-term survival and can-
cer recurrence. However, both ASA-classification and cN status are subjective parame-
ters in their clinical application that might have influenced the matching process. There 
may have been a small degree of selection bias within the Dutch cohort during the study 
period as less than 3% of patients could not undergo radiotherapy (e.g. due to history of 
radiotherapy) or had suspected lymph nodes outside the maximum radiation field, 
therefore, underwent neoadjuvant chemotherapy, and were excluded from the study. 
However, after matching 84.6% and 68.8% of patients in both groups had cT3 and cN 
positive staging, respectively, which is representative of the esophageal cancer popula-
tion in Europe. Nevertheless, it was not possible to examine the benefits of NCS and 
NCRS separately for early and advanced disease because of the sample size of matched 
patients. Furthermore, there are inevitably other confounding variables including heter-
ogeneity in surgical approach and type of chemotherapy used in the NCS group that 
may have varied between the groups. Moreover, the propensity matching reduced the 
sample size, resulting in less statistical power compared with the recently initiated Neo-
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AEGIS trial, and especially impeded correction for year of treatment and age as contin-
uous variables. To overcome this limitation, data were also analyzed using Cox regres-
sion analysis. During the study period, there was some variation in the definition of 
complications, with the international consensus only recently published.29 However, 
anastomotic leak was defined similarly in all centers with clinical or radiological evi-
dence of leak and postoperative contrast evaluation of the anastomosis was standard of 
care in all participating centers. Unfortunately, data on toxicity of chemoradiotherapy 
and chemotherapy were not available in all participating centers. Patients were selected 
based on whether they underwent surgical resection (and not on whether they were 
planned to undergo NCS or NCRS), which impeded an intention-to-treat analysis. 
Therefore, patients not surgically resected due to disease progression, complete clinical 
response or patient physiological status were not included in this study. In the CROSS 
trial, 10% of patients in the multimodality arm did not undergo surgical resection due to 
toxicity or tumor progression, whereas in the MAGIC trial and OEO2 trial this was 17% 
and 14%, respectively.3, 4 Finally, follow-up was not sufficient to compare long-term (≥5-
year) survival between NCRS and NCS, further emphasizing the need for publication of 
the long-term results from the MAGIC-trial. 
In conclusion, this multi-center European study suggests that any prognostic differ-
ences between neoadjuvant chemoradiotherapy plus surgery and neoadjuvant chemo-
therapy plus surgery for the treatment of locally advanced esophageal and junctional 
adenocarcinoma are likely to be small. Our study suggests that loco-regional tumor 
control is of great importance, and can either be achieved through neoadjuvant chemo-
therapy with extended lymphadenectomy or concurrent chemoradiotherapy with lim-
ited lymphadenectomy. The benefit, if any, of extended lymphadenectomy after neoad-
juvant chemoradiotherapy has not been addressed by this study and remains unclear. 
Therefore, future randomized trials evaluating multimodality treatment of esophageal 
adenocarcinoma must not only comprise an adequate sample size, but must also control 
and monitor quality of surgery during the trial. We would like to emphasize that this 
retrospective study does not provide a definitive answer to the unsolved question of the 
comparative benefits on NCS and NCRS in esophageal adenocarcinoma but supports 
the importance of the ongoing NeoAEGIS trial and its surgical quality measures. 
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Table 1. Comparative analysis of patient demographics and surgical techniques from unmatched and propen-
sity matched groups. 
 Before Matching After Matching 
 NCRS 
(n=301) (%) 
NCS 
(n=307) (%) 
p-value NCRS 
(n=221) (%) 
NCS 
(n=221) (%) 
p-value 
Age (median (range)) 61.3 (19 – 83) 63.9 (30 – 82) 0.013 62 (19 – 83) 63.3 (30 – 82) 0.936 
Age ≥ 70 66 (21.9) 88 (28.7) 0.056 50 (22.6) 50 (22.6) >0.999 
Male 258 (85.7) 252 (82.1) 0.224 192 (86.9) 192 (86.9) >0.999 
ASA* 
  I 
  II 
  III 
  IV 
 
54 (19.4) 
190 (68.1) 
35 (12.5) 
0 (0) 
 
18 (5.9) 
214 (69.7) 
74 (24.1) 
1 (0.3) 
 
<0.001 
 
16 (7.2) 
173 (78.3) 
32 (14.5) 
0 (0) 
 
16 (7.2) 
173 (78.3) 
32 (14.5) 
0 (0) 
 
>0.999 
WHO performance 
status* 
  0 
  1 
  2 
 
 
252 (83.7) 
47 (15.6) 
2 (0.7) 
 
 
113 (89) 
14 (11) 
0 (0) 
 
 
0.293 
 
 
181 (81.9) 
38 (17.2) 
2 (0.9) 
 
 
61 (88.4) 
8 (11.6) 
0 (0) 
 
 
0.381 
cT stage* 
  1 
  2 
  3 
  4 
 
10 (3.4) 
43 (14.4) 
236 (79.2) 
9 (3) 
 
6 (2) 
36 (11.7) 
248 (80.8) 
17 (5.5) 
 
0.120 
 
3 (1.4) 
23 (10.4) 
187 (84.6) 
8 (3.6) 
 
3 (1.4) 
23 (10.4) 
187 (84.6) 
8 (3.6) 
 
>0.999 
cN stage* 
  Negative 
  Positive 
 
108 (35.9) 
193 (64.1) 
 
93 (30.3) 
214 (69.7) 
 
0.17 
 
69 (31.2) 
152 (68.8) 
 
69 (31.2) 
152 (68.8) 
 
>0.999 
Operation 
  Transhiatal 
  Transthoracic 
  3-Stage 
 
168 (55.8) 
127 (42.2) 
6 (2) 
 
1 (0.3) 
284 (92.5) 
22 (7.2) 
 
<0.0001 
 
136 (61.5) 
81 (36.7) 
4 (1.8) 
 
1 (0.5) 
209 (94.6) 
11 (5) 
 
<0.001 
NCRS, neoadjuvant chemoradiotherapy and surgery. NCS, neoadjuvant chemotherapy and surgery. ASA, 
American Society of Anesthesiologists classification. *Missing data 
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Table 2. Comparative analysis of tumor pathology from unmatched and propensity matched groups.  
 Before Matching After Matching 
 NCRS 
(n= 301) (%) 
NCS 
(n=307) (%) 
p-value NCRS 
(n=221) (%) 
NCS 
(n=221) (%) 
p-value 
Tumour location* 
  Proximal 
  Middle 
  Distal / EGJ 
 
1 (0.3) 
13 (4.4) 
284 (95.3) 
 
0 (0) 
6 (2) 
300 (98) 
 
0.141 
 
1 (0.5) 
9 (4.1) 
210 (95.5) 
 
0 (0) 
5 (2.3) 
216 (97.7) 
 
0.329 
pT stage* 
  0 
  I 
  2 
  3 
  4 
 
85 (28.2) 
45 (15) 
61 (20.3) 
108 (35.9) 
2 (0.7) 
 
16 (5.2) 
27 (8.8) 
76 (24.8) 
174 (56.9) 
13 (4.2) 
 
<0.001 
 
59 (26.7) 
32 (14.5) 
49 (22.2) 
79 (35.7) 
2 (0.9) 
 
11 (5) 
19 (8.6) 
58 (26.2) 
125 (56.6) 
8 (3.6) 
 
<0.001 
pN stage 
  0 
  1 
  2 
  3 
 
189 (62.8) 
82 (27.2) 
21 (7) 
9 (3) 
 
98 (31.9) 
92 (30) 
57 (18.6) 
60 (19.5) 
 
<0.001 
 
140 (63.3) 
65 (29.4) 
11 (5) 
5 (2.3) 
 
71 (32.1) 
76 (34.4) 
41 (18.6) 
33 (14.9) 
 
<0.001 
Mandard TRG* 
  1 
  2 
  3 
  4/5 
 
85 (28.5) 
73 (24.5) 
80 (26.8) 
60 (20.1) 
 
14 (5.4) 
19 (7.4) 
46 (17.8) 
178 (68.9) 
 
<0.001 
 
59 (27.1) 
58 (26.6) 
62 (28.4) 
39 (17.9) 
 
11 (5.6) 
12 (6.1) 
32 (16.3) 
141 (71.9) 
 
<0.001 
Resection margin* 
  R0 
  R1/2 
 
278 (92.4) 
23 (7.6) 
 
220 (77.5) 
64 (22.5) 
 
<0.001 
 
204 (92.3) 
17 (7.7) 
 
165 (78.2) 
46 (21.8) 
 
<0.001 
LN harvest (median 
(range)) 
  Total 
  Positive 
 
 
 
15 (0 – 53) 
0 (0 – 28) 
 
 
31 (0 – 129) 
2 (0 – 44) 
 
 
<0.001 
<0.001 
 
 
14 (0 – 52) 
0 (0 – 9) 
 
 
27 (0 – 129) 
2 (0 – 33) 
 
 
<0.001 
<0.001 
NCRS, neoadjuvant chemoradiotherapy and surgery. NCS, neoadjuvant chemotherapy and surgery. EGJ, 
esophago-gastric junction. TRG, tumor regression grade. *Missing data 
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Table 3. Comparative analysis of short-term outcomes and three-year recurrence from unmatched and pro-
pensity matched groups. 
 Before Matching After Matching 
 NCRS 
(n=301) (%) 
NCS 
(n=307) (%) 
p-value NCRS 
(n=221) (%) 
NCS 
(n=221) (%) 
p-value 
30-day mortality 9 (3) 5 (1.6) 0.263 9 (4.1) 3 (1.4) 0.140 
90-day mortality 15 (5) 7 (2.3) 0.074 13 (5.9) 5 (2.3) 0.090 
Anastomotic leak* 61 (20.4) 15 (5.6) <0.001 51 (23.1) 13 (6.8) <0.001 
Pulmonary 
complications* 
135 (44.9) 103 (38.9) 0.15 101 (45.7) 72 (38.3) 0.134 
Cardiac 
complications* 
58 (19.3) 56 (21.1) 0.581 43 (19.5) 36 (19.1) >0.999 
Chyle leak* 22 (7.3) 24 (9.1) 0.448 17 (7.7) 13 (6.9) 0.850 
Reoperation 27 (9.1) 20 (6.5) 0.108 22 (10.2) 14 (6.5) 0.050 
Recurrence 
  Locoregional 
  Distant 
  Mixed 
 
15 (5.0) 
73 (24.3) 
30 (10.0) 
 
19 (6.2) 
70 (22.8) 
22 (7.2) 
 
0.542 
 
10 (4.5) 
56 (25.3) 
19 (8.6) 
 
14 (6.3) 
60 (27.1) 
14 (6.3) 
 
0.660 
NCRS, neoadjuvant chemoradiotherapy and surgery; NCS, neoadjuvant chemotherapy and surgery. *Missing 
data 
Table 4. Cox regression analysis for overall survival, with correction for year of treatment and age as continu-
ous variables. 
    95% Confidence Interval 
 Hazard Ratio Lower Upper P value 
Neoadjuvant therapy 
  NCS 
  NCRS 
 
1.00 
0.86 
 
 
0.66 
 
 
1.11 
 
 
0.232 
Age 1.01 1.00 1.02 0.195 
Gender 
  Male 
  Female 
 
1.00 
0.87 
 
 
0.62 
 
 
1.21 
 
 
0.402 
ASA 
  I 
  II 
  III and IV 
 
1.00 
1.04 
1.60 
 
 
0.70 
1.01 
 
 
1.56 
2.53 
0.013 
 
0.839 
0.045 
cT stage 
  1 
  2 
  3 and 4 
 
1.00 
0.47 
0.80 
 
 
0.21 
0.39 
 
 
1.05 
1.64 
0.038 
 
0.065 
0.541 
cN stage 
  cN0 
  cNpositive 
 
1.00 
1.55 
 
 
1.17 
 
 
2.05 
 
 
0.002 
Year of surgery 0.98 0.93 1.02 0.306 
NCRS, neoadjuvant chemoradiotherapy and surgery; NCS, neoadjuvant chemotherapy and surgery. 
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Figure 1a. Unmatched Kaplan-Meier survival analysis showing a significant (p=0.047) improvement in overall 
survival with neoadjuvant chemoradiotherapy plus surgery (NCRS, n=301) compared with neoadjuvant 
chemotherapy plus surgery (NCS, n=307) for esophageal adenocarcinoma. 
 
Figure 1b. Propensity-matched Kaplan-Meier survival analysis showing no significant difference (p=0.391) in 
overall survival between neoadjuvant chemoradiotherapy plus surgery (NCRS, n=221) and neoadjuvant 
chemotherapy plus surgery (NCS, n=221) for esophageal adenocarcinoma. 
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Figure 2a. RA-CUSUM analysis of lymph node harvest vs. overall survival in chemoradiotherapy plus surgery 
group (NCRS); lymph node harvest does not affect survival with no discernable pattern to this CUSUM curve.  
 
 
Figure 2b. RA-CUSUM analysis of lymph node harvest vs. overall survival in chemotherapy plus surgery 
group (NCS); change point as illustrated by the plateau of curve at 22–52 lymph nodes. Above 52 lymph nodes 
there were significant improvements in disease-free survival (22 to 36 months; p=0.028), and overall recur-
rence (47.1% to 15.9%; P<0.001) and non-significant improvement in overall survival (27 to 38 months; 
p=0.171).  
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Appendix 
The NCRS regimen consists of weekly administration of paclitaxel (50 mg/m2 body-
surface area) and carboplatin (area under the curve: 2 mg/ml/min) for five weeks and 
concurrent radiotherapy (41.4 Gy in 23 fractions, 5 days per week).22, 23 The MAGIC 
NCS regimen comprises 3 preoperative and 3 postoperative cycles of intravenous epiru-
bicin (50 mg/m2 body-surface area) and cisplatin (60 m/m2 body-surface area) on day 1, 
and a continuous intravenous infusion of fluorouracil (200 mg/m2/day) for 21 days.24 
The OEO2 NCS regimen comprises 2 cycles of cisplatin (80mg/m2 body-surface area) by 
intravenous infusion on day 1 and fluorouracil (1,000 mg/m2 body-surface area daily) as 
a continuous infusion over 96 hours every 3 weeks.19 The OEO5 NCS regimen compris-
es four 3-weekly cycles of epirubicin (50 mg/m2 body-surface area) and cisplatin (60 
mg/m2 body-surface area) given by intravenous infusion on day 1, and capecitabine 
given orally continuously for 12 weeks at a total daily dose of 1250mg/m2 body surface 
area.9 
  
Multimodality treatment for esophageal adenocarcinoma 
87 
References 
1. Shapiro J, van Lanschot JJ, Hulshof MC et al. Neoadjuvant chemoradiotherapy plus surgery versus 
surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised con-
trolled trial. Lancet Oncol. 2015;16(9):1090-8. 
2. van Hagen P, Hulshof MC, van Lanschot JJ et al. Preoperative chemoradiotherapy for esophageal or 
junctional cancer. N Engl J Med. 2012;366(22):2074-84. 
3. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for 
resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11-20. 
4. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of 
surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 
2009;27(30):5062-7. 
5. Burmeister BH, Thomas JM, Burmeister EA et al. Is concurrent radiation therapy required in patients 
receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II tri-
al. Eur J Cancer. 2011;47(3):354-60. 
6. Stahl M, Walz MK, Stuschke M et al. Phase III comparison of preoperative chemotherapy compared with 
chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J 
Clin Oncol. 2009;27(6):851-6. 
7. Klevebro F, Alexandersson von Dobeln G, Wang N et al. A randomized clinical trial of neoadjuvant 
chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-
oesophageal junction. Ann Oncol. 2016. 
8. Reynolds JV, Preston SR, O'Neill B et al. ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the 
oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS). BMC Cancer. 
2017;17(1):401. 
9. Alderson D, Langley RE, Nankivell MG et al. Neoadjuvant chemotherapy for resectable oesophageal and 
junctional adenocarcinoma: results from the UK Medical Research Council randomised OEO5 trial 
(ISRCTN 01852072). J Clin Oncol. 2015;33(Abstr 4002). 
10. Sobin LH, Gospodarowicz MK, Wittekind C, International Union against Cancer., ebrary Inc. TNM 
classification of malignant tumors. New York: Wiley-Blackwell; 2009. Available from: 
http://site.ebrary.com/lib/yale/Doc?id=10342913, last accessed: January 29th, 2018. 
11. Chirieac LR, Swisher SG, Ajani JA et al. Posttherapy pathologic stage predicts survival in patients with 
esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103(7):1347-55. 
12. Hudis CA, Barlow WE, Costantino JP et al. Proposal for standardized definitions for efficacy end points 
in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007;25(15):2127-32. 
13. D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment to a 
non-randomized control group. Stat Med. 1998;17(19):2265-81. 
14. Grigg OA, Farewell VT, Spiegelhalter DJ. Use of risk-adjusted CUSUM and RSPRT charts for monitor-
ing in medical contexts. Stat Methods Med Res. 2003;12(2):147-70. 
15. Shapiro J, van Klaveren D, Lagarde SM et al. Prediction of survival in patients with oesophageal or junc-
tional cancer receiving neoadjuvant chemoradiotherapy and surgery. Br J Surg. 2016;103(8):1039-47. 
16. Talsma AK, Shapiro J, Looman CW et al. Lymph node retrieval during esophagectomy with and without 
neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival. Ann Surg. 
2014;260(5):786-93. 
17. Omloo JM, Lagarde SM, Hulscher JB et al. Extended transthoracic resection compared with limited 
transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized 
clinical trial. Ann Surg. 2007;246(6):992-1000; discussion -1. 
18. Boshier PR, Anderson O, Hanna GB. Transthoracic versus transhiatal esophagectomy for the treatment 
of esophagogastric cancer: a meta-analysis. Ann Surg. 2011;254(6):894-906. 
Chapter 4 
88 
19. Chu KM, Law SY, Fok M, Wong J. A prospective randomized comparison of transhiatal and transthorac-
ic resection for lower-third esophageal carcinoma. Am J Surg. 1997;174(3):320-4. 
20. Lykke J, Roikjaer O, Jess P, Danish Colorectal Cancer G. Tumour stage and preoperative chemoradio-
therapy influence the lymph node yield in stages I-III rectal cancer: results from a prospective nationwide 
cohort study. Colorectal Dis. 2014;16(4):O144-9. 
21. Taflampas P, Christodoulakis M, Gourtsoyianni S, Leventi K, Melissas J, Tsiftsis DD. The effect of pre-
operative chemoradiotherapy on lymph node harvest after total mesorectal excision for rectal cancer. Dis 
Colon Rectum. 2009;52(8):1470-4. 
22. Markar SR, Wiggins T, Ni M et al. Assessment of the quality of surgery within randomised controlled 
trials for the treatment of gastro-oesophageal cancer: a systematic review. Lancet Oncol. 2015;16(1):e23-
31. 
23. Smyth EC, Fassan M, Cunningham D et al. Effect of Pathologic Tumor Response and Nodal Status on 
Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. J Clin Oncol. 
2016;34(23):2721-7. 
24. Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for high-risk 
surgery. N Engl J Med. 2011;364(22):2128-37. 
25. Mamidanna R, Ni Z, Anderson O et al. Surgeon Volume and Cancer Esophagectomy, Gastrectomy, and 
Pancreatectomy: A Population-based Study in England. Ann Surg. 2016;263(4):727-32. 
26. Markar SR, Karthikesalingam A, Thrumurthy S, Low DE. Volume-outcome relationship in surgery for 
esophageal malignancy: systematic review and meta-analysis 2000-2011. J Gastrointest Surg. 
2012;16(5):1055-63. 
27. Markar SR, Arya S, Karthikesalingam A, Hanna GB. Technical factors that affect anastomotic integrity 
following esophagectomy: systematic review and meta-analysis. Ann Surg Oncol. 2013;20(13):4274-81. 
28. van Workum F, Rosman C. Netherlands Trial Register: NTR4333 2013 [Available from: 
http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=4333. 
29. Low DE, Alderson D, Cecconello I et al. International Consensus on Standardization of Data Collection 
for Complications Associated With Esophagectomy: Esophagectomy Complications Consensus Group 
(ECCG). Ann Surg. 2015;262(2):286-94. 
 
  
 89 
Chapter 5 
Optimal surgical approach for esophageal 
cancer in the era of MIE and neoadjuvant 
therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.J. Noordman1, B.P.L. Wijnhoven1, J.J.B. van Lanschot1 
 
Diseases of the Esophagus 2016;29(7):773-779 
 
Department of Surgery1, Erasmus MC – University Medical Center – Rotterdam, the Netherlands 
  
Chapter 5 
90 
Summary 
The optimal surgical technique for the potentially curative treatment of patients with 
esophageal cancer is still under debate. The transhiatal esophagectomy with limited 
lymphadenectomy mainly focuses on a decrease of postoperative morbidity and mor-
tality by preventing a formal thoracotomy. The transthoracic esophagectomy (TTE) 
with extended two-field lymphadenectomy attempts to improve the radicality of the 
resection and thus to increase locoregional tumor control, but is associated with in-
creased postoperative morbidity. The recent introduction of different minimally inva-
sive techniques probably decreases postoperative morbidity following TTE, with reduc-
tion of especially pulmonary complications, but high-quality evidence is still limited. It 
is widely agreed that extended lymphadenectomy as performed during TTE provides the 
benefit of more accurate staging, but its effect on improvement of survival is still debat-
ed. The literature on this topic is contradictory and the choice of surgical approach is 
primarily driven by personal opinions and institutional preferences. Moreover, the 
available evidence is mainly based on patients who underwent surgery alone without 
neoadjuvant therapy. Results of recent studies suggest that neoadjuvant chemoradio-
therapy abolishes any possibly positive effect of extended lymphadenectomy as per-
formed during TTE on survival, but this effect should be confirmed in future research. 
This review gives an overview and reflects the authors’ personal view on the role of TTE 
and THE in the treatment of potentially curative treatment of patients with locally ad-
vanced esophageal cancer in the era of minimally invasive esophagectomy and neoadju-
vant treatment and outlines future research perspectives. 
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Introduction 
For several decades it has been debated what is the optimal surgical technique for the 
potentially curative primary treatment of patients with locally advanced esophageal 
cancer. Over the years two main different surgical strategies have evolved. On the one 
hand the limited transhiatal approach (transhiatal esophagectomy, [THE]) was devel-
oped, which mainly focused on a decrease of postoperative morbidity and mortality by 
preventing a formal thoracotomy. On the other hand the extended transthoracic ap-
proach (transthoracic esophagectomy, [TTE]) was introduced with two-field lymphade-
nectomy (posterior mediastinum and upper abdomen) in an attempt to improve the 
radicality of the resection and thus to increase locoregional tumor control.1-5 It is widely 
agreed that extensive lymphadenectomy provides the benefit of more accurate staging, 
but its effect on improvement of survival is still under debate.6-9 
In esophageal cancer, lymphatic dissemination occurs early and is unpredictable. It 
has been shown that 20-40% of all early submucosal (T1b) esophageal tumors have 
already disseminated to regional lymph nodes.10-16 Therefore, endoscopic treatment is 
generally reserved for patients with mucosal (T1a) disease. Moreover, the pattern of 
lymphatic dissemination is unpredictable with skip metastases at more distant sites 
while lymph nodes in the direct vicinity of the primary tumor are negative.17 This is one 
of the reasons why the sentinel node concept is still considered experimental in the 
surgical treatment of esophageal cancer patients. Extended lymphadenectomy – as per-
formed during TTE – theoretically increases the chance of radical removal of all positive 
lymph nodes and thereby improves regional tumor control and long term survival. 
However, due to a lack of high-quality clinical evidence, especially in the present era of 
minimally invasive surgery and neoadjuvant treatment, institutional preferences and 
clinical opinions dominate the choice of surgical approach. In this review, we give an 
overview of the role of TTE and THE in the treatment of squamous cell carcinomas 
(SCC) and adenocarcinomas (AC) of the esophagus and esophagogastric junction 
(EGJ). 
Role of lymphadenectomy 
In a large retrospective study on 2,303 patients (60% AC, 40% SCC) that underwent R0 
resections from nine high-volume centers around the world it was shown using multi-
variable analysis that a high total number of resected nodes is an independent prognos-
ticator of (favorable) survival  after primary surgical resection of esophageal or junc-
tional cancer. The optimal threshold for this survival benefit was removal of at least 23 
nodes and the operation most likely to achieve this threshold was found to be an en bloc 
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resection.18 These findings are arguments in favor of maximizing the extent of lymphad-
enectomy and therefore in favor of TTE over THE. 
In contrast, a recent nonrandomized study from two British centers showed a simi-
lar long-term oncological outcome after THE and TTE for patients with AC (88%) or 
SCC (12%), while hospital stay was shorter after THE.19 This advantage of THE over 
TTE in short-term recovery without substantially jeopardizing long-term oncological 
outcome was also confirmed in a recent meta-analysis that included 52 studies with 
3,389 TTE patients and 2,516 THE patients (52% AC, 48% SCC). In addition to shorter 
hospital stay (on average 4 days less in patients who underwent THE, 95% confidence 
interval [CI] 1-7, p<0.01), THE was associated with shorter operative time (THE proce-
dures took a mean of 85 minutes shorter, 95% CI 40-129, p<0.001), less pulmonary 
complications (17.3% vs. 21.4%, odds ratio [OR] 1.37, 95% CI 1.05-1.79, p=0.02) and 
lower postoperative mortality (7.2% vs. 10.6%, OR 1.48, 95% CI 1.20-1.83, p<0.001). On 
the other hand, patients who underwent THE experienced more anastomotic leaks and 
more recurrent nerve palsies. Furthermore, lymph node retrieval was significantly high-
er after TTE, with a mean difference of eight nodes (95% CI 1-14, p=0.02). These results 
must be interpreted with caution, because this analysis included both randomized and 
non-randomized studies which probably led to a selection bias in favor of the THE 
group, because more advanced tumors might have been treated preferentially with 
TTE.20 Finally, it should be noted that the enhanced short-term recovery after THE was 
questioned in a large-volume, multicenter observational study in more than 17,000 
patients who underwent THE or TTE; no differences were found in overall morbidity 
and mortality. However, a preference for THE in patients with poor performance status 
probably led to selection bias in favor of the TTE group.21 
HIVEX trial 
The limited THE and the extended TTE have been compared in a randomized trial 
(HIVEX trial), which was performed in two high-volume Dutch academic centers. 22 
This trial included 220 patients with AC of the mid-to-distal esophagus or AC of the 
gastric cardia substantially involving the distal esophagus. By preventing a formal thora-
cotomy postoperative pulmonary complications occurred less frequently (27% after 
THE vs. 57% after TTE, p<0.001) and artificial ventilation time (1 day after THE vs. 2 
days after TTE, p<0.001) and hospital stay (15 days after THE vs. 19 days after TTE, 
p<0.001) were shorter after THE. However, in-hospital mortality was comparable be-
tween the two groups (2% after THE vs. 4% after TTE, p=0.45). Interestingly, the more 
extended TTE did not lead to a higher percentage of tumor-free resection margins (72% 
in the THE group vs. 71% in the TTE group) , but the median number of removed 
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lymph nodes was two times as high after TTE compared to THE (median 31 vs. 16, 
p<0.001).22 This improved lymph node retrieval did not translate into a significantly 
better overall 5-year survival; 34% after THE  and 36% after TTE (p=0.71).23 However, 
in a subgroup analysis of patients with a truly esophageal (type-1) cancer a better long-
term survival was achieved, more specifically in those patients with a limited number (1-
8) of positive nodes (23% after THE vs. 64% TTE, p= 0.02). It should be noted that stage 
migration might have played a role in the improved survival in this TTE group, because 
the total number of resected lymph nodes was higher after TTE. Furthermore, relevance 
and level of evidence of these results are questionable for SCC, because only patients 
with AC were included. The final conclusion of that randomized trial was that in ad-
vanced type-1 esophageal cancer patients TTE was the preferred technique, especially in 
case of a limited number of positive nodes, while THE should be preferred in patients 
with a type-2 tumor which is located at the EGJ and in patients with a poor general 
condition without clinically suspected lymph nodes at or above the carina.23 
Role of minimally invasive esophagectomy 
Over the last decade minimally invasive techniques (laparoscopy, thoracoscopy) have 
been developed and are increasingly applied in esophageal cancer surgery.  The poten-
tial advantage of minimally invasive esophagectomy (MIE) might be the limitation of 
surgical trauma, while potentially preserving the radicality of the resection and the ex-
tent of lymph node dissection. Several surgical approaches and combinations of tech-
niques have been described, varying from hybrid procedures (thoracoscopy in combina-
tion with laparotomy or thoracotomy with laparoscopy) to even completely minimally 
invasive approaches (thoracoscopy with laparoscopy). So far, only one randomized trial 
has been published as a full paper, comparing open with minimally invasive TTE.24 This 
trial included 115 patients with resectable cancer of the esophagus or EGJ. MIE was 
shown to have a lower postoperative pulmonary infection rate (relative risk 0.35, 95% CI 
0.16–0.78, p=0.005).24 However, this trial was criticized, mainly because of the subjectiv-
ity of the primary endpoint, the limited number of included patients, the short length of 
follow-up and the high recurrent nerve palsy rate with a (secondary?) high pneumonia 
rate in the open esophagectomy group.25-27 It was concluded that larger trials with longer 
follow-up are needed to establish more definite conclusions concerning the exact role of 
minimally invasive techniques.26 Recently, the results of the French MIRO trial have 
been presented and published in abstract form. This trial randomly assigned 207 pa-
tients between open TTE and hybrid MIE (laparoscopic gastric mobilization and open 
thoracotomy). Both postoperative morbidity (OR 0.31, 95% CI 0.18-0.55, p=0.0001) and 
pulmonary complications (30.1% vs. 17.7%, p=0.037) were lower in the hybrid arm.28 
Chapter 5 
94 
These preliminary results suggest that a hybrid TTE approach using laparoscopy and 
thoracotomy reduces postoperative complications as compared to open TTE using both 
laparotomy and thoracotomy. In order to determine whether the complication rate after 
hybrid TTE can be decreased even more, a trial is needed in which patients are random-
ized between hybrid MIE and fully minimally invasive MIE. 
Thoracoscopic TTE clearly diminishes the surgical trauma to the chest wall in com-
parison with a conventional thoracotomy, potentially leading to a decreased postopera-
tive pulmonary complication rate.24 In comparison with a limited transhiatal resection 
(which completely abolishes the necessity of a thoracotomy/thoracoscopy), however, 
thoracoscopic TTE still requires a limited trauma to the chest wall (four port sites) and a 
prolonged (partial) collapse of the right lung throughout the thoracic phase of the oper-
ation. It is well established that a lung collapse leads to an increased risk of pulmonary 
complications.22 Taking into account the relatively low complication rate after open 
THE, the impact of this prolonged partial lung collapse in combination with the limited 
trauma to the chest wall during thoracoscopic TTE needs to be evaluated in a random-
ized trial, comparing the minimally invasive TTE with a conventional or minimally 
invasive THE.29, 30 
Thoracic versus cervical anastomosis 
Using the transhiatal technique, an anastomosis between the proximal esophagus and 
the replacement conduit is required at the cervical level. In contrast, a transthoracic 
technique allows for a choice between a cervical and a thoracic anastomosis. After TTE, 
some surgeons favor a cervical anastomosis despite the increased rate of leakage31, pos-
sible stricture formation and recurrent laryngeal nerve damage, because of a longer 
proximal tumor free margin and a potentially reduced morbidity in case of an anasto-
motic leak.32 The latter is based on the assumption that an anastomotic leakage will 
likely be confined to the neck, instead of leaking into the mediastinum and pleural cavi-
ty. However, a recent meta-analysis on this topic did not find significant differences in 
pulmonary complications (OR 0.86, 95% CI 0.13-5.59, p=0.87) or tumor recurrence (OR 
2.01, 95% CI 0.68-5.91, p=0.21).33 This study included only three small randomized 
trials with a total of 175 patients, but suggests that performing a cervical anastomosis 
after TTE does not decrease the risk of intrathoracic complications as compared to a 
thoracic anastomosis after TTE. Indeed, in two large retrospective cohort studies, the 
risk of developing intrathoracic manifestations due to leakage of a cervical anastomosis 
was shown to be significantly less in patients who underwent THE as compared to pa-
tients who underwent TTE. This was explained by the difference in pleural dissection. It 
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was hypothesized, that after THE a bilaterally intact parietal pleura may confine infec-
tions and prevent extension into the mediastinum and pleural cavity.34, 35 
These studies have been performed before the introduction of neoadjuvant therapy 
and studies comparing cervical with thoracic anastomoses after neoadjuvant therapy are 
lacking. In the randomized CROSS trial comparing neoadjuvant chemoradiotherapy 
followed by surgery to surgery alone, almost all anastomoses were performed at the level 
of the neck and no significant difference was identified in anastomotic leakage rate.36 
However, the effect of radiotherapy on anastomotic healing in the chest might be of 
significant importance and should be further explored. In case of a thoracic anastomosis 
the required length of the gastric tube can be shorter with potentially improved oxygen-
ation of the tip and enhanced anastomotic healing. On the other hand, the intrathoracic 
esophageal remnant might show more radiation damage, which might hamper intratho-
racic anastomotic healing. 
Impact of neoadjuvant chemoradiotherapy on surgical strategy 
It should be underlined, that all above trials comparing different surgical techniques 
mainly included patients who underwent primary surgical resection without neoadju-
vant therapy. But even after careful selection of patients for potentially curative primary 
surgical resection, 5-year survival rarely exceeds 40% and the majority of patients still 
dies of recurrent disease.23 For that reason many studies have been performed world-
wide to test the potential value of adding preoperative neoadjuvant therapy to primary 
surgical resection. The most recent meta-analysis has shown that both neoadjuvant 
chemotherapy (nCT) and neoadjuvant chemoradiotherapy (nCRT) are able to improve 
long-term treatment outcome.37 This meta-analysis showed a  trend in favor of nCRT 
over nCT by comparing treatment arms of different trials (hazard ratio [HR] for all-
cause mortality for nCRT vs. nCT 0.88, 95% CI 0.76-1.01, p=0.07), but direct compari-
sons are limited. Especially for patients with AC, explaining why the Neo-AEGIS trial, 
that compares nCRT with nCT in patients with AC, is ongoing. Ever since, a Dutch 
multicenter randomized controlled study (CROSS trial) was completed, comparing 
nCRT followed by surgery with surgery alone in patients with SCC or AC of the esopha-
gus (type-1) or EGJ (type-2).36 The applied regimen of five cycles of carboplatin and 
paclitaxel with 23 fractions of 1.8 Gy concurrent confocal radiotherapy was shown to 
have low toxicity with >90% of patients tolerating the complete planned regimen. In-
hospital mortality after subsequent surgical resection was not influenced (4% in both 
treatment arms), and also in-hospital morbidity was comparable between the two 
groups. Interestingly, median survival doubled from 24% in the surgery alone arm to 
49% in the combined treatment arm (p=0.003), and 5-year survival improved from 34% 
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to 47%.36, 38 The difference in overall survival in the CROSS trial was not due to poor 
survival in the surgery alone group, but can be attributed to improved survival in the 
chemoradiotherapy followed by surgery group. This is supported by the superior overall 
survival in the surgery alone group in the CROSS trial as compared to that reported in 
earlier randomized trials.39, 40 Based on these results, nCRT according to CROSS fol-
lowed by surgery is now considered standard of care in many countries. It should be 
noted that the survival benefit of nCRT found in the CROSS trial was not supported by a 
recently published French randomized trial (Fédération Francophone de Cancérologie 
Digestive (FFCD) 9901 trial) comparing nCRT followed by surgery with surgery alone 
in patients with stage I and II esophageal cancer. Neoadjuvant therapy consisted of cis-
platin and fluorouracil with 45 Gy concurrent radiotherapy. Neither the 3-year overall 
survival rate nor the microscopically radical resection rate were improved in the nCRT 
followed by surgery group.41 Based on these results, the benefit of nCRT for patients 
with early-stage tumors is debatable. Possibly, treatment with surgery alone is already 
effective in these patients, which is supported by the high radical resection rate (92%) in 
the surgery alone group of the French trial. However, the generalizability of the results 
of the French trial has been questioned due to its low case volume in many of the partic-
ipating centers, its toxic nCRT regimen with less sophisticated radiation techniques in 
comparison with the CROSS trial and its remarkably high postoperative mortality rate. 
Therefore, we caution to conclude that nCRT is not beneficial in early-stage cancer and 
we believe that, as long as high quality evidence on the effect of nCRT on early-stage 
tumors is lacking, the results from the CROSS trial (which included stage II cancers) 
should be considered leading, especially for stage II cancers.42 
Neoadjuvant treatment according to CROSS has a significant down staging effect 
both on the primary tumor and on the regional lymph nodes. In the CROSS trial the 
percentage of patients with (residual) positive lymph nodes in the resection specimen 
decreased from 76% in the surgery alone group to 32% in the combined treatment 
group.36 Moreover, a substantial number of patients (29%) did not have any vital tumor 
cells left in the resection specimen after nCRT. This high pathologically complete re-
sponse rate led to the imperative to reconsider the necessity of standard esophagectomy 
in all patients. Therefore, we hope to propose in the near future a “Surgery As Needed 
approach in Oesophageal cancer patients (SANO-approach)”. In this approach, patients 
will undergo active surveillance after completion of nCRT. Esophagectomy will be of-
fered only to patients in whom a locoregional recurrence is highly suspected or proven. 
This organ-preserving strategy would be preferred, but only if long term survival would 
be comparable to that of the present standard surgery approach. As a first step towards 
an organ-preserving strategy, we are currently performing the multicenter phase II fea-
sibility preSANO-trial to determine the accuracy by which residual disease after nCRT 
can be detected.43 Furthermore, in France, a phase II/III randomized trial comparing 
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standard surgery with surgery on demand in case of recurrence in clinically complete 
responders after nCRT is currently being initiated (ESOSTRATE-trial).44 
As underlined above, the randomized HIVEX trial comparing THE and TTE for 
subcarinal tumors was performed in patients who did not undergo neoadjuvant therapy. 
In that trial TTE did not lead to a higher rate of tumor free margins (71% after TTE vs. 
72% after THE), but roughly doubled the number of removed nodes (median ± stand-
ard deviation = 31 ± 14 after TTE vs. 16 ± 9 after THE, p<0.001). The randomized 
CROSS trial has shown, however, that in patients after nCRT the total number of resect-
ed nodes is significantly lower than in patients after primary surgery.45 Importantly, in 
patients after primary surgery in the CROSS trial there was a positive correlation be-
tween the total number of resected nodes and the number of resected positive nodes. 
However, this positive association was not present after nCRT: by resecting more nodes 
the number of resected positive nodes remained unchanged. Furthermore, after primary 
surgery the total number of resected nodes had a positive correlation with survival (HR 
per 10 additionally resected nodes, 0.76; p=0.007), which is in line with an earlier retro-
spective international study, as discussed above.18, 45 Interestingly, this positive correla-
tion between the total number of resected nodes and survival was completely absent 
after nCRT (HR 1.00; p=0.98). After surgery alone a higher number of resected nodes 
was associated with improved survival, while in a comparable group of patients who 
were randomly allocated to undergo nCRT plus surgery, this association was lost. The 
randomization procedure within the CROSS trial renders asymmetry between both 
treatment arms unlikely as a possible explanation for the (disappearance of the) ob-
served association in this secondary analysis. These data question the necessity of max-
imization of surgical lymph node retrieval after nCRT, both for diagnostic purposes and 
for therapeutic reasons. 
The same phenomenon was identified in a larger (albeit retrospective) analysis of 
391 patients who underwent primary surgery and 626 patients who underwent nCRT 
according to CROSS followed by surgery.46 In the surgery alone group, TTE was associ-
ated with a significantly more favorable prognosis as compared to THE (HR for TTE vs 
THE = 0.73, p=0.023), whereas in patients treated with nCRT followed by surgery TTE 
was associated with a (non-significantly) less favorable prognosis (HR TTE vs. THE = 
1.18, p=0.246). Again, these data suggest that maximization of surgical lymph node 
retrieval is probably relevant in patients who undergo surgery alone, but question its 
necessity after nCRT.  
In order to confirm these indirect arguments, a randomized trial is needed compar-
ing TTE and THE in patients with (type-1) esophageal cancer who undergo nCRT ac-
cording to CROSS. In our opinion, such trial should focus on patients with (type-1) 
esophageal cancer and not on patients with (type-2) junctional cancer, because the 
HIVEX trial has already shown sufficiently that in patients with type-2 junctional cancer 
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THE suffices. Even if they undergo primary surgical resection without preoperative 
neoadjuvant therapy; let alone in patients with type-2 junctional cancer who undergo 
nCRT followed by surgery. It should be noted that in the HIVEX trial also type-1 malig-
nancies were included and conclusions regarding the absence of benefit of TTE for type-
2 cancer are obtained from a subgroup analysis.  
Conclusion and future directions 
The optimal surgical strategy (transthoracic or transhiatal resection) for esophageal carci-
noma remains unclear. A trend towards an improved 5-year survival after TTE was shown 
in a randomized trial, but this study was performed before implementation of nCRT and 
MIE.22 The extended lymphadenectomy in TTE might decrease the rate of locoregional 
recurrences and thus increase survival. However, the necessity of maximization of surgical 
lymph node retrieval after nCRT has recently been questioned.45, 46 The recent introduc-
tion of MIE might decrease postoperative morbidity following TTE, with reduction of 
especially pulmonary complications, but high-quality evidence is still limited.  
Therefore, some important questions remain to be addressed. First, several minimally 
invasive TTE approaches have been described, but the superiority of one technique over 
another in terms of postoperative complications and oncological outcome remains un-
known. Randomization between the hybrid procedure as performed in the recent MIRO 
trial28 versus a fully minimally invasive esophagectomy as described in the TIME trial24, 
will reveal possible advantages of thoracoscopy over thoracotomy, both combined with 
laparoscopic gastric mobilization. A reduction in postoperative (pulmonary) complication 
rate after thoracoscopic TTE would only be acceptable if this is accompanied by a similar 
or improved oncological outcome. Furthermore, such trial design would allow for a sec-
ond randomization procedure within each arm between a thoracic and a cervical anasto-
mosis (4-arm study), to define the optimal location of the anastomosis. 
Second, the oncological necessity of extended lymph node dissection in patients with 
type-1 esophageal AC or SCC (located below the carina) in the era of neoadjuvant therapy 
should be studied. If a randomized trial comparing TTE with THE shows that THE is ade-
quate after nCRT, this will clearly have advantages in reducing especially pulmonary com-
plications. Moreover, the discussion on thoracoscopy vs. thoracotomy would then be futile. 
Finally, direct comparison between minimally invasive THE and open THE will clar-
ify whether the relatively low complication rate of an open THE can be decreased even 
more. Especially if THE would prove to be sufficient for patients who have been pre-
treated with nCRT or in the growing elderly population, minimization of surgical trau-
ma and avoidance of postoperative complications is crucial. 
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In patients with oesophageal cancer, the effect of lymphadenectomy on survival remains 
unclear. A recent retrospective cohort study suggests that extensive lymphadenectomy 
does not improve survival and might even hamper it in patients with early T-stage tu-
mours. The available data show conflicting results and the introduction of neoadjuvant 
chemoradiotherapy might decrease any positive effect of extensive lymphadenectomy 
on survival. 
It is established that extensive lymphadenectomy during oesophagectomy for oe-
sophageal cancer provides the benefit of more-accurate staging, but its effect on survival 
is still under debate.1, 2 Extensive lymphadenectomy theoretically increases the probabil-
ity of radical removal of all tumour-positive lymph nodes, and thereby might improve 
long-term survival. However, some researchers consider lymph-node metastases only as 
indicators of systemic disease, and not as governors of survival.3 In this regard, any 
suggested therapeutic effect is explained by stage migration, with positive nodes in the 
extended part of the dissection leading to an increased N-stage, but a more-favourable 
prognosis compared with patients harbouring the same number of positive nodes after a 
limited dissection. In this context stage migration leads to biased stage-by-stage com-
parisons of survival. 
In a recently published study, it has been reported that extensive lymphadenectomy 
during surgery for oesophageal cancer does not improve survival.4 This nationwide 
population-based cohort study from Sweden in 1,044 patients with oesophageal cancer 
who had undergone oesophagectomy analysed the independent effect of lymphadenec-
tomy on long-term survival.4 The number of lymph nodes resected were analysed both 
as a continuous variable and as a median and quartile variable. The data were adjusted 
for age, sex, comorbidities, T-stage, neoadjuvant therapy, surgeon volume and calendar 
period. No influence of the number of lymph nodes removed on overall 5-year mortali-
ty, when analysed as a continuous variable, was found (hazard ratio [HR] for mortality 
1.00, 95% CI 0.99– 1.01). Furthermore, no differences in overall 5-year mortality were 
reported in patients in the third (7–15 nodes) and fourth (16–114 nodes) quartiles as 
compared to patients in the lowest two quartiles combined (<7 nodes, HR 1.13, 95% CI 
0.95– 1.35 and HR 1.17, 95% CI 0.94–1.42, respectively). However, a comparison be-
tween the combined quartiles 1 and 2 versus quartiles 3 and 4 showed a significantly 
increased HR in favour of the lower quartiles (HR 1.21, 95% CI 1.03– 1.42, p=0.02). 
Moreover, in a subgroup analysis of patients with early T-stage tumours (Tis-T1), an 
unfavourable HR was found for patients in the combined quartiles 3 and 4 (7–114 
nodes) as compared to patients in quartiles 1 and 2 (<7, HR 1.53, 95% CI 1.13– 1.27, 
p=0.006). These results suggest that maximization of surgical lymph-node retrieval does 
not improve survival and might hamper survival in patients with early T-stage tu-
mours.4 
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The large sample size and nationwide design of this study with complete follow-up 
of at least 24 months led to sufficient statistical power and a relatively low risk of selec-
tion bias. The homogeneity of the study population is further improved by the use of the 
same surgical technique (transthoracic oesophagectomy, [TTO]) in 95% of all included 
patients.4 Furthermore, the adjustment for a number of well-known prognostic factors, 
as mentioned above, decreased the possibility of confounding.  
The investigators state that it is unfeasible to study the effects of the number of re-
moved nodes in a randomized trial design and conclude that an observational study 
design remains the best option. However, a randomized trial comparing TTO with ex-
tensive lymphadenectomy (with a median number of lymph nodes removed of 31) ver-
sus transhiatal oesophagectomy (THO) with limited lymphadenectomy (median num-
ber of lymph nodes removed of 16) did not show differences in overall 5-year survival 
between both arms.5 A subgroup analysis of patients with Siewert type-1 oesophageal 
cancer with a limited number (1–8) of positive nodes showed an improved survival in 
favour of the TTO group;6 however, this effect might be explained, at least partially, by 
stage migration.  
The retrospective design of the present study4 necessitates a correction for possible 
confounding factors owing to a lack of random distribution of patients in terms of the 
number of lymph nodes removed. While most of the relevant factors have been ad-
dressed well, an important prognostic factor that was not considered, but might influ-
ence the extent of lymphadenectomy, is the number of suspected regional lymph-node 
metastases preoperatively and peroperatively (clinical N-stage). Although accuracy of 
clinical N-staging is poor, patients suspected for a high number of lymph-node metasta-
ses are more likely to undergo a more-extensive lymphadenectomy as compared to 
patients without or with a limited number of suspected regional lymph nodes metasta-
ses. Therefore, patients with more-advanced tumours and a less-favourable prognosis 
might have a higher number of lymph nodes resected. In oesophageal cancer, lymphatic 
dissemination is chaotic and unpredictable and occurs early in tumorigenesis; thus, 
adjustment only for T-stage does not properly correct for any differences in clinical N-
stage. 
Moreover, it should be noted that the median number of removed and identified 
nodes of seven in the Swedish study is relatively low compared with the available litera-
ture on TTO, with means varying from 15 to 34.5, 7 A large international retrospective 
study8 on 2,303 patients showed that a high number of resected nodes is an independent 
prognostic factor for favourable survival after surgery alone in patients with oesophageal 
or gastro-oesophageal junction cancer, a result that is in sharp contrast with the results 
from the Swedish study. The optimal threshold for this survival benefit was shown to be 
at least 23 nodes removed.8 A recent meta-analysis that compared TTO with extensive 
lymphadenectomy versus THO with limited lymphadenectomy in 5,905 patients from 
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52 studies, showed a similar 5-year survival after TTO or THO, while short-term recov-
ery was more favourable after THO. These results, however, must be interpreted with 
caution because the analysis included both non-randomized and randomized studies.7 
This limitation probably led to a selection bias in favour of the THO group, since more-
advanced tumours might have been treated with TTO. 
Finally, after publication of the results of the randomized CROSS II trial comparing 
neoadjuvant chemoradiotherapy followed by surgery versus surgery alone in patients 
with oesophageal cancer,9 this multimodal approach has become standard of care in 
many countries. The studies we have discussed mainly included patients who did not 
undergo neoadjuvant therapy. Neoadjuvant chemoradiotherapy has a marked down-
staging effect on the primary tumour as well as on the regional lymph nodes. This ‘steri-
lizing’ effect on lymph nodes theoretically diminishes the potential positive impact of 
extensive lymphadenectomy on survival. Therefore, separate analyses of patients who 
underwent neoadjuvant chemoradiotherapy plus surgery and patients who underwent 
surgery alone are mandatory. In the CROSS trial, the total number of resected nodes in 
patients who underwent surgery alone had a positive association with overall survival,10 
which correlates well with the already discussed international retrospective study.8 In-
terestingly, this relationship between the total number of resected nodes and overall 
survival was completely lost in the group receiving neoadjuvant chemoradiotherapy. 
The same phenomenon has been shown in a larger (albeit retrospective) study on 391 
patients who underwent surgery alone and 626 patients who underwent neoadjuvant 
chemoradiotherapy according to the same scheme as used in the CROSS trial, followed 
by surgery.11 These data suggest that maximal lymph-node retrieval is relevant in pa-
tients who undergo surgery alone, but question whether such an approach is necessary 
after neoadjuvant chemoradiotherapy. 
In conclusion, the effect of the extent of lymphadenectomy on survival remains con-
troversial. The available literature on this topic shows conflicting results, with personal 
opinions and institutional preferences continuing to dominate the choice of lymphade-
nectomy procedure. High-quality evidence is needed to reduce the variations in clinical 
practice. Future research should distinguish between patients treated with surgery alone 
and patients who undergo neoadjuvant therapy before surgery. Neoadjuvant therapy 
has been suggested to abolish any positive effect of extensive lymphadenectomy on 
survival, but this effect should be further explored, preferably in a randomized setting 
comparing TTO with THO after neoadjuvant chemoradiotherapy, and focused on truly 
oesophageal (Siewert type-1) tumours. One such trial is currently being initiated in the 
Netherlands and its results are eagerly awaited. 
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Abstract 
Objective 
To compare overall survival in patients with esophageal adenocarcinoma who under-
went transhiatal esophagectomy with limited lymphadenectomy (THE) or transthoracic 
esophagectomy with extended lymphadenectomy (TTE) with or without neoadjuvant 
chemoradiotherapy (nCRT).  
Background 
The application of neoadjuvant therapy might change the association between the extent 
of lymphadenectomy and survival in patients with esophageal adenocarcinoma. This 
may influence the choice of surgical approach in patients treated with nCRT. 
Methods 
Patients with potentially curable subcarinal esophageal adenocarcinoma treated with 
surgery alone or nCRT followed by surgery in 7 centers were included. The effect of 
surgical approach on overall survival, differentiated by the addition or omission of 
nCRT, was analyzed using a multivariable Cox regression model that included well-
known prognostic factors and factors that might have influenced the choice of surgical 
approach. 
Results 
In total, 701 patients were included, of whom 318 had TTE with extended lymphadenec-
tomy and 383 had THE with limited lymphadenectomy. TTE had differential effects on 
survival (p for interaction=0.02), with a more favorable prognostic effect in patients who 
were treated with surgery alone (hazard ratio [HR]=0.77, 95% confidence interval [CI] 
0.58–1.03). This association was statistically significant in a subgroup of patients with 1-
8 positive lymph nodes in the resection specimen (HR=0.62, 95% CI 0.43–0.90). The 
favorable prognostic effect of TTE over THE was absent in the nCRT plus surgery group 
(HR=1.16, 95% CI 0.80–1.66) and in the subgroup of nCRT-patients with 1 to 8 positive 
lymph nodes in the resection specimen (HR=1.00, 95% CI 0.61–1.68). 
Conclusions 
Compared to surgery alone, the addition of nCRT may reduce the need for TTE with 
extended lymphadenectomy in order to improve long-term survival in patients with 
esophageal adenocarcinoma. 
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Introduction 
The optimal surgical approach for the treatment of patients with esophageal adenocar-
cinoma is still under debate. Transhiatal esophagectomy (THE) with limited lymphade-
nectomy mainly focuses on a decrease of postoperative morbidity and mortality by pre-
venting a formal thoracotomy. The transthoracic esophagectomy (TTE) with extended 
two-field lymphadenectomy attempts to improve the radicality of the resection and thus 
to increase locoregional tumor control. TTE is, however, associated with increased post-
operative morbidity.1 
For esophageal carcinoma at or above the level of the carina TTE with a two-field 
lymph node dissection is mandatory. For adenocarcinomas located below the level of 
the carina, either TTE or THE can be performed, depending on surgeon’s preference 
and patient characteristics. For adenocarcinomas involving the esophagogastric junction 
and/or gastric cardia, a survival benefit for TTE over THE is theoretically unlikely and 
has never been proven.1 
Neoadjuvant therapy downstages the primary tumor as well as the regional lymph 
node metastases. The ‘sterilizing’ effect on lymph nodes theoretically reduces the poten-
tial positive impact of extended lymphadenectomy on survival.2, 3 This may have an 
impact on the required extent of lymphadenectomy in patients treated with neoadjuvant 
therapy and thus on the choice of the operative approach. 
Therefore, the objective of this study was to assess the effect of surgical approach 
(TTE with extended lymphadenectomy vs. THE with limited lymphadenectomy) on 
survival, differentiated by the addition or omission of neoadjuvant chemoradiotherapy 
(nCRT), in patients with a subcarinal esophageal adenocarcinoma treated with nCRT 
followed by surgery versus surgery alone. It was hypothesized that TTE is associated 
with a more favorable prognosis compared to THE in patients who have surgery alone, 
but that this benefit is absent in patients who receive nCRT before surgery. 
Methods 
Patients 
Patients were included with potentially curable subcarinal esophageal adenocarcinoma 
(including Siewert type 1). Included patients underwent surgery alone as standard of 
care in the Erasmus MC, Rotterdam (January 1996–January 2001) and in the Academic 
Medical Center (AMC), Amsterdam (January 1996-December 2004), nCRT followed by 
surgery as part of the phase 2 CROSS-I trial in the Erasmus MC4 (April 2001–March 
2004), surgery alone or nCRT followed by surgery as part of the phase 3 multicenter 
randomized CROSS-II trial in the seven participating centers5, 6 (June 2004–February 
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2009), or nCRT followed by surgery as standard of care at the Erasmus MC or the AMC 
(March 2009–August 2013). Only patients who underwent a transthoracic or transhiatal 
resection were included. The choice for surgical technique was driven by personal pref-
erences with both techniques performed in all participating centers, but after publica-
tion of the long-term results of the HIVEX trial in 2007 there was an overall shift to-
wards TTE.1 Patients with Siewert type 2 cancers were excluded, because a survival ben-
efit for TTE over THE is theoretically unlikely and has never been proven.1 Further-
more, patients who did not undergo at least 80% of the planned dose of chemo- and/or 
radiotherapy, who received a different nCRT regimen, who had signs of distant metasta-
ses at the time of surgery or in whom the tumor was not resected during surgery were 
excluded. The in- and exclusion criteria of the CROSS-II trial were retrospectively ap-
plied to all patients of the surgery alone group, i.e. all included patients that underwent 
the complete clinical staging protocol (see below) and had locally advanced disease at 
clinical staging (cT2-T4a and cT1N+).5 
Clinical staging 
Pretreatment staging procedures consisted of endoscopy with histological biopsy, endo-
scopic ultrasonography (with fine needle aspiration when indicated), CT scan of the 
neck, chest and abdomen and external ultrasonography of the neck (when indicated). 
PET scans were not routinely performed during the study period. Tumor location was 
determined by pretreatment endoscopy. Clinical T-stage and N-stage were determined 
by endoscopic ultrasonography and CT-scanning and/or fluorodeoxyglucose-PET-
scanning and (re)scored according to the Union for International Cancer Control 
(UICC) tumor node metastasis classification (TNM) Cancer Staging, 6th edition.7 
Treatment 
The nCRT regimen consisted of weekly administration of paclitaxel (50 mg/m2 body-
surface area) and carboplatin (area under the curve: 2 mg/ml/min) for five weeks and 
concurrent external beam radiotherapy  with a total dose of 41.4 Gy in 23 fractions, 5 
days per week. Patients underwent either TTE with extended lymphadenectomy or THE 
with limited lymphadenectomy. In both the transthoracic and the transhiatal approach, 
an upper abdominal lymphadenectomy was routinely performed, including removal of 
nodes along the origin of the left gastric artery, the hepatic artery and the splenic artery 
(lymph node stations 1-10 and 15-20 according to the American Joint Committee of 
Cancer 7th edition8). 
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Pathology 
All pathological data were collected from prospectively maintained databases. Histologi-
cal tumor type was determined in the pretreatment biopsy. The definition for a micro-
scopically radical resection (R0) was a tumor-free resection margin ≥ 1 mm. R1 was 
defined as a microscopically tumor-free resection margin <1 mm, with a macroscopical-
ly radical resection. Pathological T-stage and N-stage were (re)scored according to the 
UICC TNM Cancer Staging, 7th edition9, N0: no nodes positive; N1: 1-2 lymph nodes 
positive; N2: 3-6 lymph nodes positive; N3: ≥7 lymph nodes positive. 
Follow-up and data collection 
All clinical data were taken from prospectively collected institutional databases. Overall 
survival was determined using municipal registers. Disease free survival was defined as 
the interval between start of therapy and the earliest occurrence of disease recurrence. 
Statistical analysis 
Results are presented as frequencies with percentages for categorical variables or as 
medians with interquartile range in case of continuous variables. The treatment groups 
were compared using the Student’s t test or the Mann-Whitney test as adequate to com-
pare continuous variables, whereas χ2 test or Fisher’s exact test was used for comparison 
of categorical data. 
The association between surgical approach and survival was analyzed using a multi-
variable Cox regression model, including tests for interaction with the addition or omis-
sion of nCRT. Besides well-known prognostic factors (age, sex, American Society of 
Anesthesiologist [ASA] classification, pathological T stage and year of treatment), this 
model contained factors that might have influenced the preference of surgical approach 
(pulmonary and cardiovascular comorbidities and clinical N stage). The variables 
pathological N stage and radicality of resection were not included in the primary model, 
because these factors were believed to be potentially influenced directly by the type of 
surgical approach. As a sensitivity analysis, multivariable analysis was also performed 
after inclusion of these two additional parameters in the model. Statistical significance 
was set at p<0.05. 
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Results 
Patients 
A total of 701 patients were included with potentially curable subcarinal esophageal 
adenocarcinoma, of whom 358 were treated with surgery alone and 343 underwent 
nCRT followed by surgery. In the surgery alone group 107 patients had TTE and 251 
had THE, in the nCRT group this was 221 and 132, resp. Median age at diagnosis was 63 
years in the surgery alone group and 61 years in the multimodality group (Table 1a and 
1b). The majority of patients were male (85% and 86%, resp.), most often clinically 
staged as cT3 (72% and 77%, resp.). Statistically significant  differences in pretreatment 
characteristics were observed between the surgery alone group and nCRT plus surgery 
group for clinical N-stage (47% clinically node positive in the surgery alone group vs 
69% in the nCRT plus surgery group, p<0.01). Furthermore, THE was performed signif-
icantly more often in the surgery alone group as compared to the nCRT plus surgery 
group. Within the surgery alone group patients who underwent TTE were significantly 
younger (median age 62 vs. 65, p<0.01) and had better ASA-classification scores 
(p<0.01). On the other hand, these patients had significantly more advanced tumors, 
based on clinical T and N staging (p=0.02 and p=0.04, respectively). In the nCRT group, 
patients who underwent TTE were also younger and had better ASA-classifications, 
although these differences were not statistically significant. Also, nCRT patients treated 
with TTE were more often clinically staged pretreatment as node positive (p=0.02). 
Lymph node retrieval 
The median number (interquartile range) of resected lymph nodes in patients who un-
derwent surgery alone was 26 (18 - 36) in the TTE group and 14 (8 – 18) in the THE 
group (p<0.01). In patients treated with nCRT followed by surgery these numbers were 
21 (16 – 28) and 12 (7 – 16), respectively (p<0.01). 
Overall survival 
In multivariable Cox regression analysis including the parameters age, gender, ASA-
classification, pathological T stage, pulmonary and cardiovascular comorbidities and 
clinical N stage, TTE had differential effects on overall survival in patients who under-
went surgery alone compared to patients who underwent nCRT plus surgery (p for 
interaction=0.02). TTE was independently associated with a more favorable prognosis 
in patients who were treated with surgery alone (hazard ratio [HR] 0.77, 95% confidence 
interval [CI] 0.58 – 1.03, p=0.08, Table 2). Results were comparable in a subgroup of 
patients with clinically suspected lymph node involvement (HR 0.69, 95% CI 0.47 – 
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1.02, p=0.07), whereas in a subgroup of patients who had surgery alone and 1 to 8 posi-
tive lymph nodes in the resection specimen, this association was statistically significant 
(HR 0.62, 95% CI 0.43 – 0.90, p=0.01). The favorable prognostic effect of TTE over THE 
after surgery alone was absent in the nCRT followed by surgery group (HR 1.16, 95% CI 
0.80 – 1.66, p=0.44, Table 2) and in the subgroups of nCRT patients with clinically sus-
pected lymph node involvement (HR 1.35, 95% CI 0.87 – 2.14, p=0.18) and with 1 to 8 
positive lymph nodes in the resection specimen (HR 1.00, 95% CI 0.61 – 1.68, p=0.98).  
Addition of pathological N-stage and radicality of resection to the Cox regression 
models showed comparable results: HR 0.78 in favor of TTE, 95% CI 0.59 – 1.04, 
p=0.09, for patients in the surgery alone group and HR 0.99, 95% CI 0.69 – 1.43, p=0.97, 
for patients who underwent nCRT followed by surgery. 
Disease free survival 
Analysis of disease free survival was performed using the same Cox regression model.  
TTE had differential effects on disease free survival in the surgery alone group com-
pared to the nCRT plus surgery group (p for interaction=0.03). TTE was associated with 
a more favorable disease free survival in patients who had surgery alone (HR 0.79, 95% 
[CI] 0.58 – 1.07, p=0.13, Table 3), whereas this favorable effect was absent and even 
slightly but not significantly reversed in patients who received nCRT plus surgery (HR 
1.27, 95% CI 0.85 – 1.91, p=0.24). 
Discussion 
The present study shows that the choice of surgical technique has a differential effect on 
overall survival in patients with subcarinal esophageal adenocarcinoma who underwent 
surgery alone compared to patients who received nCRT prior to surgery.  TTE was in-
dependently associated with a more favorable prognosis in patients who underwent 
surgery alone, especially in patients with a limited number of positive lymph nodes. This 
benefit was, however, absent in patients who underwent nCRT. 
A retrospective analysis of 2,303 patients (60% AC, 40% SCC) who underwent R0-
resections, showed that the total number of resected nodes is an independent prognostic 
factor of (favorable) survival after surgery alone.10 These findings are indirect arguments 
in favor of TTE over THE in patients treated without nCRT. In contrast, a non-
randomized study by two British high-volume centers showed comparable long-term 
survival after THE and TTE for patients with SCC (12%) or AC (88%).11 These results 
were confirmed in a meta-analysis of 52 studies that included 3,389 TTE patients and 
2,516 THE patients (48% SCC, 52% AC).12 It should be noted that this meta-analysis 
included both randomized and non-randomized studies. This probably led to a selection 
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bias in favor of the patients who underwent THE, because the more advanced tumors 
probably were selected to undergo a thoracotomy. On the other hand, THE might have 
been the preferred technique in frail patients in order to minimize complications by 
avoiding a thoracotomy. Hence, due to the unknown effects of these confounding fac-
tors, results must be interpreted with caution. 
The HIVEX trial randomly assigned 220 patients with esophageal AC located both 
below the carina (Siewert type-1) and of the gastric cardia (Siewert type-2) to primary 
TTE or THE (without nCRT). The higher lymph node yield in the TTE group of the 
HIVEX trial (median 31 vs. 16, resp., p<0.001), treated by surgery without nCRT, did 
not translate into a significantly increased five-year overall survival rate. However, pa-
tients with a truly esophageal adenocarcinoma treated with TTE, and more specifically 
those with a limited number (1–8) of positive lymph nodes, had a significantly im-
proved 5-year overall survival compared to THE patients (39% after TTE vs. 19% after 
THE, 95% CI for the difference 3% to 37%, p=0.05), which is confirmed by the current 
study. The final conclusion of the HIVEX trial was that in patients with advanced truly 
esophageal adenocarcinoma, especially with a limited number of positive nodes, TTE 
should be the preferred technique, while THE should be regarded as the preferred tech-
nique in patients with a tumor located at the EGJ or in patients with a poor performance 
status (especially in case of pulmonary comorbidities), in absence of clinically suspected 
lymph nodes at or above the level of the carina.1 For that reason, these variables were 
included in the multivariable Cox regression model of the present study.  Based on the 
long-term results of the HIVEX trial, there was a shift in preferred surgical technique 
over time for truly esophageal adenocarcinoma from of THE to TTE, which is reflected 
in the proportions of TTE and THE during the time period of the present study. 
It has been reported that nCRT decreases the number of lymph nodes detected in the 
resection specimen,  which is also reflected by the results of the present study.13-15 Fur-
thermore, in a post-hoc analysis of the CROSS-II trial, the total number of resected 
nodes was correlated with improved overall survival after surgery alone (HR per 10 
additionally resected nodes 0.76, 95% CI 0.61–0.95, p=0.007), which corresponds with 
the above described retrospective international study.2, 10 However, this correlation was 
absent in patients pretreated with nCRT (HR 1.00, 95% CI 0.84–1.25 p=0.98). The ran-
domized design of the CROSS trial excludes selection bias as an explanation for this 
finding. Therefore, these results question the necessity of extended lymph node dissec-
tion in patients treated with nCRT. 
The same phenomenon was shown in a recent retrospective propensity matched 
comparison of 301 patients who underwent perioperative chemotherapy combined with 
surgery and 307 patients who underwent nCRT followed by surgery. In the nCRT 
group, total lymph node harvest and survival were not associated. Interestingly, in the 
perioperative chemotherapy group, the number of resected nodes was positively corre-
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lated with progression free survival. These data suggest, that TTE might be beneficial in 
patients treated with perioperative chemotherapy but not after nCRT.16 This difference 
in effect of lymphadenectomy might be explained by the substantial ‘sterilizing’ effect of 
radiotherapy on the regional lymph nodes. 
If the results of the present analysis can be confirmed in future studies, factors such 
as the risk for postoperative complications, patient’s quality of life and surgeon’s prefer-
ence may determine the choice of surgical approach in patients treated with nCRT, 
rather than the impact on long-term survival. In the last decade, minimally invasive 
techniques are increasingly applied in esophageal cancer surgery, with the potential 
advantage of limitation of surgical trauma, possibly without jeopardizing the potential 
to perform a radical resection with extensive lymphadenectomy. Although the necessity 
of the latter is questioned after nCRT by the results of the present and earlier studies, an 
additional advantage of a thoracic approach is the possibility to perform an intrathorac-
ic anastomosis, instead of the cervical anastomosis that is always required when using 
the transhiatal technique. Multiple studies have suggested a lower leakage rate after an 
intrathoracic anastomosis compared to a cervical anastomosis and this is currently be-
ing investigated in the Dutch randomized iCAN-trial.17, 18 Consequently, in the absence 
of oncological benefit for TTE and if minimally invasive transthoracic techniques can 
reduce the incidence of postoperative (pulmonary) complications to rates comparable to 
that of THE, this lower anastomotic leakage rate might be ultimately decisive in the 
choice of surgical approach after nCRT.  
This study has some limitations including its retrospective design. The multivariable 
Cox regression analysis controlled for important factors that are known to influence the 
choice of surgical approach and long-term survival. There are probably other confound-
ing factors between the two groups, and both cN status and ASA-classification are sub-
jective parameters. In the surgery-alone group, less patients had clinically suspected 
lymph nodes and cN stage does not associated with survival, highlighting the limited 
accuracy of clinical N-staging, particularly in that time period. Nevertheless, addition of 
cardiovascular and pulmonary comorbidities in the regression model further strength-
ens the correction for comorbidities, whereas the sensitivity analysis with pN stage 
(which is more accurate than cN stage) included showed results comparable to the orig-
inal model. Therefore, we feel that correction for more advanced disease and nodal 
positivity in the TTE group is adequate. Moreover, the exact location of suspected re-
gional lymph nodes, which may have influenced the choice between TTE and THE, was 
not available for the included patients. Furthermore, the time period in which these 
patients were included was relatively long (1996-2013), which might have introduced 
bias between patients who underwent surgery alone and those who underwent nCRT 
followed by surgery (e.g. improved staging as a result of the introduction of PET-CT, 
which was performed routinely for cT3 tumors since 2012). To improve homogeneity 
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between both treatment groups, patients in the surgery alone group were retrospectively 
selected following the inclusion criteria of CROSS-I and -II trials and year of treatment 
was included in the Cox regression model.5, 6, 7 
Conclusion 
In conclusion, compared to surgery alone, the addition of nCRT may reduce the need 
for TTE with extended lymphadenectomy in order to improve long-term survival in 
patients with subcarinal esophageal adenocarcinoma.  
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Table 1a. Pretreatment characteristics in 358 patients with potentially curable subcarinal esophageal adeno-
carcinoma, treated with surgery alone. 
  total  TTE  THE  
  (n= 358)  (n= 107)  (n= 251)  
  1996 – 2009   
  n (%)*  n (%)*  n (%)* p ** 
age [years]       <0.01 
 median (p25 – p75)  63 (56 – 70)  62  (54 – 68)  65 (57 – 72)  
        
gender          0.49 
 female  54 (15)  14 (13)  40 (16)  
 male  304 (85)  93 (87)  211 (84)  
           
cT-stage‡          0.02 
 cT1  4 (2)  1 (1)  3 (1)  
 cT2  83 (25)  16 (15)  67 (28)  
 cT3  256 (72)  90 (84)  166 (69)  
 cT4a  3 (2)  0 (0)  3 (1)  
 missing  12   0   12   
           
cN-stage‡       0.04 
 cN0  164 (53)  40 (38)  124 (50)  
 cN1  188 (47)  65 (62)  123 (50)  
 missing  6   2   4   
           
ASA classification          <0.01 
 I  66 (16)  29 (28)  37 (15)  
 II  233 (66)  66 (64)  167 (67)  
 III and IV  52 (17)  8 (8)  44 (18)  
 missing  7   4   3   
* Data presented as median (interquartile range) or number (%). Percentages may not add up to 100 due to 
rounding. 
** Data were compared between the surgery alone and nCRT plus surgery groups using Student’s t-test for 
continuous variables and χ2 test for categorical variables. 
‡ Clinical T-stage and N-stage were determined by endoscopic ultrasonography and/or CT-scanning and/or 
FDG-PET-scanning according to the Union for International Cancer Control (UICC) TNM Cancer Staging, 
6th edition.7 
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Table 1b. Pretreatment characteristics in 343 patients with potentially curable subcarinal esophageal adeno-
carcinoma, treated with neoadjuvant chemoradiotherapy followed by surgery. 
  total  TTE  THE  
  (n= 343)  (n= 211)  (n= 132)  
  2001 – 2013   
  n (%)*  n (%)*  n (%)* p ** 
age [years]       0.11 
 median (p25 – p75)  61 (56 – 70)  61  (55 – 69)  64 (56 – 71)  
        
gender          0.08 
 female  48 (14)  35 (17)  13 (10)  
 male  295 (86)  176 (83)  119 (90)  
           
cT-stage‡          0.61 
 cT1  4 (1)  3 (1)  1 (1)  
 cT2  69 (21)  42 (21)  27 (21)  
 cT3  257 (77)  158 (77)  99 (76)  
 cT4a  4 (1)  1 (0)  3 (2)  
 missing  9   7   2   
           
cN-stage‡       0.02 
 cN0  110 (31)  57 (28)  53 (40)  
 cN1  226 (69)  148 (72)  78 (60)  
 missing  7   6   1   
           
ASA classification          0.07 
 I  70 (21)  50 (24)  20 (15)  
 II  210 (63)  126 (62)  84 (64)  
 III and IV  56 (17)  29 (14)  27 (21)  
 missing  7   6   1   
* Data presented as median (interquartile range) or number (%). Percentages may not add up to 100 due to 
rounding. 
** Data were compared between the surgery alone and nCRT plus surgery groups using Student’s t-test for 
continuous variables and χ2 test for categorical variables. 
‡ Clinical T-stage and N-stage were determined by endoscopic ultrasonography and/or CT-scanning and/or 
FDG-PET-scanning according to the Union for International Cancer Control (UICC) TNM Cancer Staging, 
6th edition.7 
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Table 2. Multivariable Cox regression analysis comparing transthoracic esophagectomy with transhiatal 
esophagectomy in patients who underwent surgery alone or neoadjuvant chemoradiotherapy (nCRT) fol-
lowed by surgery including the variables age, gender, ASA-classification, pulmonary and cardiovascular 
comorbidities, clinical N stage (cN) and  pathological T stage (pT). 
 surgery alone  nCRT plus surgery 
 (n=358)  (n=343) 
 1996 – 2009  2001 – 2013 
 HR 95% CI p  HR 95% CI p 
surgical approach         
 transhiatal approach 1 (ref) – –  1 (ref) – – 
 transthoracic approach  0.77 (0.58 – 1.03) 0.08  1.16 (0.80 – 1.66) 0.44 
        
age 1.01 (1.00 – 1.03) 0.09  1.01 (0.99 – 1.03) 0.32 
        
gender        
 male 1 (ref) – –  1 (ref) – – 
 female 0.94 (0.66 – 1.33) 0.72  0.86 (0.55 – 1.32) 0.48 
        
ASA         
 I 1 (ref) – –  1 (ref) – – 
 II 1.00 (0.71 – 1.40) 0.99  1.03 (0.70 – 1.54) 0.86 
 III and IV 1.12 (0.69 – 1.80) 0.65  1.57 (0.93 – 2.63) 0.09 
        
pulmonary comorbidities        
 no  1 (ref) – –  1 (ref) – – 
 yes 1.34 (0.93 – 1.92) 0.12  1.25 (0.86 – 1.81) 0.19 
        
cardiovascular comorbidities         
 no  1 (ref) – –  1 (ref) – – 
 yes 0.88 (0.67 – 1.17) 0.39  1.00 (0.74 – 1.38) 0.97 
        
cN-stage         
 cN0 1 (ref) – –  1 (ref) – – 
 cN-positive 1.13 (0.88 – 1.47) 0.34  1.50 (1.08 – 2.08) 0.02 
        
(y)pT-stage        
 ypT0 – – –  1 (ref) – – 
 (y)pT1 1 (ref) – –  1.34 (0.81 – 2.20) 0.26 
 (y)pT2 1.58 (0.87 – 2.89) 0.14  1.36 (0.83 – 2.22) 0.22 
 (y)pT3/4 4.85 (2.85 – 8.24) <0.01  1.89 (1.27 – 2.81) 0.02 
        
Year of treatment 0.95 (0.92 – 0.99) 0.01  0.98 (0.93 – 1.04) 0.58 
HR: hazard ratio, CI: confidence interval 
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Table 3. Multivariable Cox regression analysis for disease free survival comparing transthoracic esophagecto-
my with transhiatal esophagectomy in patients who underwent surgery alone or neoadjuvant chemoradiother-
apy (nCRT) followed by surgery including the variables age, gender, ASA-classification, pulmonary and 
cardiovascular comorbidities, clinical N stage (cN) and  pathological T stage (pT). 
 surgery alone  nCRT plus surgery 
 (n=332*)  (n=321*) 
 1996 – 2009  2001 – 2013 
 HR 95% CI p  HR 95% CI p 
surgical approach         
 transhiatal approach 1 (ref) – –  1 (ref) – – 
 transthoracic approach  0.79 (0.58 – 1.07) 0.13  1.27 (0.85 – 1.91) 0.24 
        
age 1.01 (0.99 – 1.02) 0.41  1.00 (0.98 – 1.02) 0.72 
        
gender        
 male 1 (ref) – –  1 (ref) – – 
 female 0.93 (0.65 – 1.35) 0.71  0.79 (0.48 – 1.30) 0.35 
        
ASA         
 I 1 (ref) – –  1 (ref) – – 
 II 0.92 (0.64 – 1.30) 0.62  1.04 (0.67 – 1.60) 0.86 
 III and IV 1.04 (0.63 – 1.70) 0.89  1.07 (0.58 – 1.99) 0.83 
        
pulmonary comorbidities        
 no  1 (ref) – –  1 (ref) – – 
 yes 1.25 (0.84 – 1.85) 0.28  1.05 (0.65 – 1.77) 0.82 
        
cardiovascular comorbidities         
 no  1 (ref) – –  1 (ref) – – 
 yes 0.92 (0.68 – 1.24) 0.57  0.86 (0.60 – 1.22) 0.39 
        
cN-stage         
 cN0 1 (ref) – –  1 (ref) – – 
 cN-positive 1.05 (0.80 – 1.39) 0.71  1.79 (1.22 – 2.64) <0.01 
        
(y)pT-stage        
 ypT0 – – –  1 (ref) – – 
 (y)pT1 1 (ref) – –  1.38 (0.67 – 2.52) 0.29 
 (y)pT2 2.87 (1.23 – 6.71) 0.02  1.54 (0.87 – 2.74) 0.14 
 (y)pT3/4 7.81 (3.63 – 16.82) <0.01  2.34 (1.47 – 3.72) <0.01 
        
Year of treatment 0.96 (0.92 – 1.00) 0.03  0.99 (0.93 – 1.05) 0.68 
HR: hazard ratio, CI: confidence interval *26 patients in the surgery alone group and 22 patients in the nCRT 
group had missing data regarding disease free survival. 
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Abstract 
Purpose 
To compare pre-agreed health-related quality of life (HRQOL) domains in patients with 
esophageal or junctional cancer who received neoadjuvant chemoradiotherapy (nCRT) 
followed by surgery or surgery alone. Secondary aims were to examine the effect of 
nCRT on HRQOL before surgery and the effect of surgery on HRQOL.  
Patients and Methods 
Patients were randomly assigned to nCRT (carboplatin plus paclitaxel with concurrent 
41.4-Gy radiotherapy) followed by surgery or surgery alone. HRQOL was measured 
using the European Organisation for Research and Treatment of Cancer Quality of Life 
Questionnaire–Core 30 (QLQC30) and –Oesophageal Cancer Module (QLQ-OES24) 
questionnaires pretreatment and at 3, 6, 9, and 12 months postoperatively. The nCRT 
group also received preoperative questionnaires. Physical functioning (PF; QLQ-C30) 
and eating problems (EA; QLQ-OES24) were chosen as predefined primary end points. 
Predefined secondary end points were global QOL (GQOL; QLQ-C30), fatigue (FA; 
QLQ-C30), and emotional problems (EM; QLQ-OES24).  
Results 
A total of 363 patients were analyzed. No statistically significant differences in postoper-
ative HRQOL were found between treatment groups. In the nCRT group, PF, EA, 
GQOL, FA, and EM scores deteriorated 1 week after nCRT (Cohen’s d -0.93, p<0.001; 
0.47, p<0.001; -0.84, p<0.001; 1.45, p<0.001 and 0.32, p=0.001, respectively). In both 
treatment groups, all end points declined 3 months postoperatively compared with 
baseline (Cohen’s d -1.00; 0.33; -0.47; -0.34 and 0.33, resp., all p<0.001), followed by a 
continuous gradual improvement. EA, GQOL, and EM were restored to baseline levels 
during follow-up, whereas PF and FA remained impaired 1 year postoperatively (Co-
hen’s d 0.52 and -0.53, respectively, both p<0.001). 
Conclusion 
Although HRQOL declined during nCRT, no effect of nCRT was apparent on postoper-
ative HRQOL compared with surgery alone. In addition to the improvement in survival, 
these findings support the view that nCRT according to the Chemoradiotherapy for 
Esophageal Cancer Followed by Surgery Study–regimen can be regarded as a standard 
of care. 
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Introduction 
Esophageal cancer is characterized by high recurrence rates and poor 5-year survival after 
primary surgical resection.1 To improve the radicality of surgery and long-term survival, 
many trials on the added value of neoadjuvant therapy have been undertaken.2-8 
One of the largest and most recent trials is the Chemoradiotherapy for Esophageal 
Cancer Followed by Surgery Study (CROSS). The randomized CROSS trial compared 
carboplatin plus paclitaxel– based neoadjuvant concurrent chemoradiotherapy (nCRT) 
regimen plus surgery with surgery alone in patients with esophageal or esophagogastric 
junctional cancer from eight centers in the Netherlands. Long-term results showed a 
statistically significant and clinically relevant increase in survival for both squamous cell 
and adenocarcinoma subtypes, with acceptable toxicity.9, 10 On the basis of these results, 
the CROSS regimen is now standard treatment in many countries.  
The enhanced emphasis on health-related quality of life (HRQOL) and other pa-
tient-reported outcome measures assumes a more prominent role for these factors as 
end points in clinical cancer trials.11 An esophagectomy is a major operation with sub-
stantial morbidity and mortality and may have a profound effect on patients’ QOL.12-14 
However, in the field of esophageal cancer, only limited high-quality data on HRQOL 
are available. So far, HRQOL data have been reported in two randomized esophageal 
cancer trials, which compared transthoracic versus transhiatal esophagectomy in pa-
tients who underwent primary surgery without neoadjuvant therapy and primary sur-
gery versus definitive CRT.15, 16 Results from randomized trials in patients with esopha-
geal cancer investigating the effect of combined neoadjuvant therapy and surgery on 
HRQOL have not yet been published. The available evidence comes from two small 
observational studies. Both studies suggested that the addition of nCRT to surgery had 
no influence on postoperative HRQOL, but they were likely influenced by selection bias 
and lacked statistical power.17, 18  
The primary aim of this substudy of the CROSS trial, with HRQOL as a secondary 
end point, was to compare HRQOL in patients with esophageal or junctional cancer 
who received nCRT plus surgery or surgery alone. Furthermore, the effect of nCRT on 
HRQOL before surgery and the effect of surgery on HRQOL were examined over time. 
It was hypothesized that nCRT impairs HRQOL before surgery but does not affect post-
operative recovery in terms of HRQOL. 
Patients and methods 
Details of this randomized trial have been reported previously and are summarized in 
the Appendix Trial Design (online only).9, 10, 19  
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HRQOL measurement  
The self-report questionnaires were mailed after random assignment and 3, 6, 9, and 12 
months postoperatively. Postoperative HRQOL was compared between both groups 
using date of surgery as reference point. Patients who were randomly assigned to the 
nCRT group also received questionnaires 1 week after nCRT (ie, 3 to 5 weeks before 
surgery). Cancer-specific HRQOL was measured with the European Organisation for 
Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire–Core 30 
(QLQ-C30), a validated self-report questionnaire for patients with cancer.20 Tumor-
specific HRQOL was measured by the EORTC QLQ–Oesophageal Cancer Module 
(QLQ-OES24), because the currently used derivative QLQ-OES18 was not yet 
available.21 End points were predefined by consensus discussion with experienced up-
per-GI surgical oncologists, medical oncologists, and nurse practitioners before analysis 
of the data. End points were selected based on clinical relevance and hypothesized asso-
ciation with nCRT. This led to the primary end points of physical functioning (PF; 
QLQ-C30) and eating problems (EA; QLQ-OES24). Secondary end points were defined 
as global QOL (GQOL; QLQ-C30), fatigue (FA; QLQ-C30), and emotional problems 
(EM; QLQ-OES24). 
Statistical analysis 
Data were analyzed on an intention-to-treat basis, with comparison of HRQOL as pri-
mary objective. Pretreatment characteristics were compared using the Mann-Whitney 
or Student’s t test for continuous variables and the x2 or Fisher’s exact test for categori-
cal data. Questionnaire scores were computed according to EORTC guidelines.22 Base-
line HRQOL scores were compared using the Student’s t test. Differential effects over 
time between treatment groups and longitudinal comparison of the baseline scores and 
scores from follow-up measurements (3, 6, 9, and 12 months postoperatively) were 
performed using mixed modeling. If there were no statistically significant differences 
over time between both groups, baseline scores and scores from the postoperative meas-
urements of both groups were combined to analyze longitudinal HRQOL. Use of mixed 
modeling enabled the analysis of all data, because it allowed for inclusion of question-
naire scores from patients with different numbers of completed measurements.23 There-
fore, the statistical analyses included data from patients who were unable to complete 
the questionnaires on one or more occasions and from those who dropped out during 
the trial. Mean differences over time and differential effects over time between treatment 
groups were described for statistically significant outcomes. Cohen’s d (CD) effect sizes 
were calculated to give an indication of the clinical relevance of effects and to enable 
standardized comparison between results from different outcome variables. CD effect 
sizes were derived from the beta estimates in the mixed modeling procedure through 
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standardization of both outcome and predictor variables. CD values of 0.2, 0.5, and 0.8 
indicate small, medium, and large effects, respectively.24 Values ≥0.5 were considered 
clinically relevant.25 In a separate analysis, recurrence of disease and death in the subse-
quent time period were included as control variables, which enabled the evaluation of 
possible effect of recurrence of disease and death on the trajectory of HRQOL scores. 
Recurrence of disease was defined as the earliest occurrence of disease progression re-
sulting in irresectability, locoregional recurrence (after completion of therapy), or dis-
tant dissemination (before, during, or after treatment). To correct for multiple testing, 
statistical significance was set at p<0.01 (the main analyses included five comparisons, 
and thus, a Bonferroni correction of .05/5 was applied), except for baseline comparisons. 
For those latter analyses, p<0.05 was considered significant. All reported P values are 
two sided. Statistical analysis was performed using Statistical Package for the Social 
Sciences software, version 21.0 (SPSS, Chicago, IL). 
Results 
Of the 368 randomly assigned patients, 363 were included in the HRQOL analysis. Two 
withdrew consent, two were enrolled in the trial before the HRQOL study started, and 
one center (which included one patient) did not participate in the HRQOL study (Fig 1). 
There were no clinically relevant differences in pretreatment characteristics between 
groups (Table 1). Because of an administrative error, 89 patients did not receive baseline 
questionnaires (nCRT group, n = 58; surgery-alone group, n = 31). These patients were 
not excluded, because their baseline characteristics did not differ significantly from the 
study population (data not shown), and follow-up questionnaires were correctly com-
pleted.  
Overall response rates at the different measurement points were 54% to 76% and 
were lower in the surgery-alone group than in the nCRT group (Table 2). At each meas-
urement point, pretreatment characteristics (age, sex, tumor location, cT stage, cN stage, 
and WHO performance status) of patients who completed the questionnaires were not 
statistically different between the two groups (data not shown). In the nCRT group, the 
median time to surgery calculated from the day of last radiation treatment was 46 days 
(interquartile range, 40 to 55 days). Mean scores of HRQOL domains that were not 
predefined end points are listed in Table 3. 
Predefined primary end points  
PF. As shown in Figure 2A, baseline PF levels and all changes over time were compara-
ble between groups (p=0.60 and p=0.18, respectively). PF declined at 3months postop-
eratively (-18, p<0.001; CD -1.00, 95% CI -1.14 – -0.86) and improved from 3 to 6 
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months postoperatively (+5, p<0.001; CD 0.30, 95% CI 0.18 – 0.41). From then, the 
improvement was no longer statistically significant (9 vs. 6 months, p=0.07; 12 vs. 9 
months, p=0.27), and baseline levels were not reached during follow-up (-8, p<0.001, 
CD -0.53, 95% CI -0.67 – -0.39). In the nCRT group, PF declined 1 week after nCRT (-
17, p<0.001; CD -0.93, 95% CI -1.12  – -0.74).  
EA. As shown in Figure 2B, no statistically significant differences in EA were found 
at baseline (p=0.20), and changes over time were comparable between groups (p=0.45). 
Three months postoperatively, EA had worsened in both groups (+8, p<0.001; CD 0.32, 
95% CI 0.15 – 0.50) and thereafter improved from 3 to 6 months (-9, p<0.001; CD -0.32, 
95% CI -0.44 – -0.20) and from 6 to 9 months (+5, p=0.001; CD -0.22, 95% CI -0.34 – -
0.09). In both groups, 6 months postoperatively, EA levels returned to baseline (p=0.98), 
and no further improvement was found after 12months of follow-up compared with 
baseline levels (p=0.01). The nCRT group reported a deterioration in EA 1 week after 
completion of nCRT (+12, p=0.001; CD 0.47, 95% CI 0.21 – 0.72). 
Predefined secondary end points. 
GQOL. As shown in Figure 2C, baseline GQOL scores and all changes in GQOL over 
time were comparable between groups  (p=0.53 and p=0.76, respectively). GQOL scores 
significantly declined 3 months postoperatively (-10, P = 0.002; CD -0.47, 95% CI -0.62 
– -0.31), improved between 3 and 6 months postoperatively (+4, p=0.001; CD 0.24, 95% 
CI 0.10  – 0.37), reached baseline levels 9 months postoperatively (p=0.31), and stabi-
lized subsequently (p=0.34). Compared with baseline, patients in the nCRT group re-
ported significantly worse GQOL 1 week after nCRT (-17, p<0.001; CD -0.84, 95% CI -
1.08 – -0.60).  
FA. As shown in Figure 2D, baseline FA levels were comparable between groups 
(p=0.42), and there were no statistically significant differences in changes over time 
(p=.30). Postoperatively, FA levels worsened (+24, p<0.001; CD 1.01, 95% CI 0.86 – 
1.16) but subsequently improved in the periods from 3 to 6 months (-8, p<0.001; CD -
0.34, 95% CI -0.46 – -0.22). Thereafter, FA levels remained stable from 6 to 9 months 
(p=0.04) and from 9 to 12 months (p=0.58) but did not return to baseline levels (+10, 
p<0.001; CD 0.52, 95% CI 0.38 – 0.65). In the nCRT group, a significant deterioration 
was reported 1 week after nCRT (+34, p<0.001, CD 1.45, 95% CI 1.23 – 1.66). 
EM. As shown in Figure 2E, baseline EM scores were comparable between groups 
(p=0.26), and both groups reported comparable changes over time (p=0.75). Three 
months postoperatively, EMworsened (+8, p<0.001; CD 0.33, 95% CI 0.18 – 0.49) but 
improved from 3 to 6 months (-6, p<0.001; CD -0.26, 95% CI -0.40 – -0.13) and from 6 
to 9 months (-5, p=0.003; CD -0.22, 95% CI -0.36 – -0.08) postoperatively and stabilized 
thereafter (9 to 12 months, p=0.74). Baseline levels were reached at 6 months (p=0.39) 
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and stabilized thereafter (p=0.05). Patients in the nCRT group reported a deterioration 
in EM 1 week after nCRT (+9, p=0.001; CD 0.32, 95% CI 0.14 – 0.50).  
Results of the model including randomized grouping for longitudinal effects are 
shown in Appendix Tables A1 to A5. 
Influence of recurrence of disease and death 
Inclusion of recurrence of disease and death as control variables did not influence the 
overall trends in HRQOL trajectories (data not shown). However, the deterioration and 
restoration of primary and secondary end points during follow-up were worse for pa-
tients who developed recurrent disease and for patientswho died in the subsequent time 
period (data not shown). Patients in the surgery-alone group who died during follow-up 
showed themost severe deteriorations, especially in the 6- and 9-month follow-up 
measures. 
Influence of missing baseline questionnaires 
Availability of a completed baseline questionnaire was included as control variable. 
Inclusion of this variable did not influence the described overall trends in HRQOL 
trajectories (data not shown). 
Discussion 
This randomized trial did not show statistically significant differences in postoperative 
HRQOL in patients with esophageal or junctional cancer treated with a multimodality 
regimen based on carboplatin plus paclitaxel with 41.4 Gy of concurrent radiotherapy 
plus surgery, compared with patients who underwent surgery alone. Patients in the 
nCRT group experienced deterioration in all HRQOL end points immediately after 
completion of nCRT, but this did not affect recovery during the first postoperative year 
in terms of HRQOL.  
In both treatment groups, all primary and secondary HRQOL end points declined 
postoperatively, but most were restored to pretreatment levels within 1 year 
postoperatively. GQOL, EA, and EM reached baseline levels 6 months (GQOL and EA) 
and 9 months postoperatively (EM) and stabilized from then. However, PF and FA 
levels were not restored to pretreatment levels during the first year of follow-up, and 
corresponding effect sizes were clinically relevant (CD,-0.53 and 0.52, respectively). The 
scores of these domains stabilized 6 and 9 months postoperatively, which suggests that 
further spontaneous improvement to be unlikely. 
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This study is the first clinical trial and the largest available analysis to our knowledge 
comparing HRQOL in patients with esophageal cancer who underwent neoadjuvant 
therapy plus surgery or surgery alone. Two small observational studies have suggested 
that postoperative HRQOL is not affected by addition of nCRT to surgery, but these 
studies used different nCRT regimens and were criticized because of the potential 
influence of selection bias and lack of statistical power.17, 18 The randomized design of 
our study largely excludes selection bias, and the relatively large sample size increases 
the power to detect small but clinically relevant differences. Hence, these results 
demonstrate more reliably that postoperative HRQOL is not affected by nCRT, thereby 
confirming the results fromthese previous studies. These findings can help clinicians 
and patients to make more properly informed treatment decisions, especially patients 
who fear the negative effect of neoadjuvant treatment. Besides the relatively low toxicity 
and the strong effect on survival after nCRT plus surgery according to CROSS,9, 10 the 
comparable effect on postoperative HRQOL with surgery alone confirms that the 
benefits of this effective regimen outweigh its harms. Nevertheless, it should be noted 
that the application of nCRT delays surgery and subsequent postoperative recovery by 2 
to 3 months. This delay is substantial, especially for patients who turn out to be 
nonsurvivors. Furthermore, the long-term effects of adding nCRT to surgery on 
HRQOL are largely unknown and need to be further explored. Although it has been 
shown that nCRT containing cisplatin and fluorouracil with 66 Gy of concurrent 
radiotherapy significantly hampers long-term HRQOL, the CROSS regimen 
theoretically may have fewer negative effects because of the mild toxicity of the applied 
chemotherapeutic agents and the relatively low radiation dose.26 
In line with our study, a profound deterioration in HRQOL scores immediately after 
completion of nCRT has been described in the phase II CROSS-I trial and other 
observational studies.17, 18, 27 This decline in all end points 1 week after completion of 
nCRT is explained by persisting adverse effects of chemotherapy and radiotherapy, such 
as anorexia, FA, esophagitis, and hematologic toxicity. This emphasizes the need for 
sufficient time between nCRT and surgery, which allows patients to recover and reach 
more optimal physical condition before surgery. Earlier studies have suggested that 
postponement of surgery to at least 12 weeks after nCRT does not jeopardize long-term 
oncologic outcome and even tends to increase the pathologic complete response rate, 
which might improve prognostication.28, 29 Unfortunately, no HRQOL assessment was 
performed during nCRT or just before surgery. In clinical practice, we have witnessed 
general improvements in patients’ condition in the period between nCRT and surgery. 
Therefore, we recommend timing of surgery to be guided by patients’ condition, and we 
advocate that surgery should be postponed to up to 12 weeks after completion of nCRT 
in case of persisting adverse events or bad general condition. To further optimize the 
timing of surgery, the course of HRQOL in the period between nCRT and surgery 
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should be monitored more carefully. On the basis of the available literature and our 
clinical experience, it seems that HRQOL substantially improves over a period of 6 to 12 
weeks.17 
Although some studies have suggested that the effect of esophagectomy onHRQOL 
is restored within 1 year postoperatively15 or can be attributed to only a small group of 
patients,30 most studies have shown lasting and substantial negative effects.13, 14, 31 This is 
confirmed by the results of our study, in which two of the five end points (ie, PF and 
FA) did not return to baseline levels during the first year follow-up, and none of the end 
points improved compared with baseline levels (for patients suffering from esophageal 
cancer). These effects could only partly be explained by recurrence of disease or death in 
the subsequent study period, emphasizing the adverse effect of esophagectomy on 
HRQOL. Cognitive behavioral therapy, which was not routinely offered in our study, 
might be successful in treating patients with lasting FA.32 Furthermore, new treatment 
strategies, such as minimally invasive esophagectomy and an active surveillance 
approach after nCRT (instead of standard surgery), might improve HRQOL in these 
patients.33, 34 
Limitations of this study include overall attrition and lower response rates in the 
surgery-alone group than in the nCRT group. Attrition is inevitable in HRQOL studies 
with severely ill patients. Nevertheless, at each measurement point, pretreatment 
prognostic parameters of patients who completed the questionnaires were comparable 
between the two treatment groups, suggesting the effect of attrition bias to be small. 
Lower response rates in the surgery-alone group might be explained by primary surgery 
being standard treatment during the performance of the trial. Consequently, patients in 
the surgery-alone group could have been less motivated to complete HRQOL 
questionnaires than patients in the experimental nCRT group. Another possible 
explanation is the increasing rate of recurrence being more common in the surgeryalone 
group. 
Because of the relatively low number of older patients (patients age ≥76 years were 
excluded from the trial) and patients with poorer performance status (patients with 
WHO 2 were also excluded), results from this study cannot be generalized to these 
specific categories of vulnerable patients. The effect of this treatment regimen on 
HRQOL will need to be tested for these subgroups of patients in future studies. 
Furthermore, it has been pointed out previously that patients who receive 
neoadjuvant treatment may report better recovery from surgery, as a result of 
adjustments to toxicity as experienced during neoadjuvant treatment leading to a re-
evaluation of internal standards (ie, response shift). In our study, it was not possible to 
correct for this potential effect.17 
Finally, although formally validated, sensitivity of HRQOL questionnaires remains 
uncertain, and these questionnaires might be too crude to detect small but clinically 
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relevant differences. To optimize precision, both generic and disease-specific 
questionnaires were used, and together with the large sample size of the current trial, we 
expect sensitivity to be relatively high compared with that of earlier studies on this topic. 
Of note, the QLQ-OES24 questionnaire has been refined into the QLQ-OES18, with 
revision of the hypothesized scales and the removal of two single items. We do not 
believe this invalidates the results of our study, because the EA scale was retained in its 
original form. The EM scale showed modest to high correlations within all validation 
analyses but was deleted because of overlap with the QLQ-C30 questionnaire.21 
In conclusion, although HRQOL declined immediately after nCRT, no effect of 
nCRT according to CROSS was apparent on postoperative short-term HRQOL 
compared with surgery alone. In addition to the earlier described improvement in long-
term overall and disease-free survival, these results support the view that nCRT 
according to this effective regimen should be regarded as a standard of care for patients 
with locally advanced resectable esophageal or esophagogastric junctional cancer. 
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Table 1. Baseline characteristics of patients with potentially curable esophageal or esophagogastric junction 
cancer, according to treatment group.* 
Characteristic nCRT plus surgery 
(N = 177) 
Surgery alone 
(N = 186) 
Age — yr.   
  Median 60 60 
  IQR 55 - 67 54 - 66 
Male sex — no. (%) 134 (76) 151 (81) 
Tumor type — no. (%)   
  Adenocarcinoma 134 (76) 140 (75) 
  Squamous-cell carcinoma 40 (23) 42 (23) 
  Large cell undifferentiated 3 (2) 4 (2) 
Tumor location — no. (%)†   
  Esophagus   
     Proximal third 4 (2) 4 (2) 
     Middle third 24 (14) 23 (12) 
     Distal third  104 (59) 107 (58) 
  Esophagogastric junction 39 (22) 48 (26) 
  Missing data 6 (3) 4 (2) 
Clinical T stage — no. (%)‡   
  cT1 1 (1) 1 (1) 
  cT2 26 (15) 35 (19) 
  cT3 149 (84) 145 (78) 
  cT4§ 0 1 (1) 
  Could not be determined¶ 1 (1) 4 (2) 
Clinical N stage — no. (%)ǁ   
  N0 59 (33) 58 (31) 
  N1 115 (65) 118 (63) 
Could not be determined¶ 3 (2) 10 (5) 
WHO performance status — no. (%)**   
  0 144 (81) 161 (87) 
  1 33 (19) 25 (13) 
* Percentages may not add up to 100 because of rounding.  
† Tumor length and location were determined by means of endoscopy. 
‡ Clinical tumor (cT) stage was assessed by means of endoscopic ultrasonography or computed tomography 
(CT) and was classified according to the International Union against Cancer (UICC) tumor–node–metastasis 
(TNM) classification, 6th edition. 
§ One patient was originally staged as cT3 stage but revised to cT4 based on central revision of all endoscopy 
reports.9 
¶ This category included patients in whom the tumor could not be fully investigated by means of a transducer 
for endoscopic ultrasonography owing to a stenosis caused by the tumor. 
ǁ Clinical lymph-node (N) stage was assessed by means of endoscopic ultrasonography, CT, or 18F-
fluorodeoxyglucose positron-emission tomography and was classified according to UICC TNM classification, 
6th edition. 
** WHO performance status scores are on a scale of 0 to 5, with lower numbers indicating better performance 
status; 0 indicates fully active, and 1 unable to carry out heavy physical work. 
IQR, interquartile range; nCRT, neoadjuvant chemoradiotherapy; WHO, World Health Organization.  
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Table 2. Patients eligible for quality of life assessment, returning the quality of life questionnaire, deceased, not 
returning the quality of life questionnaire because they were too ill or because of random reasons at each 
measurement point. 
Status Baseline Post-
nCRT 
3 months 
postop 
6 months 
postop 
9 months 
postop 
12 months 
postop 
Eligible 
  nCRT + surgery 
  surgery alone 
363 
177 
186 
177 
177 
342 
163 
179 
308 
151 
157 
285 
145 
140 
260 
136 
124 
Returned total (% of eligible) 
  nCRT + surgery (%) 
  surgery alone (%) 
235 (65) 
134 (76) 
101 (54) 
104 (59) 
104 (59) 
NA 
228 (67) 
119 (73) 
109 (61) 
210 (68) 
113 (75) 
97 (62) 
185 (65) 
103 (71) 
82 (59) 
166 (64) 
94 (69) 
72 (58) 
Deceased 0 0 21 55 78 103 
Too ill 0 24 38 27 36 32 
Randomly missing / other 128* 49 76 71 64 62 
NA, not applicable; nCRT, neoadjuvant chemoradiotherapy. 
*(of whom 89 due to administrative error) 
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Figure 1. CONSORT diagram. 
HRQOL, health related quality of life 
873 patients assessed for esophageal
esophagagojunctional 
 368 patients enrolled and randomly  assigned 
469  excluded 
 180 assigned to neoadjuvant  chemoradiotherapy  188 assigned to surgery alone 
177  assigned to neoadjuvant  chemoradiotherapy 
186  assigned to surgery alone 
2  withdrew 
t 1included before start HRQOL study 
1 center (1 patient )
did not participate in HRQOL study  
1 included before start HRQOL study 
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Figure 2. Mean scores with standard deviations for primary endpoints (A) physical functioning, (B) eating 
problems and secondary endpoints (C) global quality of life, (D) fatigue and (E) emotional problems accord-
ing to treatment group. nCRT, neoadjuvant chemoradiotherapy 
A 
 B 
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Appendix 
Supplementary Table 1. Mixed modeling analysis including randomized grouping for longitudinal effects on 
physical functioning. 
Parameter Cohen's d p-value 95% Confidence Interval 
Baseline scores for nCRT group 0.56 <0.001 0.47 to 0.65 
  Difference for surgery alone -0.04 0.598 -0.18 to 0.10 
  
Comparison with baseline 
   
  1 week post-nCRT (nCRT) -0.93 <0.001 -1.12 to -0.74 
  3 months postop (nCRT) 
    Difference for surgery alone 
-1.09 
0.21 
<0.001 
0.157 
-1.29
-0.08
 to -0.90 
 to 0.49 
  6 months postop (nCRT) 
    Difference for sugery alone 
-0.70 
0.01 
<0.001 
0.968 
-0.89
-0.27
 to -0.52 
 to 0.28 
  9 months postop (nCRT) 
    Difference for surgery alone 
-0.53 
-0.15 
<0.001 
0.287 
-0.72
-0.43
 to -0.35 
 to 0.13 
  12 months postop (nCRT) 
    Difference for surgery alone 
-0.51 
-0.05 
<0.001 
0.717 
-0.69
-0.34
 to -0.32 
 to 0.23 
  
Comparison with previous measurement 
   
  3 months postop (nCRT) -0.16 0.164 -0.38 to 0.07 
  6 months postop (nCRT) 
    Difference for surgery alone 
0.39 
-0.20 
<0.001 
0.079 
0.24
-0.43
 to 0.54 
 to 0.02 
  9 months postop (nCRT) 
    Difference for surgery alone 
0.17 
-0.16 
0.022 
0.159 
0.02
-0.38
 to 0.32 
 to 0.06 
  12 months postop (nCRT) 
    Difference for surgery alone 
0.03 
0.10 
0.730 
0.430 
-0.14
-0.15
 to 0.19 
 to 0.35 
*Cohen’s D effect-sizes were derived from the beta-estimates in the mixed modelling procedure through 
standardization of both outcome and predictor variables. Results from different models were combined into 
one table (per outcome measure) for reasons of conciseness. Differences between the two treatment groups at 
baseline measurement and differences in change between measurements are referred to as “difference for 
surgery alone”. 
nCRT, neoadjuvant chemoradiotherapy 
  
Effect of neoadjuvant chemoradiotherapy on quality of life 
157 
Supplementary Table 2. Mixed modeling analysis including randomized grouping for longitudinal effects on 
global health status. 
Parameter Cohen's d p-value 95% Confidence Interval 
Baseline scores for nCRT group 0.22 0.004 0.07 to 0.37 
  Difference for surgery alone -0.07 0.533 -0.30 to 0.16 
  
Comparison with baseline 
   
  1 week post-nCRT (nCRT) -0.84 <0.001 -1.08 to -0.60 
  3 months postop (nCRT) 
    Difference for surgery alone 
-0.52 
0.11 
<0.001 
0.467 
-0.72
-0.19
 to -0.31 
 to 0.42 
  6 months postop (nCRT) 
    Difference for sugery alone 
-0.21 
-0.04 
0.058 
0.801 
-0.42
-0.36
 to 0.01 
 to 0.28 
  9 months postop (nCRT) 
    Difference for surgery alone 
-0.06 
-0.05 
0.574 
0.776 
-0.29
-0.39
 to 0.16 
 to 0.29 
  12 months postop (nCRT) 
    Difference for surgery alone 
-0.04 
0.05 
0.729 
0.799 
-0.27
-0.31
 to 0.19 
 to 0.40 
  
Comparison with previous measurement 
   
  3 months postop (nCRT) 0.33 0.008 0.09 to 0.57 
  6 months postop (nCRT) 
    Difference for surgery alone 
0.31 
-0.16 
0.001 
0.255 
0.13
-0.42
 to 0.49 
 to 0.11 
  9 months postop (nCRT) 
    Difference for surgery alone 
0.14 
-0.01 
0.145 
0.958 
-0.05
-0.30
 to 0.34 
 to 0.28 
  12 months postop (nCRT) 
    Difference for surgery alone 
0.02 
0.09 
0.792 
0.491 
-0.15
-0.18
 to 0.20 
 to 0.37 
*Cohen’s D effect-sizes were derived from the beta-estimates in the mixed modelling procedure through 
standardization of both outcome and predictor variables. Results from different models were combined into 
one table (per outcome measure) for reasons of conciseness. Differences between the two treatment groups at 
baseline measurement and differences in change between measurements are referred to as “difference for 
surgery alone”. 
nCRT, neoadjuvant chemoradiotherapy 
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Supplementary Table 3. Mixed modeling analysis including randomized grouping for longitudinal effects on 
fatigue. 
Parameter Cohen's d p-value 95% Confidence Interval 
Baseline scores for nCRT group -0.63 <0.001 -0.76 to -0.49 
  Difference for surgery alone 0.08 0.421 -0.12 to 0.29 
  
Comparison with baseline 
    
  1 week post-nCRT (nCRT) 1.45 <0.001 1.23 to 1.67 
  3 months postop (nCRT) 
    Difference for surgery alone 
1.12 
-0.23 
<0.001 
0.137 
0.91 to 1.32 
-0.53 to 0.07 
  6 months postop (nCRT) 
    Difference for sugery alone 
0.74 
-0.14 
<0.001 
0.331 
0.54 to 0.93 
-0.44 to 0.15 
  9 months postop (nCRT) 
    Difference for surgery alone 
0.53 
0.05 
<0.001 
0.754 
0.34 to 0.72 
-0.25 to 0.34 
  12 months postop (nCRT) 
    Difference for surgery alone 
0.49 
0.05 
<0.001 
0.723 
0.31 to 0.68 
-0.23 to 0.33 
  
Comparison with previous measurement 
    
  3 months postop (nCRT) -0.33 0.002 -0.54 to 0.12 
  6 months postop (nCRT) 
    Difference for surgery alone 
-0.38 
0.08 
<0.001 
0.487 
-0.54 to -0.22 
-0.15 to 0.32 
  9 months postop (nCRT) 
    Difference for surgery alone 
-0.21 
0.19 
0.010 
0.119 
-0.37 to -0.05 
-0.05 to 0.43 
  12 months postop (nCRT) 
    Difference for surgery alone 
-0.03 
0.00 
0.656 
0.970 
-0.19 to 0.12 
-0.23 to 0.24 
*Cohen’s D effect-sizes were derived from the beta-estimates in the mixed modelling procedure through 
standardization of both outcome and predictor variables. Results from different models were combined into 
one table (per outcome measure) for reasons of conciseness. Differences between the two treatment groups at 
baseline measurement and differences in change between measurements are referred to as “difference for 
surgery alone”. 
nCRT, neoadjuvant chemoradiotherapy 
 
  
Effect of neoadjuvant chemoradiotherapy on quality of life 
159 
Supplementary Table 4. Mixed modeling analysis including randomized grouping for longitudinal effects on 
emotional problems. 
Parameter Cohen's d p-value 95% Confidence Interval 
Baseline scores for nCRT group -0.09 0.262 -0.26 to 0.07 
  Difference for surgery alone 0.18 0.159 -0.07 to 0.43 
  
Comparison with baseline 
    
  1 week post-nCRT (nCRT) 0.32 0.001 0.14 to 0.50 
  3 months postop (nCRT) 
    Difference for surgery alone 
0.40 
-0.15 
<0.001 
0.346 
0.19 to 0.61 
-0.46 to 0.16 
  6 months postop (nCRT) 
    Difference for sugery alone 
0.14 
-0.15 
0.215 
0.362 
-0.08 to 0.36 
-0.48 to 0.18 
  9 months postop (nCRT) 
    Difference for surgery alone 
-0.14 
0.00 
0.218 
0.992 
-0.37 to 0.09 
-0.35 to 0.35 
  12 months postop (nCRT) 
    Difference for surgery alone 
-0.14 
-0.06 
0.210 
0.712 
-0.36 to 0.08 
-0.40 to 0.28 
  
Comparison with previous measurement 
    
  3 months postop (nCRT) 0.08 0.459 -0.13 to 0.28 
  6 months postop (nCRT) 
    Difference for surgery alone 
-0.26 
0.00 
0.006 
0.989 
-0.45 to -0.07 
-0.28 to 0.27 
  9 months postop (nCRT) 
    Difference for surgery alone 
-0.28 
0.15 
0.003 
0.295 
-0.47 to -0.10 
-0.13 to 0.43 
  12 months postop (nCRT) 
    Difference for surgery alone 
0.00 
-0.06 
0.982 
0.675 
-0.19 to 0.19 
-0.36 to 0.23 
*Cohen’s D effect-sizes were derived from the beta-estimates in the mixed modelling procedure through 
standardization of both outcome and predictor variables. Results from different models were combined into 
one table (per outcome measure) for reasons of conciseness. Differences between the two treatment groups at 
baseline measurement and differences in change between measurements are referred to as “difference for 
surgery alone”. 
nCRT, neoadjuvant chemoradiotherapy 
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Supplementary Table 5. Mixed modeling analysis including randomized grouping for longitudinal effects on 
eating problems. 
Parameter Cohen's d p-value 95% Confidence Interval 
Baseline scores for nCRT group -0.10 0.294 -0.28 to 0.09 
  Difference for surgery alone 0.21 0.136 -0.07 to 0.49 
  
Comparison with baseline 
    
  1 week post-nCRT (nCRT) 0.47 0.001 0.21 to 0.72 
  3 months postop (nCRT) 
    Difference for surgery alone 
0.43 
-0.25 
0.001 
0.177 
0.19 to 0.68 
-0.61 to 0.11 
  6 months postop (nCRT) 
    Difference for sugery alone 
0.07 
-0.15 
0.582 
0.403 
-0.17 to 0.30 
-0.50 to 0.20 
  9 months postop (nCRT) 
    Difference for surgery alone 
-0.13 
-0.19 
0.267 
0.283 
-0.37 to 0.10 
0.55 to 0.16 
  12 months postop (nCRT) 
    Difference for surgery alone 
-0.21 
-0.05 
0.086 
0.774 
-0.45 to 0.03 
-0.42 to 0.31 
  
Comparison with previous measurement 
    
  3 months postop (nCRT) -0.03 0.816 -0.30 to 0.23 
  6 months postop (nCRT) 
    Difference for surgery alone 
-0.37 
0.10 
<0.001 
0.422 
-0.53 to -0.21 
-0.14 to 0.33 
  9 months postop (nCRT) 
    Difference for surgery alone 
-0.20 
-0.04 
0.022 
0.741 
-0.37 to -0.03 
-0.30 to 0.21 
  12 months postop (nCRT) 
    Difference for surgery alone 
-0.08 
0.14 
0.280 
0.212 
-0.22 to 0.07 
-0.08 to 0.36 
*Cohen’s D effect-sizes were derived from the beta-estimates in the mixed modelling procedure through 
standardization of both outcome and predictor variables. Results from different models were combined into 
one table (per outcome measure) for reasons of conciseness. Differences between the two treatment groups at 
baseline measurement and differences in change between measurements are referred to as “difference for 
surgery alone”. 
nCRT, neoadjuvant chemoradiotherapy 
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Abstract 
Background 
Knowledge about the course of health-related quality of life (HRQOL) during and after 
completion of neoadjuvant chemoradiotherapy (nCRT) for oesophageal or junctional 
carcinoma is needed to optimize the timing of surgery. This study aimed to assess the 
course of HRQOL in the period from the start of nCRT until standard surgery.  
Patients and methods 
This was a multicentre prospective cohort study. Patients with locally advanced oesoph-
ageal or oesophago-gastric junctional cancer who were planned for nCRT plus oesoph-
agectomy were eligible. HRQOL was measured with the EORTC-QLQ-C30, QLQ-OG25 
and QLQ-CIPN20 questionnaires before nCRT, during the last cycle of nCRT, and 2, 4, 
6, 8, 10, 12, 14, and 16 weeks after nCRT and before surgery. Endpoints were prede-
fined, based on the hypothesized impact of nCRT. Primary endpoints were physical 
functioning, odynophagia and sensory symptoms. Secondary endpoints were global 
quality of life, fatigue, weight loss and motor symptoms. Mixed modelling analysis was 
used to evaluate changes over-time. 
Results 
Ninety-six of 106 eligible patients (91%) were included. Returned questionnaires ranged 
from 94%-99% until week 12 and dropped to 78% in week 16 following nCRT. There 
was a profound negative impact of nCRT on all HRQOL-endpoints during the last cycle 
of nCRT (all p<0.001) and at two weeks after nCRT (all p<0.001). Physical functioning, 
odynophagia and sensory symptoms were restored to pre-treatment levels at 8, 4 and 6 
weeks after nCRT, respectively. Secondary endpoints were restored to baseline levels at 
4-6 weeks after nCRT. Odynophagia, fatigue and weight loss improved after nCRT, as 
compared to baseline levels at 6 (p<0.001), 16 (p=0.001) and 12 weeks (p<0.001), respec-
tively. 
Conclusion 
HRQOL decreases significantly after completion of nCRT for oesophageal cancer, but 
all HRQOL endpoints are restored to baseline levels within 8 weeks. Odynophagia, fa-
tigue and weight loss improved after 6-16 weeks following nCRT, compared to baseline 
levels. 
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Introduction 
Neoadjuvant chemoradiotherapy (nCRT) followed by surgery is a standard of care for 
patients with potentially curable oesophageal or oesophagogastric junctional cancer.1, 2 
Although oesophagectomy has profound impact on both long-term and short-term 
patients’ health related quality of life (HRQOL), addition of nCRT to surgery does not 
jeopardize HRQOL after surgery, compared to surgery alone.3, 4 However, immediately 
after completion of nCRT (prior to surgery), patients show a profound drop in HRQOL 
compared to baseline levels.3, 5, 6 This deterioration improves after surgery, suggesting 
that HRQOL is restored in the period between completion of nCRT and surgery.3, 5 
However, the detailed course of HRQOL during and after completion of nCRT is un-
known. Such information might impact the timing of surgery, which is under debate. 
Traditionally, surgery is planned 4-6 weeks after completion of nCRT. However, it has 
been shown that a longer time to surgery (up to 12 weeks) does not endanger oncologi-
cal outcome.7 Increasing the time to surgery would allow patients to recover from nCRT 
and optimize their physical condition before surgery. Furthermore, a longer waiting 
time to surgery has been suggested to increase pathologically complete response (i.e. no 
viable tumour cells in the resection specimen) rate, which might improve prognostica-
tion.7  
The primary aim of this study was to assess the course of HRQOL in the period from 
the start of nCRT until surgery in patients with locally advanced oesophageal or junc-
tional carcinoma. 
Methods 
This was a multicentre prospective cohort study. Patients with locally advanced oesoph-
ageal or oesophago-gastric junctional cancer who were planned to undergo nCRT ac-
cording to the CROSS regimen (weekly administration of carboplatin and paclitaxel 
plus 41.4 Gy concurrent radiotherapy) were considered eligible.1 Patients who were 
considered insufficiently fluent in the Dutch language or cognitively unable to under-
stand the questionnaire were excluded. Consecutive patients were recruited prior to the 
start of nCRT in the Erasmus MC – University Medical Centre, Rotterdam and in the 
Elisabeth-Tweesteden Hospital, Tilburg. The study was approved by the ethics commit-
tee of the Erasmus MC (MEC-2016-250). 
Health-related quality of life measurement 
Patients were informed about the study by their own physician. Subsequently, patients 
were asked to participate by telephone by one of the investigators. Participating patients 
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received the self-report questionnaires by mail and were asked by telephone to complete 
questionnaires at baseline (prior to nCRT), at the date of the last cycle of nCRT, and 
every two weeks thereafter until the date of surgery, with a maximum follow-up of 16 
weeks after completion of nCRT. All patients were reminded two times by telephone by 
one of the investigators during each assessment. 
Cancer-related general HRQOL was measured with the EORTC-QLQ-C30, a vali-
dated questionnaire for cancer patients.8 Oesophageal cancer-specific HRQOL was as-
sessed with the EORTC-QLQ-OG25, a validated questionnaire for patients with cancer 
of the oesophagus, the oesophago-gastric junction and the stomach.9 Chemotherapy-
induced peripheral neuropathy (CIPN) symptoms were assessed using the EORTC-
QLQ-CIPN20, a questionnaire designed to elicit patients' experience of symptoms relat-
ed to CIPN.10 
Prior to the start of the study, endpoints were defined by individual consensus dis-
cussion with upper-GI surgical oncologists, medical oncologists and nurse practitioners. 
Primary and secondary endpoints from each questionnaire were chosen based on hy-
pothesized impact of nCRT. This led to assignment of physical functioning (EORTC-
QLQ-C30), odynophagia (EORTC-QLQ-OG-25) and sensory symptoms (EORTC-
QLQ-CIPN20) as primary endpoints; and global quality of life, fatigue (both QLQ-C30), 
weight loss (EORTC-QLQ-OG25) and motor symptoms (EORTC-QLQ-CIPN20) as 
secondary endpoints. 
Statistical analysis 
Data were analysed on intention-to-treat basis. Pre-treatment clinicopathological char-
acteristics were collected and described. Questionnaire scores were transformed into a 
0-100 scale according to EORTC-guidelines.11 Higher scores for functional and global 
scales (e.g. physical functioning and global quality of life) indicate better HRQOL. High-
er scores on symptom scales (e.g. fatigue) indicate worse HRQOL. Over-time changes in 
the follow-up measurements were analysed using mixed modelling analysis, a technique 
that enables analysis of all completed questionnaires, by allowing for inclusion of data 
from patients with different numbers of completed measurements.12 Mean over-time 
differences were described. Cohen's d (CD) effect sizes based on the beta-estimates from 
the mixed modelling analyses were used to allow for standardized comparison between 
different endpoints and to assess clinical relevance of the found effects. CD values of 0.2, 
0.5 and 0.8 indicate small, medium and large effects, respectively.13 Effect sizes ≥0.5 were 
defined as clinically relevant.14  
On an exploratory basis, we investigated the effects of several background variables 
on the trajectory of HRQOL-scores. As the investigated sample showed variation in 
timing of surgery, this could have influenced the course of HRQL. Some patients (n=29) 
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participated in the diagnostic preSANO trial.15, 16 In that trial, patients underwent a 
clinical response evaluation 4-6 weeks after nCRT to determine the accuracy of detect-
ing residual disease. Patients with residual disease or no-pass during clinical response 
evaluation after 4-6 weeks underwent immediate surgical resection, whereas remaining 
patients had surgery 10-14 weeks after completion of nCRT. Patients with (substantial) 
residual disease after nCRT might experience worse HRQOL after nCRT, which poten-
tially induces a bias. Furthermore, variations in time to surgery can be attributed to 
patient-related characteristics, such as comorbidities or general condition. More vulner-
able patients could have longer time to surgery intentionally. This might negatively 
influence HRQOL at longer follow-up measurements, so HRQL may improve more 
strongly at the later measures if all patients could have been included. Therefore, the 
presence of residual disease during clinical response evaluation (only for patients who 
participated in the preSANO trial), comorbidities (Charlson comorbidity index) and 
ASA-score were included in a separate analysis to investigate their potential effect on the 
course of HRQL.17 
As correction for multiple comparisons, p<0.006 was considered statistically signifi-
cant (a Bonferroni correction of 0.05/9 was applied, since the main analyses included 
nine comparisons (with pre-treatment levels). All p-values are two-sided. Data were 
analysed using SPSS version 24.0. 
Results 
Of 106 eligible patients, 96 (91%) were included from May 2016 through June 2017 (10 
patients refused participation). Rates of response to the questionnaires were 78% - 99% 
(Table 1). Median age of patients was 68 (IQR 61-71) and 77 (80%) patients were men. 
Most patients had cT3 tumour (80%) and suspicious regional lymph nodes (66%, as 
determined by endoscopic ultrasound, CT and/or PET-CT, Table 2). 
Predefined primary endpoints 
Physical functioning (Figure 1A) 
Over-time changes in physical functioning levels were statistically significant (p<0.001). 
Physical functioning had declined at the last cycle of nCRT (-16, p<0.001; CD -0.80, 95% 
CI -1.00 - -0.59) compared to baseline levels, and remained stable from two weeks after 
nCRT (p=0.79) during follow-up. Physical functioning improved from 2 to 10 weeks 
after nCRT (4 vs. 2 weeks +6, p<0.001; CD 0.30, 95% CI 0.17 – 0.42, 6 vs. 4 weeks +6, 
p<0.001; CD 0.28, 95% CI 0.17 – 0.39, 8 vs. 6 weeks +5, p<0.001; CD 0.24, 95% CI 0.15 – 
0.32, 10 vs. 8 weeks +3, p=0.003; CD 0.15, 95% CI 0.05 – 0.24, resp.). From then on-
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wards, the improvement was no longer statistically significant. Baseline levels were 
reached at 8 weeks (p=0.95), but were not exceeded during follow-up (p>0.006). 
Odynophagia (Figure 1B) 
There were statistically significant over-time changes in odynophagia levels (p<0.001). 
Compared to baseline levels, odynophagia levels had worsened at the last cycle of nCRT 
(14, p<0.001; CD -0.45, 95% CI 0.20 - 0.70), and remained at that level 2 weeks after 
nCRT (p=0.038). Thereafter, odynophagia levels improved from 2 to 4 weeks (-21, 
p<0.001; CD -0.69, 95% CI -0.89 - -0.49) and from 4 to 6 weeks (-11, p<0.001; CD -0.37, 
95% CI -0.50 - -0.24). From then onwards, improvement was no longer statistically 
significant, as compared to the previous measurement. Four weeks after nCRT, baseline 
levels were reached (p=0.68), and from 6 weeks, odynophagia levels had improved com-
pared to baseline levels (6 weeks -15, p<0.001; CD -0.42, 95% CI -0.64 - -0.20, 10 weeks -
24, p<0.001; CD -0.77, 95% CI -0.98 - -0.57). 
Sensory symptoms (Figure 1C) 
Generally, over-time changes in sensory symptoms were not statistically significant 
(p=0.009). However, the specific comparisons between occasions showed that sensory 
symptoms had worsened at the last cycle of nCRT as compared to pre-treatment levels, 
(+4, p<0.001; CD 0.53, 95% CI 0.28 - 0.80). At 6 weeks after nCRT, sensory symptoms 
had returned to baseline levels (p=0.013). There was no further statistically significant 
improvement compared to previous measurements. 
Predefined secondary endpoints 
Global quality of life (Figure 1D) 
Global quality of life scores showed statistically significant changes over-time (P<0.001). 
At the last cycle of nCRT global quality of life scores had declined (-16, p<0.001; CD -
0.77, 95% CI -0.96 - -0.57,) and had further worsened 2 weeks thereafter (-6, p=0.002; 
CD -0.29, 95% CI -0.47 - -0.11). From 2 to 8 weeks after nCRT, global quality of life 
levels improved, as compared to the previous measurement (4 vs. 2 weeks +11, p<0.001; 
CD 0.51, 95% CI 0.33 – 0.69, 6 vs. 4 weeks +7, p<0.001; CD 0.34, 95% CI 0.19 – 0.49, 8 
vs. 6 weeks +5, p=0.001; CD 0.24, 95% CI 0.10 – 0.39, resp.). From then onwards, im-
provement was no longer statistically significant. At 6 weeks after nCRT baseline levels 
were reached (p=0.031). Baseline levels were not exceeded during follow-up.  
Fatigue (Figure 1E) 
Over time, fatigue levels changed statistically significantly (p<0.001). Compared to base-
line, fatigue levels increased at the last cycle of nCRT (+34, p<0.001; CD 1.21, 95% CI 
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1.04 – 1.39) and remained stable until 2 weeks after nCRT (p=0.32). From then on-
wards, there was an improvement until 6 weeks, as compared to the previous measure-
ments (4 vs. 2 weeks -15, p<0.001; CD -0.57, 95% CI -0.73 – -0.41, 6 vs. 4 weeks -13, 
p<0.001; CD -0.46, 95% CI -0.60 – -0.32). Baseline levels were reached at 6 weeks 
(p=0.007). Thereafter, there was no statistically significant improvement compared to 
the previous measurement. Compared to baseline levels, there was an improvement at 
16 weeks after nCRT (-8, p=0.001; CD -0.28, 95% CI -0.44 – -0.11).  
Weight loss (Figure 1F) 
Weight loss scores changed statistically significantly over-time (p<0.001). At the last 
cycle of nCRT weight loss had worsened compared to baseline levels (+10, p=0.002, CD 
0.36, 95% CI 0.13 – 0.58), which did not improve at 2 and 4 weeks after nCRT compared 
to the previous measurement (p=0.263 and p=0.038, resp.). From then onwards, scores 
returned to baseline levels at 4 weeks after nCRT (p=0.031) and further improved (6 vs. 
4 weeks -9, p<0.001; CD -0.31, 95% CI -0.47 – -0.16, 8 vs. 6 weeks -7, p<0.001; CD -0.24, 
95% CI -0.37 – -0.12). At 12 weeks after nCRT, weight loss scores had improved com-
pared to baseline levels (-15, p<0.001; CD -0.52, 95% CI -0.79 – -0.26).  
Motor symptoms (Figure 1G) 
There was a statistically significant over-time change in motor symptoms (p<0.001). 
Motor symptoms had worsened at the last cycle of nCRT (+4, p<0.001; CD 0.47, 95% CI 
0.26 – 0.68). At 4 weeks after nCRT, motor symptoms had returned to baseline levels 
(p=0.028). There were no further improvements in motor symptoms compared to pre-
vious measurements.  
Other endpoints 
Mean scores of HRQOL domains other than the predefined endpoints are presented in 
Table 3. 
Influence of residual disease, comorbidities and general condition 
Inclusion of the presence of residual disease during clinical response evaluation, comor-
bidities (Charlson comorbidity index) and ASA score as control variables did not impact 
the reported overall trends in HRQOL-trajectories (data not shown). However, patients 
with Charlson comorbidity index >4 showed worse physical functioning, global quality 
of life and fatigue levels, but changes over-time were similar compared to patients with 
Charlson comorbidity index ≤4. Furthermore, patients with a positive clinical response 
evaluation at 4-6 weeks after nCRT showed a more profound decrease in global quality 
of life scores during nCRT, and more severe odynophagia symptoms during all meas-
urement points. 
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Discussion 
This prospective cohort study shows a profound negative, short-term impact of nCRT 
on all HRQOL-endpoints in oesophageal or junctional cancer patients treated with a 
multimodality regimen based on carboplatin/paclitaxel combined with 41.4Gy of con-
current radiotherapy. Subsequently, all primary and secondary HRQOL endpoints were 
restored to baseline levels in 4-10 weeks after completion of nCRT. Odynophagia, fa-
tigue and weight loss even improved after nCRT, as compared to baseline levels at 6, 16 
and 12 weeks, respectively. 
This is the first study investigating the detailed short-term course of HRQOL after 
nCRT for oesophageal or junctional cancer. A previous study showed a negative impact 
of nCRT on HRQOL 12 weeks after the start of neoadjuvant treatment, which was re-
stored to baseline levels 3 weeks prior to surgery.6 However, this study employed a small 
sample size (n=34), only two measurements after nCRT with respect to the start of 
nCRT instead of the end of nCRT, and date of surgery hampering precise assessment of 
the HRQOL trajectory after nCRT. The HRQOL analysis of the CROSS-trial also 
showed a profound deterioration one week after completion of nCRT compared to 
baseline scores in all primary and secondary HRQOL-endpoints (physical functioning, 
global quality of life, fatigue, eating and emotional functioning). However, this study 
lacked extra measurements between the end of nCRT and the date of surgery.3  
The results of the present study underline the value of sufficient recuperation time 
between completion of nCRT and oesophagectomy to enable patients to undergo sur-
gery in optimal physical condition, potentially improving surgical outcome. It has been 
suggested that delaying oesophagectomy up to 12 weeks after completion of nCRT does 
not jeopardize oncological outcome. Moreover, delayed surgery tends to increase the 
pathologically complete response rate, potentially improving prognosis.7, 18 We recom-
mend that timing of surgery is guided by patients’ condition. It is advocated that surgery 
should be postponed to up to 12 weeks after completion of nCRT, and even more than 
that, when patients experience persisting adverse events or are in bad general condition, 
especially in the absence of residual disease. 
Previous studies have shown lasting deterioration of HRQOL after multimodality 
treatment on HRQOL in patients with oesophageal cancer.4, 19-21 Given the current re-
sults,  these negative findings are likely attributable to oesophagectomy and not to 
chemoradiotherapy per se. Definitive chemoradiotherapy without oesophagectomy 
circumvents the adverse effects of surgery, however, long-term oncological outcome has 
been suggested inferior, compared to (nCRT plus) surgery.22 An active surveillance 
strategy after completion of nCRT is  topic of investigation in the ESOSTRATE and 
SANO trials.15, 23 In this novel treatment strategy, patients undergo frequent clinical 
examinations after completion of nCRT and oesophagectomy is offered only to patients 
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with a histologically proven or highly suspected locoregional regrowth,  without signs of 
distant dissemination. This active surveillance strategy might reduce the number of 
patients who need oesophagectomy by 30-40%, reducing the impact of surgery on 
HRQOL. Results of the present study can be used when informing patients in whom a 
(future) active surveillance strategy is considered, since the stable HRQOL levels during 
the last measurements likely reflect HRQOL levels during active surveillance.   
Limitations of the current study include the differences in timing of surgery between 
patients, which introduced different follow-up times between patients. Nevertheless, 
inclusion for the confounders presence of residual disease during clinical response eval-
uation (only patients in preSANO trial), comorbidities (Charlson comorbidity index) 
and ASA score did not influence the overall trends in HRQOL-trajectories. 
In conclusion, there was a substantial decrease in HRQOL after completion of nCRT 
for oesophageal cancer, which was restored to baseline levels for all endpoints within 10 
weeks. Odynophagia, fatigue and weight loss had improved within 16 weeks after nCRT, 
compared to baseline levels. These results support delay of surgery, especially in vulner-
able patients, and can be used to inform patients in whom a (future) active surveillance 
strategy is considered. 
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Table 1. Patients eligible for quality of life assessment, returning the quality of life questionnaire, underwent 
surgery, deceased, not returning the quality of life questionnaire because they were too ill or because of ran-
dom reasons at each measurement point. 
Status Baseline Last 
cycle 
2 weeks 4 weeks 6 weeks 8 weeks 10 weeks 12 weeks 14 weeks 16 weeks 
Eligible 96 96 96 96 93 88 56 49 42 32 
Returned total (% 
of eligible) 
95 (99) 90 (94) 93 (97) 92 (96) 89 (96) 83 (94) 51 (91) 46 (94) 37 (88) 25 (78) 
Surgery 0 0 0 0 3 8 39 46 53 63 
Deceased 0 0 0 0 0 0 1 1 1 1 
Too ill 0 4 1 1 1 1 1 1 3 4 
Randomly missing 
/ other 
1 2 2 3 3 4 4 2 2 3 
Table 2. Clinicopathological characteristics of the study patients  
Characteristic N=96 
Age at randomization — yr.  
  Median 68 
  IQ Range 61 – 71 
Male sex — no. (%) 77 (80) 
Tumour type — no. (%)  
  Squamous-cell carcinoma 18 (19) 
  Adenocarcinoma 78 (81) 
Clinical T stage — no. (%)†  
  cT1  
  cT2 
1 (1) 
15 (16) 
  cT3 77 (80) 
  cT4 3 (3) 
Clinical N stage — no. (%)¶  
  cN0 33 (34) 
  cN1 38 (4) 
  cN2 19 (20) 
  cN3 6 (6) 
ASA classification — no. (%)ǁ  
  1 15 (16) 
  2 65 (68) 
  3 14 (15) 
  Missing 2 (2) 
 
† Clinical tumour (cT) stage was assessed by means of endoscopic ultrasonography or computed tomography 
(CT) and was classified according to the International Union for Cancer Control (IUCC) tumour–node–
metastasis (TNM) classification, 7th edition. 
Clinical lymph-node (N) stage was assessed by means of endoscopic ultrasonography, CT, or 18F-
fluorodeoxyglucose positron-emission tomography and was classified according to IUCC TNM classification, 
7th edition. 
ǁ ASA classification is on a scale of 0 to 5, with lower numbers indicating better physical status; 1 indicates a 
normal healthy patient, 2 a patient with mild systemic disease, and 3 a patient with severe systemic disease. 
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Table 3. Mean scores for all domains in the three EORTC questionnaires that were not predefined endpoints. 
Status Baseline Last 
cycle 
2 weeks 4 weeks 6 weeks 8 weeks 10 weeks 12 weeks 14 weeks 16 weeks
QLQ-C30           
Functional scales           
  Role 82 (23) 56 (32) 50 (32) 26 (30) 71 (27) 79 (23) 81 (22) 81 (25) 82 (25) 85 (25) 
  Emotional 75 (20) 74 (24) 72 (23) 78 (19) 80 (20) 81 (17) 81 (19) 83 (16) 82 (17) 82 (19) 
  Cognitive 91 (16) 81 (25) 82 (20) 86 (19) 91 (16) 92 (16) 91 (17) 93 (14) 93 (13) 95 (12) 
  Social 88 (18) 70 (30) 69 (27) 78 (23) 86 (20) 88 (18) 89 (18) 89 (18) 90 (19) 91 (18) 
Symptom scores           
  Nausea and 
  vomiting 
12 (23) 28 (30) 32 (32) 13 (20) 10 (19) 5 (15) 3 (8) 5 (11) 5 (11) 1 (3) 
  Pain 14 (19) 32 (28) 38 (31) 22 (26) 14 (20) 11 (20) 12 (22) 11 (21) 12 (24) 9 (19) 
  Dyspnoea 8 (16) 20 (26) 22 (26) 20 (26) 12 (21) 11(21) 11 (21) 13 (19) 11 (19) 8 (15) 
  Insomnia 27 (30) 35 (33) 33 (34) 24 (31) 20 (25) 16 (24) 18 (24) 17 (26) 14 (20) 12 (25) 
  Loss of appetite 21 (28) 46 (35) 52 (35) 33 (34) 18 (26) 12 (24) 12 (22) 12 (24) 11 (21) 7 (17) 
  Constipation 9 (21) 25 (33) 25 (32) 13 (24) 7 (16) 5 (14) 7 (15) 4 (13) 4 (10) 7 (17) 
  Diarrhoea 6 (17) 16 (26) 15 (26) 5 (16) 4 (12) 5 (13) 7 (13) 3 (9) 4 (13) 5 (12) 
  Financial worries 3 (12) 8 (22) 6 (18) 5 (14) 5 (17) 5 (16) 4 (16) 4 (13) 4 (10) 4 (11) 
           
QLQ-OG25           
Symptom scores           
  Dysphagia 27 (25) 41 (28) 56 (30) 25 (25) 16 (19) 13 (21) 10 (17) 6 (12) 6 (15) 4 (7) 
  Eating 42 (28) 57 (28) 62 (28) 40 (31) 27 (28) 20 (27) 16 (23) 13 (20) 10 (17) 9 (15) 
  Reflux 9 (18) 14 (23) 16 (26) 8 (21) 5 (14) 3 (10) 3 (12) 3 (11) 1 (6) 1 (7) 
Pain and 
discomfort 
15 (23) 29 (28) 30 (32) 22 (28) 14 (23) 13 (22) 10 (19) 7 (17) 7 (17) 10 (20) 
Anxiety 52 (25) 46 (26) 47 (27) 43 (25) 41 (27) 43 (26) 42 (26) 41 (22) 39 (26) 36 (27) 
Eating with others 27 (33) 34 (35) 36 (26) 21 (30) 11 (24) 7 (17) 5 (12) 5 (14) 4 (10) 1 (7) 
Dry mouth 13 (23) 26 (28) 29 (30) 17 (24) 13 (20) 9 (20) 12 (21) 13 (27) 9 (22) 7 (14) 
Trouble with taste 18 (32) 44 (37) 46 (35) 32 (32) 21 (27) 12 (24) 10 (20) 8 (20) 5 (12) 7 (17) 
Trouble with 
swallowing saliva 
13 (27) 24 (32) 24 (30) 14 (26) 7 (18) 5 (15) 3 (11) 3 (12) 2 (8) 3 (9) 
Choked when 
swallowing 
10 (22) 9 (17) 9 (18) 5 (14) 3 (10) 4 (13) 2 (9) 4 (13) 5 (14) 3 (9) 
Trouble with 
coughing 
26 (26) 32 (28) 34 (28) 28 (27) 21 (23) 23 (24) 19 (24) 19 (25) 17 (22) 16 (17) 
Trouble talking  6 (18) 10 (19) 13 (24) 8 (18) 3 (10) 3 (11) 5 (13) 4 (13) 4 (10) 4 (11) 
Hair loss 10 (25) 22 (29) 19 (26) 21 (29) 19 (31) 16 (26) 14 (28) 14 (31) 17 (36) 5 (13) 
           
QLQ-CIPN20           
  Autonomic scale 11 (15) 21 (19) 22 (19) 18 (18) 14 (16) 14 (15) 14 (15) 14 (16) 14 (18) 14 (18) 
Scores are presented as mean. Standard deviations are shown between parentheses. 
EORTC: European organization for research and treatment of cancer. 
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Figure 1. Mean scores with standard deviations for a) physical functioning, b) odynophagia, c) sensory symp-
toms (primary endpoints), d) global quality of lfie, e) fatigue, f) weight loss and g) motor symptoms (second-
ary endpoints). 
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Abstract 
Background 
Neoadjuvant chemoradiotherapy (nCRT) plus surgery is a standard of care for patients 
with esophageal or junctional cancer, but the long-term impact of nCRT on health-
related quality of life (HRQOL) is unknown. The purpose of this study is to compare 
very long-term HRQOL in long-term survivors of esophageal cancer who received 
nCRT plus surgery or surgery alone. 
Patients and methods 
Patients were randomly assigned to receive nCRT (carboplatin/paclitaxel with 41.4Gy 
radiotherapy) plus surgery or surgery alone. HRQOL was measured using EORTC-
QLQ-C30, EORTC-QLQ-OES24 and K-BILD questionnaires after a minimum follow-
up of 6 years. To allow for examination over time, EORTC-QLQ-C30 and QLQ-OES24 
questionnaire scores were compared to pre-treatment and 12-months-postoperative 
questionnaire scores. Physical functioning (QLQ-C30), eating problems (QLQ-OES24) 
and respiratory problems (K-BILD) were predefined primary endpoints. Predefined 
secondary endpoints were global quality of life and fatigue (both QLQ-C30). 
Results 
After a median follow-up of 105 months, 123/368 included patients (33%) were still 
alive (70 nCRT plus surgery, 53 surgery alone). No statistically significant or clinically 
relevant differential effects in HRQOL-endpoints were found between both groups. 
Compared to one-year postoperative levels, eating problems, physical functioning, glob-
al quality of life and fatigue remained at the same level in both groups. Compared to 
pre-treatment levels, eating problems had improved (Cohen’s d -0.37, p=0.011) during 
long-term follow-up, whereas physical functioning and fatigue were not restored to pre-
treatment levels in both groups (Cohen’s d -0.56 and 0.51, resp., both p<0.001). 
Conclusion(s) 
Although physical functioning and fatigue remain reduced after long-term follow-up, 
no adverse impact of nCRT is apparent on long-term HRQOL compared to patients 
who were treated with surgery alone. In addition to the earlier reported improvement in 
survival and the absence of impact on short-term HRQOL, these results support the 
view that nCRT according to CROSS can be considered as a standard of care. 
Clinical trials number 
Trial registration number: Netherlands Trial Register NTR487 
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Introduction 
Esophageal cancer is characterized by frequent locoregional and distant recurrence. The 
5-year overall survival rate rarely exceeds 40% after primary surgery. In order to im-
prove locoregional control and overall survival, neoadjuvant chemo(radio)therapy has 
been investigated in many clinical trials.1 
The ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study 
(CROSS) trial compared a carboplatin and paclitaxel based neoadjuvant chemoradio-
therapy (nCRT) regimen plus surgery with surgery alone. Eight centers in The Nether-
lands participated. After a minimum follow up of 5 years, a clinically relevant and statis-
tically significant benefit in overall- and progression free survival rates was shown for 
the multimodality group. Treatment-related toxicity and postoperative complication 
rate were acceptable.2, 3 Based on these results, nCRT followed by surgery according to 
the CROSS-regimen is a standard care in many countries.4 
The increasing emphasis on patient-reported outcome measures (PROMs) and 
health-related quality of life (HRQOL) leads to a more prominent role of these measures 
as endpoints in clinical trials. Thus far, HRQOL has received limited attention in the 
field of esophageal cancer, but the wide introduction of nCRT and the associated in-
creased survival emphasize the need for high-quality HRQOL-data from these patients. 
It is known that esophagectomy has profound and lasting impact on patients’ HRQOL.5, 
6 The short-term HRQOL-analysis of the CROSS trial (follow-up ≤1 year) showed that 
adding nCRT to surgery does not adversely impact postoperative HRQOL6, which is in 
line with results from earlier retrospective studies.7-9 However, follow-up of these studies 
did not exceed 24 months.6-9 Importantly, side-effects of radiotherapy can develop years 
after treatment, with  the lungs being the most radiosensitive organ in the chest.10 
Therefore, long-term HRQOL-data from patients treated with nCRT plus surgery are 
desired. 
The aim of this sub-study of the CROSS trial was to compare HRQOL in long-term 
survivors (>6 years) who received nCRT plus surgery or surgery alone. 
Methods 
Details of this randomized trial have been reported previously.2, 3 Briefly, patients with 
locally advanced (clinical stage T1N1M0 or T2–3N0–1M0, 6th edition of the Union for 
International Cancer Control TNM cancer staging)11 esophageal or esophagogastric 
junctional squamous cell carcinoma or adenocarcinoma were eligible. Patients were 
randomized between nCRT plus surgery and surgery alone. The study protocol was 
approved by the ethical committees of the participating centers, and ethical approval for 
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long-term HRQOL-measurement was provided by the medical ethical committee of the 
Erasmus MC. All included patients provided written informed consent. 
Procedures  
Patients assigned to nCRT were treated with carboplatin (AUC 2 mg/mL per min) and 
paclitaxel (50 mg/m2 of body-surface area) for five weekly cycles. Concomitant radia-
tion therapy was given in 23 fractions of 1.8 Gy (41.4 Gy total). Patients assigned to 
surgery alone were operated as soon as possible, whereas patients in the nCRT group 
underwent surgery 4–6 weeks after completion of nCRT. Patients with carcinomas at or 
above the level of the carina underwent a transthoracic esophagectomy with two-field 
lymphadenectomy, whereas patients with carcinomas below the carina, either had a 
transthoracic esophagectomy with two-field lymphadenectomy or a transhiatal esoph-
agectomy with upper abdominal and lower mediastinal lymphadenectomy, depending 
on patient characteristics and local preferences. For patients with carcinomas involving 
the esophagogastric junction, a transhiatal esophagectomy was recommended. 
Health-related quality of life measurement 
Cancer-specific HRQOL was assessed using the EORTC-QLQ-C30, a validated self-
completed questionnaire designed for cancer patients.12 Tumor-specific HRQOL was 
assessed using the EORTC-QLQ-OES24 self-completed questionnaire.13 The EORTC-
QLQ-OES24 was used to allow for comparison with baseline and 12-months postopera-
tive questionnaires, as the currently used derivative, EORTC QLQ-OES18, was not 
available at that time. During long-term follow-up assessment, the K-BILD question-
naire was added to assess pulmonary effects of radiotherapy. The K-BILD is a self-
completed validated questionnaire for interstitial lung disease patients.14 
The self-completed questionnaires were mailed to all patients who were alive after a 
minimum follow-up of 6 years after surgery. Patients who had not completed the ques-
tionnaires within one month were reminded two times by telephone. To allow for exam-
ination of HRQOL over time, questionnaire scores were compared to pretreatment and 
12-months-postoperative questionnaire scores from the earlier short-term HRQOL-
study (follow-up ≤1 year after surgery).6 Prior to the analysis, endpoints were predefined 
by consensus discussion with experienced medical oncologists, upper-GI surgical on-
cologists and nurse practitioners. Endpoints were defined based on clinical relevance 
and hypothesized relation with long-term outcome of nCRT. Primary endpoints were 
physical functioning (QLQ-C30), eating problems (QLQ-OES24) and total respiratory 
problems (K-BILD). Secondary endpoints were global quality of life and fatigue (both 
QLQ-C30). 
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Statistical analysis 
Patients who were alive during long-term follow-up assessment (July 2015) were includ-
ed in the analysis. Pre-treatment patient characteristics were compared using the Stu-
dent’s t or Mann-Whitney test for continuous characteristics, whereas χ2 test or Fisher’s 
exact tests were used for comparison of categorical characteristics. 
Questionnaire scale scores were transformed into a 0-100 scale as was described pre-
viously.14, 15 Baseline (questionnaire) scores of the two treatment groups were compared 
using the Student’s t test. Over-time differential effects between the treatment groups 
and longitudinal differences of the follow-up measurements  were investigated using 
mixed modeling analysis. If no statistically significant differential effects were found 
between both groups, results of the combined groups are reported. Mixed modeling 
allows for inclusion of questionnaires from subjects with different numbers of complet-
ed measurements and thereby enables analysis of all available data.16 Hence, all available 
questionnaires were included in the analyses. Mean changes between groups and over 
time differential effects were described. Cohen's d (CD) effect sizes were calculated to 
assess clinical relevance of the effects and to enable standardized comparison between 
different outcome variables. CD effect-sizes were derived from the beta-estimates in the 
mixed modeling procedure. CD values of 0.2, 0.5 and 0.8 reflect small, medium and 
large effects, respectively.17 Values greater than 0.5 indicate clinically relevant effects.18 
As multiple comparisons correction, p<0.025 was considered statistically significant 
for the mixed models analyses (the main analyses included two comparisons and thus a 
Bonferroni correction of 0.05/2 was applied), whereas p<0.05 was considered statistical-
ly significant for clinical characteristics and baseline-score comparisons. All p-values are 
two-sided. Data were analyzed using SPSS version 21.0. 
Results 
Of the 368 patients included in the CROSS trial, 123 (33%) were still alive (70 nCRT 
plus surgery, 53surgery alone ). Median follow-up was 105 months. Patients in the 
nCRT-group were older, but there were no other statistically significant differences in 
pre-treatment clinicopathological characteristics between the groups (Table 1). The 
majority of patients was male (76% and 77%, resp.), most patients had an adenocarci-
noma (73% and 76%, resp.)and most tumors were clinically staged as cT3 (77% and 
76%, resp.). Most patients had suspected locoregional lymph node metastases (54% and 
69%, resp.). Due to an administrative error, 32 of the long-term survivors did not re-
ceive baseline HRQOL-questionnaires. These patients were not excluded from the anal-
ysis, because their pre-treatment characteristics were not significantly different from the 
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total study group (data not shown) and follow-up questionnaires were correctly mailed 
and completed.6 
Overall response rate to the HRQOL-questionnaires in the 123 long-term survivors 
was 89% (Table 2). In the nCRT-group response rate was 94%, whereas in the surgery 
alone group this was 83% (p=0.07). Mean scores of all HRQOL-domains of the EORTC-
questionnaires and K-BILD-questionnaire are reported in Table 3a and Table 3b, re-
spectively. 
Primary endpoints 
Pretreatment, there were no statistically significant differences in physical functioning 
between both groups (p=0.32). Effects over time were comparable in both groups 
(p=0.46). Physical functioning had declined 12 months after surgery compared to base-
line (-6, p<0.001; CD -0.37, 95% CI -0.58– -0.16), and stayed stable during long-term 
follow-up (-3, p=0.10; CD -0.19, 95% CI -0.42–0.04, Figure 1A). 
Baseline eating problems scores and overall changes over time were comparable in 
both groups (p=0.52, p=0.90, resp.). Twelve months postoperatively, eating problems 
were comparable to baseline (-4, p=0.24; CD -0.18, 95% CI -0.48–0.12) and remained 
stable after long-term follow-up (-5, p=0.09; CD -0.20, 95% CI -0.43–0.03). Compared 
to baseline, a significant improvement was reported after long-term follow-up (-9, 
p=0.011; CD -0.37, 95% CI -0.66– -0.09, Figure 1B).   
After long-time follow-up, there were no statistically significant differences in over-
all respiratory problems between both groups (p=0.69; CD 0.08, 95% CI -0.32–0.48).  
Secondary endpoints 
No statistically significant differences in global quality of life were found at baseline 
(p=0.35), and no differential effects between both groups over time-up were detected 
(p=0.57). One year after surgery, scores were comparable to baseline (+2, p=0.56; CD 
0.08, 95% CI -0.20–0.37) and no statistically significant improvement was found after 
long-term follow-up compared to 12 months postoperatively (+2, p=0.96; CD 0.01, 95% 
CI -0.24–0.26). 
Baseline fatigue levels were comparable in both groups (p=0.60) and all effects over 
time were comparable between the groups (p=0.48). One year after surgery, fatigue 
levels had worsened compared to baseline (+9, p<0.001; CD 0.39, 95% CI 0.16–0.62), 
and remained stable during long-term follow-up (+2, p=0.24; CD 0.12, 95% CI -0.08–
0.31).  
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Influence of missing baseline questionnaires 
In order to investigate the effect of missing baseline questionnaires, the availability of 
baseline questionnaires was included as control variable in a separate analysis. This did 
not influence the described trends in HRQOL-trajectory (data not shown). 
Discussion 
There were no clinically relevant differential effects in HRQOL between long-term sur-
vivors of esophageal or esophagogastric junctional cancer treated with nCRT and sur-
gery, compared to surgery alone. In both groups, eating problems improved compared 
to one-year-postoperative-levels, whereas physical functioning, global HRQOL and 
fatigue remained at the same level. Physical functioning and fatigue were not restored to 
pretreatment levels and corresponding effect sizes were clinically relevant (CD -0.56 and 
0.51, resp.). These results indicate a lasting impact of surgery, regardless of the use of 
nCRT. 
Earlier studies have shown that adding nCRT to surgery does not adversely impact 
postoperative HRQOL. However, most of these studies have been criticized by their 
non-randomized designs and small sample sizes, which make them prone for selection 
bias and limit their ability to detect small but potentially clinically relevant differences.7-9 
Methodological strengths of the current study include its randomized design and low 
attrition rate after long-term follow-up, thereby minimizing the risks of selection and 
attrition bias. Furthermore, the availability of pretreatment and one-year postoperative 
data enabled investigation of change trajectories. Notably, none of the previous studies 
focused on long-term follow-up.7-9 Late side-effects of radiotherapy can develop years 
after initial treatment, with the lungs being the most radiosensitive organ in the chest. 
Symptomatic radiotherapy-induced pulmonary fibrosis is reported in up to 10% of 
patients after thoracic radiotherapy. Its incidence depends on the total radiation dose, 
the irradiated lung volume and the use of chemotherapy. Especially concurrent chemo-
therapy is associated with an increased incidence of (chemo-)radiotherapy induced 
pulmonary fibrosis. Symptoms include dyspnea, chest pain, cough, malaise and weight 
loss, which  may exert profound effects on HRQOL, thereby underlining the relevance 
of effect studies.10 The finding that adding nCRT to surgery does not adversely impact 
postoperative HRQOL, confirms the relatively low toxicity of the CROSS-regimen.2, 6 
Interestingly, an earlier study found a lasting impairment in physical functioning and 
dyspnea after chemoradiotherapy, compared to surgery alone. These conflicting results 
can be explained by the higher dose of radiotherapy (66Gy) and the more toxic chemo-
therapeutic agents that were applied in that study (5-FU /cisplatinum).19 It should be 
noted that novel radiotherapy techniques applied in the CROSS trial have likely also 
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reduced therapy related complications. Besides the improvement in survival, the absent 
impact on HRQOL is an important argument to apply the CROSS-regimen as regimen 
of first choice.3 
Although no impact of nCRT on HRQOL was apparent, both treatment groups ex-
perienced long-lasting impact of oesophagectomy on HRQOL. The reported deteriora-
tion in physical functioning and fatigue might also be explained by increasing age. How-
ever, studies that used a matched reference population also reported reduced long-term 
HRQOL.20, 21 Moreover, pretreatment HRQOL-data were obtained after patients had 
been confronted with the diagnosis of esophageal cancer, when they already were suffer-
ing from disease symptoms and were psychologically affected by their recent diagnosis. 
Consequently, pretreatment HRQOL-levels probably represent an underestimation of 
patients’ HRQOL-levels before diagnosis, thereby further emphasizing the (negative) 
impact of esophagectomy.  
The lasting deterioration in HRQOL is in line with earlier studies.5, 21, 22 Our short-
term analysis on all included patients showed impaired physical functioning and fatigue 
one year after surgery.6 The current analysis in long-term survivors shows comparable 
results, indicating that these symptoms last. This suggests that impairment cannot be 
attributed to a selected group of patients (e.g. patients with subclinical disease recur-
rence), as was suggested earlier.20 A recent study investigated HRQOL in patients who 
were alive 10 years after surgical treatment. Although these patients underwent primary 
surgery, results are in line with those of the current study, showing that long-term 
HRQOL remains substantially impaired.21 These findings not only call for long-term 
supportive care including long-lasting rehabilitation such as cognitive behavior therapy 
for patients with lasting fatigue23, but also for new treatment strategies with optimal 
preservation of HRQOL.  
Definitive chemoradiotherapy without esophagectomy has been evaluated for pa-
tients with squamous cell carcinoma. Locoregional recurrence rates and long-term sur-
vival were found to be inferior, as compared to (nCRT followed by) surgery. Therefore, 
definitive chemoradiotherapy with active surveillance and salvage surgery for non-
responders is a treatment option.4 Furthermore, the effects of minimally invasive and 
hybrid surgical techniques, and an active surveillance strategy after nCRT (instead of 
standard esophagectomy) on HRQOL should be investigated.24, 25  
Limitations of the current study include its relatively small sample size. This is inevi-
table in long-term follow-up studies investigating diseases with poor survival. The cur-
rent study provides the largest available dataset on long-term HRQOL after nCRT, and 
its sample size has sufficient power to detect clinically relevant differences. Nevertheless, 
the ability of this data set to capture long-term complications that are present in a mi-
nority of patients is limited. Patients in the nCRT-group were slightly older than pa-
tients in the surgery alone group. However, survivors were selected from randomized 
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groups with similar baseline characteristics, suggesting that this difference in age is a 
result of the experimental treatment (nCRT), rather than of selection bias.2, 3 Moreover, 
it does not seem plausible that the higher age has positively influenced HRQOL. Fur-
thermore, patients completed questionnaires at one point in time, which introduced 
different follow-up times between patients who were included at different time points. 
However, there were no differences in median follow-up time between both groups and 
it is unlikely that treatment-related-HRQOL still changes substantially after more than 6 
years of follow-up. Therefore, we feel that the effect of differences in follow-up duration 
on HRQOL-outcome is negligible. Since this trial included relatively few patients with 
poor performance status (patients with WHO>2 were excluded) and high age (patients 
>75 years were also excluded), the results cannot be extrapolated to other categories of 
more vulnerable patients. The effect of the CROSS-regimen on (long-term) HRQOL in 
more vulnerable subgroups of patients remains to be investigated. Finally, the EORTC-
QLQ-OES24 has been revised into the EORTC-QLQ-OES18, with refinement of the 
hypothesized scales and removal of two single items.13 To allow for comparison with 
baseline and 12-months postoperative questionnaires, we used the EORTC-QLQ-
OES24. We believe that this did not limit the validity of the results, because the eating 
problems domain was retained in its original form. 
In conclusion, no impact of nCRT is apparent on long-term HRQOL compared to 
surgery alone. In addition to the improvement in long-term survival and the absent 
impact on postoperative recovery, these results support the view that nCRT can be con-
sidered as a standard care for patients with locally advanced esophageal or esophagogas-
tric junctional cancer. 
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Table 1. Clinicopathological characteristics of patients with potentially curable esophageal or esophagogastric 
junction cancer, according to treatment allocation. 
Characteristic nCRT plus surgery 
(N = 70) 
Surgery alone 
(N = 53) 
p-value 
Follow-up — months  
  Median  
 
104 
 
105 
 
0.635 
  IQ Range 90 – 116 87 – 117  
Age at randomization — yr.    
  Median 60 57 0.024 
  IQ Range 55 - 65 51 - 62  
Male sex — no. (%) 53 (76) 41 (77) 0.832 
Tumor type — no. (%)   0.205 
  Adenocarcinoma 51 (73) 40 (76)  
  Squamous-cell carcinoma 19 (27) 11 (21)  
  Other 0 2 (4)  
Tumor location — no. (%)†   0.571 
  Esophagus    
     Proximal and middle third 12 (18) 6 (12)  
     Distal third  36 (54) 32 (62)  
  Esophagogastric junction 19 (28) 14 (27)  
  Missing data 3 1  
Clinical T stage — no. (%)‡   0.965 
  cT1/cT2 16 (23) 12 (24)  
  cT3 53 (77) 39 (76)  
  Could not be determined§ 1 2  
Clinical N stage — no. (%)¶   0.116 
  N0 31 (46) 16 (31)  
  N1 37 (54) 35 (69)  
Could not be determined§ 2 2  
WHO performance status — no. (%)ǁ   0.425 
  0 57 (81) 46 (87)  
  1 13 (19) 7 (13)  
* Percentages may not add up to 100 because of rounding. WHO denotes World Health Organization. 
† Tumor length and location were determined by means of endoscopy. 
‡ Clinical tumor (cT) stage was assessed by means of endoscopic ultrasonography or computed tomography 
(CT) and was classified according to the International Union against Cancer (UICC) tumor–node–metastasis 
(TNM) classification, 6th edition. 
§ This category included patients in whom the tumor could not be fully investigated by means of a transducer 
for endoscopic ultrasonography owing to a stenosis caused by the tumor. 
Clinical lymph-node (N) stage was assessed by means of endoscopic ultrasonography, CT, or 18F-
fluorodeoxyglucose positron-emission tomography and was classified according to UICC TNM classification, 
6th edition. 
ǁ WHO performance status scores are on a scale of 0 to 5, with lower numbers indicating better performance 
status; 0 indicates fully active, and 1 unable to carry out heavy physical work. 
  
Chapter 10 
192 
Table 2. Patients eligible for quality of life assessment, returning the quality of life questionnaire, deceased, not 
returning the quality of life questionnaire because they were too ill or because of random reasons at each 
measurement point. 
Status Pre-treatment 12 months 
postoperatively 
Long-term follow-up 
(>6 years 
postoperatively) 
Eligible 
  nCRT + surgery 
  surgery alone 
123 
70 
53 
123 
70 
53 
123 
70 
53 
Returned total (% of eligible) 
  nCRT + surgery (%) 
  surgery alone (%) 
83(67) 
57 (81) 
26 (49) 
79 (64) 
49 (70) 
30 (57) 
110 (89) 
66 (94) 
44 (83) 
Deceased N/A N/A N/A 
Too ill 0 1 1 
Randomly missing / other 40* 43 12 
* (of whom 32 due to administrative error) 
Table 3a. Mean scores for all domains in the two EORTC questionnaires according to treatment group. 
  Pre-treatment 12 months  
postoperatively 
Long-term follow-up 
(>6 years postoperatively) 
  nCRT plus surgery surgery  
alone 
nCRT plus 
surgery 
surgery  
alone 
nCRT plus 
surgery 
surgery  
alone 
QLQ-C30       
Global quality of life 76(19) 73(15) 76(17) 77(22) 76(22) 78(19) 
Functional scales       
  Physical 96(9) 94(8) 89(16) 91(10) 86(16) 86(20) 
  Role 88(27) 85(22) 80(25) 78(23) 82(24) 82(25) 
  Emotional 68(24) 67(18) 86(17) 79(20) 87(18) 84(22) 
  Cognitive 92(17) 85(19) 88(18) 83(19) 85(19) 84(20) 
  Social 85(23) 81(21) 90(16) 78(24) 87(20) 80(24) 
Symptom scores       
  Fatigue 13(17) 16(21) 25(20) 20(15) 27(22) 22(24) 
  Nausea and vomiting 5(11) 6(12) 11(16) 15(20) 7(14) 10(21) 
  Pain 12(19) 14(22) 6(11) 18(20) 10(20) 10(17) 
  Dyspnea 5(12) 2(9) 16(22) 11(18) 19(25) 14(21) 
  Insomnia 23(26) 20(31) 14(23) 16(25) 20(27) 20(27) 
  Loss of appetite 10(24) 7(17) 10(19) 10(18) 12(23) 15(28) 
  Constipation 8(19) 1(6) 8(20) 11(20) 10(17) 5(12) 
  Diarrhea 2(11) 0(0) 16(24) 18(23) 16(24) 17(26) 
  Financial worries 7(18) 9(24) 9(19) 13(26) 12(25) 11(28) 
       
QLQ-OES24       
Eating problems 29(27) 33(28) 24(21) 29(27) 20(20) 22(23) 
Emotional problems* 36(25) 48(18) 29(20) 33(23) 29(22) 25(24) 
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Table 3a. Continued 
 Pre-treatment 12 months  
postoperatively 
Long-term follow-up 
(>6 years postoperatively) 
 nCRT plus 
surgery 
surgery  
alone 
nCRT plus 
surgery 
surgery  
alone 
nCRT plus 
surgery 
surgery  
alone 
Dysphagia 74(33) 63(35) 83(28) 69(38) 82(31) 76(36) 
Deglutition 16(27) 9(16) 16(26) 13(19) 12(20) 18(22) 
Swallowing of saliva 18(34) 11(23) 14(30) 10(22) 10(25) 17(32) 
Aspiration 14(27) 7(14) 18(28) 16(23) 13(24) 18(25) 
GI symptoms (24)* 16(19) 21(16) 21(22) 25(25) 20(19) 25(30) 
GI symptoms (18) 10(20) 7(13) 19(26) 22(27) 19(24) 26(32) 
Pain 16(20) 23(27) 8(14) 9(15) 8(16) 7(11) 
Dry mouth 8(21) 12(19) 17(25) 14(23) 17(25) 13(24) 
Trouble with taste 7(19) 9(24) 9(21) 8(14) 8(20) 8(23) 
Trouble with coughing 13(21) 12(21) 17(21) 20(21) 17(24) 18(27) 
Trouble with speaking 4(17) 0(0) 12(27) 10(26) 9(22) 11(22) 
Hair loss* 0(0) 0(0) 13(17) 33(33) 8(23) 0(0) 
Scores are presented as mean. Standard deviations are shown between parentheses. 
* Domains were removed after validation and refinement of the QLQ-OES24 into the QLQ-OES18 question-
naire. 
EORTC: European organization for research and treatment of cancer.  
Table 3b. Mean scores for all domains in the K-BILD questionnaire according to treatment group. 
  >6 years  
postoperatively 
  nCRT plus surgery surgery  
alone 
p-value 
Psychological symptoms 86 (19) 87 (17) 0.95 
Breathlessness and activity 73 (23) 77(23) 0.41 
Chest symptoms 89 (17) 93 (16) 0.24 
Total 81 (18) 83 (17) 0.69 
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Figure 1. Mean scores with standard deviations for a) physical functioning, b) eating problems (primary 
endpoints), c) global quality of life and d) fatigue (secondary endpoints) according to treatment allocations. 
 A 
 B 
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Abstract 
Background 
Results from the recent CROSS trial showed that neoadjuvant chemoradiotherapy 
(nCRT) significantly increased survival as compared to surgery alone in patients with 
potentially curable esophageal cancer. Furthermore, in the nCRT arm 49% of patients 
with a squamous cell carcinoma and 23% of patients with an adenocarcinoma had a 
pathologically complete response in the resection specimen. These results provide a 
rationale to reconsider and study the timing and necessity of esophagectomy in (all) 
patients after application of the CROSS-regimen.  
Objective 
We propose a surgery as needed approach after completion of nCRT. In this approach, 
patients will undergo active surveillance after completion of nCRT. Surgical resection 
would be offered only to those patients in whom residual disease or a locoregional re-
currence is highly suspected or proven. However, before a Surgery As Needed approach 
in Oesophageal cancer patients (SANO) can be tested in a randomized controlled trial, 
we aim to determine the accuracy of detecting the presence or absence of residual dis-
ease after nCRT (preSANO trial).  
Methods 
This study is set up as a prospective, single arm, multicenter, diagnostic trial. Operable 
patients with potentially curable squamous cell- or adenocarcinoma of the esophagus or 
esophago-gastric junction will be included. Approximately 4-6 weeks after completion 
of nCRT all included patients will undergo a first clinical response evaluation (CRE-I) 
including endoscopy with (random) conventional mucosal biopsies of the primary tu-
mor site and of any other suspected lesions in the esophagus and radial endo-
ultrasonography (EUS) for measurement of tumor thickness and -area. Patients in 
whom no locoregional or disseminated disease can be proven by (cyto)histology will be 
offered a postponed surgical resection, 6-8 weeks after CRE-I (i.e. approximately 12-14 
weeks after completion of nCRT). In the week preceding the postponed surgical resec-
tion a second clinical response evaluation (CRE-II) will be planned, which will include a 
whole body PET-CT, followed again by endoscopy with (random) conventional muco-
sal biopsies of the primary tumor site and any other suspected lesions in the esophagus, 
radial EUS for measurement of tumor thickness and –area and linear EUS plus fine 
needle aspiration of PET-positive lesions and/ or suspected lymph nodes. The main 
study parameter is the correlation between the clinical response assessment during 
CRE-I and CRE-II and the final pathological response in the resection specimen. 
Detection of residual disease after neoadjuvant chemoradiotherapy (preSANO): protocol 
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Results 
Enrolment began July 23, 2013, results expected January 2016. 
Discussion 
If this preSANO trial shows that the presence or absence of residual tumor can be pre-
dicted reliably 6 or 12 weeks after completion of nCRT, a randomized trial comparing 
nCRT plus standard surgery versus chemoradiotherapy plus ‘surgery as needed’ will be 
conducted (SANO trial). 
Registration 
Netherlands Trial Register (NTR4834) 
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Background 
Cancer of the esophagus remains a highly lethal malignancy, as reflected by an average 
overall five-year survival of 17%.1 In the Netherlands, the incidence of esophageal cancer 
resembles the growing trend in Western countries, with an estimated incidence of 
15/100,000 for men and 6/100,000 for women2, and more than 2,500 new cases diag-
nosed nationally each year. 
At present, surgical resection is still considered the cornerstone of curative treatment 
for patients eligible with stage cT1b-4aN0-3M0 disease. The reported five-year survival 
rate for patients who undergo an esophagectomy ranges from 20 to 50%, but rarely 
exceeds 35%.3-7. Esophagectomy is associated with postoperative mortality rates of 1-5% 
in high-volume centers, severe postoperative morbidity and a substantial impact on the 
quality of life.8-13 In order to improve the radicality of surgical resection and the long 
term survival after surgical resection many trials have been performed to study the effect 
of (neo-) adjuvant chemo- and/or radiation therapy.14-17 One of the largest trials is the 
recently published CROSS trial. This randomized trial compared neoadjuvant chemora-
diotherapy (nCRT) plus surgery to surgery alone.18 During a five-year period 366 pa-
tients from 5 academic and 2 non-academic high-volume teaching hospitals in the 
Netherlands were included. This study showed that the addition of nCRT (Carboplatin 
AUC2, Paclitaxel 50 mg/m2 and 41.4 Gy of concurrent radiotherapy) to surgery signifi-
cantly increases long term survival as compared to surgery alone. Median overall surviv-
al of patients who received nCRT plus surgery was 49 months, compared to 24 months 
for those who received surgery alone and the 3-year overall survival was superior in the 
nCRT arm (hazard ratio (HR) = 0.66; 95% confidence interval (CI) 0.50-0.87; p=0.003). 
Therefore, nCRT plus surgery is now considered the therapy of choice in the Nether-
lands and several other countries for potentially curable esophageal cancer (cT2-3N0-
3M0 and cT1N1-3M0, according to the UICC TNM classification, 7th ed.).19 In subse-
quent analyses of secondary endpoints of the CROSS trial an interesting observation was 
made. In the nCRT arm, 49% of patients with a squamous cell carcinoma (SCC) and 
23% of patients with an adenocarcinoma (AC) had a pathologically complete response 
(pCR) in the resection specimen (i.e. no viable tumor cells were found, neither at the site 
of the primary tumor nor in the resected regional lymph nodes, as determined by con-
ventional histological examination).18 Therefore, these results provide a rationale to 
reconsider and study the timing and necessity of standard esophagectomy in (all) pa-
tients after application of the CROSS regimen. 
We propose a surgery as needed approach after completion of nCRT for carcinoma 
of the esophagus. In this surgery as needed approach, patients will undergo active sur-
veillance after completion of nCRT. Surgical resection would be offered only to those 
patients in whom a locoregional recurrence is highly suspected or proven, in the absence 
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of any signs of distant dissemination. Such an organ-preserving strategy would clearly 
have great advantages. Postoperative mortality and severe morbidity (grade ≥3 accord-
ing to the Clavien-Dindo classification20) after esophagectomy in the Netherlands is 5% 
and 60%, respectively. Thus, a non-surgical treatment strategy in patients with a clini-
cally complete response after nCRT, theoretically saves 5% mortality and 60% severe 
morbidity in this patient group. Moreover, this approach might improve quality of life 
and might lead to a reduction in health care costs. However, this surgery as needed ap-
proach is only favorable if long term survival would be comparable to that of the trimo-
dality approach comprising nCRT followed by standard surgery. Before a surgery as 
needed approach can be tested in a randomized trial, we aim to determine the feasibility 
of accurate detection of residual disease after chemoradiotherapy. 
The aim of this present prospective, multicenter, diagnostic preSANO study trial is 
to determine the accuracy by which we can detect the presence or absence of residual 
disease after nCRT. The results of this trial will inform us about the percentage of pa-
tients with a clinically complete response after nCRT, and will help to estimate the 
number of patients needed for a subsequent randomized controlled trial. This future so 
called SANO-trial (Surgery As Needed in Oesophageal cancer patients) will randomize 
patients to nCRT plus surgery versus nCRT followed by active surveillance. 
Methods 
Study design 
The preSANO trial is a prospective, multicenter, diagnostic trial including 120 patients, 
using a single arm. Five high-volume centers in the Netherlands are currently participat-
ing in this study (Erasmus Medical Center, Rotterdam; Academic Medical Center, Am-
sterdam; University Medical Center, Utrecht; Catharina Cancer Center, Eindhoven; 
Atrium Medical Center, Heerlen). The study has been approved by the medical ethics 
committee of the Erasmus Medical Center (MEC2013-211) and has been registered in 
the Netherlands Trial Register (NTR4834). 
Study population 
We plan to include individuals from a population of operable patients with potentially 
curable SCC or AC of the esophagus or esophago-gastric junction. All patients who are 
planned to undergo nCRT according to the CROSS regimen18, followed by surgical 
resection are eligible to participate. Patients with dementia or altered mental status pro-
hibiting the understanding and giving of informed consent will be excluded from partic-
ipation in this study. Patients will undergo conventional pre-treatment selection (in-
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cluding at least a “partial body” F18-FDG PET-CT to assess the avidity of the primary 
tumor process; Figure 1 and Table 1). 
Study algorithm 
Overview 
All included patients will receive nCRT according to the CROSS protocol (Carboplatin, 
Paclitaxel and 41.4 Gy of concurrent radiotherapy).18 Patients will be reevaluated either 
once or twice before undergoing surgical resection during clinical response evaluations 
(CRE). The aim of these CREs will be to identify those patients in whom residual and/or 
disseminated disease is present. 
CRE-I 
The first CRE (CRE-I) will be performed 4-6 weeks after completion of chemoradio-
therapy (Figure 1). During CRE-I, all patients will undergo esophagogastroduodenosco-
py (EGD) with registration of endoscopic images for future reference and biopsies of 
any suspected lesions, including mucosal biopsies at the site of the primary tumor (one 
regular biopsy per centimeter in each of the 4 quadrants), radial endoscopic ultrasonog-
raphy (EUS) for measurement of maximal tumor thickness and –area and linear EUS. 
Patients with (cyto)histological evidence of locoregional residual disease, but without 
evidence of disseminated disease, will be offered immediate surgical resection. These 
patients have no clear benefit from postponement of surgical resection and should 
therefore have no delay according to current recommendations. Patients without (cy-
to)histological evidence of locoregional residual disease and without disseminated dis-
ease will be considered to be clinically complete responders and will be offered a post-
poned surgical resection. In these patients a surgical resection will be postponed for an 
additional 6-8 weeks, allowing patients more time to reach a better condition for sur-
gery.  
CRE-II 
In the week preceding the planned postponed surgical resection a second clinical re-
sponse evaluation (CRE-II) will be scheduled. CRE-II will be performed only in patients 
who were considered to be clinically complete responders (i.e. no viable tumor found) at 
CRE-I. CRE-II will consist of a PET-CT (standard for all patients at CRE-II and only for 
tumor positive patients at CRE-I), an EGD with registration of endoscopic images for 
future reference and biopsies of any suspected lesions, including (random) mucosal 
biopsies at the site of the primary tumor, radial endoscopic ultrasonography (EUS) for 
measurement of maximal tumor thickness and -area and linear EUS plus fine needle 
aspiration (FNA) of PET-positive lesions and/ or suspected lymph nodes.  
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An important difference between CRE-I and CRE-II will be that during CRE-I clini-
cally complete responders will be offered a postponed surgical resection, whereas after 
CRE-II both locoregionally complete- and non-complete responders will be advised to 
undergo a surgical resection (Figure 1). In other words, all patients who are considered 
clinically complete responders at CRE-I and are therefore allowed to postpone their 
surgery by an additional 6-8 weeks, will undergo CRE-II followed by the postponed 
surgical resection, irrespective of the locoregional findings during CRE-II. The diagnos-
tic results from CRE-II will later be compared with results from both CRE-I and the 
final pathological analysis of the resection specimen. However, patients with (cy-
to)histological evidence of disseminated disease during CRE-I or CRE-II will be exclud-
ed from further curative therapy and will be referred for palliative care. 
If after CRE-II the planned operation is postponed for more than 4 weeks (e.g. be-
cause the patient has not yet sufficiently recovered from the nCRT), a CRE-III (compa-
rable to CRE-II) will be performed one week before the (further) postponed operation. 
Surgery 
Surgical resection will be attempted immediately after CRE-I only in those patients who 
present at CRE-I with (cyto)histologically proven residual disease after completion of 
nCRT, without any signs of disseminated disease. All other patients will undergo surgi-
cal resection after CRE-II in the absence of distant metastases.  
A transthoracic esophageal resection or a transhiatal approach can be performed, 
depending on both patient characteristics and local expertise and preference. Both open 
and minimally invasive techniques are allowed.  
A wide local excision including the regional lymph nodes is carried out in both tech-
niques including a standard dissection of the lymph nodes around the coeliac axis. The 
continuity of the digestive tract will preferably be restored by a gastric tube reconstruc-
tion or if required by a colonic interposition. 
At least 15, but preferably 23 or more lymph nodes should be aimed to be removed 
in every patient, since it has been shown that long-term survival is maximized with the 
removal of at least 23 nodes.21 Moreover, the risk of understaging the tumor in these 
patients should be minimized. If an insufficient number of nodes is removed, the patient 
might be erroneously staged as ypN0, while in fact ypNpos nodes have been left in-situ 
(stage migration). 
Pathology 
All resection specimens will be revised centrally by two independent expert pathologists, 
using a standard protocol. In case of a discordant outcome, the specimens will be re-
viewed by a third independent expert pathologist. A final diagnosis will be made only if 
at least two pathologists agree. Also, all the CRE-II biopsies of patients who were con-
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sidered negative at CRE-II, but who had >10% residual tumor in their resection speci-
men will be revised centrally following the same strategy. In these specimens special 
attention will be given to the effects of the preoperative chemoradiation, i.e. tumor re-
duction and therapy effects. The lymph node dissection should contain at least 15, but 
preferably 23 or more nodes derived from both mediastinum and upper abdomen which 
are essential for correct ypTNM staging. The resection margins, especially the circum-
ferential margin, will be evaluated with a 1mm cut-off point for vital tumor. This im-
plies that the tumor-free margin should be >1mm in order to be classified as R0. If vital 
tumor is present at ≤1mm from the surgical resection margin it is considered micro-
scopically positive (R1). 
Interim analysis 
An interim analysis will be performed by an independent safety committee after a total 
inclusion of 60 patients in order to carefully monitor serious complications during CRE-
I and CRE-II and to assess the achieved radicality of the performed operations. 
Main study parameter/endpoint 
The main study parameter in this study is the correlation between the clinical response 
assessment during CRE-I and CRE-II and the final pathological response in the resec-
tion specimen, as measured by the modified tumor regression grading (TRG) system of 
Chirieac22; no residual carcinoma (TRG1), 1-10% residual carcinoma (TRG2), 11-50% 
residual carcinoma (TRG3), 51-100% residual carcinoma (TRG4).  
We propose that in this study TRG2 residual tumors may be missed as long as we 
expect them to be detectable reliably as soon as they have outgrown from TRG2 to 
TRG3-4 during follow up. The risk that TRG2 residual tumors will lead to irresectability 
in the short-term is likely to be small/negligible. However, we do propose that TRG3 
and TRG4 residual tumors should be detected without further delay in order to prevent 
short-term loss of resectability and to minimize the risk of long-term distant disease 
dissemination. The validity of these assumptions can only be determined in a future 
SANO trial, in which an active surveillance strategy will be compared with standard 
surgery in all patients after nCRT. 
Statistical analysis 
Sample size calculation 
As was seen in the previous CROSS trial approximately 40% of the included patients will 
have TRG3 or TRG4 residual tumor in the resection specimen.18 With a total inclusion 
of 120 patients, approximately 45 patients will have TRG3 or TRG4 residual tumor. We 
consider 45 patients a sufficiently large sample for determining the accuracy of individ-
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ual and/or combined diagnostic tests. In order to estimate the distribution of 120 pa-
tients planned to be included, data were used from the CROSS trial as indicated in Fig-
ure 2. Furthermore, several assumptions were made: 
- We assume that during the first clinical response evaluation (CRE-I), clinically 
complete responders will comprise patients with TRG1 or TRG2 (as taken from the 
pathological response data of the CROSS trial), whereas clinically non-complete re-
sponders will be patients with TRG3 or TRG4. 
- The percentage of patients with SCC and AC with TRG1 or TRG2 in the CROSS 
trial was 78% and 57%, respectively. This means that approximately 60% of included 
patients are expected to have negative (cyto)histology at CRE-I.  
- In a trial by Blom et al 23 approximately 10% of patients who were re-evaluated by 
PET-CT after completion of nCRT had newly discovered disseminated disease. We 
assume less newly found disseminated disease with positive (cyto)histology at CRE-II, 
because a number of these patients are expected to be discovered during CRE-I. 
- We assume that approximately 25% of clinically complete responders will refuse to 
undergo the postponed resection and choose to undergo an active surveillance strategy 
if no alarming results are found during CRE-II. 
These calculations indicate that approximately 60 patients will show a clinically 
complete response after combined diagnostic investigations, during CRE-I and CRE-II 
(including EUS-FNA with tumor thickness measurements and PET-CT). Of these, ap-
proximately 15 patients will refuse to undergo surgery and will undergo active surveil-
lance and approximately 30 patients will have a pathologically complete response 
(TRG1). The 15 remaining patients are expected to have residual disease, of whom ap-
proximately 12 patients will have TRG2 residual tumor and approximately 3 patients 
will have TRG3 or TRG4 residual tumor. As we proposed above, TRG2 residual tumors 
may be missed. Therefore, we expect that approximately 3 patients with clinically rele-
vant residual disease (TRG3 or TRG4) will be missed. 
In case of unexpected aberrant distribution of patients in the preSANO-trial that 
leads to decreased TRG3 and TRG4 rates, results of the first 120 patients will be ana-
lyzed following the present protocol. If these results are promising but do not reach 
statistical significance, possibly due to a lack of power, inclusion of extra patients will be 
considered. If inclusion of extra patients is desirable, the protocol will be amended and 
assessed by the medical ethics committee. 
Data analysis 
The clinical response evaluation will consist of different diagnostic modalities. Results of 
each diagnostic modality will be presented as categorical or continuous data, depending 
on the outcome measure of each diagnostic modality. These results will be correlated to 
the (categorical) tumor regression grading in the resection specimen, using a chi-square 
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based test (categorical-categorical) or a one-way ANOVA test (continuous-categorical) 
with post-hoc testing.  
Results 
The first patient has been enrolled on July 23, 2013 and results are expected in January 
2016. 
Discussion 
The uniqueness of this study lies in the prospective evaluation of a sufficiently large 
number of patients, using multiple diagnostic modalities on different time points. Alt-
hough (cyto)histological assessment of biopsies and / or FNAs is the most objective 
parameter, several studies have shown that the response to nCRT is reflected by tumor 
size or volume as assessed by EUS.24-27 The rationale to include a second clinical re-
sponse evaluation before a planned surgical resection is to allow for a comparison be-
tween multiple measurements and to increase the chance of detecting residual- and/or 
disseminated disease. It is expected that during CRE-II (due to an extended time period 
from the end of nCRT) the F18-FDG PET-CT signal will have a more favorable signal-
to-noise ratio than has been described previously28-33, because after 12 weeks the arte-
facts due to radiation-induced inflammation are expected to have largely dissolved. This 
allows for identification of suspected lymph nodes to be targeted by FNA during CRE-
II.  
The reason to include patients with SCC as well as patients with AC in the preSANO 
trial, is that the CROSS regimen has been shown to be effective in both groups of pa-
tients. The pCR rate of 49% in patients with SCC and 23% in patients with AC in the 
CROSS trial, provide a rationale for a SANO approach in both histological subtypes . 
Furthermore, together with the low frequency of toxic effects of the CROSS regimen 
(91% received the full treatment regimen of nCRT), these high pCR rates advocate the 
use of the relatively low dose of 41.4 Gy radiotherapy.18 
Although we have not yet clearly shown that we are able to detect a clinically threat-
ening residual cancer 4-6 weeks after nCRT, there are several arguments why it is not 
deemed necessary to do so before we can further delay the planned surgical resection 
with an additional 6-8 weeks. Recently, it was shown that prolonged time to surgery 
after nCRT up to at least 12 weeks had no effect on disease-free- and overall survival 
(HR=1.00 and HR=1.06 per additional week, p=0.976 and p=0.139, respectively). More-
over, prolonged time to surgery increased the probability of pCR in the resection speci-
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men (odds ratio, OR=1.35 per additional week of time to surgery, p=0.0004).34 Compa-
rable results have been published by other groups.35, 36 
Postoperative mortality and severe morbidity (grade ≥3 according to the Clavien-
Dindo classification20) after esophagectomy in the Netherlands is 5% and 60%, respec-
tively. Thus, a non-surgical treatment strategy in patients with a clinically complete 
response after nCRT, theoretically saves up to 5% mortality and 60% severe morbidity in 
this patient group. Moreover, this approach might improve quality of life and might 
lead to a reduction in health care costs. Therefore, we will consider this study as success-
ful when the results of the combined diagnostic modalities lead to a maximum percent-
age of clinically false-negative TRG3 and TRG4 tumors of twice the postoperative mor-
tality (i.e. 10%). If more than 10% of TRG3 or TRG4 tumors will be missed, the SANO 
trial will be reconsidered. 
If the preSANO trial shows that TRG3 and TRG4 residual tumor can be predicted 
reliably, a randomized trial comparing nCRT plus standard surgery versus chemoradio-
therapy plus ‘Surgery As Needed in Oesophageal cancer patients’ (the SANO trial) will be 
conducted. Hopefully, this SANO trial will result in an organ-preserving treatment 
strategy for a selected group of patients and therefore reduce treatment related morbidi-
ty and mortality, improve quality of life and lead to a reduction in health care costs. 
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Table 1.  Study algorithm 
1 Hematology: CBC, differential  
2 Biochemistry: serum protein, albumin, magnesium, electrolytes, serum creatinin, bilirubin, alkaline phospha-
tase, AST, and pregnancy test if indicated at baseline only 
3 Radial EUS: with measurement of maximum tumor thickness and –area 
4 Linear EUS: with fine-needle aspiration (FNA) of any suspected lymph nodes  
5 Bronchoscopy: when tumor is located above the carina and when there is suspicion for invasion of the tra-
cheo-bronchial tree 
6 Toxicity: to be evaluated after each cycle (incidence and grade according to CTC toxicity scale) 
7 PET-CT: during CRE-I, after EGD and EUS, only for clinically non-complete responders, to exclude dissem-
inated disease 
8 PET-CT: during CRE-II, prior to EGD and EUS, for all patients (all were clinically complete responders 
during CRE-I) to guide EGD and EUS in targeting suspected locoregional lesions and to exclude disseminated 
disease 
  
Parameter Pretreatment First clinical response 
evaluation (CRE-I) 
Second clinical response 
evaluation (CRE-II) 
History, Physical 
Examination 
X X X 
Performance status X X X 
Haematology1 X   
eGFR X   
Biochemistry2 X   
Endoscopy + (random) 
biopsies 
X X X 
Radial EUS3 X X X 
Linear EUS (+FNA)4 X  X 
CT of neck, thorax, 
abdomen and pelvis 
X   
PET-CT X  “partial body” X7  “whole body” X8  “whole body” 
Pulmonary function tests X   
Bronchoscopy5 X   
ECG X   
Toxicity6 Baseline   
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Figure 1. Study algorithm. 
 
 
 
Pretreatment work-up and clinical response evaluations include: 
- ‘partial body’ or ‘whole body’ 18F-FDG PET-CT1 
- EGD (with biopsies) 
- EUS (with FNA)2 
- Dedicated CT of neck, thorax, abdomen and pelvis (in pretreatment work-up and on indication) 
- Externa US of the neck (in pretreatment work-up and on indication) 
1 During the pretreatment work-up, it suffices when a “partial body”  F18-FDG PET-CT of the esophagus will 
be performed (to test for avidity of the primary lesion); if it is preferred to make a “whole-body” PET-CT not 
only after, but also before  the neoadjuvant chemoradiotherapy in order to detect distant metastases at an 
earlier stage,  the indication for performing an external US with FNA of the neck can be limited to those 
patients who have a suspected lymph node on the PET-CT 23. In the period after neoadjuvant therapy one 
whole-body F18-FDG PET-CT will be performed either at CRE-I (for the clinically non-complete responders) 
or at CRE-II (for the clinically complete responders at CRE-I).  
2 EUS with FNA of suspected lymph nodes only during CRE-II, not during CRE-I 
CRE: clinical response evaluation; CT: computed tomography; EUS: endoscopic ultrasonography; FNA: fine-
needle aspiration; nCRT: neoadjuvant chemoradiotherapy; EGD: esophagogastroduodenoscopy; PET: posi-
tron-emission tomography; US: ultrasonography.  
Pretreatment work - up 
Inclusion 
nCRT 
CRE - I 
CRE - II 
Disseminated diease ,  
proven by  ( cyto ) histology 
Locregional disease  only ,  
proven by histology 
Disseminated diease ,  
proven by  ( cyto ) histology Everyone else 
  6 weeks 
6   weeks 
No histological proof of  
residual disease 
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Figure 2. Expected distribution of patients (based partly on CROSS-trial data) 
 
 
 
All numbers are based on an inclusion of 120 patients. CI: confidence interval; CRE: clinical response evalua-
tion; nCRT: neoadjuvant chemoradiotherapy; N: number of patients; TRG: tumor regression grade, as meas-
ured by the modified TRG system of Chirieac.22 Of the 45 patients who will undergo a postponed resection 
following CRE-II, 15 patients are expected to have a pathologically incomplete response (at least TRG2). 
  
Pretreatment work - up 
Inclusion 
nCRT 
CRE - I 
CRE - II 
Disseminated diease ,  
proven by  ( cyto ) histology 
Locregional disease  only ,  
proven by histology 
Disseminated diease ,  
proven by  ( cyto ) histology 
6   weeks 
  6 weeks No histological proof of  residual disease 
n = 120 
n = 36 
95 %  CI  ( 26 - 47 ) 
n = 12 
95 %  CI  ( 6 - 20 ) 
n = 6 
95 %  CI  ( 2 - 13 ) 
n = 6 
95 %  CI  ( 2 - 13 ) 
Surgery 
Locregional disease  only , 
proven by  ( cyto ) histology 
Everyone else n = 60 95 %  CI  ( 49 - 71 ) 
TRG n 95 %  CI 
TRG 1 30 ( 22 - 38 ) 
TRG 2 12 - 15 ( 6 - 23 ) 
TRG 3 - 4 0 - 3 ( 0 - 8 ) 
Refusal 15 ( 9 - 23 ) 
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Summary 
Background  
After neoadjuvant chemoradiotherapy for oesophageal cancer, roughly half of the pa-
tients with squamous cell carcinoma and a quarter of those with adenocarcinoma have a 
pathological complete response of the primary tumour before surgery. Thus, the neces-
sity of standard oesophagectomy after neoadjuvant chemoradiotherapy should be re-
considered for patients who respond sufficiently to neoadjuvant treatment. In this 
study, we aimed to establish the accuracy of detection of residual disease after neoadju-
vant chemoradiotherapy with different diagnostic approaches, and the optimal combi-
nation of diagnostic techniques for clinical response evaluations.  
Methods 
The preSANO trial was a prospective, multicentre, diagnostic cohort study at six centres 
in the Netherlands. Eligible patients were aged 18 years or older, had histologically 
proven, resectable, squamous cell carcinoma or adenocarcinoma of the oesophagus or 
oesophagogastric junction, and were eligible for potential curative therapy with neoad-
juvant chemoradiotherapy (five weekly cycles of carboplatin [area under the curve 2 
mg/mL per min] plus paclitaxel [50 mg/m² of body-surface area] combined with 41.4 
Gy radiotherapy in 23 fractions) followed by oesophagectomy. 4–6 weeks after comple-
tion of neoadjuvant chemoradiotherapy, patients had oesophagogastroduodenoscopy 
with biopsies and endoscopic ultrasonography with measurement of maximum tumour 
thickness. Patients with histologically proven locoregional residual disease or no-pass 
during endoscopy and without distant metastases underwent immediate surgical resec-
tion. In the remaining patients a second clinical response evaluation was done (PET–
CT, oesophagogastroduodenoscopy with biopsies, endoscopic ultrasonography with 
measurement of maximum tumour thickness, and fine-needle aspiration of suspicious 
lymph nodes), followed by surgery 12–14 weeks after completion of neoadjuvant 
chemoradiotherapy. The primary endpoint was the correlation between clinical re-
sponse during clinical response evaluations and the final pathological response in resec-
tion specimens, as shown by the proportion of tumour regression grade (TRG) 3 or 4 
(>10% residual carcinoma in the resection specimen) residual tumours that was missed 
during clinical response evaluations. This study was registered with the Netherlands 
Trial Register (NTR4834), and has been completed.  
Findings 
Between July 22, 2013, and Dec 28, 2016, 219 patients were included, 207 of whom were 
included in the analyses. Eight of 26 TRG3 or TRG4 tumours (31% [95% CI 17–50]) 
were missed by endoscopy with regular biopsies and fine-needle aspiration. Four of 41 
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TRG3 or TRG4 tumours (10% [95% CI 4–23]) were missed with bite-on-bite biopsies 
and fine-needle aspiration. Endoscopic ultrasonography with maximum tumour thick-
ness measurement missed TRG3 or TRG4 residual tumours in 11 of 39 patients (28% 
[95% CI 17–44]). PET–CT missed six of 41 TRG3 or TRG4 tumours (15% [95% CI 7–
28]). PET–CT detected interval distant histologically proven metastases in 18 (9%) of 
190 patients (one squamous cell carcinoma, 17 adenocarcinomas).  
Interpretation 
After neoadjuvant chemoradiotherapy for oesophageal cancer, clinical response evalua-
tion with endoscopic ultrasonography, bite-on-bite biopsies, and fine-needle aspiration 
of suspicious lymph nodes was adequate for detection of locoregional residual disease, 
with PET–CT for detection of interval metastases. Active surveillance with this combi-
nation of diagnostic modalities is now being assessed in a phase 3 randomised con-
trolled trial (SANO trial; Netherlands Trial Register NTR6803). 
Research in context 
Evidence before this study 
We did not do a formal search of published work before this trial. The randomised 
CROSS trial established chemoradiotherapy (weekly administration of carboplatin and 
paclitaxel plus 41.4 Gy concurrent radiotherapy) followed by surgery as the standard of 
care for patients with oesophageal cancer, compared with surgery alone. However, after 
neoadjuvant chemoradiotherapy plus surgery, 29% of treated patients achieve a patho-
logical complete response (as measured by histological examination of resection speci-
mens), which provides a rationale for an active surveillance approach after neoadjuvant 
chemoradiotherapy with oesophagectomy offered only to patients with proven locore-
gional recurrence and without evidence of distant metastases. In a systematic review of 
four small retrospective studies, promising overall survival outcomes were associated 
with active surveillance after neoadjuvant chemoradiotherapy in patients with oesopha-
geal cancer who had a clinically complete response. Additionally, previous small retro-
spective studies of single diagnostic modalities (endoscopy plus biopsy, endoscopic 
ultrasonography, or 1⁸F-fluorodeoxyglucose PET–CT) for detection of residual disease 
after neoadjuvant chemoradiotherapy have shown poor diagnostic accuracy. So far, the 
optimal combination of diagnostic tests for detection of residual disease in patients with 
oesophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy 
is unknown. 
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Added value of this study 
By contrast with previous studies, in this multicentre, prospective cohort study, all avail-
able diagnostic modalities used for pre-treatment staging in clinical practice were ap-
plied to detect residual disease during active surveillance. These findings establish the 
optimal set of diagnostic modalities to accurately detect residual disease after neoadju-
vant therapy in patients with oesophageal cancer, allowing the stratification of patients 
who would benefit from active surveillance versus radical oesophagostomy. 
Implications of all the available evidence 
Clinical response evaluations after neoadjuvant chemoradiotherapy for oesophageal 
cancer should consist of endoscopic ultrasonography with bite-on-bite biopsies and 
fine-needle aspiration of suspicious lymph nodes for detection of locoregional residual 
disease and PET–CT for detection of interval metastases. The promising diagnostic 
results of this study provide the rationale for a phase 3, randomised, controlled trial of 
active surveillance versus standard surgery in patients with oesophageal cancer treated 
with neoadjuvant chemoradiotherapy. Our results can be used to define the composi-
tion of the clinical response evaluations and subsequent surveillance examinations in 
future trials that could establish a new management protocol for patients with oesopha-
geal cancer. 
Introduction 
Oesophageal cancer is an aggressive malignancy: the proportion of patients who achieve 
5-year survival after primary oesophagectomy rarely exceeds 35%.1 Overall survival has 
improved substantially in the past two decades, however, mainly as a result of the wide-
spread use of neoadjuvant chemo-radiotherapy.2 Five weekly cycles of carboplatin (area 
under the curve 2 mg/mL per min) plus paclitaxel (50 mg/m² of body-surface area) plus 
41.4 Gy radiotherapy in 23 fractions followed by oesophagectomy significantly im-
proved overall survival at 5 years compared with oesophagectomy alone (47% [95% CI 
39–54] in the neoadjuvant group vs 33% [26–40] in the surgery only group; hazard ratio 
0.68 [95% CI 0.53–0.88]; log-rank p=0.003).3, 4 In 47 (29%) of 161 patients with oesoph-
ageal carcinoma (18 [49%] of 37 with squamous cell carcinoma and 28 [23%] of 121 
with adenocarcinoma), a pathological complete response was noted after neoadjuvant 
chemoradiotherapy—ie, no viable tumour cells were detected in the resected specimen 
during conventional histological examination.3 
This high frequency of pathological complete response provides a rationale to recon-
sider the necessity of standard oesophagectomy after neoadjuvant chemoradiotherapy. 
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Theoretically, active surveillance could be feasible in patients without locoregional or 
disseminated disease, given that oesophagectomy probably does not affect oncological 
outcomes in patients with no viable tumour cells. In a pan-active surveillance approach, 
patients would undergo regular clinical investigations after neoadjuvant chemoradio-
therapy, and oesophagectomy would be offered only to those with proven locoregional 
recurrence and no evidence of distant metastases.3, 5-7 However, an active surveillance 
approach would only be justified if the associated oncological outcomes were non-
inferior to those achieved with standard surgery. To select patients for active surveil-
lance, disease should be restaged after neoadjuvant chemoradiotherapy by means of 
clinical response evaluations, which need to accurately classify patients as complete or 
incomplete responders. We aimed to establish which combination of diagnostic tests for 
clinical response evaluation most accurately detects residual disease after neoadjuvant 
chemoradiotherapy in patients with oesophageal cancer. 
Methods 
Study design and participants 
We did a prospective, multicentre, diagnostic cohort study at six centres in the Nether-
lands (appendix p 6); the study protocol has been previously published.8 After adjuvant 
chemoradiotherapy, patients underwent a first clinical response evaluation. Patients 
found to be complete responders during the first clinical response evaluation (ie, those 
with no locoregional or disseminated disease proven by cytohistology) were offered 
postponed surgical resection, and in the week preceding surgery, a second clinical re-
sponse evaluation was done before patients without distant metastases underwent oe-
sophagectomy. If the planned operation was postponed for more than 4 weeks after the 
second clinical response evaluation (eg, because the patient had not sufficiently recov-
ered from neoadjuvant chemoradiotherapy), a third clinical response evaluation was 
recommended a week before surgery. 
Eligible patients were aged 18 years or older, had histologically proven, resectable, 
squamous cell carcinoma or adenocarcinoma of the oesophagus or oesophagogastric 
junction, and were eligible for potential curative therapy with neoadjuvant chemoradio-
therapy followed by oesophagectomy.3 Patients with a severe stricture (no pass) on ini-
tial endoscopic ultrasonographic staging at baseline (ie, pre-treatment) were also in-
cluded. The study protocol was approved by the medical ethics committee of the Eras-
mus MC (Rotterdam, MEC-2013-211). All patients provided written informed consent. 
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Procedures 
All patients underwent primary clinical staging at baseline, including oesophagogastro-
duodenoscopy with biopsies, endoscopic ultrasonography with measurement of maxi-
mum tumour thickness,9 CT of the neck, chest, and upper abdomen, and 1⁸F-
fluorodeoxyglucose (18F-FDG) PET–CT. Most patients were consciously sedated with 
midazolam during endoscopic ultrasonography; general anaesthesia was not routinely 
used.  
The neoadjuvant chemoradiotherapy regimen consisted of five weekly cycles of car-
boplatin (area under the curve 2 mg/mL per min) plus paclitaxel (50 mg/m² of body-
surface area) combined with 41.4 Gy radiotherapy in 23 fractions, as per the CROSS trial 
recommendations.3 4–6 weeks after completion of the last cycle of neoadjuvant chemo-
therapy, patients underwent a first clinical response evaluation before surgery to identify 
non-responders. During this clinical response evaluation, all patients underwent oe-
sophagogastroduodenoscopy with biopsies and radial endoscopic ultrasonography with 
measurement of maximum tumour thickness and area. Patients with a severe stricture at 
endoscopy (no-pass) or histological evidence of locoregional residual disease underwent 
PET–CT to exclude distant metastases. If no distant metastases were detected, eligible 
patients underwent surgery within 2 weeks of the PET–CT assessment. Patients without 
histological evidence of residual disease during the first clinical response evaluation 
were offered postponed surgery scheduled approximately 6–8 weeks after the first clini-
cal response evaluation and approximately 12–14 weeks after neoadjuvant chemoradio-
therapy (compared with 6–8 weeks after neoadjuvant chemoradiotherapy for those with 
histological evidence of residual disease). In the week before surgery, we did a second 
clinical response evaluation to detect any residual disease that had developed or was 
previously undetected. The second clinical response evaluations comprised PET–CT, 
followed by oesophagogastroduodenoscopy with biopsies, radial endoscopic ultrasonog-
raphy for measurement of maximum tumour thickness and area, and linear endoscopic 
ultrasonography plus fine-needle aspiration of any suspicious lymph nodes or 18F-FDG-
avid lesions. After the second clinical response evaluation, all patients without distant 
metastases underwent oesophagectomy. The third clinical response evaluation (in pa-
tients who needed it) was similar to the second.  
When we designed the trial, endoscopy with random, conventional mucosal biopsies 
of the primary tumor site and of any other suspected lesions in the oesophagus were 
prespecified by protocol as part of the clinical response evaluations,8 because the safety 
of deep bite-on-bite biopsies after neoadjuvant chemoradiotherapy was unknown. An 
interim safety analysis was pre-planned after inclusion of 60 patients to monitor serious 
complications and assess the radicality of the performed operations. On April 20, 2015, 
after about 95 patients were enrolled and had a regular biopsy, the interim safety analy-
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sis showed no biopsy-related adverse events, and the protocol was amended on June 22, 
2015, to change the biopsy strategy. Thereafter, bite-on-bite biopsies were done instead 
of conventional biopsies during clinical response evaluations.10  
During bite-on-bite biopsies, a second, deep, biopsy sample is taken at the same lo-
cation as the first to increase the chance of detecting residual disease— especially sub-
mucosal—tumours (appendix p 7). Biopsies were taken from at least four different loca-
tions from the primary tumour site and from any suspicious lesions in the oesophagus. 
The regular biopsy procedure consisted of one biopsy of at least four different locations 
on the site of the primary tumour and from any suspicious lesion. All endoscopy reports 
and endoscopic ultrasonography images were reviewed by an experienced upper-
gastrointestinal gastroenterologist (MCWS), who was blinded to pathological response 
results in the resected specimen after surgery. 
During the second clinical response evaluation, fine-needle aspiration was done on 
any suspicious lymph nodes (round, hypoechogenic, and greater than 5 mm in diame-
ter), or any lymph nodes adjacent to the primary tumour. Potential contamination from 
the primary tumour during fine-needle aspiration of adjacent lymph nodes was not an 
issue because the source of residual disease was not a variable considered in the trial 
outcome analyses. Maximum tumour thickness was measured as reported previously9, 
maximum tumour thickness of 6 mm or greater during the second clinical response 
evaluation was classified as non-complete response.9  
Biopsies done at the first clinical response evaluation with uncertain outcome were 
deemed negative to reduce the risk of false-positive biopsies, whereas those with uncer-
tain outcomes done at the second clinical response evaluation were judged positive to 
reduce the risk of false-negative biopsies, in light of a future active surveillance strategy 
in patients with a clinical complete response after second clinical response evaluation.11, 
12 Fine-needle aspirates taken from suspicious lymph nodes with uncertain outcomes or 
that were not representative (ie, no lymphoid tissue present) were considered positive 
for residual disease. PET–CT was done according to the European Association of Nu-
clear Medicine guidelines.13 All scans were reviewed by an experienced PET–CT radiol-
ogist (RV), who was blinded to pathological response results  
18F-FDG PET–CT scans were visually assessed, including intensity of uptake and 18F-
FDG uptake in the environment (eg, adjacent oesophagus). A qualitative judgment was 
made, and results were scored from 1 to 5: 1 (benign), 2 (probably benign), 3 (equivo-
cal), 4 (probably malignant), and 5 (malignant). To ensure we did not exclude any tu-
mour residue, we defined all scores of 2 or higher as 18F-FDG positive. For locoregional 
response assessment, 18F-PET–CT scans from the first clinical response evaluation were 
analysed, whereas for distant dissemination scans from both clinical response evalua-
tions, if available, were used.  
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Transthoracic or transhiatal oesophagectomy was done depending on patient char-
acteristics and local preference. A wide excision, including removal of regional lymph 
nodes and standard dissection of the lymph nodes around the coeliac axis, was done in 
all patients with the aim of removing at least 15 lymph nodes. 
Resected tumours reviewed by an experienced upper gastrointestinal pathologist 
(KB [an author] and MD [a collaborator]) following a standard protocol, and classified 
and graded according to the Union for International Cancer Control TNM Cancer Stag-
ing (7th edn).14 We used the Chirieac modified tumour regression grade (TRG) 
system,15 the most commonly used system in the Netherlands, to classify pathological 
response in the resected specimens as no residual carcinoma (TRG1), 1–10% residual 
carcinoma (TRG2), 11–50% residual carcinoma (TRG3), and greater than 50% residual 
carcinoma (TRG4).15 All negative biopsies in patients with TRG3 or TRG4 tumours 
were re-reviewed by KB and MD. 
Serious adverse events, which resulted in death, were life threatening, required hos-
pital admission or prolongation of hospital stay, resulted in persistent or significant 
disability or incapacity, or were considered serious by the treating physician, were moni-
tored continuously from the first clinical response evaluation until the day that the pa-
tient underwent surgery. Participants could leave the study at any time for any reason if 
they wished to do so, and investigators could withdraw participants from the study for 
urgent medical reasons. 
Outcomes 
The primary outcome was to establish the accuracy of residual disease detection after 
neoadjuvant chemoradiotherapy, as reflected by the proportion of tumours classified as 
TRG3 or TRG4 that was missed during clinical response evaluations. The secondary 
outcome was the proportion of patients who had an R0 resection, defined as a resection 
with no gross or microscopic tumour cells present. Other prespecified outcomes were 
correlations between individual diagnostic modality (endoscopic examinations, PET–
CT, and analysis of cytohistological biopsies) and pathological findings in the resection 
specimen, and optimal cutoffs with maximal distinction between patients with and 
without clinically relevant residual disease. Results for R0 resection will be published 
elsewhere. 
Statistical analysis 
We hypothesised that TRG3 and TRG4 tumours could be detected reliably with the 
described clinical response evaluations. The estimated maximum percentage of clinical-
ly false-negative TRG3 and TRG4 tumours accounted for was 10%.8 Initially, we aimed 
to enroll 120 patients, approximately 45 (38%) of whom were estimated to have TRG3 
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or TRG4 residual tumours after surgery as per the CROSS trial results.3 However, be-
cause of the change in biopsy strategy as per protocol amendment (June 22, 2015) after 
about 95 patients were enrolled and had a regular biopsy, the total sample size was in-
creased to 215, to ensure that at least 120 patients would undergone bite-on-bite biop-
sies during the clinical response evaluations. 
Outcomes were analysed separately for both biopsy strategies (regular biopsies vs 
bite-on-bite biopsies). For endoscopic biopsies, results from both clinical response eval-
uations were combined (if either was positive, the patient was classified as having resid-
ual disease). Outcomes of endoscopic ultrasonography with measurement of maximum 
tumour thickness and PET–CT were analysed in the overall patient population, because 
these modalities were not amended during the trial. Patients who did not have neoadju-
vant chemoradiotherapy or who withdrew consent, and those with missing index tests 
because of protocol violation or death were excluded from all analyses. Patients with 
missing reference standard (ie, TRG) were excluded from the primary analysis. Periop-
eratively irresectable tumours (T4b) confirmed with frozen section analysis were classi-
fied as TRG4. 95% CIs were calculated according to the Wilson procedure, without a 
correction for continuity. Results of PET–CT and endoscopy with biopsies and fine-
needle aspiration, and maximum tumour thickness measurement were correlated to 
TRG with the χ² test. An interim safety analysis (the results of which will be published 
elsewhere) was done to assess the radicality of the performed operations after a total 
inclusion of 60 patients. The pre-planned stopping rule established that if the propor-
tion of patients with a radical resection was 70% or less in the first 60 patients, the trial 
would be stopped. 
We calculated sensitivity, specificity, positive predictive value, and negative predic-
tive value for TRG2, TRG3, and TRG4 combined versus TRG1. Patients with TRG2 
tumours were not excluded from sensitivity, specificity, negative predictive value and 
positive predictive value analyses because this would bias results. As a secondary sensi-
tivity analysis, we used multiple imputation of TRG for patients who had active surveil-
lance (instead of surgery) after clinical response evaluations to calculate the proportion 
of TRG3 and TRG4 residual tumours that was missed during clinical response evalua-
tions, and sensitivity, specificity, positive predictive values, and negative predictive val-
ues for combined TRG2–4 versus TRG1.16 We used a significance level of 0.05, based on 
two-sided tests. All analyses were done in SPSS (version 21.0). This study is registered 
with the Netherlands Trial Register (NTR4834).  
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Role of the funding source 
The study funder had no role in study design; data collection, analysis, interpretation, or 
writing of the report. JJBvL had access to all study data and had final responsibility for 
the decision to submit for publication.  
Results 
Between July 22, 2013, and Dec 28, 2016, 219 patients were enrolled (Figure 1); 12 (6%) 
were excluded from further analyses: eight patients withdrew consent and four did not 
received the complete neoadjuvant chemoradiotherapy regimen (one had neoadjuvant 
chemotherapy only, two had definitive chemoradiotherapy, and one received palliative 
chemotherapy). Of 207 patients who underwent clinical response evaluations, 84 (41%) 
had clinical response evaluations with upper endoscopy and regular biopsies, of whom 
61 (73%) were included in the analyses, and 123 (59%) had bite-on-bite biopsies, of 
whom 115 (93%) were included in the corresponding analyses (Figure 1). Of the 207 
patients who underwent clinical response evaluations, 113 (55%) were included in the 
endoscopic ultrasonographic examination of maximum tumour thickness, and 129 
(62%) were included in the PET–CT analysis (Figure 1). Baseline characteristics of all 
patients who underwent clinical response evaluations are shown in Table 1. 
Outcomes of regular biopsies and fine-needle aspiration during clinical response 
evaluations were significantly associated with the TRG of resected specimens (p=0.0036; 
Table 2). Eight of 26 patients who had a regular biopsies and fine-needle aspiration, with 
a passable endoscopy, had negative biopsies despite having a TRG3 or TRG4 tumour 
(proportion of clinically false-negative cases 31% [95% CI 17–50]). 31 (51%) of 61 pa-
tients had positive biopsies, positive fine-needle aspiration, or no-pass. Sensitivity, speci-
ficity, negative predictive value, and positive predictive value of TRG2–4 versus TRG1 
were 54% (95% CI 38–68; 20 of 37), 69% (42–87; nine of 13), 35% (19–54; nine of 26), 
and 83% (64–93; 20 of 24), respectively (Table 2). Four patients with TRG1 residual 
tumours had false-positive results (one had a positive biopsy, one no-pass, one had an 
uncertain biopsy at the second clinical response evaluation, and one non-representative 
fine-needle aspiration specimen from suspicious lymph node). 
Outcomes of bite-on-bite biopsies and fine-needle aspiration during clinical re-
sponse evaluations were significantly associated with the TRG of resected specimens 
(p<0.0001; Table 2). Four of 41 patients who had bite-on-bite biopsies and fine-needle 
aspiration had negative results despite having TRG3 or TRG4 tumours(proportion of 
clinically false negative cases 10% [95% CI 4–23]; Table 2). 69 (60%) of 115 patients had 
positive bite-on- bite biopsies, positive fine-needle aspiration, or nopass at endoscopy. 
After the first clinical response evaluation 45 (39%) of 115 patients who had bite-on-bite 
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biopsies had a positive index test. All four of 41 patients with a negative bite-on-bite 
biopsy (false-negative cases 10%, 95% CI 11–21; Table 2) had TRG3 residual disease—
one patient had squamous cell carcinoma and three had adenocarcinomas. Sensitivity, 
specificity, negative predictive value, and positive predictive value of TRG2–4 versus 
TRG1 were 77% (95% CI 66–85; 54 of 70), 72% (49–88; 13 of 18), 45% (28–62; 13 of 29), 
and 92% (82–96; 54 of 59), respectively (Table 2). Of the five patients with TRG1 residu-
al tumours who had false-positive results, four (80%) were no-pass, and one (20%) had a 
non-representative fine-needle aspiration specimen from a suspicious lymph node. 
Of the 69 patients with positive bite-on-bite biopsies, fine-needle aspirate, or no-
pass, seven (10%) had positive fine-needle aspirates, but negative biopsies and a passable 
tumour (ie, seven of the 24 positive second clinical response evaluations were based on 
positive fine-needle-aspiration results only). On the basis of biopsy results only (ie, 
without fine-needle aspiration data), eight (31%) of 26 TRG3 or TRG4 tumours were 
missed with regular biopsies, and seven (17%) of 41 with bite-on-bite biopsies. 
95 (84%) of 113 patients included in the endoscopic ultrasonographic examination 
during the second clinical response evaluation underwent oesophagectomy. Maximum 
tumour thickness of 6 mm or greater during the second clinical response evaluation was 
significantly associated with TRG of resection specimens (p=0.035; Table 2). 11 (28%) of 
39 patients with TRG3 or TRG4 residual disease had maximum tumour thickness of less 
than 6 mm at their second or third clinical response evaluation (proportion of clinically 
false-negative cases 28% [95% CI 17–44]; Table 2). Sensitivity, specificity, negative pre-
dictive value, and positive predictive value for TRG2–4 versus TRG1 residual disease 
were 60% (95% CI 48–71; 41 of 68), 59% (41–75; 16 of 27), 37% (24–52; 16 of 43), and 
79% (66–88; 41 of 52), respectively (Table 2). 
Outcomes of PET–CT during the second clinical response evaluation were not sig-
nificantly associated with tumour regression grades (p=0.191; Table 2). Six of 41 pa-
tients with TRG3 or TRG4 residual tumours had negative PET–CT results (proportion 
of clinically false negative cases 15% [95% CI 7–28]; Table 2). 102 (79%) of 129 patients 
had positive PET–CT results during the second or third clinical response evaluation. 
The six patients with false-negative PET–CTs comprised two (33%) patients with TRG3 
tumours and four (67%) patients with TRG4 tumours. Sensitivity, specificity, negative 
predictive value, and positive predictive value for TRG2–4 versus TRG1 were 80% (95% 
CI 70–88; 57 of 71), 37% (22–56; ten of 27), 42% (24–61; ten of 24), and 77% (66–85; 57 
of 74), respectively (Table 2). 
190 (92%) of 207 patients were included in the analysis of interval distant metastases 
(17 patients with missing follow-up scans were excluded: one participating centre did 
not do follow-up scans after a positive first clinical response evaluation). In 38 (20%) of 
190 patients, PET–CT identified possible metastases, resulting in 18 (9%) cases of histo-
logically proven metastases (one squamous cell carcinoma, 17 adenocarcinomas). De-
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tection of distant metastases was more sensitive with PET–CT than with low-dose CT: 
18F-FDG-positive metastases would have been missed by CT in three patients; in another 
three patients, distant lymph nodes smaller than 6 mm in diameter would probably not 
have been scored positive without a positive .18F-FDG-PET. In at least two of the re-
maining 12 patients, the positive findings on PET increased the confidence. 
No biopsy-related or fine-needle-aspiration-related serious adverse events were en-
countered during any clinical response evaluation in any patients included in the anal-
yses. One patient had a mucosal tear during endoscopy, but this event did not have 
treatment implications. Two patients died during the study (one because of an aorto-
oesophageal fistula and one because of pulmonary failure). Neither death was related to 
clinical response evaluations. 
Sensitivity analysis after imputation of the TRG for patients who had active surveil-
lance after clinical response evaluations showed a proportion of false-negative case rates 
for detection of residual tumour similar to those in the main analysis (Table 3), for en-
doscopy with regular biopsies and fine-needle aspiration (31% [95% CI 13–49]), endos-
copy with bite-on-bite biopsies and fine-needle aspiration (11% [1–21]), endoscopic 
ultrasonography with maximum tumour thickness at the second clinical response evalu-
ation (29% [15–43]), and PET–CT at the second clinical response evaluation (14% [3–
24]). The appendix shows outcomes for patients who were excluded from the analyses 
(p 2).  
Discussion 
To our knowledge, our trial is the first prospective study designed to assess the optimal 
composition of clinical response evaluations and the accuracy of residual disease detec-
tion in patients with oesophageal or junctional cancer. Repeated endoscopic ultrasonog-
raphy with bite-on-bite biopsies and fine-needle aspiration of suspicious lymph nodes 
was safe, and missed 10% (95% CI 4–23) of TRG3 and TRG4 residual tumours after 
neoadjuvant chemoradiotherapy for oesophageal or junctional cancer. Endoscopic ul-
trasonography with regular biopsies and fine-needle aspiration, measurement of maxi-
mum tumour thickness, and PET–CT were less accurate to detect locoregional residual 
disease, as shown by the high proportion of false-negative cases. Results were similar in 
the sensitivity analyses, which used multiple imputation of TRG for patients who re-
ceived active surveillance instead of oesophagectomy. PET–CT scans after neoadjuvant 
chemoradiotherapy detected new interval metastases in 9% (95% CI 6–14) of patients 
who had a pre-treatment or baseline PET–CT scan. These results provide insight into 
the optimal composition of clinical response evaluations after neoadjuvant chemoradio-
therapy for patients with oesophageal or junctional cancer, and might help to stratify 
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patients who would benefit from active surveillance and those who should undergo 
oesophagectomy. 
In view of the substantial postoperative morbidity and mortality associated with sur-
gery, and the effect of surgery on quality of life, an active surveillance approach could 
improve outcomes, not only for patients who do not show signs of disease after neoad-
juvant chemoradiotherapy, but also for those with subclinical distant metastases after 
neoadjuvant chemoradiotherapy.3, 5-7 All available diagnostic modalities used in clinical 
practice for pretreatment staging were applied to detect residual disease, and compared 
to establish the optimal composition of future active surveillance strategies. Previous 
studies17-22 of clinical response evaluations were retrospective and examined a single 
diagnostic modality for residual disease detection. Furthermore, the main objective of 
diagnostic examinations in previous studies17-22 was not to detect residual disease to 
identify patients who might benefit from active surveillance. Therefore, diagnostic accu-
racy might have not been accurately estimated. 
Biopsies were more accurate in our study than reported previously.17, 22, 23 Possible 
explanations for this increased accuracy are the timepoints chosen for the first and sec-
ond clinical response evaluations, and the adherence to a strict, pre-specified protocol in 
our trial, including random biopsies from the site of the primary tumour and targeted 
biopsies from any suspicious lesions. Fine-needle aspiration of suspicious lymph nodes 
also increased the sensitivity of the clinical response evaluation assessments in patients 
with negative biopsies. The percentage of TRG3 or TRG4 residual tumours that was 
missed by endoscopy plus regular biopsies and fine-needle aspiration decreased from 
31% (95% CI 17–50) to 10% (4–23) after introduction of bite-on-bite biopsies, and the 
negative predictive value increased from 35% (95% CI 19–54) to 45% (28–62). Residual 
disease is often located in the oesophageal mucosa, or the deeper submucosa, but can be 
rarely also present in isolated remnants within the muscle layer or the surrounding 
stroma (deeper than the submucosa).10 Bite-on-bite biopsies are thought to increase the 
chance of detecting residual cancer cells in deeper layers of the oesophagus, such as the 
submucosa, compared with regular biopsies, which rarely penetrate the submucosa 
(appendix p 7). 
Although the diagnostic accuracy of PET–CT for the detection of locoregional re-
sidual disease is poor, PET–CT was useful for detection of interval distant metastases (in 
9% [95% CI 6–14] of all patients) during clinical response evaluations. The extended 
period from the end of neoadjuvant chemoradiotherapy to PET–CT during the second 
clinical response evaluation supposedly improved the signal-to-noise ratio, because 
artifacts related to radiation-induced oesophagitis were expected to have diminished. 
Nevertheless, results were similar to those noted in previous studies.18, 19, 24 During active 
surveillance, PET-CT is expected to detect distant metastases, thereby preventing oe-
sophagectomy in patients with initially subclinical distant metastases. In view of the 
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high frequency of false positivity (63% [95% CI 44–78] of TRG1 tumours) of PET–CT 
for detection of locoregional disease and the limited additional value as an adjunct to 
endoscopy with bite-on-bite biopsies and fine-needle aspiration, we propose that PET–
CT should primarily be used for detection of distant metastases during response evalua-
tions. However, during active surveillance, serial PET–CT might prove valuable for 
detection of local regrowths: an increase in 18F-FDG-avidity theoretically suggests dis-
ease recurrence, whereas a decrease is more likely to depict recovery from oesophagitis.  
Results of measurement of maximum tumour thickness were similar to those from 
an earlier study.9 However, diagnostic accuracy of maximum tumour thickness was 
worse than that of endoscopic ultrasonography with bite-on-bite biopsies and fine-
needle aspiration, with 28% (95% CI 17–44) of TRG3 and TRG4 tumours missed and a 
frequency of false-positive diagnosis of 41% (95% CI 25–59) for TRG1 tumours. Taken 
together, we recommend that clinical response evaluations after neoadjuvant chemora-
diotherapy in patients with oesophageal or gastroesophageal junction cancer should 
consist of repeated endoscopy with bite-on-bite biopsies and fine-needle aspiration of 
suspicious lymph nodes for detection of locoregional residual disease and PET–CT for 
detection of interval metastases. 
The minimum diagnostic accuracy for safe active surveillance will continue to be 
debated until a clinical trial is done to establish it. Even a very small amount of residual 
disease (eg, TRG2) should ideally not be missed during clinical response evaluations, 
because patients with residual viable cancer cells do not benefit from an active surveil-
lance strategy and should have oesophagectomy as soon as possible. Conversely, if lo-
coregional residual disease is initially missed, but can be detected during active surveil-
lance while the tumour is still resectable, oncological outcomes should not be worse. 
Evidence of successful active surveillance strategies in patients with head and neck, 
rectal, or bladder cancer,25-27 supports the adoption of active surveillance after neoadju-
vant chemoradiotherapy in patients with oesophageal cancer. A systematic review7 
showed that postponed radical resection was associated with good survival outcomes (ie, 
similar to those with standard surgery; median overall survival 58 months [95% CI 27.7 
to not reached]) in most patients with oesophageal cancer who showed locoregional 
regrowth during active surveillance.7, 28, 29 This median overall survival in complete re-
sponders to neoadjuvant chemoradiotherapy managed with active surveillance is similar 
to that of patients with a complete clinical response who undergo surgery after neoadju-
vant chemoradiotherapy.28, 29 In these studies, clinical response was assessed by endos-
copy with regular biopsies and PET–CT. The use of bite-on-bite biopsies and the addi-
tion of fine-needle aspiration from suspicious lymph nodes could increase diagnostic 
accuracy. The promising results of our study in combination with those of previous 
publications justify a randomised, controlled, phase 3 trial of active surveillance versus 
standard surgery.The results of our study could serve to define the composition of the 
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clinical response evaluations and the subsequent surveillance examinations in such 
trials. 
Investigators of the ongoing, randomised, phase 3 ESOSTRATE and SANO trials are 
comparing both treatment strategies.11 Both trials aim to include 300 patients with 
squamous cell carcinoma or adenocarcinoma of the oesophagus who were clinical com-
plete responders after neoadjuvant chemoradiotherapy. Although pathological complete 
responses are more likely in patients with squamous cell carcinoma (49%), they are also 
common in those with adenocarcinoma (23%) after carboplatin and paclitaxel com-
bined with 41.4 Gy radiotherapy with low toxicity.3 The activity-toxicity ratio in both 
histological subtypes is the rationale for the use of this regimen in the preSANO and 
SANO trials, rather than a definitive chemoradiotherapy regimen without surgery.3 
Furthermore, our results show that the risk of false-negative biopsies during clinical 
response evaluations is not higher in patients with adenocarcinoma than in those with 
squamous cell carcinoma. The primary endpoint of the ESOSTRATE trial is disease-free 
survival and overall survival in the SANO trial. On the basis of the results of our study, 
clinical response evaluations in the SANO trial consist of repeated endoscopic ultraso-
nography with bite-on-bite biopsies and fine-needle aspiration, plus PET–CT scans for 
detection of distant metastases. Patients with negative results in the first and second 
clinical response evaluations after neoadjuvant chemoradiotherapy will be classified as 
clinical complete responders and allocated to either active surveillance or immediate 
surgery on the basis of stepped-wedge cluster randomisation. 
The diagnostic accuracy of clinical response evaluations is expected to improve, re-
ducing the number of patients who need postponed oesophagectomy or who have irre-
sectable regrowths during active surveillance. Dynamic contrast-enhanced MRI and 
diffusion-weighted MRI are promising new techniques that will need to be assessed in 
larger diagnostic trials.30, 31 Furthermore, the incorporation of liquid biopsies to analyse 
circulating cell-free tumour DNA derived from blood samples might improve the pre-
diction of response to neoadjuvant chemoradiotherapy and the detection of disease 
recurrence during active surveillance.  
Limitations of our study include the change in the biopsy strategy during the trial. 
The improved diagnostic accuracy of bite-on-bite biopsies compared with regular biop-
sies could be explained by a learning-curve effect. The assumption that TRG2 residual 
disease can be safely missed during initial response evaluation assessments is based on 
the hypothesis that these tumours can be reliably detected as they progress to stage 
TRG3 or TRG4, and that surgery will still be a curative option at this point. However, 
we acknowledge that this assumption can be only formally tested by comparing active 
surveillance with standard resection in a randomised, controlled, clinical trial. In the 
SANO trial, strict stopping rules have been prespecified by protocol for timely detection 
of resectable locoregional regrowth (any T stage <T4b) and the feasibility of achieving 
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radical resection in the active surveillance arm. Because of the small number of patients 
with squamous cell carcinoma included in this study, the extent to which our results can 
be generalised is unclear. However, active surveillance after definitive chemo-
radiotherapy is a standard of care in many centres for patients with squamous cell carci-
noma, and is the recommend standard of care in some guidelines.32 Nevertheless, if a 
patient has a clinical complete response based on endoscopy with bite-on-bite biopsies 
and fine-needle aspiration, the risk that there is any residual disease left seems similar in 
both subgroups of patients with oesophageal cancer, those with squamous cell carcino-
ma and those with adenocarcinoma. Repeat CT of the thorax, abdomen, and pelvis was 
not done as part of the first clinical response evaluation. Furthermore, use of a limited 
range of diagnostic modalities during the first clinical response evaluation could have 
reduced the accuracy of residual disease detection in the first clinical response evalua-
tion compared with the second. Additionally, to include any degree of possible tumour 
residue, we defined all PET–CT scores of 2 (probably benign) as 18F-FDG-positive, and 
thus probably included some cases with radioisotope uptake due to oesophagitis rather 
than oesophageal malignancy, resulting in overdiagnosis. For the same reason, fine-
needle aspiration specimens taken from suspicious lymph nodes with uncertain out-
comes or that were not representative were classified as positive, but should not be con-
sidered to be correctly diagnosed. Finally, overall and progression-free survival data 
according to TRG will be published when follow-up is sufficient. 
In conclusion, clinical response evaluation comprising endoscopic ultrasonography 
with bite-on-bite biopsies and fine-needle aspiration of suspicious lymph nodes for 
detection of locoregional residual disease in combination with PET–CT for detection of 
interval metastases after neoadjuvant chemoradiotherapy for oesophageal or gas-
troesophageal junctional cancer is an adequate strategy for clinical response evaluation. 
The ongoing, randomised, phase 3 SANO trial (Netherlands Trial Register: NTR6803) 
has incorporated this diagnostic strategy and will compare active surveillance with 
standard resection in patients who achieve a complete response after neoadjuvant 
chemoradiotherapy.  
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Table 1. Baseline characteristics of patients who underwent clinical response evaluations.* 
 Regular biopsies 
(N=84) 
Bite-on-bite biopsies 
(N=123) 
Overall 
(N=207) 
Age — yr.     
  Median 65 66 66 
  IQ Range 60 - 70 60 - 71 60 - 71 
Male sex — no. (%) 72 (86) 101 (82) 173 (84) 
Tumour type — no. (%)    
  Squamous-cell carcinoma 22 (26) 21 (17) 43 (21) 
  Adenocarcinoma 61 (73) 102 (83) 163 (78) 
  Adenosquamous cell carcinoma 1 (1) 0 (0) 1 (0) 
Clinical T stage — no. (%)*    
  cT1 0 (0) 1 (1) 1 (<1) 
  cT2 14 (17) 26 (21) 40 (19) 
  cT3 66 (79) 88 (72) 154 (74) 
  cT4 3 (4) 8 (7) 11 (5) 
  Missing  1 (1) 0 (0) 1 (<1) 
Clinical N stage — no. (%)ǁ    
  N0 21 (25) 42 (34) 63 (30) 
  N1 32 (38) 48 (39) 80 (39) 
  N2 29 (35) 28 (23) 57 (28) 
  N3 1 (1) 5 (4) 6 (3) 
Missing  1 (1) 0 (0) 1 (<1) 
Data are n (%), unless otherwise specified. Percentages might not total to 100% because of rounding. 
*Assessed by endoscopic ultrasonography or CT and classified according to the International Union against 
Cancer’s TNM classification (7th edn). 
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Table 2. Clinical response evaluation outcomes per diagnostic modalities and tumour regression grade in 
patients who underwent oesophagectomy after neoadjuvant chemoradiotherapy. 
  Tumour regression grade   
Outcome diagnostic modality TRG1 TRG2 TRG3 TRG4 Total 
Endoscopy with regular biopsies and fine-
needle aspiration* 
     
  positive 4 (31%) 2 (18%) 4 (44%) 14 (82%) 24 
  negative 9 (69%) 9 (82%) 5 (56%) 3 (18%) 26 
  Total 13 11 9 17 50 
Endoscopy with bite-on-bite biopsies and fine-
needle aspiration† 
     
  positive 5 (28%) 17 (59%) 20 (83%) 17 (100%) 59 
  negative 13 (72%) 12 (41%) 4 (17%) 0 29 
  Total 18 29 24 17 88 
EUS with maximum tumour thickness CRE-II‡      
  positive 11 (41%) 13 (45%) 13 (65%) 15 (79%) 52 
  negative 16 (59%) 16 (55%) 7 (35%) 4 (21%) 43 
  Total 27 29 20 19 95 
PET-CT CRE-II¶      
  positive 17 (63%) 22 (73%) 17 (89%) 18 (82%) 74 
  negative 10 (37%) 8 (27%) 2 (11%) 4 (18%) 24 
  Total 27 30 19 22 98 
* p=0.0036 (chi-square)  
† p<0.0001 (chi-square)  
‡ p=0.035 (chi-square) 
p=0.191(chi-square) 
CRE: clinical response evaluation  
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Table 3. Sensitivity analysis for accuracy of residual tumour detection in clinical response evaluations and 
predictive value of the tumour regression grades. 
 False-
negative 
TRG3-4 
(95% CI) 
Sensitivity 
TRG1 vs. 
TRG2-3-4 (95% 
CI) 
Specificity 
TRG1 vs. 
TRG2-3-4 (95% 
CI) 
negative predictive 
value TRG1 vs. 
TRG2-3-4 (95% 
CI) 
positive predictive 
value TRG1 vs. 
TRG2-3-4 (95% 
CI) 
Endoscopy with regular 
biopsies and fine-needle 
aspiration 
31%  
(13%-49%) 
54% 
(38%-70%) 
69% 
(44%-94%) 
35% 
(16%-53%) 
83% 
(68%-98%) 
Endoscopy with bite-on-
bite biopsies and fine-
needle aspiration 
11% 1 
(1%-21%) 
74% 
(64%-83%) 
77% 
(59%-95%) 
45% 
(29%-62%) 
92% 
(85%-99%) 
EUS with maximum 
tumour thickness 
CRE-II 
29%  
(15%-43%) 
59% 
(48%-70%) 
58% 
(40%-75%) 
38% 
(25%-52%) 
76% 
(64%-87%) 
PET-CT CRE-II 14% 
(3%-24%) 
82% 
(73%-90%) 
38% 
(21%-55%) 
44% 
26%-63%) 
77% 
(68%-87%) 
Accuracy estimates were calculated as TRG1 vs TRG2–4 after multiple imputation (for age, sex, histology, 
tumour grading, clinical T stage, clinical tumour stage, clinical lymph-node stage, WHO performance score, 
number of cycles of chemotherapy, total radiation dose, and results from endoscopic biopsies, fine-needle 
aspiration, maximum tumour thickness measurement, and PET–CT) per diagnostic modality for patients who 
had active surveillance instead of surgery after clinical response evaluations. Totals per group cannot be calcu-
lated, since this is a multiple imputation analysis. TRG=tumour regression grade. *Calculated as the propor-
tion of TRG3 and TRG4 residual tumours missed during clinical response evaluations per diagnostic modali-
ty. 
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Figure 1. Study profile. 
 
 
  
219   patients enrolled 
207   received neoadjuvant chemoradiotherapy and underwent  
clinical response evaluations 
  207 had endoscopic ultrasonography assessment 
  207 had PET - CT scan assessment 
Efficacy and safety populations : 
   61   included in regular biopsy analysis 
     115 included in bite - on - bite biopsy analysis 
     113 included in endoscopic ultrasonography analysis 
   129   included in PET - CT analysis 
12   excluded 
   8   withdrew consent 
   4   did not receive neoadjuvant chemoradiotherapy 
84   had regular biopsies 123   had bite - on - bite biopsies 
23   excluded  
   15   protocol violations 
     7 had bite - on - bite biopsies during 
      second response evaluation 
     1 died before evaluation 
  8 excluded  
     6 protocol violations 
     2 died before surgery 
  94 excluded  
     70 had no clinical response evaluation 
     12 did not undergo resection 
   9   based on central review of all  
      endoscopic ultrasonographic images 
     3 died before evaluation 
  78 excluded  
     56 had positive first clinical response evaluation 
   14   did not have follow - up scan 
     5 had non - FDG - avid baseline scans 
     3 died before evaluation 
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Appendix 
Supplementary Table 1. Outcomes of patients who were excluded from analyses. 
Outcome diagnostic modality TRG1 TRG2 TRG3 TRG4 No 
surgery 
Total 
Endoscopy with regular biopsies and FNA       
  Died before CRE 0 0 0 0 1 1 
  Regular biopsies CRE-I, bite-on-bite biopsies 
CRE-II 
0 4 1 1 1 7 
  Surgery with negative biopsies at CRE-I 0 1 0 0 0 1 
  No biopsies 1 0 0 1 2 4 
  No FNA of suspicious lymph nodes 3 1 0 1 5 10 
  Total 4 6 1 3 9 23 
Endoscopy with bite-on-bite biopsies and 
FNA 
      
  Died before CRE 0 0 0 0 2 2 
  Surgery with negative biopsies at CRE-I 3 1 0 0 0 4 
  No biopsies 0 0 0 1 0 1 
  No FNA of suspicious lymph nodes 0 0 1 0 0 1 
  Total 3 1 1 1 2 8 
EUS with maximum tumour thickness CRE-
II 
      
  Died before CRE 0 0 0 0 3 3 
  No CRE-II measurement 9 17 14 13 17 70 
  Excluded based on revision 2 1 1 4 1 9 
  No revision performed, because no resection 0 0 0 0 12 12 
  Total 11 18 15 17 33 94 
PET-CT CRE-II       
  Died before CRE 0 0 0 0 3 3 
  Positive CRE-I 6 15 11 12 12 56 
  No follow-up scan 4 2 4 3 1 14 
  Non-FDG-avid 1 0 1 1 2 5 
  Total 11 17 16 16 18 78 
TRG: tumour regression grade, FNA: fine-needle aspiration, CRE: clinical response evaluation. 
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Supplementary Table 2. Outcomes of EUS-FNA from suspicious lymph nodes as determined by PET-CT 
and/or EUS. 
 TRG1 TRG2 TRG3 TRG4 No surgery Total 
Presence tumour FNA       
  No tumour 5 5 0 1 3 15 
  Tumour 0 0 1 3 4 8 
  Uncertain 2 2 2 2 1 9 
  Total 7 7 3 6 8 32 
EUS: endoscopic ultrasonography, FNA: fine-needle aspiration, TRG: tumour regression grade. 
Supplementary Table 3. Clinical response evaluations using different diagnostic modalities in relation to 
tumour regression grade of the resection specimen (gold standard) in patients with squamous cell carcinoma 
who underwent oesophagectomy after neoadjuvant chemoradiotherapy. 
  Tumour regression grade  
Outcome diagnostic modality TRG1 TRG2 TRG3 TRG4 Total 
Endoscopy with regular biopsies and FNA*      
  positive 2 0 1 3 6 
  negative 5 1 0 0 6 
  Total 7 1 1 3 12 
Endoscopy with bite-on-bite biopsies and 
FNA† 
     
  positive 2 2 3 3 10 
  negative 4 1 1 0 6 
  Total 6 3 4 3 16 
EUS with maximum tumour thicknessCRE-II‡      
  positive 2 1 0 3 6 
  negative 10 2 2 0 14 
  Total 12 3 2 3 20 
PET-CT CRE-II¶      
  positive 5 2 1 4 12 
  negative 7 1 1 0 9 
  Total 12 3 2 4 21 
TRG: tumour regression grade, FNA: fine-needle aspiration, CRE: clinical response evaluation. 
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Supplementary Table 4. Clinical response evaluations using different diagnostic modalities in relation to 
tumour regression grade of the resection specimen (gold standard) in patients with adenocarcinoma who 
underwent oesophagectomy after neoadjuvant chemoradiotherapy. 
  Tumour regression grade  
Outcome diagnostic modality TRG1 TRG2 TRG3 TRG4 Total 
Endoscopy with regular biopsies and FNA*      
  positive 2 2 3 10 17 
  negative 4 8 5 3 20 
  Total 6 10 8 13 37 
Endoscopy with bite-on-bite biopsies and 
FNA† 
     
  positive 3 15 17 14 49 
  negative 9 11 3 0 23 
  Total 12 26 20 14 72 
EUS with maximum tumour thickness CRE-II‡      
  positive 9 12 13 12 46 
  negative 6 14 5 4 26 
  Total 15 26 18 16 75 
PET-CT CRE-II¶      
  positive 12 20 16 14 62 
  negative 3 7 1 4 15 
  Total 15 27 17 18 77 
TRG: tumour regression grade, FNA: fine-needle aspiration, CRE: clinical response evaluation. 
Supplementary Table 5. Sites from which patients were recruited, principle investigator responsible for this 
site and the number patients which were recruited from that site. 
 Principle investigator Number of patients 
Erasmus MC – University Medical Centre 
Rotterdam 
J. Jan B. van Lanschot 106 
Academic Medical Centre Mark I. van Berge Henegouwen 36 
Zuyderland Medical Centre Meindert N. Sosef 28 
Catharina Hospital Grard A.P. Nieuwenhuijzen 28 
University Medical Centre Utrecht Richard van Hillegersberg 18 
Radboud University Medical Centre Peter D. Siersema 3 
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Supplementary Figure 1. Bite-on-bite biopsies (1+2+3+4) supposedly increase the chance of detecting sub-
mucosal tumour deposits compared to conventional biopsies (1+2). 
 
Supplementary Figure 2. Flowchart for endoscopy with regular biopsies and FNA. 
 
 
 
N = 84 
Positive CRE  ( 31 ) 
TRG   1 ( 4 ) 
TRG 2   ( 2 ) 
TRG 3   ( 4 ) 
TRG   4 ( 14 ) 
No surgery  ( 7 ) 
Metastasis  ( 5 ) 
   Active surveillance  ( 2 ) 
Negative CRE  ( 30 ) 
TRG 1   ( 9 ) 
TRG 2   ( 9 ) 
TRG 3   ( 5 ) 
TRG 4   ( 3 ) 
No surgery  ( 4 ) 
Metastasis  ( 2 ) 
Active surveillance  ( 1 ) 
Patient’s wish  ( 1 ) 
Excluded  ( 23 ) 
Died before CRE  ( 1 ) 
Regular biopsies CRE - I ,  bite - on - bite biopsies CRE - II  ( 7 ) 
Protocol violation  ( 15 ) 
surgery with negative biopsies at CRE -I  ( 1 ) 
no biopsies  ( 4 ) 
no FNA of suspected lymph nodes  (10 ) 
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Supplementary Figure 3. Flowchart for endoscopy with bite-on-bite biopsies and FNA. 
 
 
Supplementary Figure 4. Flowchart for endoscopic ultrasonography with maximum tumour thickness meas-
urement. 
 
 
 
  
N = 123 
Positive CRE  ( 69 ) 
TRG 1   ( 5 ) 
TRG 2   ( 17 ) 
TRG 3   ( 20 ) 
TRG   4 ( 17 ) 
No resection  ( 10 ) 
Metastasis  ( 5 ) 
Patient’s wish  ( 2 ) 
Active surveillance  ( 2 ) 
Peroperative cardiac arrythmia  ( 1 ) 
Negative CRE  ( 46 ) 
TRG 1   ( 13 ) 
TRG 2   ( 12 ) 
TRG 3   ( 4 ) 
TRG   4 ( 0 ) 
No surgery  ( 17 ) 
metastasis  ( 7 ) 
Active surveillance  ( 9 ) 
died  ( 1 ) 
Excluded  ( 8 ) 
Died before CRE  ( 2 ) 
Protocol violation  ( 6 ) 
surgery with negative biopsies at CRE - I  ( 4 ) 
no biopsies  ( 1 ) 
no FNA  ( 1 ) 
N = 207 
MMT≥ 6 mm  ( 59 ) 
TRG 1   ( 11 ) 
TRG 2   ( 13 ) 
TRG 3   ( 13 ) 
TRG   4 ( 15 ) 
No surgery  ( 7 ) 
Metastasis  ( 2 ) 
Active surveillance  ( 5 ) 
MMT < 6 mm ( 54 ) 
TRG 1   ( 16 ) 
TRG   2 ( 16 ) 
TRG 3   ( 7 ) 
TRG 4   ( 4 ) 
No surgery  ( 11 ) 
Metastasis  ( 4 ) 
Active surveillance  ( 4 ) 
Patient’s wish  ( 2 ) 
Died  ( 1 ) 
Excluded  ( 94 ) 
Died before CRE  ( 3 ) 
No CRE - II  ( 70 ) 
Excluded based on revision  ( 9 ) 
No revision performed ,  because no resection  ( 12 )   
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Supplementary Figure 5. Flowchart for 18-FDG PET-CT. 
 
 
 
  
N = 207 
PET  positive   ( 102 ) 
TRG  1   ( 17 ) 
TRG  2   ( 22 ) 
TRG    3 ( 17 ) 
TRG    4 ( 18 ) 
No resection   ( 28 ) 
Metastas is on PET  ( 11 ) 
Active surveillance  ( 13 ) 
D ied  ( 1 ) 
Peroperative metastasis  ( 3 ) 
PET  negative   ( 27 ) 
TRG    1 ( 10 ) 
TRG  2   ( 8 ) 
TRG  3   ( 2 ) 
TRG  4   ( 4 ) 
No resection   ( 3 ) 
   Active surveillance  ( 3 ) 
Excluded  ( 78 ) 
Died before CRE  ( 3 )    
Positive CRE - I  ( 56 ,  of whom    9 with metastases ) 
No   follow - up scan ,  only   baseline  ( 14 ) 
Non - FDG - avid  ( 5 ) 
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Abstract 
Purpose 
Aim of the study was to explore optimal evaluation of qualitative and quantitative F-18-
FDG-PET/CT in response evaluations 12-14 weeks after neoadjuvant chemoradiothera-
py (nCRT) in oesophageal cancer patients.  
Methods 
This is a side-study of the prospective preSANO trial. Baseline and FDG-PET/CT scans 
12-14 weeks after nCRT were qualitatively assessed for presence of tumour. Standard-
ised uptake values normalised for lean body mass for maximum (SULmax,) were meas-
ured in all scans. Primary endpoint was the proportion of missed patients with tumour 
regression grade (TRG) 3-4 (>10% vital residual tumour) in qualitative and quantitative 
analyses. Receiver Operating Characteristic (ROC) curve analysis for TRG1 vs. TRG3-4 
using SULmax, SUL ratio tumour/oesophagus and Δ(%)SULmax was performed to 
define optimal cut-off values. Secondary endpoints were sensitivity, specificity, negative 
predictive value (NPV) and positive predictive value (PPV) and these were calculated 
for TRG1 vs. TRG2-3-4 in both qualitative and quantitative results. 
Results 
In total, 129 of 219 patients included in preSANO were analysed 12-14 weeks after 
nCRT. Qualitative FDG-PET/CT was unable to detect TRG3-4 in 15% of patients. Sensi-
tivity, specificity, NPV and PPV in qualitative analysis for detecting TRG1 vs. TRG2-3-4 
was 80%, 37%, 42% and 77% respectively. In 18 of 190 patients (9.5%) with follow-up 
scans after nCRT, FDG-PET/CT identified interval metastases. Quantitative parameters 
missed TRG3-4 tumour in 27-61% of patients. Optimal cut-off value for detecting TRG1 
vs. TRG2-3-4 was seen with SULmax at 2.93. 
Conclusions 
Qualitative and quantitative analyses of FDG-PET/CT are unable to reliably detect 
TRG3-4 and to discriminate substantial residual disease from benign FDG-uptake after 
nCRT. Repeated FDG-PET/CT is useful for the detection of interval metastases. 
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Introduction 
Oesophageal cancer is the eighth most common type of cancer worldwide with an over-
all 5-year survival of about 35% after primary oesophagectomy.1 Since the introduction 
of neoadjuvant chemo(radio)therapy, long term survival rates have increased to 45-
50%.2-4 Neoadjuvant chemoradiotherapy (nCRT) using carboplatin and paclitaxel com-
bined with 41.4 Gy of concurrent radiotherapy induces a pathologically complete re-
sponse (ypT0N0) in 29% of patients with oesophageal cancer.5 This has raised the ques-
tion whether an active surveillance approach can be applied after nCRT. In such an 
active surveillance approach, patients without signs of residual disease after nCRT are 
regularly examined in follow-up clinical investigations. Oesophagectomy will then be 
offered to patients with proven locoregional recurrence only, in the absence of distant 
metastases. To explore the feasibility of an active surveillance strategy, reliable clinical 
response evaluations (CREs) are needed to exclude substantial residual disease. For this 
purpose, a diagnostic multicentre trial has been performed (preSANO trial, 
NL41732.078.13) comprising endoscopy, (bite-on-bite) biopsies, endoscopic ultrasound 
(EUS) with fine needle aspiration (FNA) of suspected lymph nodes and 18F-
fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG 
PET/CT) for response evaluation after nCRT.6, 7 The optimal way of analysing FDG-
PET/CT in response evaluations is topic of debate. In this side-study of the preSANO-
trial we further explore the accuracy of FDG-PET/CT parameters in predicting residual 
disease on a qualitative and quantitative basis.  
Patients and methods 
Patients 
Details of the multicentre prospective diagnostic preSANO trial have been described 
previously.6, 7 Briefly, patients with potentially curable adenocarcinoma or squamous cell 
carcinoma of the oesophagus or oesophagogastric junction, who were planned to un-
dergo nCRT according to the CROSS regimen (five weekly cycles of carboplatin (area 
under the curve of 2 mg per millilitre per minute) and paclitaxel (50 mg per square 
meter of body-surface area) combined with 41.4 Gy radiotherapy in 23 fractions) fol-
lowed by surgical resection were included.5 Pre-treatment FDG-PET/CT was performed 
at the time of diagnosis. The first CRE (CRE-1) was performed 4-6 weeks after comple-
tion of nCRT. During CRE-1, FDG-PET/CT was performed only in patients with histo-
logically proven residual disease, to detect distant metastases. In the absence of dissemi-
nated disease, patients with histologically proven locoregional residual disease were 
scheduled for surgery. In case of negative endoscopic biopsies at CRE-1, surgery was 
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postponed for another 4-6 weeks and patients underwent a second CRE (CRE-2). Dur-
ing CRE-2, all patients first underwent FDG-PET/CT, with the objective to assess lo-
coregional response and to detect possible distant metastases. Subsequently, patients 
underwent endoscopy with (bite-on-bite) biopsies and EUS with FNA of suspected 
lymph nodes and/or FDG-positive lesions. According to the study protocol, all patients 
were scheduled for surgery after CRE-2, if no distant metastases were detected. When 
surgery was further postponed (for example because of patients’ preference or poor 
physical condition) another FDG-PET/CT and endoscopy (CRE-3) were performed 
preceding planned surgery.6 The trial was approved by the medical-ethical committee of 
Erasmus MC Rotterdam (MEC-2013-211). All patients provided written informed con-
sent. 
18F-FDG PET/CT acquisition and processing 
Pre-treatment 18F-FDG PET/CT was performed to assess FDG avidity of the primary 
tumour. Scanning was performed according to EANM guidelines version 1.0, with 
scanning at 60±5 minutes post intravenous injection of 2.3 MBq/kg 18F-FDG.8 Only 
attenuation corrected and ordered subset expectation maximization (OSEM) recon-
structed images were used in the analyses. 
Before scanning, all patients were requested to fast for at least six hours and to pre-
hydrate with 1-2 litres of water. Patient’s weight and height were measured. In all pa-
tients, blood glucose levels were required to be less than 8.0 mmol/L. Patients had to be 
in resting condition before scanning. Modern equipment, including multislice CT (16-
slice or better) and if possible time-of-flight (TOF) PET, was used. PET/CT scanners 
were calibrated for quantitative standardized uptake value (SUV) measurements, ac-
cording to EARL qualifications.9 
Qualitative assessments 
For qualitative analysis, both baseline FDG-PET/CT and the last FDG-PET/CT scan 
before surgery (CRE-2 or CRE-3) were examined. CRE-1 scans (4-6 weeks after nCRT) 
were excluded, since it is expected that 4-6 weeks after nCRT the effect of radiation-
induced oesophagitis would be still substantial.10, 11 For assessment of distant dissemina-
tion both CRE-1 and CRE-2/-3 scans were used.  
If pre-treatment scans (before the start of chemoradiation) did not show a level of 
tumour FDG-uptake that was clearly above the level of the surrounding oesophagus and 
other tissues, a follow-up FDG-PET/CT could not be used to accurately assess the effects 
of the neoadjuvant treatment. These patients were considered as “non-FDG avid” and 
are described separately (Supplementary Table 1). 
18F-FDG PET/CT to detect residual disease after neoadjuvant chemoradiotherapy 
351 
Furthermore, patients with missing follow-up FDG-PET/CT scan after nCRT, prior 
to surgery, were excluded from the qualitative analysis. 
Image analysis 
The presence of residual tumour, including positive lymph nodes and/or haematog-
enous metastases, was centrally assessed by an experienced nuclear medicine physician 
(R.V.), who was blinded for all clinical information except weight, height, injected 18F-
FDG activity and time-interval between injection and start of PET. In case of disagree-
ment with the original report, a second nuclear medicine physician (L.H.G.) reviewed 
the study independently and a consensus agreement between both reviewers was estab-
lished.  
During review, tumour status on follow-up FDG-PET/CT scans was scored as either 
“no suspect lesions” or “locoregional residual lesions” (including locoregional progres-
sion). A lesion was considered FDG-positive, when any uptake in the lesion itself was 
above the adjacent oesophageal background uptake. For qualitative dichotomous analy-
sis, the FDG-PET/CT scan was classified as “FDG-negative” when no visible uptake was 
seen. An “FDG-positive” scan included locoregional residual lesions, locoregional pro-
gression, presence of haematogenous metastases, or a combination of those.  
Confidence scores were assigned for the primary tumour, lymph nodes and haema-
togenous metastases. The following scoring system was used: 1= benign/no uptake; 2= 
probably benign/minimal uptake; 3= equivocal; 4= probably malignant; 5= malignant. 
In this scoring system, a lesion was considered (probably) malignant if any focal abnor-
mal accumulation of FDG was observed, which was not explained by oesophagitis or 
other benign or physiologic cause. A scan was scored as benign, when the uptake in the 
lesion did not differ at all from the surrounding normal background uptake. A probably 
benign lesion was scored in case of diffuse, minimal uptake of FDG above the back-
ground. A lesion was scored “equivocal” if a focal accumulation could not be distin-
guished, but neither could be called “benign”. During qualitative analysis using confi-
dence scores, an “FDG-negative” scan included confidence scores “benign” and 
“probably benign”. An “FDG-positive” scan comprised the scores “equivocal”, 
“probably malignant” and “malignant”. 
Quantitative assessments 
For quantitative assessments, global volumes of interest (VOIs) were manually drawn 
over the primary tumour and visual lymph nodes (Osirix MD, version 6.5.2. Pixmeo, 
Berne, Switzerland). The same was done for the reference regions of the physiological 
oesophagus, liver and bloodpool. Standardised uptake values normalised for lean body 
mass for maximum (SULmax) and mean values (SULmean) were calculated from the activi-
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ty values inside the VOI. Lean body mass was calculated using the James equation9, 
which is defined as follows, 
LBM= ሺ1.1-G*0.03ሻ*BW-ሺ128+G*20ሻ*( BW
H
)
2
  
where G stands for gender (female = 1; male = 0), BW = body weight (kg) and H = body 
height (cm). 
In the follow-up FDG-PET/CT scans, the VOI was placed as closely as possible in 
the same locations, to obtain post-nCRT measurements. As lesions after nCRT could 
have become (very) small, SULmax parameters were used for lesions, not SULpeak. This 
was to avoid substantial partial volume effects with (very) small lesions. 
The relation between the bloodpool and liver SUVmean and body weight was deter-
mined in all available patients with CRE scans. The same was done for the bloodpool 
and liver SULmean, as to determine which parameter, SUV or SUL, should be finally used 
for the quantitative assessments. 
Histopathology  
The pathology report of the resected oesophagus served as reference (gold standard). 
Visual and quantitative assessments on FDG-PET/CT scans were compared to patho-
logic response in the resection specimen according to the tumour regression grading 
(TRG) system of Chirieac, using four categories: TRG1, no vital residual tumour cells; 
TRG2, 1-10% vital residual tumour cells; TRG3, 11-50%; and TRG4, >50%.12 An experi-
enced pathologist centrally revised all pathology results. An arbitrary “TRG4” was as-
signed to patients who were operated with intent to resect the tumour, but who were 
deemed irresectable (T4b) during surgery. 
Outcomes 
The primary outcome was the proportion of TRG3-4 residual tumours that was missed 
using qualitative assessment of FDG-PET/CT and using the quantitative parameters 
SULmax at tumour, SUL ratio (the ratio of SUL-tumour/SUL-oesophagus), absolute 
ΔSULmax and Δ%SULmax. Minimal residual tumour (TRG2) was considered acceptable to 
be missed, because it is expected that TRG2 tumour will become timely detectable dur-
ing follow-up if it has developed in TRG3-4 tumour.6 
Secondary outcomes comprised sensitivity, specificity, negative predictive value (NPV) 
and positive predictive value (PPV) for detection of TRG1 vs. TRG2-3-4 in qualitative 
and quantitative analysis of FDG-PET/CT. For correct statistical calculation of second-
ary endpoints, patients with TRG2 were also included.  
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Statistical analysis  
The calculation of the sample size in the preSANO study has been expounded earlier6, 7 
All patients eligible for analysis in this side-study were included. Chi-square test was 
used to calculate the association between qualitative PET outcomes and TRG. Receiver 
Operating Characteristic (ROC) curve analysis was performed for TRG1 versus TRG3-4 
for the PET-parameters SULmax at tumour, SUL ratio, absolute ΔSULmax and Δ%SULmax. 
Area under the ROC was calculated with a 95% confidence interval. Cut-off points were 
defined using the Youden index, that calculates the maximum of [sensitivity + specifici-
ty -1].13 For qualitative results and for the quantitative optimal cut-off points, sensitivity, 
specificity, NPV and PPV were calculated for differentiation between TRG1 versus 
TRG2-3-4, using standard formulas. 
All tests were two-sided. P-values less than 0.05 were considered statistically significant.  
Statistical analysis was performed using SPSS Statistics version 24. 
Results 
Patients  
Clinicopathological characteristics of the patients are shown in Table 1. Some 219 pa-
tients were included, of whom 12 left the study (8 withdrew informed consent, 4 did not 
have nCRT)7. Median age was 66 years (interquartile range 60-71); most patients were 
male (84%) and most tumours were adenocarcinomas (78%). 
At CRE-2/-3, a total of 129 patients were eligible for analysis of FDG-PET/CT at a 
median time of 11 weeks (interquartile range 10-12) after nCRT (CRE-2: n = 126; CRE-
3 n = 3, Figure 1). Of the 78 of 207 patients who were excluded, five had no uptake of 
FDG that was clearly above the level of the surrounding oesophagus and other tissues in 
the primary tumour at baseline, and were considered as non-FDG avid. Seventeen of 78 
patients did not have a follow-up FDG-PET/CT scan before surgery and only had base-
line scans (3 patients died before CRE; 14 patients did not have a follow-up scan, as one 
institution did not perform FDG-PET/CT after a positive CRE-1). The remaining 56 of 
78 patients did not qualify for CRE-2/-3, because of positive biopsies at CRE-1. At CRE-
1, FDG-PET/CT was performed at a median time of 7.4 weeks (interquartile range 6.0-
8.3) after nCRT. 
One patient did not have a baseline FDG-PET/CT. This patient was included in the 
analyses, since a follow-up scan after nCRT was correctly performed. In 16 patients, 
surgery was postponed due to poor physical condition or because of patients’ prefer-
ence. One patient died during the study (unrelated to oesophageal cancer). In three 
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patients, metastases were detected peroperatively and resection was not performed (2 
patients with peritoneal metastasis; 1 patient with liver metastasis). 
Baseline FDG-PET/CT scans were acquired 61.0±9.1 minutes after injection of 
212±64.3 MBq 18F-FDG. For CRE scans (CRE-1/-2/-3), this was 61.9±8.8 minutes with 
injection of 206±55.8 MBq 18F-FDG. As injection to scan intervals did not influence 
SULmean of the bloodpool, patients were not excluded based on the injection to scan 
intervals (for complete results, see Supplementary Figure 1). 
At baseline and at CRE-1/-2/-3, glucose levels were 5.9±1.3 mmol/L and 6.8±1.5 
mmol/L, respectively, and were not significantly correlated with the blood pool SULmean 
(p=0.08 and p=0.22, respectively). Patients with serum glucose >8 mmol/L (at baseline 
n=17; at CRE-1/-2/-3 n=19) were therefore also included.  
Surgery was performed at a median time of 3.7 weeks (interquartile range 2.1-5.0) af-
ter patients’ last FDG-PET/CT. For CRE-1, this was 2.0 weeks (interquartile range 1.2-
4.0); for CRE-2/-3 this was 4.2 weeks (interquartile range 3.0-5.3). Nineteen patients had 
surgery >6 weeks after CRE-2/-3 FDG-PET/CT (median 8.0 weeks, interquartile range 
6.6-8.7 weeks). 
Qualitative FDG-PET/CT analysis 
At CRE-2/-3, no stastistically significant association was found between qualitative PET 
and TRG outcome (p=0.19). Some 6 of 41 patients with TRG3-4 had visually negative 
FDG-PET/CT (false-negative TRG3-4; 15%), while 17 of 27 patients had TRG1 but a 
positive FDG-PET/CT (false positives; 63%) (Table 2). Sensitivity, specificity, NPV, PPV 
of TRG1 vs. TRG2-3-4 were 57/71 (80%), 10/27 (37%), 10/24 (42%) and 57/72 (77%), 
respectively. Outcomes of patients who were excluded from analyses are shown in Sup-
plementary Table 1. 
Since 17 patients did not have a follow-up scan performed, 190 patients were 
included for analysis of detection of interval metastases on FDG-PET/CT. Some 38 of 
190 patients (20%) had suspicion of distant metastases on PET/CT. In 18 of 38 patients 
metastases were pathologically confirmed (true-positives; 9.5%; squamous cell 
carcinoma: n = 1; adenocarcinoma: n = 17). At CRE-1, 7 patients with metastases were 
detected; at CRE-2 this was true for 11 patients. 
Adding “confidence scores” to qualitative FDG-PET/CT analyses showed that an 
overlap appears in TRG for all confidence scores, especially for TRG2 (Figure 2). No 
statistically significant association with TRG was found (p=0.072). More clinically false-
negative patients with TRG3-4 (12/41; 29%) and less false positives for TRG1 (13/27; 
48%) were seen compared to the dichotomous method of qualitative analysis. 
Consequently, the sensitivity, specificity, NPV and PPV of TRG1 vs. TRG2-3-4 were 
44/71 (62%), 14/27 (52%), 14/41 (34%) and 44/57 (81%), respectively. 
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Quantitative FDG-PET/CT analysis 
SUVmax measurements were corrected for lean body mass, since SUV showed weight 
dependency (P<0.001 for both SUVmean of the blood pool and liver); which disappeared 
with SUL (p=0.575 for the blood pool SULmean; p=0.268 for SULmean of the liver).  
In all patients with TRG outcomes (i.e. availability of surgical resection specimen), 
CRE SULmax, %ΔSULmax and SUL ratio were 3.0±1.1, -57±30 and 1.6±0.56 in patients 
with TRG1; and for TRG2 these were 3.6±1.4, -46±31 and 1.8±0.78; for TRG3-4 these 
were 4.2±2.1, -49±21 and 2.1±0.82. Supplementary Figure 2 visualizes the overlap in the 
parameters CRE SULmax, %ΔSULmax and SUL ratio parameters for the different TRG 
outcomes. Furthermore, there is an overlap in the low ranges of both SULmax and SUL 
ratio for qualitative FDG-positive and FDG-negative scans, in patients with TRG3 or 
TRG4 (Supplementary Figure 3). 
ROC-curves of CRE-2/-3 SULmax, SUL ratio and Δ(%)SULmax are shown in Figure 3 
and Table 3. For TRG1 vs. TRG3-4, optimal accuracy is seen using SULmax at a cut-off of 
2.93 (area under ROC 0.70; optimal cut-off 2.93; sensitivity 66%, specificity 74%).  
Results of implementing the optimal cut-off values for quantitative parameters are 
displayed in Supplementary Table 3. With an optimal cut-off of SULmax at 2.93, 14 of 41 
patients with TRG3-4 were missed (34% false negative). Using this cut-off, sensitivity, 
specificity, NPV and PPV for TRG1 vs. TRG2-3-4 were 43/71 (61%), 20/27 (74%), 20/48 
(42%) and 43/50 (86%), respectively.  
An optimal cut-off for SUL ratio of 1.47 missed 11 of 41 TRG3-4 (27%). The sensi-
tivity, specificity, NPV and PPV for TRG1 vs. TRG2-3-4 were 45/71 (63%), 16/27 (59%) 
16/42 (38%) and 45/56 (80%), respectively. 
For ΔSULmax at an optimal cut-off of 4.03, 23 of 41 (56%) TRG3-4 were missed. The 
sensitivity, specificity, NPV and PPV for TRG1 vs. TRG2-3-4 were 31/70 (44%), 8/27 
(30%), 8/47 (17%) and 31/50 (62%), respectively. 
With Δ%SULmax at an optimal cut-off of a decrease of 56.31%, 25 of 41 (61%) TRG3-
4 tumours were missed. Consequently, the sensitivity, specificity, NPV and PPV for 
TRG1 vs. TRG2-3-4 were 31/70 (44%), 7/27 (26%), 7/46 (15%) and 31/51 (61%), respec-
tively. 
Discussion 
The value of FDG-PET/CT at a median time of 11 weeks (interquartile range 10-12) 
after nCRT for detection of locoregional residual disease in patients with oesophageal 
cancer is limited, both qualitatively and quantitatively. In this study, qualitative dichot-
omous analysis of FDG-PET/CT scans missed TRG3-4 tumours in 15% of patients. 
FDG-PET/CT had a relatively high sensitivity of 80% for detecting TRG2-3-4 versus no 
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tumour (TRG1), but yielded a specificity of only 37%. Adding “confidence scores” to the 
visual interpretation of FDG-PET/CT scans did not increase diagnostic accuracy, and 
showed an overlap in all TRG results for different confidence scores (Figure 2). This 
illustrates the difficulty of visual response assessment on FDG-PET/CT at this specific 
time-point after nCRT, where small tumour lesions apparently cannot be distinguished 
reliably from physiologic oesophageal metabolism or post-radiation oesophagitis.  
Quantitative analysis of tumour response only moderately discriminated between 
TRG1 and TRG3-4, as shown in ROC analyses where areas under the curve did not 
exceed 0.7. The different post-nCRT FDG-PET/CT parameters missed TRG3-4 tumours 
in 27-61% of the patients, when using the optimal cut-off points from ROC analysis. 
Furthermore, for discriminating TRG2-3-4 from TRG1, the optimal cut-off value was 
SULmax at 2.93 and provided an accuracy of only 64%. Thus, quantitative analysis of 
FDG-PET/CT alone appears not sufficiently accurate to quantify pathological response 
in order to select patients for an active surveillance strategy. Also, quantitative assess-
ment cannot be used to identify visually FDG-false negatives (Supplementary Figure 3). 
Additionally, overlap is seen between qualitative outcomes and quantitative cut-off 
values in false-positive TRG1 and false-negative TRG3-4 (Supplementary Table 4 and 
5). This indicates that to a large extent patients are misqualified by both qualitative and 
quantitative methods, suggesting that biological factors may be the underlying cause of 
this misqualification. 
To our knowledge, this is the first prospective study that systematically assessed the 
role of FDG-PET/CT in clinical response evaluation after nCRT for oesophageal cancer. 
PET/CT for locoregional response evaluation was performed at 12 weeks after nCRT. 
Immediately after nCRT, a false-positive signal is frequently detected by PET due to 
radiotherapy-induced inflammation and tumour necrosis. Based on knowledge from 
other malignancies, such as lymphoma and breast cancer, we hypothesized that PET/CT 
might be more accurate to guide targeted endoscopic and endosonographic biopsies at 
12 weeks after nCRT compared to for example 6 weeks.8, 14 
The value of FDG-PET/CT in response evaluation after nCRT has been studied be-
fore.10, 15-24 Most FDG-PET/CT scans were performed at shorter time interval after com-
pletion of nCRT (during nCRT or within 6 weeks after completion of nCRT). Defini-
tions of pathologically complete response (pCR) varied from TRG1 of the primary tu-
mour to ypT0N0 and ≤10% residual tumour cells. One study, similar to the present 
study, assessed the association between any visible FDG-uptake (5-7 weeks after nCRT) 
and any residual tumour cells in the resection specimen, demonstrating a sensitivity, 
specificity and accuracy of 74%, 22% and 53%, respectively.11 This is in line with the 
qualitative analysis of this study, with a sensitivity, specificity and accuracy of 80%, 37% 
and 68%, respectively. The healing of post radiation oesophagitis may have contributed 
to the somewhat better performance of FDG-PET/CT at a longer interval after nCRT in 
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the present study. Furthermore, several studies investigated the association between 
complete metabolic response (cMR, defined as SUVmax <4 and N0) and pCR defined as 
ypT0N0.10, 17, 22 Sensitivity, specificity, NPV and PPV ranged from 51-67%, 46%-67%, 
63%-82% and 27%-79%, respectively, also demonstrating only a modest diagnostic ac-
curacy of quantitative FDG-PET analysis. With quantitative SULmax in the present study, 
comparable findings for TRG 1 vs. TRG2-3-4 were found (sensitivity 74%, specificity 
60%, NPV 64% and PPV 86%). 
It is difficult to speculate on the minimal diagnostic accuracy that is needed to safely 
postpone surgery in an active surveillance approach for oesophageal cancer. In patients 
in whom vital tumour initially has been missed, tumour recurrence may be detected in 
the window of opportunity during systematic rigorous follow-up. However, this window 
of opportunity is limited and is the topic of current research. The strategy for follow-up 
includes FDG-PET/CT for detection of suspicious lymph nodes and systemic 
metastases, and will be combined with endoscopy with bite-on-bite biopsies and endo-
ultrasonography with fine needle aspiration of suspicious lymph nodes, as is currently 
applied in the prospective SANO-trial (Surgery As Needed for Oesophageal cancer; trial 
NTR 6803).7, 25 The SANO-trial will compare treatment outcome after nCRT in patients 
who have a complete clinical response 12 weeks after nCRT, randomising patients for 
immediate oesophagectomy versus an active surveillance approach.25 
In serial follow-up, the use of qualitative and quantitative FDG-PET/CT might be 
more promising (for an example see Figure 4). As is seen in the present study, FDG-
PET/CT at a certain time-point at low SUL, no distinction can be made between small, 
but vital, residual tumour and physiological oesophageal metabolism or surrounding 
oesophagitis. Over time however, an increase in FDG-signal is expected to reflect tu-
mour recurrence. Decreasing SUL would be compatible with recovery from radiation 
induced oesophagitis or other phenomena such as Candida infection and gastro-
oesophageal reflux disease that otherwise would have caused false-positive FDG-
uptake.26 To be able to detect small FDG changes reliably, we advocate consistent and 
strict scanning protocols during follow-up.  
Apart from being used for response evaluation post-nCRT, FDG-PET/CT is most 
useful for detection of interval metastases. Other studies, with shorter time to response 
assessments, all have reported similar numbers of 8% detection of interval metastases.27-
31 FDG-PET/CT has been reported to have a sensitivity of 74% and a specificity of 91% 
in detecting (interval) metastases, and is considered a cost-effective tool preventing 
futile surgery.32 The 9.5% detection of metastases that was found in the present study 
suggests that a prolonged interval from nCRT to surgery may help to avoid unneccesary 
surgery.  
One of the limitations of this study is that, due to the multicentre character of the 
trial, not all baseline and follow-up FDG-PET/CT scans were made in the same hospital 
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using the same scanner. Some variability was encountered in quality of scanning, with 
five patients who had noisy images. However, this reflects clinical practice and these 
scans were still adequate for visual analysis. Generally, noisy images deteriorate the 
confidence of reading and the accuracy of SUL measurements. We would therefore 
strongly recommend high quality scanning using the same scanner at CRE-2 and later, 
in order to allow detection of small lesions (lymph nodes, systemic metastases) at these 
time-points. Some patients had a prolonged interval between the last FDG-PET/CT and 
surgery (Supplementary Table 2). Therefore, the amount of residual disease at the time 
of the last scan may not have been representative for TRG in the resection specimen of 
these patients. We therefore stress the importance of a short interval between the last 
PET/CT and surgery in diagnostic studies, as to prevent falsely negative results. 
Furthermore, it is a topic of debate if TRG2 tumours can be safely missed. The main 
endpoint was the percentage of TRG3-4 tumours that were missed on FDG-PET/CT. 
According to the preSANO protocol, TRG2 residual tumours were allowed to be 
missed, because of the assumption that these tumours will become detectable over time, 
before they have become irresectable. This assumption can only be tested in a large 
comparative trial, such as the current SANO-trial.6, 25 
In conclusion, the value of FDG-PET/CT approximately 12 weeks after nCRT for 
detection of locoregional recurrence of oesophageal cancer is limited, both qualitatively 
and quantitatively. Distinction of small TRG3-4 tumour from surrounding physiological 
metabolism or post-radiation oesophagitis is difficult and may cause false-positive and 
false-negative results. Therefore, a clinically useful cut-off point for detection of residual 
tumour by SUL cannot be determined. Quantitative measurements might be applicable 
to support qualitative interpretation as to monitor metabolism during serial follow-up 
in an active surveillance strategy after nCRT, provided that each follow-up scan is per-
formed on the same scanner and in the same way. Most importantly, qualitative assess-
ment of FDG-PET/CT is useful for the detection of interval metastases (9.5%) at 12 
weeks after nCRT. The current SANO-trial will assess the value of FDG-PET/CT and 
other diagnostic modalities in an active surveillance approach.7, 25 
 
  
18F-FDG PET/CT to detect residual disease after neoadjuvant chemoradiotherapy 
359 
Table 1. Baseline characteristics of the study population 7 
Baseline characteristics N=207 
Age — yr.  
  Median (interquartile range) 66 (60-71) 
Male sex — no. (%) 173 (84) 
Tumour type — no. (%)  
  Squamous-cell carcinoma 44 (21) 
  Adenocarcinoma 162 (78) 
  Adenosquamous cell carcinoma 1 (0) 
Clinical T stage — no. (%)‡  
  cT1 1 (0) 
  cT2 40 (19) 
  cT3 154 (74) 
  cT4 11 (5) 
  Missing  1 (0) 
Clinical N stage — no. (%)ǁ  
  N0 63 (30) 
  N1 80 (39) 
  N2 57 (28) 
  N3 6 (3) 
  Missing  1 (0) 
Body mass index* 26±4.4 
  Missing  4 (2) 
Lean body mass* 61±9.8 
  Missing  4 (2) 
Glucose (mmol/L) 5.9±1.3 
  Missing  6 (3) 
Injection dose 18F-FDG (Mbq) 212±64.3 
  Missing  2 (1) 
Interval between injection and scanning (min)  61.0±9.1 
  Missing  5 (2) 
Plus-minus values are means ±SD 
*The body-mass index (BMI) is the weight in kilograms divided by the square of the height in metres 
*The lean body mass (LBM) was calculated according to the James equation9 
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Table 2. Results for qualitative dichotomous FDG-PET/CT analysis at CRE-2/-3.7 
 TRG1 TRG2 TRG3 TRG4 Total 
FDG-positive 17 22 17 18 74 
FDG-negative 10 8 2 4 24 
Total 27 30 19 22 98 
p=0.19 (chi-square) 
Table 3. Accuracy of FDG-PET/CT in predicting TRG3-4 versus TRG 1 at CRE-2/-3 with optimal cut-off 
points. 
Parameter AU-ROC (95% CI) Cut-off Sensitivity (%) Specificity (%) 
SULmax tumour 0.70 (0.57– 0.83) 2.93 66 74 
SULmax ratio tumour/oesophagus (SUR) 0.70 (0.56 – 0.83) 1.47 73 63 
ΔSULmax (absolute) 0.59 (0.45 – 0.73) 4.03 56 70 
ΔSULmax (percentage) 0.64 (0.50 – 0.78) -56.31 61 74 
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Figure 1. Flowchart of final inclusion of 129 patients at CRE-2/-3.7 
 
nCRT: neoadjuvant chemoradiotherapy; CRE: clinical response evaluation; TRG, tumour regression grade 
  
N = 219 
N = 207 
Included  ( 129 ) 
   Patients with TRG outcomes  ( 98 ) 
   No resection  ( 31 ) 
       Active surveillance  ( 16 ) 
       Died unrelated to oesophagus  ( 1 ) 
       Metastasis peroperatively  ( 3 ) 
       Metastasis on PET  ( 11 ) 
   Excluded  ( 12 ) 
   W ithdrew consent   ( 8 ) 
   O ther treatment than nCRT ( 4 ) 
Excluded from analyses  ( 78 ) 
   Non - FDG avid  ( 5 ) 
   No follow - up scan ,  only baseline  ( 17 ) 
   Positive   CRE - 1   ( 56 ,  of whom  7   with 
   Metastasis on PET ) 
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Figure 2. Confidence scores in 98 patients at CRE-2/-3 
 
p=0.072 (chi-square) 
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Figure 3a. Receiver operating characteristic curve analysis of SULmax tumour and SULmax ratio tu-
mour/oesophagus at CRE-2/-3 in predicting TRG1 vs. TRG3-4. 3b. Receiver operating characteristic curve 
analysis of ΔSULmax (absolute) and ΔSULmax (percentage) at CRE-2/-3 in predicting TRG1 vs. TRG3-4. 
 
Figure 4. Serial FDG-PET/CT after nCRT shows an increase in FDG-avidity 24 weeks after completion of 
nCRT (right), after an initially clinically complete response at 12 weeks (middle). Based on these PET/CT 
findings oesophagectomy was performed and residual tumour was found in the resection specimen. The 
resection was radical and tumour margins were free (ypT3N1R0 grade 3). 
 
nCRT: neoadjuvant chemoradiotherapy 
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Appendix 
Supplementary Table 1. Outcomes of patients that were excluded from analyses.7 
Outcome FDG-PET/CT  TRG1 TRG2 TRG3 TRG4 No 
surgery* 
Total 
  Died before CRE 0 0 0 0 3 3 
  Positive CRE-I 6 15 11 12 12 56 
  No follow-up scan 4 2 4 3 1 14 
  Non-FDG avid 1 0 1 1 2 5 
  Total 11 17 16 16 18 78 
TRG: tumour regression grade; CRE: clinical response evaluation. *No surgery because of death, patient’s 
preference of poor physical condition 
Supplementary Table 2. Visual FDG-PET/CT analysis versus TRG for patients with surgery >6 weeks later 
than FDG-PET/CT for all CREs. 
 TRG1 TRG2 TRG3 TRG4  Total 
FDG-positive 4 7 2 4 17 
FDG-negative 1 0 0 1 2 
Total 5 7 2 5 19 
Supplementary Table 3. Results of quantitative FDG-PET/CT analysis at CRE-2/-3 using optimal cut-off 
values. 
  Tumour regression grade (TRG)  
PET parameter cut-off values  TRG1 TRG2 TRG3 TRG4 Total 
SULmax 2.93      
  FDG-positive 7 16 10 17 50 
  FDG-negative 20 14 9 5 48 
  Total 27 30 19 22 98 
SULmax ratio tumour/oesophagus (SUR) 1.47      
  FDG-positive 11 15 11 19 56 
  FDG-negative 16 15 8 3 42 
  Total 27 30 19 22 98 
ΔSULmax (absolute) 4.03      
  FDG-positive 19 13 9 9 50 
  FDG-negative 8 16 10 13 47 
  Total 27 29 19 22 97 
ΔSULmax (percentage) -56.31      
  FDG-positive 20 15 9 7 51 
  FDG-negative 7 14 10 15 46 
  Total 27 29 19 22 97 
TRG: tumour regression grade 
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Supplementary Table 4. Overlap of missed patients with TRG3-4 tumours in qualitative analysis and in 
quantitative analysis at CRE-2/-3 using optimal cut-off values. 
 Qualitative 
dichotomous 
FDG-negative 
Qualitative 
confidence score 
FDG-negative 
SULmax 
<2.93 
SUR 
<1.47 
abs ΔSULmax 
<4.03 
Δ%SULmax 
<56.31 
decrease 
Qualitative 
dichotomous  
FDG-negative 
6      
Qualitative 
confidence score  
FDG-negative 
6 12     
SULmax <2.93 6 8 14    
SUR <1.47 4 7 9 11   
abs ΔSULmax <4.03 2 5 8 6 23  
Δ%SULmax  
<56.31 decrease 
2 5 7 5 22 25 
SUR: SULmax ratio tumour/oesophagus; abs: absolute 
Supplementary Table 5. Overlap of false-positive patients with TRG1 (complete response) in qualitative 
analysis and quantitative analysis at CRE-2/-3 using optimal cut-off values.  
 Qualitative 
dichotomous 
FDG-positive 
Qualitative 
confidence score 
FDG-positive 
SULmax 
>2.93 
SUR 
>1.47 
abs ΔSULmax 
>4.03 
Δ%SULmax 
>56.31 
increase 
Qualitative 
dichotomous  
FDG-positive 
17      
Qualitative 
confidence score  
FDG-positive 
13 13     
SULmax >2.93 7 7 7    
SUR >1.47 11 10 6 11   
abs ΔSULmax >4.03 11 7 4 7 19  
Δ%SULmax 
>56.31 increase 
11 7 4 7 19 20 
SUR: SULmax ratio tumour/oesophagus; abs: absolute 
  
Chapter 16 
366 
Supplementary Figure 1. SULmean of the bloodpool at baseline and CRE-1/-2/-3 versus injection time to 
scanning.  
 
 
CRE: clinical response evaluation  
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Supplementary Figure 2. SULmax, %ΔSULmax and SUL ratio in all patients with various TRG outcomes. 
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Supplementary Figure 3. SULmax and SUL ratio at CRE-2/-3 for qualitatively FDG-positive and FDG-negative 
scans, in TRG3-4 tumours. 
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Abstract 
Neoadjuvant chemoradiotherapy (nCRT) followed by surgery is standard of care for 
locally advanced esophageal cancer in many countries. After nCRT up to one third of all 
patients have a pathologically complete response in the resection specimen, posing an 
ethical imperative to reconsider the necessity of standard surgery in all operable patients 
after nCRT. An active surveillance strategy following nCRT, in which patients are sub-
jected to frequent clinical investigations after the completion of neoadjuvant therapy, 
has been evaluated in other types of cancer with promising results. In esophageal cancer, 
both patients who are cured by neoadjuvant therapy alone as well as patients with sub-
clinical disseminated disease at the time of completion of neoadjuvant therapy may 
benefit from such an organ sparing approach. Active surveillance is currently applied in 
selected patients with esophageal cancer who refuse surgery or are medically unfit for 
major surgery after completion of nCRT, but this strategy is not (yet) adopted as an 
alternative to standard surgery or definitive chemoradiation. The available literature is 
scarce, but suggests that long-term oncological outcomes after active surveillance are 
non-inferior compared to standard surgical resection, providing justification for com-
parison of both treatments in a phase III trial. This review gives an overview of the cur-
rent knowledge regarding active surveillance after completion of nCRT in esophageal 
cancer and outlines future research perspectives. 
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Introduction 
Surgical resection has long been considered the primary curative treatment modality for 
stages cT1b-4aN0-3M0 esophageal or junctional cancer. In the literature reported 5-year 
survival rates for patients treated with primary surgical resection range from six to 50%, 
but rarely exceed 35%.1-5 To improve long-term survival, many trials investigated the 
added value of neoadjuvant chemo- and/or radiotherapy. 6-12 
In most countries, two neoadjuvant approaches have been adopted as standard of 
care. The first is neoadjuvant chemoradiotherapy (nCRT), now generally based on the 
CROSS regimen, which resulted in a 5-year overall survival benefit of 14%, compared to 
surgery alone.10, 11 An alternative option is perioperative or preoperative chemotherapy 
using the OEO2 or the MAGIC protocol, which showed an absolute risk reduction of 
6% and 13% at 5-years, respectively.7, 12 Except for Japan, it is widely accepted that 
chemoradiotherapy is the neoadjuvant treatment of choice for patients with squamous 
cell carcinoma. For patients with adenocarcinoma the optimal multimodality regimen is 
still topic of debate.13-15 A significant survival benefit of nCRT over nCT has never been 
proven for patients with adenocarcinoma, but nCRT is associated with a high percent-
age of pathologically complete response (pCR) for both histological subtypes.13, 16, 17 A 
pCR means that no viable tumor cells can be detected at the site of the primary tumor or 
in the resected regional lymph nodes, as determined by conventional histological exam-
ination.  
In subsequent analyses of secondary endpoints of the CROSS trial it was found that 
nearly a third (29%) of the patients had a pathologically complete response (pCR) in the 
resection specimen.  In the CROSS trial, a pCR after nCRT was seen in 49% of patients 
with a squamous cell carcinoma and 23% of patients with an adenocarcinoma. In the 
OEO2 and MAGIC trials this was 4% and 5%, respectively.10, 18 This observation raises 
the question whether a surgical resection is of benefit for patients who were already 
cured locoregionally by nCRT alone. Theoretically, an organ sparing approach might be 
feasible since, intuitively, an esophagectomy in patients with no residual viable tumor 
cells has no effect on clinical outcome. An esophagectomy is associated with a risk for 
per- and postoperative mortality and  morbidity and reduces quality of life in both the 
short and long term.19-24 This imposes an ethical imperative to reconsider the necessity 
of standard esophagectomy in patients after nCRT. An individualized approach to sur-
gery after nCRT should be studied and defined; a new treatment algorithm in which not 
every patient with potentially curable esophageal cancer needs a resection after comple-
tion of nCRT to achieve long-term survival. Such an active surveillance strategy is cur-
rently applied in selected patients who refuse surgery or are medically unfit for major 
surgery after completion of nCRT.25-28 In this review, we give an overview of the feasibil-
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ity and effectiveness of an active surveillance approach after completion of nCRT for 
carcinoma of the esophagus. 
Rationale for an active surveillance approach 
In an active surveillance strategy, patients are subjected to serial clinical investigations 
after completion of nCRT. Surgical resection will be offered only to patients in whom a 
locoregional regrowth/residual disease is highly suspected or proven, without signs of 
distant dissemination.  
In other types of cancer including rectal and head and neck cancer, similar ap-
proaches have been evaluated with excellent results.29-32 In a recent study in patients who 
received nCRT for rectal cancer, 65% of all patients with a clinically complete response 
(cCR, i.e. no residual disease based on clinical diagnostics) did not need surgery. Of the 
remaining 35%, a successful  delayed surgical resection was performed in 90% of pa-
tients. Oncological outcome was comparable between both treatment groups.30 In ad-
vanced head and neck cancer active surveillance after chemoradiotherapy is widely 
accepted nowadays. In a recent randomized controlled trial (RCT) that compared 
standard neck dissection with PET-CT guided surveillance, survival was similar for both 
groups, but surveillance resulted in considerably fewer operations and was more cost-
effective.32 
Who will benefit from an active surveillance approach? 
An organ-preserving active surveillance strategy in esophageal cancer will not only have 
advantages for individuals who are already cured by neoadjuvant therapy alone, but also 
for patients with subclinical disseminated disease (i.e. micrometastases) at the time of 
completion of neoadjuvant therapy. After tumor staging and neoadjuvant treatment, 
micrometastases may be present but yet undetectable. With time these disseminated 
tumor cells will become clinically manifest. Distant metastases, which are the main de-
terminants of long-term survival after nCRT plus surgery (especially in patients with a 
pathologically complete response), are grossly independent of locoregional therapy.7, 33 
Although the biology of distant dissemination is not fully understood, current assump-
tions hold that the process of spreading and seeding of tumor cells from the primary 
lesion is an early event. The process of tumor cell dissemination may well  have occurred 
at the time of first clinical presentation and subsequent locoregional treatment (i.e. 
nCRT with and without subsequent surgery).34 This is reflected by the large number of 
patients who develop hematogenous metastases within two years after surgery.10, 11, 35 
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Hence, no matter how timely and aggressive locoregional treatment is, it will hardly 
affect the survival-determining events of distant dissemination.  At present, patients 
with occult distant metastases undergo an esophageal resection which ultimately is of no 
benefit to them, because distant metastases are still below the detection limit at the first 
clinical evaluation after nCRT. It should be noted that another theoretical explanation 
for the high rate of distant dissemination early after esophagectomy is that the depres-
sion of the immune system after major surgery might enhance hematogenic diffusion of 
tumor cells. This phenomenon will not take place if the patient is not operated on.36 This 
hypothesis also supports an active surveillance strategy. Hence, it is hypothesized that 
application of an active surveillance strategy in patients with a clinically complete re-
sponse after nCRT may reduce the need for an esophagectomy in 30 to 40% of all pa-
tients.10, 11, 25, 27, 28 
An active surveillance approach is only justified if long-term oncological outcome is 
similar to that after nCRT followed by surgery. Therefore, tumor regrowth after nCRT 
should be detected at a curable stage, i.e. in the period between the clinical detection 
limit and the resectability limit and before the potential development of distant dissemi-
nation from disease regrowth (Figure 1). Currently, the time span of this period and its 
variation between patients is unknown. Therefore, an intensive surveillance strategy (or 
approach) should be applied aiming to detect regrowth of cancer as early as possible 
before the tumor is irresectable. Since the majority of locoregional regrowths are ex-
pected to occur within 12 months after nCRT and nearly all within 24 months, an inten-
sive surveillance strategy should be performed in the first two years.37  
Clinical response evaluations: identifying and excluding minor- and 
non-responders 
After completion of nCRT, all patients should be re-staged, which is defined as the clini-
cal response evaluation (CRE). After a CRE, patients can be categorized as clinically 
complete responders or clinically incomplete responders. Only clinically complete re-
sponders (i.e. patients in whom no locoregional or disseminated disease can be proven) 
are offered active surveillance. Clinically incomplete responders with locoregional dis-
ease in the absence of distant metastases will be referred for immediate surgery, whereas 
clinically incomplete responders with distant metastases will be referred for palliative 
care or second line chemotherapy. 
Multiple studies have focused on the accuracy of detecting residual disease during 
clinical response evaluation after nCRT for esophageal cancer. A surgical resection as 
standard treatment in a potentially curative setting was (almost) always performed. 
Although the accuracy of endoscopy with standard biopsies is limited (false negative 
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rate 41%-69%)38-40, a recent study suggested that endoscopy with deep (bite-on-bite) 
biopsies is more accurate in detecting residual disease after nCRT. Tumor-negative bite-
on-bite biopsies were 85% predictive for a pathologically complete response in the resec-
tion specimen (i.e. 15% false negative for any residual cancer).41 Bite-on-bite biopsies 
increase the chance of detecting residual submucosal tumor deposits compared to con-
ventional biopsies (Figure 2). After nCRT, residual disease is frequently located in the 
submucosa (and mucosa), and is rarely present as an isolated remnant only in the prop-
er muscle layer, surrounding stroma and/or regional lymph nodes.42 The use of fine 
needle aspiration (FNA) to detect lymph node metastases theoretically further increases 
the diagnostic accuracy, but literature regarding this topic is lacking. 
18F-FDG PET-CT can identify non-complete responders with moderate sensitivity 
(46–88 %) and specificity (56–87 %) during CREs. The substantial false negative (12 – 
54%) and false positive rates (13–44 %) of a single PET-CT after nCRT limit its applica-
bility for detection of locoregional residual disease during CRE.43-48 However, PET-CT is 
highly valuable in the detection of interval metastases, as development of metastatic 
disease during the nCRT period can be detected by PET-CT in up to 10% of all 
patients.49 Moreover, serial PET-CT during active surveillance might be useful in the 
detection of local regrowths, as a subtle increase in FDG-avidity may indicate recurrence 
of malignancy, whereas a decrease in FDG-avidity more likely depicts the recovery from 
earlier radiotherapy induced esophagitis. 
The maximum tumor thickness (MTT) and changes in MTT as determined by endo-
scopic ultrasound (EUS) are predictive for histopathological response on nCRT, as 
shown by a Swiss study.50 However, these findings need validation in an independent 
cohort.50 
At present, the Dutch preSANO trial investigates the accuracy of clinical response 
evaluation and the optimal diagnostic set for detecting residual disease after nCRT for 
esophageal cancer using a combination of endoscopy with bite-on-bite biopsies, radial 
EUS for measurement of maximal tumour thickness and –area, lineair EUS-guided FNA 
of suspected lymph nodes, and 18F-FDG PET-CT.51 Approximately six weeks after 
completion of nCRT a first CRE is performed including endoscopy with bite-on-bite 
biopsies and EUS. Patients in whom no residual disease can be proven by histology will 
be offered postponed surgery, approximately 12-14 weeks after completion of nCRT. 
One week before the planned surgical resection, a second clinical response evaluation 
(CRE-II) is performed with a PET-CT scan followed by endoscopy with bite-on-bite 
biopsies, EUS and FNA of all suspected lymph nodes and/or PET-positive lesions. The 
rationale to include this second CRE is to increase the absolute chance of detecting re-
sidual disease and to allow for a comparison between serial measurements. The safety of 
delaying surgery to 12-14 weeks is supported by a recent study suggesting that pro-
longed time to surgery after nCRT up to at least 12 weeks has no negative effect on dis-
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ease-free and overall survival (HR=1.00 and HR=1.06 per additional week). Moreover, 
prolonged time to surgery increases the probability of a pathologically complete re-
sponse in the resection specimen (odds ratio=1.35 per additional week of time to sur-
gery, p=.0004).52 Similar results have been published by other groups.53-55 The main 
study parameter of the preSANO trial is the correlation between clinical response dur-
ing the CREs and pathological response in the resection specimen. Results of the 
preSANO trial are expected end-2017 and will reveal the optimal combination of diag-
nostic tests to detect residual disease after nCRT.51 
Although several studies have investigated the accuracy of detecting residual disease 
after nCRT, the minimum accuracy needed for testing an active surveillance strategy in 
a clinical trial is under debate. Intuitively, any residual disease after nCRT may not be 
missed since these patients do not benefit from active surveillance and should undergo 
surgery as soon as possible. On the other hand, as long as tumor regrowth after nCRT 
can be detected at a curable stage during active surveillance (Figure 1), long-term onco-
logical outcome is theoretically not jeopardized and residual disease may be missed 
during initial CREs. This conception is supported by the available literature on active 
surveillance after nCRT for rectal or esophageal cancer, which shows that a delayed 
(radical) resection can be performed successfully in nearly all patients with locoregional 
regrowth that was detected during active surveillance  using endoscopy with (conven-
tional) biopsies and PET-CT (see below).25, 27, 28, 30 It should be noted that a postponed 
surgical resection has been suggested to increase the risk of postoperative complications. 
However, this phenomenon is reported mainly after treatment with high dose of defini-
tive chemoradiotherapy (radiotherapy dose >50 Gy; so called salvage esophagectomy) in 
low-volume centers and it is unknown whether this also applies after treatment with a 
lower dose of radiotherapy (CROSS regimen).56, 57 Taken together, it is felt that the deci-
sion to perform a phase III trial that compares active surveillance with standard surgery 
should not depend on a predefined minimum sensitivity or negative predictive value of 
response evaluation, but rather on results from (phase I/II) studies that have reported 
clinical outcomes of an active surveillance strategy in selected patients with a cCR after 
nCRT. Nevertheless, results from studies on diagnostic accuracy are highly valuable, 
especially for determination of the optimal composition of a diagnostic set of tests for 
response and surveillance evaluations. 
Outcomes after active surveillance: a systematic review 
A systematic review was conducted to provide a complete overview of all literature on 
clinical outcomes of active surveillance after nCRT.  
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Methods 
A systematic literature search on active surveillance after neoadjuvant chemoradiother-
apy for esophageal cancer was performed in Embase, Medline Ovid, Web of Science, 
Scopus and the Cochrane Library databases from the inception of the databases to Au-
gust 9th 2016 by using the search terms “esophageal cancer”, “active surveillance” and 
“neoadjuvant chemoradiotherapy” and its synonyms in the title and abstract fields (Ta-
ble 1). The literature search was performed by an independent specialized literature 
researcher. Two reviewers independently screened titles and abstracts of the retrieved 
publications.  
Inclusion criteria were; patients had esophageal cancer, underwent nCRT (regimen 
not specified), had a clinically complete response during response evaluation after neo-
adjuvant treatment (diagnostic modalities not specified) and were subjected to  active 
surveillance after neoadjuvant treatment.  Publications other than systematic reviews, 
randomized controlled trials, cohort studies, case-control studies or patient series were 
excluded. 
Results 
We identified 489 unique records from the database search. A total of 20 articles con-
cerning active surveillance after nCRT for esophageal cancer were identified based on 
title/abstract screening. Full text screening resulted in the final selection of four articles.  
Some 61 patients with squamous cell carcinoma (n=18), adenocarcinoma (n=40) or 
other cancer type (n=3) from MD Anderson Cancer Center who declined surgery after 
nCRT had a cCR based on PET-CT and endoscopy with regular biopsies. The 5-year 
overall survival rate was 58%. Some 12 of 13 patients who developed a locoregional 
regrowth in the absence of distant metastases during surveillance underwent a radical 
esophagectomy.27 In line with rectal cancer, these results suggest that a delayed resection 
can technically  be performed in nearly all patients with residual locoregional disease 
that has been missed initially during response evaluation.30 In a subsequent comparative 
analysis, 36 patients that underwent active surveillance from the same cohort were 
matched to 36 patients who underwent nCRT followed by standard surgery using the 
propensity-score method. Estimated median overall survival was non-significantly bet-
ter in the active surveillance group than in the standard surgery group (58 months, 95% 
confidence interval [C.I.]: 27.7 to not applicable vs. 51 months, 95% CI: 30.7 to not ap-
plicable, respectively, p=0.28). All eleven patients in the active surveillance group with 
locoregional regrowth in the absence of distant metastases underwent delayed surgery 
with excellent outcome (median overall survival 58 months). Furthermore, distant dis-
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semination rate (the percentage of patients who developed distant metastases) was com-
parable in both groups (31% in the active surveillance group and 28% in the standard 
surgery group).28 These results support the earlier described assumption that dissemina-
tion already must have occurred in most patients at time of diagnosis.  
A second study from Italy reported on patients that underwent surveillance (n=38) 
and patients after planned surgery (n=39). All patients had a cCR after nCRT for esoph-
ageal squamous cell carcinoma. Clinical response was assessed using endoscopy with 
regular biopsies and patients in the surveillance group were not operated on because 
they were considered unfit for surgery or declined surgery. Nevertheless, 5-year overall 
survival rates were comparable in both groups (57 % in the active surveillance group vs. 
50 % in the standard surgery group, p=0.99).25  
Similar outcomes were described by a small Irish study that analyzed 25 patients 
who underwent nCRT with or without surgery when a cCR was diagnosed after endos-
copy post-nCRT.26  
Based on the promising results from these explorative (phase I/II) studies, we feel 
that an active surveillance approach is feasible and can now safely be tested in a phase III 
trial. 
Conclusion and future directions 
An active surveillance approach is currently applied only in patients who refuse surgery 
or are considered unfit for surgery after completion of nCRT.  In the near future, an 
organ preserving strategy may be offered as an alternative treatment to patients with a 
cCR after completion of nCRT. However,  a phase III trial is needed to ascertain that 
active surveillance does not lead to inferior long-term oncological outcome as compared 
to standard surgery. At present, two trials, the French ESOSTRATE-trial and the Dutch-
SANO trial (Surgery As Needed for Oesophageal cancer), have been initiated to address 
this important question.58 Both trials plan to recruit 300 patients each (including adeno-
carcinoma and squamous cell carcinoma) with a cCR after completion of nCRT. Both 
trials use different nCRT regimens, with the SANO-trial using the relatively mild 
CROSS regimen and the ESOSTRATE-trial using higher doses of nCRT. The latter 
would probably increase pCR rate, but at the cost of an increase in toxicity and postop-
erative complications, potentially leading to a less beneficial effectivity/toxicity ratio. 
The primary endpoint of both trials is overall survival. After response evaluation using 
endoscopy with (bite-on-bite) biopsies, EUS with FNA and 18F-FDG PET-CT, patients 
with a cCR will be randomized to receive either active surveillance or standard surgery. 
In both studies, the sample size leads to a non-inferiority margin of 15%. Combining 
outcomes of both trials will reduce this non-inferiority margin to 10%, which is in line 
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with other non-inferiority oncological clinical trials comparing active surveillance with 
standard surgery.32 Results of both trials are expected in 2023. 
It is anticipated that in the next few years the diagnostic accuracy of tests to assess 
tumor response to nCRT will improve. Promising results have been published using 
diffusion-weighted MRI and dynamic contrast-enhanced MRI, but its clinical applica-
bility remains to be proven.59, 60 If residual disease and/or local regrowths can be detect-
ed more accurately or at an earlier stage than with the current diagnostic modalities, this 
may reduce the proportion of patients scheduled for a postponed surgical resection and 
the proportion of patients with irresectable regrowths during active surveillance. Never-
theless, current diagnostic modalities have proven to be sufficiently accurate in response 
evaluation and detection of local regrowths during active surveillance to justify testing 
of this promising treatment strategy as potential standard of care.  
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Table 1. Search strategy for systematic review on clinical outcomes after active surveillance. 
 
Database 
Search  Hits 
Embase ('esophagus cancer'/exp OR 'esophagus tumor'/de OR (((esophag* OR oesophag*) NEAR/6 
(cancer* OR neoplas* OR carcino* OR adenocarcino* OR tumor* OR tumour* OR 
malign*))):ab,ti) AND ('watchful waiting'/de OR (((watch* OR see) NEAR/3 wait*) OR (active* 
NEAR/3 surveil*) OR ((selective* OR reserv* OR selected* OR needed OR necessar* OR 
unnecessar* OR declin* OR avoid* OR on-demand ) NEAR/6 (resect* OR surg* OR resect* OR 
esophagectom* OR oesophagectom*))):ab,ti) AND ('chemoradiotherapy'/exp OR (chemoradi* 
OR radiochemo* OR (chemotherap* NEAR/6 radiotherap*)):ab,ti)  
284 
Medline 
Orvid 
("Esophageal Neoplasms"/ OR (((esophag* OR oesophag*) ADJ6 (cancer* OR neoplas* OR 
carcino* OR adenocarcino* OR tumor* OR tumour* OR malign*))).ab,ti.) AND ("Watchful 
Waiting"/ OR (((watch* OR see) ADJ3 wait*) OR (active* ADJ3 surveil*) OR ((selective* OR 
needed OR necessar* OR unnecessar* OR declin* OR avoid* OR on-demand)  ADJ6 (resect* 
OR surg* OR resect* OR esophagectom* OR oesophagectom*))).ab,ti.) AND (exp 
"Chemoradiotherapy"/ OR ("Chemotherapy, Adjuvant"/ AND "Radiotherapy, Adjuvant"/) OR 
(chemoradi* OR radiochemo* OR (chemotherap* ADJ6 radiotherap*)).ab,ti.)  
106 
Cochrane ((((esophag* OR oesophag*) NEAR/6 (cancer* OR neoplas* OR carcino* OR adenocarcino* 
OR tumor* OR tumour* OR malign*))):ab,ti) AND ((((watch* OR see) NEAR/3 wait*) OR 
(active* NEAR/3 surveil*) OR ((selective* OR needed OR necessar* OR unnecessar* OR declin* 
OR avoid* OR on-demand ) NEAR/6 (resect* OR surg* OR resect* OR esophagectom* OR 
oesophagectom*))):ab,ti) AND ((chemoradi* OR radiochemo* OR (chemotherap* NEAR/6 
radiotherap*)):ab,ti)  
110 
Web of 
science 
TS=(((((esophag* OR oesophag*) NEAR/5 (cancer* OR neoplas* OR carcino* OR 
adenocarcino* OR tumor* OR tumour* OR malign*)))) AND ((((watch* OR see) NEAR/2 
wait*) OR (active* NEAR/2 surveil*) OR ((selective* OR needed OR necessar* OR unnecessar* 
OR declin* OR avoid* OR on-demand ) NEAR/5 (resect* OR surg* OR resect* OR 
esophagectom* OR oesophagectom*)))) AND ((chemoradi* OR radiochemo* OR 
(chemotherap* NEAR/5 radiotherap*))) ) 
248 
Scopus TITLE-ABS-KEY(((((esophag* OR oesophag*) W/5 (cancer* OR neoplas* OR carcino* OR 
adenocarcino* OR tumor* OR tumour* OR malign*)))) AND ((((watch* OR see) W/2 wait*) 
OR (active* W/2 surveil*) OR ((selective* OR needed OR necessar* OR unnecessar* OR declin* 
OR avoid* OR on-demand ) W/2 (resect* OR surg* OR resect* OR esophagectom* OR 
oesophagectom*)))) AND ((chemoradi* OR radiochemo* OR (chemotherap* W/5 
radiotherap*))) ) 
5 
Total 753 
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Figure 1. Tumor response after neoadjuvant chemoradiotherapy. 
 
CRT: chemoradiotherapy; Red arrow: time of clinical response evaluation (CRE); Vertical interrupted green 
lines: boundaries of theoretical time windows. First vertical interrupted green line on each curve refers to the 
first moment after CRT that a tumor becomes clinically detectable. Second vertical interrupted green line on 
each curve refers to the moment that a tumor becomes irresectable (T4b). Circles depict progression of lo-
coregional tumor volume. The clinical detection limit is the minimal amount of disease that can be detected by 
the combination of symptoms, endoscopy with biopsies and imaging modalities. 
 
Figure 2. Bite-on-bite biopsies (1+2+3+4) supposedly increase the chance of detecting submucosal tumour 
deposits compared to conventional biopsies (1+2). 
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Figure 3. Flowchart for systematic review on clinical outcomes after active surveillance. 
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Abstract 
Background 
After neoadjuvant chemoradiotherapy (nCRT) plus surgery for oesophageal cancer, 29 
per cent of patients have a pathologically complete response in the resection specimen. 
Active surveillance after nCRT (instead of standard oesophagectomy) may improve 
health-related quality of life (HRQoL), but patients need to undergo frequent diagnostic 
tests and it is unknown whether survival is worse than that after standard oesophagec-
tomy. Factors that influence patients’ preferences, and trade-offs that patients are will-
ing to make in their choice between surgery and active surveillance were investigated 
here. 
Methods 
A prospective discrete-choice experiment was conducted. Patients with oesophageal 
cancer completed questionnaires 4–6 weeks after nCRT, before surgery. Patients’ prefer-
ences were quantified using scenarios based on five aspects: 5-year overall survival, 
short-term HRQoL, long-term HRQoL, the risk that oesophagectomy is still necessary, 
and the frequency of clinical examinations using endoscopy and PET–CT. Panel latent 
class analysis was used. 
Results 
Some 100 of 104 patients (96.2 per cent) responded. All aspects, except the frequency of 
clinical examinations, influenced patients’ preferences. Five-year overall survival, the 
chance that oesophagectomy is still necessary and long-term HRQoL were the most 
important attributes. On average, based on calculation of the indifference point between 
standard surgery and active surveillance, patients were willing to trade off 16 per cent 5-
year overall survival to reduce the risk that oesophagectomy is necessary from 100 per 
cent (standard surgery) to 35 per cent (active surveillance). 
Conclusion 
Patients are willing to trade off substantial 5-year survival to achieve a reduction in the 
risk that oesophagectomy is necessary. 
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Introduction 
The widespread introduction of neoadjuvant chemoradiotherapy (nCRT) as a standard 
of care before resection with curative intent has led to a substantial improvement in 
survival rates in oesophageal cancer.1-3 After nCRT plus surgery, about one-third of all 
patients (49 per cent of patients with squamous cell carcinoma (SCC) and 23 per cent of 
those with adenocarcinoma) have a pathologically complete response in the resection 
specimen, meaning that no viable tumour cells can be found.3 Therefore, an active sur-
veillance approach could be applied in selected patients with both histological 
subtypes.4-6 During active surveillance after nCRT, clinical investigations are performed 
to detect residual or recurrent cancer. Only patients with locoregional tumour after 
nCRT and without distant metastases undergo surgery. Active surveillance has been 
tested successfully in head and neck, rectal, prostate and bladder cancer.7-10 
An active surveillance approach has potential advantages compared with oesoph-
agectomy in all patients after nCRT.  Oesophagectomy is associated with postoperative 
morbidity and mortality, and has a lasting impact on health-related quality of life 
(HRQoL).3, 11, 12 On the other hand, active surveillance carries the risk of detecting lo-
coregional residual disease at an unresectable stage, potentially jeopardizing long-term 
survival. Patients also experience a physical burden from frequent clinical investigations 
using endoscopy and PET–CT. Moreover, patients may experience increased anxiety 
and distress owing to the idea of possibly having residual tumour that is not treated 
radically and the need for oesophagectomy at some time point during follow-up. 
To optimize shared decision-making in defining the best treatment for patients with 
oesophageal cancer, a better understanding of patients’ preferences for treatment is 
needed. Patients’ views and beliefs can differ substantially from those of their physi-
cian(s).13-17 The aim of this study was to determine the relative importance of factors 
that influence patients’ preferences for undergoing active surveillance versus oesoph-
agectomy after nCRT for oesophageal cancer, and to investigate the trade-offs patients 
make in their choice of both treatment alternatives. It was hypothesized that long-term 
outcomes (especially life expectancy and long-term HRQoL) outweigh short-term out-
comes in patients’ treatment decisions, and patients are willing to trade off survival to a 
certain extent to avoid the need for oesophagectomy. 
Methods 
This was a prospective cohort study. Patients who were treated with nCRT according to 
the CROSS (ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study) 
regimen for histologically proven SCC or adenocarcinoma of the oesophagus or oe-
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sophagogastric junction were eligible.3 Patients with altered mental status prohibiting 
understanding of the questionnaire and those who were insufficiently fluent in the 
Dutch language were excluded. Consecutive patients were recruited 4–6 weeks after 
completion of nCRT in the Erasmus MC – University Medical Centre Rotterdam and in 
Maasstad Hospital, Rotterdam. The study protocol was approved by the medical ethics 
committee, Erasmus MC – University Medical Centre Rotterdam (MEC-2015-083). 
Discrete-choice experiment 
In a discrete-choice experiment (DCE) it is assumed that interventions, such as treat-
ment strategies, can be described by their characteristics (attributes; such as 5-year over-
all survival, short-term HRQoL, long-term HRQoL).18 It is also assumed that patients’ 
preferences for an intervention are determined by the levels of these attributes (for ex-
ample, 5-year survival rates of 45, 60 and 75 per cent).18 The trade-offs that patients 
make between the attributes can be evaluated by offering a series of choices in treatment 
alternatives with different combinations of attribute levels.19 
Attributes and attribute levels 
Relevant attributes that might influence the choice of oesophagectomy versus active 
surveillance after nCRT and the attribute levels were chosen based on information in the 
literature1, 4-6, 11, 12, and consensus discussion with two upper gastrointestinal surgeons 
and five patients who underwent nCRT followed by surgical resection. Attributes were 
5-year overall survival, short-term HRQoL (3 months after treatment), long-term 
HRQoL (more than 1 year after treatment), the risk that oesophagectomy is still neces-
sary, and the average number of surveillance examinations per year involving endosco-
py and PET–CT necessary for 5 years of follow-up after treatment (Table 1). The risk 
that oesophagectomy is still necessary reflects the risk that residual disease is missed 
during the initial response evaluation, but is detected at a resectable stage during active 
surveillance. Decreased 5-year overall survival in the active surveillance alternative re-
flects the risk that a regrowth is detected at an unresectable stage during active surveil-
lance (T4b or distant metastases). HRQoL was presented on a visual analogue scale 
(VAS) ranging from 0 to 100, where 100 represents the best health status. 
Study design and questionnaire 
Clinicopathological characteristics (age, sex, ASA fitness grade, tumour histology, clini-
cal tumour and node categories) and other variables, including level of education, 
household situation and current HRQoL, were collected. HRQoL was measured using 
the five-level version of the EuroQol Five Dimensions questionnaire (EQ-5D-5L™; Eu-
roQol Group, Rotterdam, the Netherlands).20 
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The combination of five attributes, encompassing three levels, each with two possi-
ble active surveillance scenarios, leads to 88 209 ((35 × (35 – 1)/2) × 3) hypothetical sce-
narios for three different surgery scenarios. The three surgery scenarios were based on 
5-year overall survival rates of 55, 65 and 75 per cent. As it is not feasible to present all 
possible scenarios to each patient, a subset of scenarios was generated in such a way that 
all parameters of interest could be estimated. A Bayesian efficient design was generated 
by maximizing D-efficiency using NGene software (http://www.choice-metrics.com).21 
This resulted in 18 choice sets per questionnaire. To take statistical efficiency into ac-
count as well as task complexity, each choice set consisted of two active surveillance 
alternatives (active surveillance A and active surveillance B) and one surgery alternative 
(‘opt-out’). Including two active surveillance alternatives in each choice set reduced the 
total number of choice sets per questionnaire. Patients were asked to consider the three 
treatment alternatives in each scenario and to choose the alternative that appealed most 
to them. An example of a choice set is shown in Figure 1.  
Each questionnaire started with a detailed description of the treatment alternatives, 
the attributes and their levels. This included a description of the impact of the treatment 
alternatives on HRQoL and an explanation of the HRQoL scales. This was followed by 
an example of a choice task. The main part of the questionnaire consisted of 18 choice 
sets. The questionnaire also contained a question assessing the difficulty experienced in 
completing the questionnaire (5-point scale). The validity of the questionnaire was de-
termined in a pilot study including 30 patients. Pilot data were accordingly used for 
further optimization of efficiency of the choice set. 
Patients were asked to fill in the questionnaire 6 weeks after completion of nCRT, 
before surgery. Before completion of the questionnaire, all patients received a standard-
ized face-to-face explanation of the background and concept of the study, and the po-
tential risks and benefits of both treatment alternatives (active surveillance and standard 
surgery) from the investigator, including a standardized explanation of potential short- 
and long-term side-effects of the surgical procedure. 
Statistical analysis 
Calculation of the sample size for DCEs is complicated as it depends on the true values 
of the parameters estimated in the choice models.22 Studies have shown that sample sizes 
of 40–100 respondents may be sufficient for reliable statistical analyses.23-25 The aim here 
was to include 100 respondents. 
Several models exist for analysis of discrete-choice data.26 Taking into account the 
authors’ interest in preference heterogeneity, as well as the sample size, a mixed logit 
model or a latent class model were alternatives for analysis of the choice observations. A 
latent class model was selected as it had the best fit for the choice observations (pseudo-
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R2 0.48 versus 0.69 using NLogit software; http://www.limdep.com/).27 Details of the 
model are described in Appendix 1 (supporting information). 
For the class coefficients, the statistical significance of a coefficient (p<0.050) indicates 
that, conditional on belonging to that class, respondents considered the attribute im-
portant in making their choices for oesophageal treatment. The directions of coefficients 
reflect whether the attributes have a positive or negative effect on utility. It was expected 
that the attributes 5-year overall survival and one or more levels of short-term HRQoL and 
long-term HRQoL would have a positive effect.28, 29 The association between the socio-
demographic or clinicopathological parameters (age, HRQoL based on EQ-5D™ VAS 
score, anxiety/depression based on EQ-5D™ anxiety/depression dimension, sex, ASA 
grade, educational level, household situation, tumour histology and cancer stage according 
to the UICC classification30) and the probability of belonging to one of the two classes was 
analysed. In terms of the class assignment parameters, statistically significant parameter 
estimates indicate that the associated co-variable can be used to help in understanding the 
different segments. For example, if the ‘age older than 65 years’ parameter associated with 
a particular class in the assignment model is positive and significant, this is indicative that 
people over 65 years of age are more likely to belong to that particular class as given in 
equation (1) (Appendix 1, supporting information). 
Class-specific importance scores were calculated for the active surveillance alterna-
tive to visualize the relative importance of a given attribute in that class by dividing the 
difference in utility between highest and lowest level for a single attribute by the sum of 
the differences of all attributes for that class.31 An attribute with an importance score of 
1 represents the most important attribute, whereas an attribute with an importance 
score of 5 represents the least important attribute. 
Trade-offs 
Willingness to trade off 5-year survival to achieve a reduction in the risk that oesoph-
agectomy is still needed, or to achieve an improvement in long-term HRQoL, was calcu-
lated. These values represent how much one is willing to trade off for a 1-unit change in 
the attribute of interest. The average trade-offs are based on calculation of the indiffer-
ence point between standard surgery and active surveillance, after adjustment for the 
risk that oesophagectomy is still necessary of 35% and the long-term HRQoL score of 80 
in the ‘base case’ for active surveillance. 
Results 
From March 2015 to January 2017, 104 patients were included. The response rate was 
100 of 104 (96.2 per cent). Responding patients had a median age of 67 (i.q.r. 61–72) 
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years and 78 of 100 patients were men. Twenty-five had a high educational level and 32 
patients experienced symptoms of anxiety/depression. The majority had a cT3 tumour 
(76 per cent) and suspected locoregional lymph nodes as determined by endoscopic 
ultrasonography, CT and PET–CT (62 per cent) (Table 2). 
Discrete-choice experiment results 
Two classes of patients were identified using a latent class model (Table 3). Patients with 
a preference for an active surveillance approach had a higher probability of belonging to 
class 1, whereas patients who preferred surgery had a higher probability of belonging to 
class 2. The class probabilities within the sample were 0.60 for class 1 and 0.40 for class 
2. No sociodemographic or clinicopathological characteristics were associated with the 
probability of belonging to one of the two classes. 
For both latent classes, 5-year overall survival, the risk that oesophagectomy is still 
necessary and long-term HRQoL significantly influenced patients’ preference for oe-
sophageal cancer therapy. The directions of the coefficients corresponded to the prede-
fined hypotheses. The positive coefficient for 5-year overall survival and the increasing 
coefficients associated with increases in short-term HRQoL and in long-term HRQoL 
indicate that patients prefer a treatment strategy that generates an increase in these 
attributes (increased survival and HRQoL). The negative coefficient associated with the 
risk that surgery is still necessary and the decreasing coefficients associated with an 
increase in the number of surveillance examinations indicate that these attributes are 
negatively associated with patients’ preferences.  
The importance scores in both latent classes were similar, with 5-year overall survival the 
most important attribute, followe1d by the risk that oesophagectomy is still necessary, long-
term HRQoL, short-term HRQoL and frequency of surveillance examinations after comple-
tion of therapy. This was irrespective of the 5-year survival rate after surgery (55, 65 or 75 per 
cent). Seventy-four of the 100 respondents did not find the DCE questions difficult. 
Willingness to trade off survival 
Based on their preferences, patients’ willingness to trade off 5-year overall survival 
chances to obtain an improvement in one of the other attributes was assessed (Table 4). 
Keeping other attributes at the median level (short-term HRQoL VAS score 80, long-
term HRQoL VAS score 80, 3 surveillance examinations per year), patients were willing 
to trade off on average a 26, 16 and 10 per cent decrease in 5-year overall survival to 
achieve a 15, 35 and 55 per cent risk respectively that oesophagectomy is still necessary 
(compared with 100 per cent). Similarly, to achieve an increase in long-term HRQoL 
from 70 (after standard surgery) to 80 and 90 (after active surveillance), patients were 
willing to trade-off 16 and 19 per cent 5-year overall survival respectively.  
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Discussion 
This prospective study showed that 5-year overall survival, long-term HRQoL and the 
chance that oesophagectomy is still necessary influenced patients’ preference for either 
active surveillance or planned surgery after nCRT for oesophageal cancer. There was a 
substantial preference heterogeneity and two latent classes were identified. The first 
consisted of patients with a strong preference for active surveillance and the second 
comprised patients with a strong preference for standard oesophagectomy. No predis-
posing factors (such age, HRQoL, ASA grade) could be identified that would enable 
classification of patients into one of the two classes. On average, patients were willing to 
trade off 16 per cent 5-year overall survival to reduce the risk of oesophagectomy being 
necessary from 100 to 35 per cent. 
Strengths of this study include its prospective design and the low attrition rate, thereby 
excluding the risk of selection bias. The low rate of attrition can be explained by the face-
to-face setting in which the questionnaires were explained. Furthermore, questionnaires 
were completed at the most realistic time point, 6 weeks after completion of nCRT and 
before surgery. This closely matches the moment when a decision regarding active surveil-
lance or oesophagectomy is made in clinical practice. A labelled DCE design was used, in 
which the treatment alternative is mentioned in each choice option (active surveillance or 
standard surgery) (Figure 1), whereas in an unlabelled design the treatment option is pre-
sented as option A, B or C and is described by attribute levels in the choice set.  The choice 
between surgical and non-surgical treatments may evoke individual preferences that can-
not be described in a questionnaire (such as anxiety about oesophagectomy). Therefore, it 
is difficult to convey the essential differences between active surveillance and oesophagec-
tomy from a patient’s perspective. The use of a labelled design leads to more realistic sce-
narios and takes into account individual feelings/preferences for a specific treatment, 
which further increases the validity of the results.32 
The results of this study indicate that long-term treatment outcomes (survival and 
long-term HRQoL) outweigh short-term attributes (short-term HRQoL and burden of 
surveillance examinations with endoscopy and PET–CT). They confirm the results of 
another DCE, which investigated preoperative preferences of patients towards surgery 
for oesophagogastric cancer.17 The latter study found that overall survival rate and long-
term HRQoL outweighed short-term outcomes such as postoperative morbidity, hospi-
tal type and a surgeon’s reputation. These findings underline the need for addressing 
long-term outcomes of different treatment modalities during counselling, before delving 
into details of treatment options. This may lead to improvements in meeting patients’ 
treatment expectations. 
The higher choice probability (0.60) for active surveillance than for standard surgery 
(0.40) is in line with the authors’ hypothesis and with the findings of other studies.14, 33 
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Nevertheless, a substantial subgroup of patients has a strong preference for standard oe-
sophagectomy, even if long-term survival would be comparable to that achieved with 
active surveillance. This can be explained by patients who experience fear having residual 
tumour that is not treated radically. Another possible explanation is that patients have had 
a bad experience with upper gastrointestinal endoscopy. Moreover, potential external 
influences, such as the role of the wider family, might influence patients’ treatment prefer-
ences. Future research should focus on further identification of factors associated with 
patients’ a priori choice probability for active surveillance or standard oesophagectomy. 
An intriguing finding is that patients were willing to trade off on average 16 per cent 
5-year survival chance in order to avoid oesophagectomy. This phenomenon has been 
described to a lesser extent in patients with prostate cancer.14, 33 The high postoperative 
morbidity and mortality rates associated with oesophagectomy, and the lasting impact 
of such surgery on patients’ HRQoL likely underlie the substantial loss of life expectancy 
that patients are willing to trade off3,11,12. For clinicians, who tend to focus on long-term 
survival outcomes, it is important to realize that patients and physicians may differ in 
their trade-offs between different treatment options.14, 15, 17, 26, 34, 35 
The present findings may help patients and clinicians choose between active surveil-
lance and oesophagectomy. Knowledge about the preferences of other patients with 
oesophageal cancer might help patients to clarify their own thoughts, whereas under-
standing factors that influence patients’ treatment decisions may make physicians more 
sensitive to individual patient’s preferences. This may have positive effects on the quality 
of shared decision-making.  
These findings may be useful in the design of new studies in oesophageal cancer. 
Although active surveillance is applied in selected patients only, this organ-sparing ap-
proach is currently under study. The Dutch SANO (Surgery As Needed for Oesophageal 
cancer) trial and the French ESOSTRATE trial are prospective studies comparing active 
surveillance with standard oesophagectomy in patients with a clinically complete re-
sponse after nCRT.36, 37 The primary endpoint of both trials is overall survival and results 
are expected in 2023. The SANO trial has been designed as a non-inferiority trial with a 
non-inferiority margin of 15 per cent, supported by the results of the present study. As a 
secondary endpoint, the SANO trial is aiming to design a decision aid, in order to fur-
ther tailor treatment and help patients in their individual treatment decision.38 
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Figure 1. Example of a choice set.  
 
  
1. Ac ve
surveillance A
2. Ac ve
surveillance B
3. Standard
surgery
Treatment 1, 2 en 3 are diﬀerent. Wich alterna ve would you choose?
Please imagine that no residual cancer can be found a er comple on of chemoradiotherapy.
Your surgeon tells you that both “ac ve surveillance” and “standard surgery” can be considered
as treatment op ons.
70 80 60
Short-term quality of life (3 months
a er treatment) on a 0-100 scale,
due to pain, fa ue, tube feeding ,
hospital admission and treatment-
related complica ons.
70 80 70
Chance that surgery is necessary
35% (35 out of 100
pa ents)
55% (55 out of 100
patients)
Long-term quality of life (1 year
a er treatment) on a 0-100 scale,
due to impaired physical func oning,
ea ng problems, sleeping slightly
elevated and defeca on problems.
100% (100 out of
100 pa ents)
3 2 1
Chance to be alive in 5 years
45% (45 out of 100
pa ents)
45% (45 out of 100
pa ents)
Physical burden of … (number)
examina ons per year with
endoscopy and PET-CT-scanning
a r ini al treatment. This accounts
for the ﬁrst 5 years a er treatment.
75% (75 out of 100
pa ents)
  Wich alterna ve
would you choose?
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Table 1. Attributes and attribute levels for active surveillance versus standard oesophagectomy after neoadju-
vant chemoradiotherapy for oesophageal cancer. 
Attribute Levels 
Active surveillance  
  5-year overall survival (%) 45 
   60 
 75 
  Short-term HRQoL (VAS 0–100) 70 
 80 
 90 
  Long-term HRQoL (VAS 0–100) 70 
 80 
 90 
  Risk that surgery is still necessary (%) 15 
 35 
 55 
  Average no. of surveillance examinations per year 2 
 3 
 4 
Standard oesophagectomy  
  5-year overall survival (%) 55 
65 
75 
  Short-term HRQoL (VAS 0–100) 70 
  Long-term HRQoL (VAS 0–100) 70 
  Risk that surgery is necessary 100 
  Average no. of examinations per year 1 
HRQoL, health-related quality of life; VAS, visual analogue scale. 
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Table 2. Clinicopathological characteristics of the study patients.  
 No. of patients* 
(n = 100) 
Age at randomization (years)† 67 (61–72) 
Sex ratio (M : F) 78 : 22 
Educational level  
  Low  36 
  Intermediate  38 
  High  25 
  Missing 1 
Household situation  
  With partner/family member 81 
  Single 19 
EQ-5D™ VAS score† 70 (60–80) 
Anxiety/depression symptoms‡ 32 
Tumour type   
  Squamous cell carcinoma 26 
  Adenocarcinoma 74 
Clinical T category§  
  cT2 20 
  cT3 76 
  cT4 4 
Clinical N category¶  
  cN0 38 
  cN1 42 
  cN2 16 
  cN3 4 
ASA fitness grade#  
  I 6 
  II 68 
  III 25 
  Missing 1 
*Unless indicated otherwise; †values are median (i.q.r.). ‡Based on EQ-5D™ anxiety/depression dimension. 
§Assessed by endoscopic ultrasonography or CT, and classified according to the UICC TNM classification, 
seventh edition30. 
Assessed by endoscopic ultrasonography, CT or [18F]fluorodeoxyglucose PET,  and classified according to the 
UICC TNM classification, seventh edition30. #Scale of 0 to V, with lower numbers indicating better physical 
status: I, normal healthy patient; II, patient with mild systemic disease; III,  patient with severe systemic dis-
ease. 
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Table 3. Patients’ preferences for treatment of oesophageal cancer after neoadjuvant chemoradiotheraopy 
based on a latent class model with two latent classes (100 patients). 
 Latent class 1: preference for active 
surveillance 
Latent class 1: preference for 
standard surgery 
Odds ratio* Importance 
score 
Odds ratio* Importance 
score 
Constant (standard surgery) 1.23 (1.48, 3.73)†‡  9.99 (7.62, 12.36)†‡  
Alternative 1: active surveillance     
5-year overall survival, active 
surveillance (per 10%) 
3.42 (2.69, 4.39)‡ 1 5.37 (3.39, 8.33)‡ 1 
Short-term HRQoL  4  4 
  Low 0.73  1.23  
  Medium 1.14 (0.96, 1.36)  0.95 (0.66, 1.38)  
  High 1.20 (1.00, 1.45)  0.85 (0.58, 1.23)  
Long-term HRQoL  3  3 
  Low 0.63  0.80  
  Medium 1.03 (0.87, 1.23)  0.85 (0.61, 1.20)  
  High 1.54 (1.28, 1.84)‡  1.46 (1.03, 2.08)‡  
Risk that surgery is still necessary (per 
10%) 
0.63 (0.56, 0.69)‡ 2 0.76 (0.64, 0.91)‡ 2 
Annual no. of diagnostic tests     
  2 1.06 5 1.09 5 
  3 1.03 (0.87, 1.23)  0.90 (0.63, 1.26)  
  4 0.90 (0.75, 1.09)  1.03 (0.73, 1.45)  
Alternative 2: standard surgery     
5-year overall survival, standard 
surgery (%) 
    
  55 0.21  0.22  
  65 1.79 (0.94, 3.39)  0.80 (0.52, 1.25)  
  75 2.66 (1.42, 5.00)‡  5.70 (2.72, 11.94)‡  
Average class probability 0.60  0.40  
Values in parentheses are 95 per cent conﬁdence intervals. *Unless indicated otherwise; †coeﬃcient. 
‡Signiﬁcant at 5 per cent level. 
Table 4. Willingness to trade off 5-year survival.  
  Willingness to trade off 5-year survival (%) 
Risk that oesophagectomy is necessary (%)*   
  15 26 (11, 34) 
  35 16 (4, 28) 
  55 10 (–3, 22) 
Long-term HRQoL (scale 0–100)†   
  80 16 (4, 28) 
  90 19 (7, 31) 
Values in parentheses are 95 per cent confidence intervals. *Compared with 100 per cent risk that oesophagec-
tomy is necessary. †Compared with long-term health-related quality of life (HRQoL) score of 70 after stand-
ard surgery. 
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Abstract 
Background 
Neoadjuvant chemoradiotherapy (nCRT) plus surgery is a standard treatment for locally 
advanced oesophageal cancer. With this treatment, 29% of patients have a pathologically 
complete response in the resection specimen. This provides the rationale for investigating 
an active surveillance approach. The aim of this study is to assess the (cost-)effectiveness of 
active surveillance vs. standard oesophagectomy after nCRT for oesophageal cancer. 
Methods 
This is a phase-III multi-centre, stepped-wedge cluster randomised controlled trial. A total 
of 300 patients with clinically complete response (cCR, i.e. no local or disseminated disease 
proven by histology) after nCRT will be randomised to show non-inferiority of active 
surveillance to standard oesophagectomy (non-inferiority margin 15%, intra-correlation 
coefficient 0.02, power 80%, 2-sided α 0.05, 12% drop-out). Patients will undergo a first 
clinical response evaluation (CRE-I) 4-6 weeks after nCRT, consisting of endoscopy with 
bite-on-bite biopsies of the primary tumour site and other suspected lesions. Clinically 
complete responders will undergo a second CRE (CRE-II), 6-8 weeks after CRE-I. CRE-II 
will include 18F-FDG-PET-CT, followed by endoscopy with bite-on-bite biopsies and 
ultra-endosonography plus fine needle aspiration of suspected lymph nodes and/or PET- 
positive lesions. Patients with cCR at CRE-II will be assigned to oesophagectomy (first 
phase) or active surveillance (second phase of the study). The duration of the first phase is 
determined randomly over the 12 centres, i.e., stepped-wedge cluster design. Patients in 
the active surveillance arm will undergo diagnostic evaluations similar to CRE-II at 
6/9/12/16/20/24/30/36/48 and 60 months after nCRT. In this arm, oesophagectomy will be 
offered only to patients in whom locoregional regrowth is highly suspected or proven, 
without distant dissemination. The main study parameter is overall survival; secondary 
endpoints include percentage of patients who do not undergo surgery, quality of life, clini-
cal irresectability (cT4b) rate, radical resection rate, postoperative complications, progres-
sion-free survival, distant dissemination rate, and cost-effectiveness. We hypothesise that 
active surveillance leads to non-inferior survival, improved quality of life and a reduction 
in costs, compared to standard oesophagectomy. 
Discussion 
If active surveillance and surgery as needed after nCRT leads to non-inferior survival 
compared to standard oesophagectomy, this organ-sparing approach can be implement-
ed as a standard of care. 
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Background 
Oesophageal cancer is an aggressive disease with poor outcomes after primary surgery.1 
Since the introduction of neoadjuvant chemo(radio)therapy, survival rates have im-
proved substantially.2 The randomised ChemoRadiotherapy for Oesophageal cancer 
followed by Surgery Study (CROSS) showed an absolute 5-year overall survival benefit 
of 14% after neoadjuvant chemoradiotherapy (nCRT) plus surgery, compared to surgery 
alone.3, 4 Moreover, after nCRT according to CROSS, 29% of all patients (49% for squa-
mous cell carcinoma [SCC] and 23% for adenocarcinoma [AC]) had a pathologically 
complete response (pCR) in the resection specimen.3 This high pCR-rate provides the 
rationale to explore an organ-sparing active surveillance approach after nCRT since, 
intuitively, an oesophagectomy in patients with no viable residual tumour does not 
improve oncological outcome. In this organ-sparing treatment strategy, patients will 
undergo frequent diagnostic evaluations after nCRT. An oesophagectomy will be per-
formed only in patients with a proven or high suspicion of locoregional regrowth, in the 
absence of distant metastases. This treatment strategy would have great advantages, 
especially given the perioperative morbidity and mortality, and the lasting impact on 
patients’ health-related quality of life (HRQOL) that is associated with oesophagecto-
my.3, 5-9 An active surveillance approach would not only benefit patients who are cured 
by nCRT alone, but also patients with undetectable distant metastases (i.e. micrometas-
tases) after completion of nCRT. Currently, patients with occult distant metastases un-
dergo standard oesophagectomy. This theoretically is of no benefit, because distant 
metastases, which are the main determinants of long-term survival, are below the detec-
tion limit at the first clinical evaluation after nCRT. During active surveillance, these 
occult metastases might become clinically manifest, which will prevent patients from a 
non-beneficial oesophagectomy. 
At present, active surveillance is applied in selected patients who refuse oesophagec-
tomy or who are finally considered unfit for surgery after nCRT.10-13 Explorative retro-
spective studies in these patients show promising results, with comparable long-term 
survival for active surveillance vs immediate standard surgery and comparable outcomes 
of postponed oesophagectomy in patients who develop a locoregional regrowth in the 
absence of distant metastases.10-13 
In the recently completed diagnostic preSANO-trial, endoscopy with bite-on-bite 
biopsies and ultra-endosonography with fine needle aspiration (FNA) of suspected 
lymph nodes for detection of locoregional residual disease, combined with 18F-FDG 
PET-CT for detection of interval metastases was adequate for clinical response evalua-
tion after nCRT for oesophageal cancer. Using two rounds of clinical response evalua-
tions (CREs), sensitivity and specificity for differentiation between tumour regression 
grade (TRG) 3-4 (i.e. >10% vital cells) and TRG 1 (i.e. no vital cells) residual tumour 
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using endoscopy with bite-on-bite biopsies and FNA were 90% and 72%, respectively. 
18F-FDG PET-CT after nCRT detected interval metastases in 10% of patients.14, 15 
The results of the preSANO-trial in combination with results in the literature on the 
clinical outcome of active surveillance justify a phase-III trial, comparing active surveil-
lance with standard surgery in patients with a clinically complete response after nCRT. 
Objective 
The aim of this study is to assess the (cost-)effectiveness (including non-financial costs 
and survival) of active surveillance after nCRT - as compared to standard surgery - for 
patients with SCC or AC of the oesophagus or oesophagogastric junction. 
Methods 
Study design 
The SANO-trial is a phase III multi-centre, stepped-wedge, cluster randomised con-
trolled non-inferiority trial. This design involves random sequential switch of clusters of 
participating institutions from the control arm (standard surgery) to the interventional 
arm (active surveillance). Randomisation is performed at the institutional level, instead 
of the individual level (Figure 1 and 2).16 Twelve high-volume centres in the Netherlands 
are participating in this study (Erasmus Medical Centre, Rotterdam; Catharina Cancer 
Institute, Eindhoven; Zuyderland Medical Centre, Heerlen; Radboud University Medi-
cal Centre, Nijmegen; Elisabeth Tweesteden Hospital, Tilburg; Gelre Hospital, Apel-
doorn; Leiden University Medical Centre, Leiden; Maasstad Hospital, Rotterdam; Zorg-
groep Twente, Almelo; Netherlands Cancer Institute, Amsterdam; Reinier de Graaf 
Group, Delft; Medical Centre Leeuwarden). Based on these 12 participating centres, 6 
clusters with comparable estimated inclusion rates will be formed, each cluster compris-
ing 2 participating centres. Based on the expected inclusion period of 36 months and the 
inclusion of 60 clinically complete responders from the preSANO trial (see below; Sta-
tistical Analysis; Sample Size Calculation), every 4.5 months one cluster will switch from 
the control arm to the interventional arm. Clusters will be determined by randomisa-
tion, but always consist of a centre with high expected total inclusion (≥45) and a centre 
with a lower (<30) expected total inclusion. 
During the first 4.5 months of the trial, all centres will provide standard immediate 
surgery and will gain experience in the performance of clinical response (and surveil-
lance) evaluations. After 4.5 months, a cluster of 2 centres (Erasmus MC and Zuyder-
land Medical Centre) with extensive experience in CREs and a large number of patients 
included in the preSANO-trial, will start to provide the novel strategy (active surveil-
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lance). After the next 4.5 months, another cluster of 2 participating centres will be ran-
domly assigned by the sponsor using a computer-generated number sequence to begin 
with active surveillance. This procedure will be repeated after 4.5 months until all clus-
ters have crossed over into the active surveillance arm. The final phase of the trial, with 
all sites including patients in the active surveillance arm, finishes approximately 9 
months after the last cluster of two sites have switched from the control arm to the in-
terventional arm (Figure 2).  
Patients who prefer the treatment that is not offered as study treatment in that par-
ticular centre at that time (e.g. active surveillance in a centre that has not yet crossed 
over into the active surveillance group) cannot be included in the trial. These patients 
will still be treated in the same centre, but outside the trial. 
Expected numbers of patients included in both study arms during the different time 
periods and predefined clusters with comparable expected numbers of inclusions are 
shown in Figure 2. Inclusion rate will be closely monitored during the trial, and time 
periods will be adjusted if the number of included patients differ substantially from the 
expectations. 
Study population 
Operable patients with locally advanced resectable SCC or AC of the oesophagus or 
oesophagogastric junction who are planned to undergo nCRT according to CROSS 
followed by surgical resection are eligible for inclusion.3 Patients with language difficul-
ties, dementia or altered mental status prohibiting the understanding and giving of in-
formed consent and patients with non-FDG-avid tumours at baseline will be excluded 
from participation in this study. Patients will have conventional pre-treatment work-up 
(including F18-FDG PET-CT to assess the avidity of the primary tumour). 
Study algorithm (Table 1, Figure 1, Figure 3) 
All included patients will undergo nCRT according to CROSS (Carboplatin AUC 2 
mg/mL per min,  Paclitaxel 50 mg/m2 of body-surface area and 41.4 Gy of concurrent 
radiotherapy in 23 fractions).3 Patients will be re-staged after nCRT during CREs to 
select those who may benefit from active surveillance. CREs categorise patients as clini-
cally complete responders or clinically incomplete responders. Only patients in whom 
no locoregional or disseminated disease is proven (cCR) during CREs, will be included 
in the comparative part of this trial. 
CREs 
Approximately 4-6 weeks after completion of nCRT all included patients will undergo a 
first clinical response evaluation (CRE-I) including oesophagogastroduodenoscopy 
Surgery As Needed for Oesophageal cancer (SANO trial) 
411 
(OGD) with at least 8 (random) biopsies, including at least 4 bite-on-bite biopsies of the 
primary tumour site and of any other suspected lesions. Patients with (cyto)histological 
evidence of locoregional residual disease during CRE-I will be offered a subsequent 18F-
FDG PET-CT to exclude disseminated disease and will be offered immediate surgery 
(i.e. 6-8 weeks after completion of nCRT). Patients who are found to be cCR will under-
go a second CRE (CRE-II) 6-8 weeks after CRE-I (i.e. 10-14 weeks after completion of 
nCRT). CRE-II will include an 18F-FDG PET-CT, followed by OGD with bite-on-bite 
biopsies of the primary tumour site and any other suspected lesions, radial EUS and in 
case of PET-positive lesions and/or suspected lymph nodes, even if these lymph nodes 
are located directly adjacent to the primary tumour site, linear EUS with FNA. The 18F-
FDG PET-CT during CRE-II must be available to guide the endoscopist in taking biop-
sies and FNA during OGD and EUS. Patients with (cyto)histological evidence of locore-
gional residual disease or highly suspected locoregional residual disease on 18F-FDG 
PET-CT, and without distant metastases during CRE-II will undergo surgery immedi-
ately after CRE-II (i.e. 10-14 weeks after completion of nCRT). Patients with distant 
metastases will be referred for palliative care.  
Patients without (cyto)histological evidence of residual disease during CRE-II (cCR), 
in the absence of distant metastases, will be assigned to active surveillance (experimental 
arm) or standard surgery (control arm), according to the randomisation at the institu-
tional level.  
Active surveillance 
Patients in the active surveillance arm will undergo active surveillance by 18F-FDG 
PET-CT, OGD with at least 8 biopsies, including at least 4 bite-on-bite biopsies and EUS 
plus FNA of all suspected lymph nodes at 6, 9, 12, 16, 20, 24, 30, 36, 48 and 60 months 
after completion of nCRT or when symptoms or results of any diagnostic test require 
shorter assessment intervals. Patients with (cyto)histological evidence of disseminated 
disease during active surveillance will be referred for palliative care (Figure 3). 
Surgery 
All patients in the control arm without distant metastases will be offered oesophagecto-
my after CRE-II, whereas patients in the active surveillance arm will be offered surgery 
only when locoregional regrowth is highly suspected or proven, also without any signs 
of distant dissemination (Figure 3).  
A transthoracic oesophagectomy or a transhiatal oesophagectomy will be performed, 
depending on both patient characteristics and local expertise and preference. Open, 
hybrid and completely minimally invasive techniques are allowed. At least 15 lymph 
nodes should be harvested in every patient. An en-bloc resection of the primary tumour 
and the regional lymph nodes should be carried out including a standard dissection of 
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the lymph nodes around the coeliac axis (separately collected for nodes along the left 
gastric, common hepatic and splenic artery). In the chest, at least the right paratracheal, 
subcarinal and para-oesophageal lymph nodes should be harvested.  
Pathology 
All CRE- and surveillance biopsies will be assessed by expert GI pathologists. Initially, 
all biopsies will be analysed based on the regular HE-slides (which contains two or three 
levels). If analysis at these levels reveals obvious vital tumour, the biopsy will be classi-
fied (diagnosed) as positive. If the assessment of this HE-slide is negative for malignancy 
(no malignancy), deeper sections will be performed (two or three additional levels, de-
pending on the amount of tissue on the paraffin block). In case of doubt regarding the 
presence of tumour (cells) after analysis of a biopsy at the aforementioned additional 
levels, extra dPAS and (pan)keratin staining will be performed. In case of an originally 
diagnosed signet-ring cell carcinoma or a poorly cohesive carcinoma with mucin pro-
duction, analysis at three additional (deeper) levels and dPAS and keratin staining will 
be performed consistently. 
Only the CRE- and surveillance biopsies with uncertain outcome will be revised at 
the Department of Pathology of the Erasmus MC following the same strategy.  
The resection specimens will be assessed using the 7th edition of the UICC TNM 
cancer staging. Microscopically radical resection (R0) will be defined as a tumour-free 
resection margin (margin >1mm not required). Also, prepTNM staging will be estimat-
ed as described earlier.17 Tumour regression grade (TRG) will be determined according 
to the modified Mandard classification (TRG 1 to 4).15 
Centralised multidisciplinary tumour board 
During CRE-I and CRE-II, positive (cyto)histology is preferably available when offering 
a patient surgical resection. However, during active surveillance we do allow a central-
ised multidisciplinary tumour board (MTB, Erasmus MC) to recommend surgical resec-
tion in selected patients who have a high clinical / diagnostic suspicion of tumour re-
growth, despite repeatedly negative (cyto)histology. This centralised MTB will monitor 
and decide on all such suspected patients from all participating centres. The reason for 
offering surgical resection in patients with a (strong) clinical suspicion of regrowth, but 
without positive (cyto)histology is to minimise the risk that a difficulty in confirming 
regrowth by histology causes a delay that will permit a tumour regrowth to expand into 
an irresectable stage. If for instance the intensity of a hotspot on 18F-FDG PET-CT 
substantially increases over time during surveillance but positive (cyto)histology cannot 
be obtained, the MTB can decide to recommend surgery. 
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Follow-up 
Follow-up visits of patients in both study arms will occur at 6, 9, 12, 16, 20, 24, 30, 36, 48 
and 60 months after completion of nCRT. Additional visits will be scheduled if com-
plaints will arise before the next visit. In cases of suspected recurrence, thoraco-
abdominal CT, PET-CT and/or upper gastrointestinal endoscopy will be performed. In 
order to accurately compare distant dissemination rates between both treatment arms, 
18F-FDG PET-CT scan will be performed in all patients in the standard surgery arm 
after one and two years of follow-up, after which most (>80% and >90%, resp.) distant 
metastases will likely have been detected.18 If a patient in the active surveillance will 
undergo postponed oesophagectomy due to a locoregional regrowth without distant 
metastases, follow-up will be performed according to the Dutch Guideline for oesopha-
geal cancer.19 
Study parameters/endpoints 
The main study parameter in this study is overall survival of patients with cCR at CRE-
II (i.e. 10-14 weeks after completion of nCRT). Secondary study parameters include: 
- The percentage of patients in the active surveillance arm who do not undergo sur-
gery (i.e. patients who are cured by nCRT or who have occult distant metastases 
during initial staging, which become manifest during active surveillance);  
- HRQOL as measured with EQ-5D20, QLQ-C3021, QLC-OG2522 and Cancer Worry 
Scale23 questionnaires;  
- Clinical irresectability (cT4b) rate; R0-resection rate defined as percentage of patients 
within the entire randomised population who undergo resection, defined as a tu-
mour-free resection margin;  
- Postoperative morbidity/complications for all randomised patients with cCR who 
undergo resection, as defined by the Esophageal Complications Consensus Group24;  
- Postoperative mortality for all patients with cCR who undergo resection, defined as 
90 day- and/or in-hospital mortality;  
- Progression-free survival, defined as the interval between randomisation and the 
earliest occurrence of disease progression resulting in primary (or peroperative) ir-
resectability of disease, locoregional regrowth (after completion of therapy);  
- Distant dissemination rate; 
- Cost-effectiveness. 
Safety and stopping rules 
Delaying surgical resection in patients in the active surveillance arm should neither lead 
to a significant reduction in tumour resectability and radical resection rate, nor to a 
significant increase in postoperative mortality and distant dissemination rate. Therefore, 
the following parameters are closely monitored;  
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- Proportion of all patients in the active surveillance arm that present with an irresec-
table or incurable (T4b or R2) regrowth, in the absence of distant metastases; 
- Proportion of all patients in the active surveillance arm that undergo a microscopi-
cally non-radical (R1) resection; 
- Postoperative morbidity; postoperative in-hospital mortality in all patients in the 
active surveillance arm, proportion of all patients in the active surveillance arm with 
hospital stay >60 days or who develop postoperative trachea-neo-oesophageal fistu-
la; 
- Proportion of all patients in the active surveillance arm that develop distant dissemi-
nation after one and two years of follow-up. 
If outcomes of one or more of these parameters in the active surveillance arm signifi-
cantly exceed the outcomes in the standard surgery arm or in the Dutch Upper-GI Can-
cer Audit (DUCA) data 2016, all participating centres will be notified immediately and 
further inclusion will be stopped.25 Patients who have been already included will be 
informed and offered the possibility of immediate (high-priority) surgical resection, 
even in the absence of suspicion of regrowth. Continuation of active surveillance will 
also still be offered. 
Statistical analysis 
Sample size calculation 
In the present phase-III study, we plan to randomise at institutional level 300 patients 
with cCR during CRE-II between active surveillance and standard surgical resection. 
Simulation of trial outcomes with expected equal 3-year overall survival rates of 67% in 
both trial arms and an intra-correlation coefficient of 0.02 to account for between-
institution variation (inter-quartile range for 3-year overall survival rates of 63%-71%) 
indicates a total sample size of 264 patients to show non-inferiority of surveillance to 
standard surgery with 80% power.26 Non-inferiority is defined as a 3-year survival rate 
that is no more than 15 percentage points below the expected 67% 3-year survival rate 
among patients in the standard surgery arm (data based on the CROSS-trial).3, 4 To al-
low for a 12% drop-out  (e.g. patients in the active surveillance-arm who request imme-
diate surgery in the absence of clinically proven or suspected regrowth) 300 patients are 
required for randomisation. Based on preliminary data from the current preSANO-trial, 
we expect that 50% of all included patients will have cCR during CRE-II, leading to a 
total required inclusion of 600 patients.14 
To reduce the number of newly included patients and to optimally use the data from 
the preSANO-trial, all recently (≥ May 2015) included patients with cCR during CRE-II 
from the current preSANO-trial who underwent bite-on-bite biopsies during CRE-I and 
CRE-II will be included in the control arm (n=60 patients). Assuming a 50% cCR rate, 
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the total number of required patients to be newly included in the SANO-trial will drop 
from 600 to 480 patients. Consequently, patients with cCR are randomised at an institu-
tional level in a 3:5 ratio. 
No interim analyses are planned for survival outcomes. 
Data analysis 
The difference in survival over a 3-year horizon between the control arm and the exper-
imental treatment arm will be analysed with a mixed-effects Cox regression model. Use 
of a mixed regression model – including an institution-level random effect – is required 
to capture the potential between-institutional variation in survival.27 To correct for po-
tential selection bias, the treatment effect will be estimated with adjustment for prognos-
tic factors for survival, i.e. age, sex, histologic subtype of tumour, clinical N stage, and 
WHO performance score. We will also use the mixed-effects Cox regression model to 
study potential differences in treatment effect between subgroups of patients. Subgroups 
are predefined according to age, sex, histologic subtype of tumour, clinical N stage, and 
WHO performance score. HRQOL data will be analysed according to the EuroQol, 
EORTC and Cancer Worry Scale scoring manuals.20-23 Repeated measurement analysis 
will be used to evaluate within and between group differences. Data will be analysed 
following the intention-to-treat principle, including protocol deviators. A per protocol 
analysis will be performed as a secondary analysis. 
Ethical and regulatory considerations 
The study has been approved by the medical ethics committee of the Erasmus MC 
(MEC2017-392) and has been registered in the Netherlands Trial Register (NTR 6803). 
The study will be conducted according to the principles of the Declaration of Helsinki 
(10th version, Fortaleza, 2013) and in accordance with the Dutch Medical Research 
Involving Human Subjects Act (WMO) and other applicable guidelines, regulations and 
Acts. In each participating centre, the local coordinating or principal investigator will be 
responsible for recruitment, data collection, follow-up of included patients, completion 
of case report forms and adherence to the study protocol. The supervising physician or 
any other physician of the multidisciplinary team will inform subjects about the study 
and ask for their consent using standard information letters and informed consent 
forms. Both patient information letters and informed consent forms are attached as 
separate documents. 
An independent safety committee will be established to perform on-going safety 
surveillance and to perform interim analyses to assess the safety data and the stopping 
rules as described in “safety and stopping rules”. Each stopping rule will be repeatedly 
tested when the first 10, 20, 30 and 50 events for that particular stopping rule have oc-
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curred (i.e. [ad 1 and 2] detection of locoregional regrowth, [ad 3] the performance of 
delayed surgery or [ad 4] the detection of distant metastases).  
The project leader (JL) is responsible for the study design and conduct of the trial, 
for the preparation of the protocol and revisions and for preparation of case report 
forms. Revisions of the study protocol will be communicated to all local chief investiga-
tors. The Clinical Trial Centre (CTC) of the Erasmus MC – University Medical Centre 
Rotterdam is responsible for the data master file, data verification and randomisation. 
Randomisation will be performed via a computer-generated random numbers sequence.  
Data will be collected using individual trial case numbers on standardised case report 
forms collated centrally by the CTC. Patients will not be individually identifiable. The 
final dataset will be available to all study investigators but will not be analysed per cen-
tre. Authorships will be defined following the International Committee of Medical 
Journal Editors guidelines.28 Results will be communicated via international confer-
ences, via publications and via the NTR. 
Discussion 
Trials comparing surgical and non-surgical treatment modalities often fail due to low 
accrual if randomisation is at the patient level, which might be explained by patient 
preferences for an intervention.29-32 Therefore, a stepped-wedge cluster design is applied 
in the present trial.33 In a stepped-wedge design, randomisation takes place at the insti-
tutional level, and not at the patient level. Consequently, at the moment of inclusion 
patients know which treatment arm they will be assigned to, thereby overcoming uncer-
tainty about which treatment patients will undergo. We expect that this will improve 
patients’ willingness to participate. When proven successful, the stepped-wedge design 
might be used as a new standard for comparing surgical with conservative treatments in 
clinical trials. 
We will include both patients with SCC and patients with AC, since SCC and AC 
both respond to nCRT and no statistically significant differential effects were found in 
the CROSS-trial. Both patients with SCC and AC have a substantial pCR rate (49% and 
23% in CROSS respectively).3 Moreover, preliminary results of the preSANO-trial sug-
gests that residual disease can be diagnosed with comparable accuracy in patients with 
both histological subtypes. 
Furthermore, in combination with the relatively low frequency of toxicity of the 
CROSS-regimen (91% completed the full nCRT-regimen), the high pCR-rate supports 
the use of the relatively low radiation dose of 41.4 Gy.3 The beneficial effectivity/toxicity 
ratio is the rationale to apply the CROSS-regimen in the SANO-trial, and not a defini-
tive chemoradiotherapy regimen (≥50 Gy of radiotherapy). The latter could increase the 
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pCR-rate, but probably at the cost of a substantial increase in toxicity and postoperative 
complications, leading to a less beneficial effectivity/toxicity ratio. It should be noted 
that postponement of surgical resection, as will be performed in patients who develop 
locoregional regrowth in the absence of distant metastases, has been suggested to in-
crease the incidence of postoperative complications. However, this phenomenon has 
been reported primarily after treatment with high-dose of definitive chemoradiotherapy 
(so called salvage esophagectomy) in low-volume centres.34, 35 The SANO-trial will reveal 
whether this also applies to a lower dose of radiotherapy (CROSS regimen) in high-
volume centres. 
If the SANO-trial shows that active surveillance after nCRT for oesophageal cancer 
leads to non-inferior survival compared to standard oesophagectomy, this organ-
sparing approach could be implemented as a standard of care. Of note, the French 
ESOSTRATE-trial is also comparing active surveillance with standard surgery in pa-
tients with cCR after nCRT. The ESOSTRATE-trial aims to include a total of 300 pa-
tients with SCC or AC with cCR after nCRT.36 The primary endpoint is overall survival, 
as in the SANO-trial. Combining results from the ESOSTRATE-trial and the SANO-
trial would lead to more certainty. Recently, we have shown that 54% and 61% of all 
patients are willing to trade-off 15% and 10% overall survival, respectively, to undergo 
active surveillance instead of standard surgery.37 Therefore, the statistical power of the 
SANO-trial is for a non-inferiority margin of 15%; combination with the French 
ESOSTRATE-trial would reduce this margin to 10%. Hence, the future combination of 
results with the ESOSTRATE-trial is important to further increase our knowledge of an 
active surveillance approach beyond what we will learn from the SANO-trial only. 
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Table 1.  Study algorithm. 
 Pretreatment CRE-I 
(4-6 weeks after 
nCRT) 
CRE-II 
(10-14 weeks 
after nCRT) 
Standard 
surgery arm 
(6, 9, 12, 16, 20, 
24, 30, 36, 48 
and 60 months 
after nCRT) 
Active 
surveillance arm 
(6, 9, 12, 16, 20, 
24, 30, 36, 48 and 
60 months after 
nCRT) 
Informed consent X     
Inclusion   X   
Treatment allocation*   X   
ECOG performance 
status 
X X X X X 
Endoscopy with bite-
on-bite biopsies 
X X X  X 
Radial EUS X  X  X 
Linear EUS with FNA 
of suspected lymph 
nodes 
X  X  X 
18F-FDG PET-CT 
(whole-body) 
X X1 X2 X3 X2 
Quality of Life (EQ-5D, 
QLQ-C30, QLC-OG25 
en Cancer Worry Scale) 
X  X X4 X4 
Oesophagectomy  X5 X6 All At indication7 
1 18F-FDG PET-CT: during CRE-I, after OGD, only for clinically non-complete responders, to exclude dis-
seminated disease. 
2 18F-FDG PET-CT: during CRE-II and active surveillance, prior to OGD and EUS, for all patients (all were 
clinically complete responders during CRE-I) to guide endoscopists in taken biopsies / FNA during OGD and 
EUS and to exclude disseminated disease. 
3 PET-CT in the standard surgery arm will be performed at 12 and 24 months after nCRT only, to exclude 
disseminated disaese. 
4 Quality of life will be assessed during the first 2 years only. 
5 Only for patients with locoregional disease. 
6 After CRE-II: Only  for patients with cCR who are allocated to surgery. 
7 Only for patients in whom a locoregional regrowth is highly suspected or proven, without any signs of dis-
tant dissemination. 
CRE: clinical response evaluation; nCRT: neoadjuvant chemoradiotherapy; ECOG: Eastern Cooperative 
Oncology Group EUS: endo-ultrasonograpy; FNA: fine needle aspiraton. *At this point the patient will be 
allocated to one of the two treatment arms, dependent on the institution. Randomisation has already been 
performed at the institutional level and will be known to the patient at the moment of inclusion 
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Figure 1. Study algorithm. 
 
 
nCRT: neoadjuvant chemoradiotherapy; CRE: clinical response evaluation; cNCR: clinically non-complete 
response; cCR: clinically complete response. *At  this point the patient will be allocated to one of the two 
treatment arms, dependent on the institution in which the actual treatment takes place. Randomisation will be 
performed at the institutional level. Patients will know their allocated treatment at the moment of inclusion. 
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Figure 2.  Stepped-wedge cluster design with addition of preSANO cCR-patients and sequential cross-over of 
6 clusters comprising 2 centres every 4.5 months. 
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 Expected number of patients with cCR included in each treatment arm per time period 
 60 25 22 18 13 8 4 N = 150 
 5 10 16 22 28 34 35 N = 150 
Total 60 25 27 28 29 30 32 34 35 N = 300 
  
   cCR from preSANO-2 (control)  
   control arm (standard surgery)  
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cCR: clinically complete response (based on results from the preSANO trial, it is expected that 50% of all included patients have a 
cCR). 
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Figure 3.  Expected distribution of patients. 
nCRT: neoadjuvant chemoradiotherapy; CRE: clinical response evaluation; S1: first surveillance evaluation; 
S2: second surveillance evaluation etc.  Treatment allocation*: randomisation will be performed at institution-
al level and will be known already at the moment of inclusion; immediate surgery arm of randomisation not 
shown. 
Inclusion  
nCRT 
CRE - II 
CRE - I 
“Randomisation” * 
S 1 
4 -   6 weeks 
S 2 
S 3 
No recurrence 
No recurrence 
  
3 months 
S 4 
No residual disease  
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Disseminated disease 
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Locoregional disease only 
6 - 8   weeks 
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Negative biopsies 
4   months 
Etc 
. 
4  months 
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Summary 
In many countries, neoadjuvant chemoradiotherapy (nCRT) plus surgery is standard 
treatment for resectable oesophageal cancer. After nCRT, up to 30% of all patients have 
no residual disease in the resection specimen. Consequently, an active surveillance ap-
proach, in which patients undergo frequent clinical investigations after nCRT instead of 
standard oesophagectomy, is increasingly applied in selected patients. Here, we describe 
outcomes for three patients who underwent active surveillance. A 63-year old woman 
was considered unfit for surgery after nCRT. Four years after completion of nCRT, she 
still had no signs of disease recurrence. The second patient, a 57-year old woman, re-
fused surgery when no residual disease was detectable after nCRT. One year following 
treatment, she developed a vertebral metastasis, in the absence of locoregional disease. 
The third patient concerned a 66-year old man with a clinically complete response after 
nCRT, who also refused surgery. During active surveillance, he developed a locoregional 
regrowth and underwent a (postoponed) microscopically radical oesophagectomy. 
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Introduction 
Oesophagectomy has been considered an elementary component of curative treatment 
for patients with locally advanced oesophageal cancer. Last years, patients undergo 
chemoradiotherapy prior to surgery. Consequently, 5-year overall survival rates have 
been improved and in some patients, no vital tumour cells can be found in the resection 
specimen. This questions the necessity of an oesophagectomy in all patients; perhaps 
this operation can be postponed or even omitted in a subgroup of these patients. 
Thanks to preoperative chemoradiotherapy 5-year overall survival has increased 
from 35% to 50%. NCRT is highly effective and in about 30% of all cases no malignant 
cells are present in the resection specimen, as determined by conventional histopatho-
logical analysis (so called pathologically complete response). Chances on a pathologically 
complete response differ between histological subtypes, but are substantial in both most 
common subtypes (about 25% for adenocarcinoma and 50% for squamous cell carci-
noma).1  
Such an organ sparing treatment strategy with active surveillance after nCRT is al-
ready applied successfully in patients with bladder carcinoma, rectal carcinoma or head 
and neck cancer.2-4 Here, we illustrate the possible scenarios of an active surveillance 
strategy in oesophageal cancer, by describing clinical outcomes of three typical patients 
who underwent active surveillance after nCRT at our institute. 
Patient A is a 63-year old single woman with no offspring. She has been smoking 
until 4 years ago. Her history includes severe rheumatoid arthritis and bilateral implan-
tation of hip prostheses. Her rheumatoid arthritis is treated with anakinra and predni-
sone.  
Five years ago she developed progressive dysphagia, resulting in the inability for oral 
nutrition. She was diagnosed with a locally advanced squamous cell cancer of 14 cm 
length in the mid- and distal part of the oesophagus (cT3N1M0). The multidisciplinary 
tumour board advised nCRT (41.4 Gy during 4.5 weeks with weekly cycles of car-
boplatin and paclitaxel), followed by oesophagectomy. Six weeks after completion of 
nCRT she underwent clinical investigations. Pathological assessment of endoscopic 
biopsies suggested a clinically complete response: none of the biopsies contained vital 
tumour cells. Because of her limited physical condition and the absence of detectable 
vital tumour, oesophagectomy was provisionally omitted and an active surveillance 
strategy was conducted.  
Currently, four years after completion of nCRT, the patient is doing fairly good. Her 
body weight is stable without artificial nutrition. During repeated clinical investigations 
consisting of endoscopy with biopsies and 18FDG PET-CT there is still a clinically com-
plete response. If after 5 years of active surveillance no residual disease is shown, she will 
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be discharged from further follow-up, since we believe that the risk of recurrence would 
be negligible. 
Patient B is a 57-year old divorced woman with no offspring and no medical history. 
She visited her general practitioner with feelings of general illness and 6kg unintended 
weight loss. At haemotological investigation she had anaemia (Hb 7.0 mmol/ml). Gas-
troscopy  was performed, showing a poorly differentiated squamous cell carcinoma of 
the mid-part of the oesophagus (T1smN1M0). 
After diagnostic work-up with 18FDG PET-CT, endoscopy and endo-
ultrasonography nCRT followed by oesophagectomy was proposed. She was included in 
the preSANO trial (pre-Surgery As Needed for Oesophageal cancer).5, 6 This trial evalu-
ates the tumour response on nCRT by performing clinical response evaluations consist-
ing of endoscopy with biopsies, endo-ultrasonography and 18FDG PET-CT at 6 and 12 
weeks after completion of nCRT. No signs of vital residual disease were found and fol-
lowing the study protocol the patient should have underwent oesophagectomy. Howev-
er, based on extensive conversation with other patients who underwent oesophagecto-
my, she refused surgery, fearing the potential impact of surgery on health-related quality 
of life. She preferred active surveillance. One year after completion of nCRT, an 18FDG 
PET-CT was performed as part of the active surveillance strategy and showed a laesion 
suspicious for a solitary distant metastasis in the vertebral column at level L4 (Figure 1). 
After histological confirmation with a biopsy of the laesion, the patient underwent palli-
ative radiotherapy using the so called cyberknife (two times 12Gy). Except for some pain 
radiating to the left buttock, the patient had no complaints after this treatment.  
Currently, more than two years after diagnosis, she still has no complaints. Based on 
18FDG PET-CT and endoscopy there is still a clinically complete response. The rapid 
detection of the distant metastasis suggests that it was already present in an undetectable 
stage during initial diagnosis. Regardless of the locoregional response to nCRT, this 
patient would not benefit from oesophagectomy, since her prognosis is determined 
mainly by the distant metastasis. 
Patient C, a 66-year old married man with two daughters and a history of depres-
sion, complained about retrosternal pain during intake of food and hot beverages. After 
extensive clinical investigations using 18FDG PET-CT, endoscopy and endo-
ultrasonography, he was diagnosed with a poorly differentiated adenocarcinoma (cT2-
3N1M0) of the oesophago-gastric junction. After discussion in the multidisciplinary 
tumour board the patient was advised to undergo nCRT followed by oesophagectomy.  
The patient was included in the preSANO-trial, like patient B.5, 6 During clinical re-
sponse evaluations at 6 and 12 weeks after completion of nCRT no signs of vital residual 
tumour were found (clinically complete response). Based on this outcome, the patient 
preferred active surveillance instead of standard oesophagectomy. Six months after 
completion of nCRT, an 18FDG PET-CT showed an increase in FDG-avidity at the loca-
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tion of the initial primary tumour (Figure 2). During endoscopy a laesion suspected for 
regrowth of disease was found, but no biopsies were taken. 
Based on 18FDG PET-CT and endoscopy the patient was strongly suspected to have a 
locoregional regrowth, without distant metastases. Therefore, the tumour board advised 
oesophagectomy, and the patient agreed. The thorocolaparoscopic operation was per-
formed at 6.5 months after completion of nCRT without any complications. The resec-
tion specimen showed a microscopically radically resected tumour (ypT3N1R0G3). 
Postoperatively, the patient developed a thoracic seroma, which was treated by percuta-
neous drainage. The patient was discharged on day 10 postoperatively. 
Six months after surgery the patient is doing fine and there are no signs of disease 
recurrence. Follow-up is performed according to the same regimen as patients who 
undergo immediate surgery following completion of nCRT. This regimen consists of 
frequent outpatient visits during 5 years after surgery and additional investigations 
when indicated. 
Discussion 
In patients with a clinically complete response after nCRT who undergo active surveil-
lance, there are several potential clinical scenarios. 
Subclinical micrometastatic disease 
The group of patients who benefit from active surveillance not only consists of patients 
who are cured by nCRT alone, but also of patients with subclinical distant metastases at 
the time of completion of nCRT. The latter group, as reflected by patient B, would not 
benefit from oesophagectomy, since micrometastases are already present during initial 
staging. Over time, these disseminated tumour cells become clinically manifest. Distant 
metastases are the main determinants for long-term survival after nCRT followed by 
oesophagectomy, and are not curable with the currently available systemic therapies. 
Although the biology of distant dissemination is not fully understood, assumptions hold 
that spreading and seeding of tumour cells from the primary laesion is an early event 
and has already occurred in many patients at the time of first clinical presentation and 
subsequent locoregional treatment (i.e. nCRT with and without subsequent surgery).7 
This is supported by the large number of patients who develop distant metastases within 
2 years after surgery.1, 8, 9 No matter how timely and aggressive locoregional treatment 
will be, it will hardly affect the survival-determining events of distant dissemination.  At 
present, patients with occult distant metastases undergo a non-beneficial oesophagec-
tomy because the metastases are below the detection limit at the first clinical evaluation 
after nCRT. 
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Active surveillance 
It is expected that an active surveillance strategy can reduce the need for oesophagecto-
my in 30-40% of all patients with locally advanced oesophageal cancer, as a result of 
either cure after nCRT alone or manifestation of distant dissemination during active 
surveillance.8, 10, 11 This is expected to improve health-related quality of life, to reduce 
treatment-related morbidity and mortality, and to reduce costs. 
However, active surveillance is only justified if long-term survival is comparable to 
nCRT followed by immediate oesophagectomy. Tumour regrowth after nCRT should be 
detected at a curable stage, and before the development of distant dissemination from 
disease regrowth. Therefore, an intensive surveillance regimen is necessary (frequent 
18FDG PET-CT, endoscopy and endo-ultrasonography with cytological puncture of 
suspicious lymph nodes), aiming to detect as many regrowths, as early as possible before 
they become irresectable. In order to reduce the risk of false-negative biopsies, extensive 
biopsies of the original tumour area should be taken, preferably using a bite-on-bite 
technique. The optimal set of investigations for detection of residual disease after nCRT 
was topic of investigation of the preSANO-trial, clinical response evaluation after neo-
adjuvant chemoradiotherapy is adequate using endoscopy with (bite-on-bite) biopsies 
and endo-ultrasonography with aspiration of suspicious lymph nodes for detection of 
locoregional residual disease and 18FDG PET-CT for detection of interval distant metas-
tases.6 
Patient C is an example of a case in which the regrowth was detected in a curable 
stage. Although no biopsies were taken to obtain histopathological evidence of locore-
gional regrowth, the increase in FDG-avidity was so convincing, that the tumour board 
deemed renewed endoscopy to take biopsies not necessary.  
Regrowth in irresectable stage 
We are not experienced with locoregional regrowths detected in an irresectable stage 
(T4b). This is an important risk of active surveillance and is accompanied with a bad 
prognosis, since there is currently no curative treatment available for these patients. 
Based on the (scarcely available) literature, nCRT plus active surveillance with frequent 
investigation using at least 18FDG PET-CT and endoscopy with biopsies leads to similar 
long-term survival, as compared to nCRT followed by immediate oesophagectomy.8, 10, 11 
This should be carefully examined in a prospective clinical trial. Furthermore, outcomes 
of active surveillance might improve by the use of new diagnostic modalities during 
response evaluation, such as MRI and circulating tumour DNA. 
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Postponed surgery 
Next to the risk of detection of a locoregional regrowth in an irresectable stage, litera-
ture suggests that late effects of radiotherapy increase the risk of postoperative compli-
cations in case of postponed surgery. However, this phenomenon has been described 
especially in patients who underwent high dose radiotherapy (>50Gy, whereas the 
Dutch CROSS-regimen consists of 41.4 Gy) and in low-volume centres.12 It is unknown 
whether this increased risk of postoperative complications also applies for patients who 
are treated according to the CROSS-regimen and undergo oesophagectomy in a high-
volume centre (>20 oesophagectomies per year). Moreover, the potential increase in 
postoperative complications in this small group of patients who need postponed surgery 
is probably counterbalanced by the number of patients who avoid unnecessary surgery 
as a results of the active surveillance strategy.  
Active surveillance in selected patients 
Active surveillance is not (yet) a standard of care, but it is applied increasingly in select-
ed patients with a clinically complete response.10, 11 Although squamous cell carcinoma 
has a higher probability to achieve a pathologically complete response (50%), this prob-
ability is also substantial for adenocarcinoma (25%). Therefore, active surveillance is 
applied in patients with both histological subtypes. In current practice, this concerns 
mainly patients who refuse surgery (e.g. patients B and C), or who are medically unfit 
for surgery (patient A).  
Before an active surveillance strategy can be applied as a standard of care, the non-
inferiority of this organ-sparing strategy compared to nCRT plus immediate surgery 
must be tested in a clinical trial. In order to answer this research question, the current 
SANO-trial (Surgery As Needed for Oesophageal cancer) is comparing both treatment 
strategies in 12 Dutch high-volume centres.13  
Ladies and gentlemen, an active surveillance strategy can save selected patients with 
oesophageal cancer and a clinically complete response after nCRT from a potentially 
unnecessary oesophagectomy. If this treatment is applied, we recommend frequent 
clinical investigations using 18FDG PET-CT, endoscopy with (bite-on-bite) biopsies and 
ultra-endosongraphy with cytological puncture of suspicious lymph nodes. 
Before an active surveillance strategy can be applied as a standard of care for patients 
with a clinically complete response after nCRT, a clinical trial should assess whether this 
treatment strategy leads to comparable long-term oncological outcome without increase 
of perioperative morbidity. 
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Figure 1. CT (left) and FDG PET-CT (right) one year after completion of neoadjuvant chemoradiotherapy 
showing a lesion suspicious for solitary distant metastasis in  the vertebral body of L4. 
 
 
Figure 2. Serial FDG PET-CT after neoadjuvant chemoradiotherapy shows an increase in FDG-avidity 24 
weeks after completion of neoadjuvant chemoradiotherapy (right), after an initially clinically complete re-
sponse at 12 weeks (middle). Based on these PET-CT findings a radical oesophagectomy was performed. 
 
nCRT: neoadjuvant chemoradiotherapy 
  
Organ-sparing treatment: feasible and safe? 
437 
References 
1. van Hagen P, Hulshof MC, van Lanschot JJ et al. Preoperative chemoradiotherapy for esophageal or 
junctional cancer. N Engl J Med. 2012;366(22):2074-84. 
2. Mehanna H, Wong WL, McConkey CC et al. PET-CT Surveillance versus Neck Dissection in Advanced 
Head and Neck Cancer. N Engl J Med. 2016;374(15):1444-54. 
3. Renehan AG, Malcomson L, Emsley R et al. Watch-and-wait approach versus surgical resection after 
chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched 
cohort analysis. Lancet Oncol. 2016;17(2):174-83. 
4. Rödel C, Wiess C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J 
Clin Oncol. 2006;24(35):5536-44. 
5. Noordman BJ, Shapiro J, Spaander MC et al. Accuracy of detecting residual disease after CROSS neoad-
juvant chemoradiotherapy for esophageal cancer (preSANO Trial): rationale and protocol. JMIR Res 
Protoc. 2015;4(2):e79. 
6. Noordman BJ, Spaander MC, Wijnhoven BP et al. Accuracy of detecting residual disease after neoadju-
vant chemoradiotherapy for oesophageal cancer (preSANO trial). In press, Lancet Oncol. 2017. 
7. Chambers AF, Groom AC, MacDonald IC. Metastasis: Dissemination and growth of cancer cells in 
metastatic sites. Nat Rev Cancer. 2002;2(8):563-72. 
8. Shapiro J, van Lanschot JJ, Hulshof MC et al. Neoadjuvant chemoradiotherapy plus surgery versus 
surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised con-
trolled trial. Lancet Oncol. 2015;16(9):1090-8. 
9. Shiozaki H, Sudo K, Xiao L et al. Distribution and timing of distant metastasis after local therapy in a 
large cohort of patients with esophageal and esophagogastric junction cancer. Oncology. 2014;86(5-
6):336-9. 
10. Castoro C, Scarpa M, Cagol M et al. Complete clinical response after neoadjuvant chemoradiotherapy for 
squamous cell cancer of the thoracic oesophagus: is surgery always necessary? J Gastrointest Surg. 
2013;17(8):1375-81. 
11. Taketa T, Correa AM, Suzuki A et al. Outcome of trimodality-eligible esophagogastric cancer patients 
who declined surgery after preoperative chemoradiation. Oncology. 2012;83(5):300-4. 
12. Markar S, Gronnier C, Duhamel A et al. Salvage surgery after chemoradiotherapy in the management of 
esophageal cancer: is it a viable therapeutic option? J Clin Oncol. 2015;33(33):3866-73. 
13. Noordman BJ, Wijnhoven BPL, Lagarde SM et al. Neoadjuvant chemoradiotherapy plus surgery versus 
active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial. BMC Cancer. 
2018;18(1):142. 
  

 439 
Chapter 21 
Summary 
  
  
 441 
Chapter 21A 
Summary in English 
 
 
  
Chapter 21 
442 
Esophageal cancer is an aggressive disease with a poor prognosis. At the time of diagno-
sis, most patients are incurable due to distant metastases. For patients without distant 
metastases, surgery to remove part of the esophagus and surrounding lymph nodes has 
been the cornerstone of curative therapy for decades. Surgical techniques are described 
in chapter 2. However, these operations imply major surgery, associated with substan-
tial morbidity and even mortality and have severe impact on quality of life. Moreover, 
even after intentionally curative surgery, around one third of all patients die due to re-
lapse of the disease. In order to improve outcomes, preoperative chemo- and/or radio-
therapy (so called multimodality treatment) have been tested in clinical studies (chapter 
3). The randomized CROSS-trial compared preoperative concurrent chemo- and radio-
therapy followed by surgery with surgery alone. Results showed a 5-year survival benefit 
of 14% in favor of the combined chemoradiotherapy plus surgery group.1 Based on these 
results, preoperative chemoradiotherapy followed by surgery is now standard of care in 
many countries, including the Netherlands. In this thesis, we describe the treatment 
implications of this therapeutic approach as standard of care. Results of the presented 
research are discussed in two parts; PART I focusses on implications of preoperative 
chemoradiotherapy on surgical treatment and PART II focusses on a novel active sur-
veillance treatment strategy in which surgery might be omitted in a substantial number 
of patients who had preoperative chemoradiotherapy. 
PART I. Implications of neoadjuvant chemoradiotherapy on surgical 
treatment 
Multimodality treatment of esophageal cancer is the standard of care in Western centers. 
Two preoperative approaches have been adopted. The first is preoperative chemoradio-
therapy, generally based on the CROSS regimen.1, 2 An alternative option mainly for pa-
tients with the adenocarcinoma subtype is perioperative or preoperative chemotherapy.3, 4 
In chapter 4 it is shown that the survival differences between preoperative chemoradio-
therapy and preoperative chemotherapy are modest, if present at all. Moreover, it is shown 
that preoperative chemoradiotherapy confers significant pathological benefits in terms of 
tumor and lymph node down-staging. Previously, it has been shown that extended lym-
phadenectomy (i.e. resection of lymph nodes) improves prognostication of survival and 
probably also has a beneficial therapeutic effect in patients who are treated with surgery 
alone.5, 6 However, the down-staging effect of preoperative chemoradiotherapy has been 
suggested to reduce the prognostic and therapeutic effect of extended lymphadenectomy. 
We focused on the prognostic and therapeutic effect of lymphadenectomy in chapters 4-6. 
In chapter 5, we provide an overview of the current literature on this topic. In chapter 6 
we critically appraise a recent publication on this topic. Subsequently, the oncological 
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benefit of extended lymphadenectomy is analyzed in chapter 7. In a large series of patients 
from two Dutch high volume centers, a surgical technique with extended lymphadenec-
tomy (transthoracic esophagectomy) is compared with a surgical technique with limited 
lymphadenectomy (transhiatal esophagectomy). The surgical technique with extended 
lymphadenectomy had differential effects on survival, with a favorable prognostic and 
(probably) therapeutic effect in the surgery alone group. However, this effect was absent in 
patients who had received preoperative chemoradiotherapy. Hence, the use of preopera-
tive chemoradiotherapy may reduce the need for extended lymphadenectomy in an at-
tempt to improve long-term survival. Therefore, we conclude that after preoperative 
chemoradiotherapy the choice for surgical approach should depend on the relative risk of 
complications and patient’s quality of life rather than on long-term survival.  
In chapter 8-10, we focus on the impact of preoperative chemoradiotherapy on pa-
tients’ quality of life. In chapter 8 it is shown that, although quality of life declined during 
chemoradiotherapy, no effect of chemoradiotherapy was apparent on postoperative recov-
ery in terms of health-related quality of life, compared with surgery alone. In chapter 9, we 
further explore the course of health-related quality of life immediately after preoperative 
chemoradiotherapy in order to optimize the timing of surgery. Results show that health-
related quality of life returns to pre-treatment levels eight weeks after completion of 
chemoradiotherapy, and that some aspects of health-related quality of life even improve 
after chemoradiotherapy, compared to pre-treatment levels. These results support delay of 
surgery, especially in vulnerable patients. In chapter 10, long-term effects of preoperative 
chemoradiotherapy on quality of life are investigated. Compared to surgery alone, no 
adverse impact of preoperative chemoradiotherapy was apparent on long-term quality of 
life. In addition to the earlier described improvement in long-term survival and the absent 
(negative) impact on postoperative recovery described in chapter 7, these results support 
the view that preoperative chemoradiotherapy according to CROSS is well tolerated and 
can be considered as a standard of care. Nevertheless, after long-term follow-up physical 
functioning and fatigue remain reduced, both with and without preoperative chemoradio-
therapy. These results indicate a lasting (negative) impact of surgery on quality of life, 
regardless of the use of preoperative chemoradiotherapy.  
After preoperative chemoradiotherapy, both the pretreatment and posttreatment 
number of suspected tumor positive lymph nodes are associated with survival.7 In current 
practice, pretreatment lymph node status is determined by endoscopic ultrasound and 
PET-CT examination, whereas posttreatment lymph node status is determined by analysis 
of the number of tumor positive lymph nodes in the resection specimen. Previously, a 
novel staging system to assess the pretreatment number of suspected lymph nodes based 
on regressive changes resulting from chemoradiotherapy (i.e. scarring) in the resection 
specimen has been tested. This staging system was of superior prognostic performance 
compared to regular clinical lymph node staging using endoscopic ultrasound and PET-
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CT.(8) In chapter 11, we externally validate and confirm these findings in an independent 
series of patients from a high volume institute (Cologne, Germany). 
PART II. Active surveillance after neoadjuvant chemoradiotherapy 
After preoperative chemoradiotherapy, one third of all patients does not have viable tu-
mor cells in the resection specimen.2 Based on this finding, the question is raised whether 
surgery is of benefit to these patients. Therefore, we propose to investigate the feasibility of 
an organ-sparing approach after completion of chemoradiotherapy. In this approach, 
patients will undergo active surveillance instead of standard surgery after completion of 
chemoradiotherapy. An active surveillance strategy implies frequent clinical examination 
to ensure timely detection of residual or recurrent locoregional disease. Surgery would be 
offered only to those patients in whom residual disease in the esophagus or surrounding 
lymph nodes is highly suspected or proven, without distant metastases. Before active sur-
veillance can be tested safely, we need to accurately distinguish patients who need imme-
diate surgery (with viable residual tumor) from patients who might benefit from active 
surveillance (without viable residual tumor). Therefore, the disease should be re-staged 
during so called clinical response evaluations. In chapter 12, an overview of the literature 
on the accuracy of the most common diagnostic tests for re-staging is provided. Results 
suggest insufficient reliability of endoscopy, endoscopic ultrasound  and PET-CT for de-
tecting residual disease after neoadjuvant chemoradiotherapy. However, most studies have 
been criticized because of their retrospective design and the use of only one diagnostic 
modality. Moreover, diagnostic tests in most studies were not performed with the aim to 
detect residual disease for the selection of patients who might benefit from active surveil-
lance. This may have reduced diagnostic accuracy. In chapter 13 we describe the study 
protocol of the diagnostic preSANO-trial, which prospectively investigated the accuracy of 
clinical response evaluations and the optimal diagnostic set for detecting residual disease 
after preoperative chemoradiotherapy using a combination of endoscopy, endoscopic 
ultrasound with puncture of suspected lymph nodes, and PET-CT. This trial included 219 
patients from six centers in the Netherlands who were planned to undergo preoperative 
chemoradiotherapy according to CROSS followed by surgery. The main results of this trial 
are presented in chapter 14, showing that response evaluation after preoperative chemo-
radiotherapy for esophageal cancer is adequate using endoscopy with bite-on-bite biopsies 
and endoscopic ultrasound with puncture of suspected lymph nodes. This diagnostic set is 
able detect 90% of all patients with substantial residual tumor in the esophagus after pre-
operative chemoradiotherapy. Moreover, PET-CT detected new so called intercurrent 
distant metastases in 9% of all patients, sparing them from a non-beneficial esophagecto-
my. In-depth analyses of the results of endoscopic ultrasound and PET-CT are reported in 
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chapter 15 and chapter 16, respectively. Although endoscopic ultrasound measurements 
can accurately detect substantial residual tumors (low false-negative rate), these measure-
ments frequently classify patients without residual disease as disease positive (high false-
positive rate, chapter 15). Comparable results were found for in-depth PET-CT analyses 
(chapter 16). Therefore, we concluded that the value of endoscopic ultrasound and PET-
CT in detection of residual disease in the esophagus after preoperative chemoradiotherapy 
is limited.  
An organ-sparing approach theoretically has major advantages for patients, by 
avoiding the risk of postoperative complications and decreased quality of life. In chapter 
17 it is shown that patients are willing to trade-off a substantial 5-year survival chance  
(on average 16%)  in order to achieve a reduction in the risk that surgery is still neces-
sary from 100% (as in current practice) to 35%, as is expected during the to be tested 
active surveillance strategy. Furthermore, it is shown that two classes of patients can be 
identified. The first class consisted of patients with a strong preference for active surveil-
lance and the second class comprised patients with a strong preference for standard 
esophagectomy. These findings may help patients and clinicians in the future to choose 
between active surveillance and standard esophagectomy and may have positive effects 
on quality of shared decision making. In an overview of the (scarcely available) literature 
provided in chapter 18, comparable long-term survival is described in patients without 
detectable disease after preoperative chemoradiotherapy who undergo either active 
surveillance or immediate surgery. Furthermore, it is suggested that after delayed resec-
tion surgical radicality can be achieved in nearly all patients with recurrent disease in the 
esophagus or surrounding lymph nodes that has been missed initially during clinical 
response evaluation. Also, distant dissemination rate (the percentage of patients who 
developed distant metastases) seems comparable after active surveillance and standard 
esophagectomy.9 These results from small explorative studies support an active surveil-
lance approach. Combined with the results from chapter 15, a large clinical trial com-
paring active surveillance with standard surgery is justified. The protocol of such trial is 
described in chapter 19. In this so called SANO-trial (Surgery As Needed for Oesopha-
geal cancer), which is currently running in 12 Dutch centers, the (cost)effectiveness is 
examined of active surveillance after preoperative chemoradiotherapy using the diag-
nostic modalities described in chapter 15, as compared to standard surgery. If active 
surveillance and surgery as needed after preoperative chemoradiotherapy lead to non-
inferior survival compared to standard esophagectomy, this organ-sparing approach can 
be implemented as a new standard of care. This would have important future implica-
tions for  therapy. In chapter 20 we describe outcomes in three typical patients without 
signs of residual disease after completion of preoperative chemoradiotherapy who un-
derwent active surveillance, because they refused surgery or were considered medically 
unfit for surgery.  
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Slokdarmkanker is een agressieve ziekte en kent een slechte prognose. Op het moment 
van diagnose is de ziekte in veel gevallen al uitgezaaid naar andere organen, waardoor 
veel patiënten niet meer in aanmerking komen voor curatieve behandeling. Voor pati-
enten zonder afstandsmetastasen is chirurgische verwijdering van de slokdarm en om-
liggende lymfeklieren een belangrijk onderdeel van de behandeling. Chirurgische tech-
nieken worden beschreven in  hoofdstuk 2. Slokdarmoperaties kennen echter een aan-
zienlijke perioperatieve sterfte, potentieel ernstige postoperatieve complicaties en heb-
ben een negatieve invloed op de kwaliteit van leven. Bovendien zal na operatie ongeveer 
een derde van alle patiënten alsnog overlijden door terugkeer van de ziekte. Om deze 
uitkomsten te verbeteren, is het nut van  preoperatieve chemo- en/of radiotherapie (zo-
genaamde multimodaliteit behandeling) in vele onderzoeken getest (hoofdstuk 3). Re-
cent heeft het Nederlandse ‘ChemoRadiotherapy for Oesophageal cancer followed by 
Surgery Study’(CROSS)-onderzoek aangetoond dat preoperatieve chemoradiotherapie, 
gevolgd door een slokdarmresectie, leidt tot een verbetering van de 5-jaarsoverleving, in 
vergelijking met alleen een operatie.1 Deze behandeling is daarom nu eerste keus in veel 
landen. Dit proefschrift beschrijft de behandelconsequenties van deze nieuwe therapie. 
De resultaten van dit onderzoek zijn beschreven in twee delen; DEEL I richt zich op de 
implicaties van preoperatieve chemoradiotherapie voor chirurgische behandeling en 
DEEL II richt zich op een nieuw beleid van ‘actieve surveillance’,  waarbij  na preopera-
tieve chemoradiotherapie een slokdarmoperatiemogelijk achterwege kan worden gela-
ten bij een deel van de patiënten. 
DEEL I. Implicaties van preoperatieve chemoradiotherapie voor 
operatieve behandeling 
Multimodaliteit behandeling van slokdarmkanker is behandeling van eerste keus ge-
worden in Westerse centra. Er zijn twee algemeen geaccepteerde preoperatieve behan-
delstrategieën. Allereerst preoperatieve chemoradiotherapie, meestal op basis van het 
CROSS-schema.1, 2 Het alternatief, met name voor patiënten met het adenocarcinoom 
subtype, is perioperatieve of peroperatieve chemotherapie.3, 4 In hoofdstuk 4 wordt 
aangetoond dat eventuele verschillen in effect op overleving tussen beide behandelingen 
beperkt zijn. Wel heeft preoperatieve chemoradiotherapie in pathologisch opzicht voor-
delen in de zin van reductie van tumorgrootte en het aantal aangedane lymfklieren (zo-
genaamde downstaging). Eerder onderzoek heeft aangetoond dat uitgebreide lymfklier-
verwijdering leidt tot verbetering van het inschatten van de overleving, en waarschijnlijk 
ook een therapeutisch effect heeft bij patiënten die zijn behandeld met alleen chirurgie, 
d.w.z. zonder preoperatieve chemoradiotherapie.5, 6 Het effect van preoperatieve chemo-
radiotherapie op de tumor en lymfeklieren vermindert deze prognostische en therapeu-
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tische waarde van een uitgebreide lymfklierverwijdering. Hoofdstuk 5-7 richten zich op 
het prognostische en therapeutische effect van lymfklierverwijdering. In hoofdstuk 5 
wordt een samenvatting van de literatuur over dit onderwerp gegeven. Hoofdstuk 6 is 
een kritische reactie op een recente publicatie over dit onderwerp. In hoofdstuk 7 wordt 
ingegaan op het oncologische voordeel (ten aanzien van de overlevingskans) van uitge-
breide lymfklierverwijdering. In dit hoofdstuk wordt een chirurgische techniek met 
uitgebreide lymfklierverwijdering (transthoracale slokdarmverwijdering) vergeleken 
met een chirurgische techniek met beperkte lymfklierverwijdering (transhiatale slok-
darmverwijdering) in een grote serie patiënten uit twee Nederlandse hoog-volume cen-
tra. De operatie met uitgebreide lymfklierverwijdering had wel een gunstig effect op 
overleving (met een prognostisch én therapeutisch voordeel) in de groep patiënten die 
alleen operatie onderging. Dit effect was echter afwezig in patiënten die preoperatieve 
chemoradiotherapie ondergingen. Concluderend vermindert het gebruik van preopera-
tieve chemoradiotherapie mogelijk de noodzaak tot uitgebreide lymfklierverwijdering. 
Daarom zou de keuze van operatietechniek na preoperatieve chemoradiotherapie ons 
inziens met name moeten afhangen van het bijbehorende risico op complicaties en de 
kwaliteit van leven, en niet zo zeer van de langetermijn overleving. 
Hoofdstuk 8-10 richten zich op het effect van preoperatieve chemoradiotherapie op 
kwaliteit van leven. Hoofdstuk 8 laat zien dat, hoewel de kwaliteit van leven verslechtert 
tijdens chemoradiotherapie, er geen nadelig effect meetbaar is van preoperatieve che-
moradiotherapie op de postoperatieve kwaliteit van leven, in vergelijking met alleen 
chirurgie. Hoofdstuk 9 gaat dieper in op het beloop van kwaliteit van leven direct na 
preoperatieve chemoradiotherapie, met als doel de timing van operatie te optimaliseren. 
Resultaten tonen dat kwaliteit van leven terugkeert op het niveau van vóór behandeling 
binnen 8 weken na het einde van de chemoradiotherapie, en dat sommige aspecten van 
kwaliteit van leven zelfs verbeteren na chemoradiotherapie, ten opzichte van de situatie 
vóór de behandeling. Hoofdstuk 10 beschrijft de langetermijn effecten  van preoperatie-
ve chemoradiotherapie op kwaliteit van leven. In vergelijking met alleen chirurgie, was 
er geen sprake van verminderde kwaliteit van leven na preoperatieve chemoradiothera-
pie op lange termijn. Naast de verbetering in langetermijn overleving en de afwezigheid 
van invloed op korte termijn kwaliteit van leven (hoofdstuk 7), ondersteunen deze resul-
taten het gebruik van preoperatieve chemoradiotherapie volgens het CROSS-schema als 
behandeling van eerste keus. Echter, na langetermijn follow-up blijven de aspecten van 
kwaliteit van leven “fysiek functioneren” en “vermoeidheid” slechter dan voorafgaand 
aan de behandeling. Deze resultaten suggereren een langdurige negatieve invloed van 
chirurgie op kwaliteit van leven, ongeacht het gebruik van preoperatieve chemoradio-
therapie.  
Na preoperatieve chemoradiotherapie zijn zowel het aantal tumor positieve lymf-
klieren vóór als het aantal tumor positieve lymfklieren ná behandeling geassocieerd met 
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overleving.7 Lymfklier status voorafgaand aan behandeling wordt in de huidige klinische 
praktijk bepaald met behulp van endoscopisch echo-onderzoek en PET-CT. Lymfklier-
status ná behandeling wordt bepaald door middel van analyse van het aantal tumor 
positieve lymfklieren in het resectiepreparaat. Een nieuw stadiëringssysteem om het 
aantal tumor positieve lymfklieren voorafgaand aan de behandeling nauwkeuriger te 
kunnen bepalen is gebaseerd op regressieve veranderingen ten gevolge van voorafgaan-
de chemoradiotherapie (met name verlittekening) in het resectiepreparaat.8 Eerder on-
derzoek heeft aangetoond dat dit nieuwe pathologische stadiëringssysteem een betere 
prognostische waarde heeft dan een systeem dat gebaseerd is op endoscopisch echo-
onderzoek en PET-CT. In hoofdstuk 11 valideren we deze bevindingen in een onafhan-
kelijke serie patiënten uit een hoog-volume centrum (Keulen, Duitsland). 
DEEL II. Actieve surveillance na preoperatieve chemoradiotherapie 
Na behandeling met preoperatieve chemoradiotherapie, heeft 29% van de patiënten een 
complete respons in het resectiepreparaat.2 Dit betekent dat er geen vitale tumorrest 
aantoonbaar is tijdens histopathologisch onderzoek. Deze bevindingen hebben ertoe 
geleid dat de noodzaak om alle patiënten na chemoradiotherapie te opereren ter discus-
sie staat. Wij onderzoeken de haalbaarheid van een orgaansparende behandeling na het 
einde van de chemoradiotherapie. In deze strategie van zogenaamde actieve surveillan-
ce, zullen patiënten frequente klinische controles ondergaan na het einde van de chemo-
radiotherapie, in plaats van een standaard slokdarmoperatie. Een operatie zou dan al-
leen maar worden verricht bij patiënten met een sterke verdenking op, of een bewezen 
aanwezigheid van tumorrest in de slokdarm of omliggende lymfklieren, zonder uitzaai-
ingen op afstand. Voordat actieve surveillance veilig kan worden onderzocht, dient er 
betrouwbaar  onderscheid te kunnen worden gemaakt tussen patiënten die direct moe-
ten worden geopereerd (met vitale tumor) en patiënten die mogelijk baat hebben bij 
actieve surveillance (zonder vitale tumor). Daartoe dient de ziekte opnieuw te worden 
gestadieerd na chemoradiotherapie tijdens zogenaamde klinische respons evaluaties.  
Hoofdstuk 12 toont een overzicht van de literatuur over de accuratesse van de meest 
gebruikte diagnostische tests voor herstadiëring na preoperatieve chemoradiotherapie. 
De resultaten suggereren dat endoscopie, endoscopisch echo-onderzoek en PET-CT 
onvoldoende in staat zijn om tumorrest na preoperatieve chemoradiotherapie aan te 
kunnen tonen. Echter, de meeste beschreven onderzoeken waren retrospectief en on-
derzochten slechts één diagnostische test. Ook waren de tests in de meeste onderzoeken 
niet verricht met als doel tumorrest aan te tonen om patiënten te selecteren voor een 
beleid van actieve surveillance. Dit kan de beschreven diagnostische accuratesse negatief 
hebben beïnvloed. Hoofdstuk 13 beschrijft het studieprotocol van het diagnostische 
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preSANO-onderzoek. Dit prospectieve onderzoek test de nauwkeurigheid van klinische 
respons evaluaties en het optimale diagnostische pakket voor het klinisch aantonen van 
vitale tumorrest na preoperatieve chemoradiotherapie met endoscopie, endoscopische 
echografie met punctie van verdachte lymfklieren, en PET-CT. In totaal werden 219 
patiënten uit 6 verschillende Nederlandse ziekenhuizen onderzocht die werden behan-
deld met preoperatieve chemoradiotherapie volgens het CROSS-schema. De belangrijk-
ste resultaten worden beschreven in hoofdstuk 14. Respons evaluatie met endoscopie 
met bite-on-bite biopten en endoscopische echografie met punctie van verdachte lymf-
klieren detecteerde 90% van alle patiënten met substantiële tumorrest in de slokdarm na 
preoperatieve chemoradiotherapie. PET-CT detecteerde bovendien nieuwe zogenaamde 
intercurrente uitzaaiingen op afstand bij 9% van alle patiënten, waardoor hen een onno-
dige slokdarmoperatie bespaard is gebleven. Hoofstuk 15 en hoofstuk 16 beschrijven 
gedetailleerde analyses van respectievelijk endoscopische echografie metingen en PET-
CT metingen. Hoewel endoscopische echografie metingen goed staat zijn tumorrest te 
detecteren (laag fout-positief percentage), wordt een groot deel van de patiënten zonder 
tumorrest onterecht als positief voor tumorrest geclassificeerd (hoog fout-positief per-
centage) (hoofdstuk 15). Vergelijkbare resultaten werden gevonden bij nadere analyse 
van de PET-CT data (hoofdstuk 16). Op basis hiervan concluderen wij dat de waarde 
van endoscopische echografie metingen en PET-CT metingen bij het aantonen van 
vitale tumorrest in de slokdarm na preoperatieve chemoradiotherapie beperkt is.  
Een orgaansparende behandeling heeft theoretisch belangrijke voordelen voor pati-
enten, omdat het risico op complicaties en vermindering van kwaliteit van leven wordt 
voorkómen. Hoofdstuk 17 laat zien dat patiënten bereid zijn om een substantiële 5-
jaars overlevingskans (gemiddeld 16%) in te leveren om het risico dat een slokdarmope-
ratie nodig is te verkleinen van 100% (zoals in de huidige praktijk) naar 35%, zoals 
wordt verwacht tijdens een (toekomstig) beleid van actieve surveillance. Verder zijn er 
twee groepen patiënten te onderscheiden. De eerste groep bestaat uit patiënten met een 
sterke voorkeur voor actieve surveillance, terwijl de tweede groep bestaat uit patiënten 
met een sterke voorkeur voor standaard operatie. Deze bevindingen kunnen clinici en 
patiënten in de toekomst helpen bij het maken van de keuze tussen actieve surveillance 
en standaard operatie, en komen gezamenlijke besluitvoering ten goede. De samenvat-
ting van de literatuur in hoofdstuk 18 toont vergelijkbare langetermijn overleving bij 
patiënten zonder aantoonbare ziekte na preoperatieve chemoradiotherapie die ofwel 
actieve surveillance ondergaan, ofwel standaard operatie. Bovendien suggereert de lite-
ratuur dat een uitgestelde operatie pathologisch radicaal kan worden verricht bij bijna 
alle patiënten bij wie tijdens actieve surveillance tumorrest wordt ontdekt in de slok-
darm of in de omliggende lymfklieren. Ook het percentage patiënten dat uitzaaiingen op 
afstand ontwikkelt, lijkt vergelijkbaar na actieve surveillance en standaard operatie.9 
Deze resultaten van kleine exploratieve onderzoeken ondersteunen een beleid van actie-
Chapter 21 
452 
ve surveillance. In combinatie met de resultaten van hoofdstuk 15, is een groot klinisch 
onderzoek naar actieve surveillance gerechtvaardigd. Van een dergelijk onderzoek is het 
onderzoeksprotocol beschreven in hoofdstuk 19. Deze zogenaamde SANO-trial (Sur-
gery As Needed for Oesophageal cancer) loopt thans in 12 Nederlandse ziekenhuizen en 
onderzoekt de (kosten)effectiviteit van actieve surveillance na preoperatieve chemora-
diotherapie met behulp van de diagnostische tests zoals beschreven in hoofdstuk 15, 
vergeleken met standaard operatie. Als actieve surveillance na preoperatieve chemora-
diotherapie leidt tot een non-inferieure overleving vergeleken met standaard operatie, 
zal deze orgaansparende behandeling worden geïmplementeerd als nieuwe behandeling 
van eerste keus. In hoofdstuk 20 beschrijven wij drie typische patiënten zonder aan-
toonbare tumorrest na het einde van preoperatieve chemoradiotherapie, die actieve 
surveillance ondergingen (in plaats van standaard operatie), omdat zij een operatie 
weigerden dan wel een sterk verhoogd operatierisico hadden.  
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Esophageal cancer is currently the sixth most common cause of cancer death globally.1 
In Western countries, and the incidence of esophageal adenocarcinoma is growing rap-
idly. This aggressive disease has substantial impact on health-related quality of life, even 
in the curative setting. Over the last decades, survival after intentionally curative treat-
ment for esophageal cancer has improved dramatically, as reflected by 5-year overall 
survival rates of 10% in the 1960’s, 20% in the 1980’s and 47% in the recent CROSS-trial. 
Nevertheless, about 50% of all patients still die from recurrent disease, mainly due to 
distant dissemination. Currently, no successful therapy for patients with disease recur-
rence after nCRT plus surgery is available. Future research should focus on less cancer, 
better quality of life and more cure. 
Less cancer 
Earlier diagnosis of (pre)malignant lesions would improve prognosis. However, screen-
ing and surveillance using the only currently available modality (endoscopy with biop-
sies) might not be feasible or cost-effective and can be accompanied by morbidity. Im-
proved selection of high risk patients and the use of new minimally invasive screening 
modalities might allow for a future screening program. Currently, promising tools such 
as breath analysis and cytosponge are explored, but more research is necessary before 
these modalities can be applied in routine clinical practice.2, 3  
Better quality of life 
As is shown in part I of this thesis, esophagectomy has profound impact on patients’ 
quality of life, irrespective of the use of neoadjuvant treatment. Minimally invasive and 
hybrid surgical techniques improve postoperative recovery, but it is questionable if this 
will reduce the long-term and lasting impact of surgery. Therefore, organ-sparing 
treatment strategies should be further explored. Definitive chemoradiotherapy without 
esophagectomy has been evaluated as such for patients with squamous cell carcinoma, 
reducing the long-term consequences of surgery. However, locoregional recurrence 
rates and long-term survival results have been suggested inferior, as compared to (nCRT 
followed by) surgery.4 Based on the high pathologically complete response rate in the 
CROSS-trial, we propose testing of an active surveillance strategy after completion of 
nCRT, which is currently investigated in the French ESOSTRATE and Dutch SANO 
trials.5, 6 In this new treatment strategy, patients are subjected to frequent clinical inves-
tigations after the completion of nCRT and (postponed) surgical resection is offered 
only to patients with a proven locoregional regrowth in the absence of distant metasta-
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ses. It is estimated that an active surveillance strategy might reduce the need for esoph-
agectomy in 30-40% of all patients, thereby reducing the lasting negative effects of sur-
gery on HRQOL. This number might even  increase when more effective neoadjuvant 
treatment will be developed (see below). However, oncological safety of active surveil-
lance remains to be proven. Results of the SANO-trial are expected in 2023. 
It is expected that the diagnostic accuracy of CREs will improve. Increased accuracy 
of CREs may reduce the number of patients who need postponed esophagectomy and 
the number of patients with irresectable regrowths detected during active surveillance. 
Promising results have been suggested by dynamic contrast-enhanced MRI and diffu-
sion-weighted MRI, but these results need confirmation in larger diagnostic trials.7, 8 
Furthermore, molecular analysis of circulating cell-free tumor DNA (ctDNA) derived 
from blood samples might be useful. These so called ‘liquid biopsies’ can be easily ob-
tained from the patient with minimal burden and minimal potential harm. Liquid biop-
sies may be used to evaluate the presence of residual disease after nCRT and to monitor 
disease recurrence (locoregional and/or distant) during active surveillance with use of 
multiple assessments over time.9, 10 Moreover, ctDNA analysis might be used to identify 
in an early phase which patients will develop distant disease recurrence during follow-
up. These patients might be saved from a non-curative resection. 
If the SANO-trial will show non-inferior survival after active surveillance compared 
to standard esophagectomy, future patients will be confronted with the choice between 
active surveillance or standard surgery. Despite the clinical advantages of active surveil-
lance, there are concerns on whether this organ sparing approach can be applied to all 
patients with a clinically complete response. For some, the possible stress of frequent 
monitoring and invasive investigations might outweigh the possibility of unnecessary 
surgery.11 Future research should focus on patients’ motivation to opt (out) for active 
surveillance. An increased understanding of what truly matters to patients in making 
their treatment decisions will help physicians to attune to patients’ needs. In this way 
shared decision making during clinical consultation can be facilitated. In addition, a 
decision aid for patients and physicians facing the complex decision between active 
surveillance or immediate surgery should be developed. This tool will further contribute 
to making well-balanced shared decisions. 
More cure 
Improvement of long-term survival might be achieved by improved efficacy of neoadju-
vant treatment, application of adjuvant treatment or resection of metastatic disease.  
After application of the CROSS-regimen followed by surgical resection, only 1% of all 
patients develop isolated recurrences within the radiotherapy field without distant dissem-
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ination.12 This indicates that intensification of the locally acting radiotherapy might im-
prove outcome only in a small minority of all patients. Therefore, efficacy improvement of 
neoadjuvant treatment should focus on the systemic component in order to reduce the 
number of outfield recurrences. This might consist of adding chemotherapy cycles prior to 
nCRT. Although previous studies did not show any survival benefit of this strategy, a 
benefit for subgroups of patients with well or moderately differentiated tumors has been 
suggested.13 Furthermore, new chemotherapy regimens such as the FLOT regimen have 
shown promising results in the perioperative setting (without radiotherapy).(14) Addition 
of this perioperative regimen to selected patients with high risk of distant dissemination 
might improve survival, but potentially at the cost of an increased toxicity. 
The rapid development of targeted therapies has shown promising results in other 
types of cancer. Nevertheless, most trials investigating targeted therapies in esophageal 
cancer have not been successful. Only trials investigating HER2-inhibitors have shown a 
(modest) positive effect in patients with distant dissemination and should be further 
explored in patients with potentially curative disease.15, 16 Potential future targets of 
therapeutic interest include impaired DNA repair mechanisms  (e.g. CDK6) and 
dysregulation of cell cycle regulators.17, 18 
In other cancers, immunotherapy using checkpoint inhibitors has shown substantial 
survival benefits. Especially cancers with high rates of somatic mutations, such as mela-
noma and lung cancer, have shown sensitivity for these new therapies. Interestingly, 
esophageal cancer is also characterized by a high number of somatic mutations, provid-
ing a rationale to study targeted immune therapy.19 Explorative trials in metastatic esoph-
ageal cancer patients have shown promising results, with response rates to anti-PD-1 
antibody pembroluzimab of 17%-40% and an acceptable adverse event rate.20, 21 
Personalized immunotherapy, such as chimeric antigen-receptor T-cells or adoptive 
T-cell transfer of mutation specific T-cells, has been successful in other types of 
cancer.22, 23 However, application of these therapies is in early development and requires 
considerable expertise. 
Finally, in selected patients with oligometastatic esophageal cancer, multimodality 
treatment should be further explored as a potentially curative approach. Resection of a 
limited number of livermetastases from colorectal cancer is now considered standard 
treatment with 5-year survival rates of up to 60%.24 Several small retrospective studies in 
patients with esophageal cancer have shown promising results, especially in patients 
with oligometastases treated with neoadjuvant or perioperative chemotherapy plus 
surgery.25, 26 The feasibility of neoadjuvant chemo(radiotherapy) followed by hepatic 
resection and esophagectomy or gastrectomy is currently investigated in the LIME-trial, 
initiated by the Erasmus MC.  
Based on the above mentioned therapeutic opportunities, the improvements made 
in the last decades can hopefully be continued in the near future. 
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